Inhibition of hairless protein mRNA

ABSTRACT

Methods for inhibition of hairless protein mRNA using RNA interference is described, in particular methods for hair removal. Also described are nucleic acid constructs for RNAi-mediated inhibition of hairless protein mRNA and compositions including such constructs.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application is a continuation of U.S. application Ser. No. 11/113,423 filed Apr. 22, 2005, now abandoned which is based on U.S. Provisional Application Ser. No. 60/565,127 filed Apr. 23, 2004, the contents of each of which are incorporated by reference herein, and to each of which priority is claimed.

SEQUENCE LISTING

The specification further incorporates by reference a substitute Sequence Listing submitted via EFS on Jul. 2, 2007. Pursuant to 37 C.F.R. §1.52(e)(5), the substitute Sequence Listing text file, identified as 700503051.txt, is 2.0 Mb and was created on Jul. 2, 2007. The substitute Sequence Listing, electronically filed herewith, does not extend beyond the scope of the specification and thus does not contain new matter.

The sequence listing, submitted in duplicate on compact disk (CD), in lieu of a paper copy in compliance with 37 C.F.R. §§1.821(c) and 1.52(e), and in duplicate on CD (CRF copy), in compliance with 37 C.F.R. §1.821 (e) has been generated from the specification and figures and does not constitute new matter. The Sequence Listing has been prepared using FastSeq for Windows Version 4.0 software. Four identical CDs, labeled COPY 1, COPY 2, CRF of Sequence Listing submitted under 37 C.F.R. §1.821(e)—COPY 1 and CRF of Sequence Listing submitted under 37 C.F.R. §1.821(e)—COPY 2, (total four (4) CDs), created on Apr. 22, 2005 each contain file: “AP36462_SEQLIST.TXT”, of size 2.28 MB (2,398,842 bytes). The specification incorporates herein by reference, the CD copies of the Sequence Listing submitted under 37 C.F.R §§1.821(c) and 1.52(e). The sequence listing, submitted herein, does not extend beyond the scope of the specification, and thus, does not contain new matter.

BACKGROUND OF THE INVENTION

The following is a discussion of some relevant art relating to hairless protein, and to RNAi. This discussion is provided only to assist the understanding of the reader, and does not constitute an admission that any of the information provided or references cited constitutes prior art to the present invention.

As described in Christiano et al., PCT/US99/02128, WO 99/38965, The human hair follicle is a dynamic structure which generates hair through a complex and highly regulated cycle of growth and remodeling. Hardy, 1992, Trends Genet. 8:159; Rosenquist and Martin, 1996, Dev. Dynamics 205:379. Hair growth is typically described as having three distinct phases. In the first phase, knows as anagen, the follicle is generated and new hair grows.

During the second phase, known as catagen, the follicle enters the stage where elongation ceases and the follicle regresses because the matrix cells stop proliferating. At this stage, the lower, transient half of the follicle is eliminated due to terminal differentiation and keratinization, and programmed cell death. Rosenquist and Martin, 1996, Dev. Dynamics 205:379. Also during catagen, although the dermal papilla remains intact, it undergoes several remodeling events, including degradation of the extracellular matrix that is deposited during anagen. At the close of catagen, the hair is only loosely anchored in a matrix of keratin, with the dermal papilla located just below. The catagen stage occurs at a genetically predetermined time, which is specific for each hair type in a species.

The third phase, known as telogen, is characterized by the follicle entering a quiescent phase, during which the hair is usually shed. When a new hair cycle is initiated, it is thought that a signal from the dermal papilla stimulates the stem cells, which are thought to reside in the permanent portion of the follicle, to undergo a phase of downward proliferation and genesis of a new bulbous base containing matrix cells which then surround the dermal papilla. As the new anagen state progresses, these hair matrix cells produce a new hair, the cycle begins again. Each follicle appears to be under completely asynchronous control, resulting in a continuum of follicles in anagen, catagen, and telegen phases, leading to a relatively homogeneous hair distribution. Hardy, 1992, Trends Genet. 8:159; Rosenquist and Martin, 1996, Dev. Dynamics 205:379.

Christiano et al., PCT/US99/02128, WO 99/38965 describes isolated nucleic acid encoding human hairless protein, the isolated protein, and methods for identifying a compound that is capable of enhancing or inhibiting expression of a human hairless protein, and states that “A therapeutic approach using antisense to human hairless can be used to directly interfere with the translation of Human hairless protein messenger RNA into protein.” It further states that “antisense nucleic acid or ribozymes could be used to bind to the Human hairless protein mRNA or to cleave it.”

Thompson, U.S. Pat. No. 6,348,348, issued Feb. 19, 2002, describes human hairless gene and protein, and screening methods to identify agents that affect expression of the human hairless gene.

Christiano, U.S. patent application Ser. No. 10/122,013, publication 20030077614 (and corresponding Internation Application PCT/US02/11683, WO 02/083891), indicates that “The present invention provides DNAzymes and ribozymes that specifically cleave Hairless Protein mRNA.” The present invention also provides antisense oligonucleotides that specifically inhibit translation of Hairless Protein mRNA. (Abstract.) Also, it states that “This invention provides a nucleic acid molecule that specifically hybridizes to Hairless Protein mRNA so as to inhibit the translation thereof in a cell”; (Specification ¶ 0099) and that “Antisense oligodeoxynucleotides were synthesized as directed to the inhibition of Hairless expression based on the Hairless mRNA sequence.”

SUMMARY OF THE INVENTION

The present invention concerns the use of RNA interference (RNAi) to inhibit mRNA's involved in hair growth, resulting in inhibition of hair growth. For many applications, short interfering RNA (siRNA) are used. Thus, inhibition of hairless protein mRNA, particularly during catagen phase, can result in permanent or at least long term inhibition of hair growth, and thus provides a method for hair removal. Consequently, inhibition of hairless protein mRNA can be used for hair removal and/or hair growth inhibition in cosmetic, therapeutic, and industrial applications.

Thus, in a first aspect, the invention provides a method for hair removal from a mammal, e.g., a human. The method involves applying to a human in an area comprising hair follicles a double stranded nucleic acid molecule that includes a sequence of at least a portion of human hairless protein mRNA and a sequence complementary thereto.

In particular embodiments, the inhibition of hair growth in the treated area persists at least 1, 2, 4, 6, 8, 10, 12, or 24 months, or longer, or permanently.

In certain embodiments, the method also involves synchronizing hair growth cycles for hair follicles in the treated area, e.g., by extracting hairs such as by waxing. Such extraction causes follicles in anagen to transition into catagen thereby making those follicles susceptible to inhibition using this invention, and triggers new hair growth of follicles in telogen and thus makes those follicles suitable for transitioning into catagen. Thus, these methods synchronize hair follicles in the hair cycle.

As used in connection with this invention, the term “hair removal” refers to physical removal and continuing inhibition of hair growth from one or more hair follicles. Typically the hair removal applies to a plurality of hair follicles in a skin area on a subject. For example, the area can be up to 2, 5, 10, 20, 50, 100, 200, 400, or more cm². For hair removal in an area, the hair removal may apply to all or a fraction of the hair follicles in the area.

The term “hair follicle” is used conventionally to refer to a biological hair producing structure.

As used in connection with the present methods, the term “applying” indicates that a substance is placed such that the substance is physically present on or in an area.

The term “nucleic acid molecule” refers to a polymer that includes a plurality of linked nucleotides or nucleotide analogs, and may include one or more modified internucleotidic linkages.

The term “hairless gene” refers to a mammalian gene that corresponds to reference human cDNA GenBank reference number NM_(—)005144, FIG. 1 (SEQ ID NO: 11412) and version NM_(—)005144.3, GI:62750351, FIG. 2 (SEQ ID NO:11413), recognizing that polymorphisms and potentially sequencing errors may be present, or a species homolog of that sequence, e.g., mouse homolog cDNA sequence NM_(—)021877. Similarly the terms “hairless protein mRNA” and “hairless mRNA” refer to an mRNA encoding a hairless gene protein, and “human hairless mRNA” refers to a human homolog of such mRNA.

The phrase “inhibition of hair growth” is used to refer to a reduction or stoppage of hair growth caused at least in part by an agent not normally present in cells in a hair follicle.

As used herein, the phrase “synchronizing hair growth cycles” means that at least 10% of hair follicles in catagen or telogen phase in a particular area are caused to enter anagen phase essentially simultaneously (i.e., within 2 weeks). Such synchronizing can be accomplished, for example, with a physical action such as hair extraction or with one or more chemical or biomolecular agents.

As used herein, the term “hair extraction” refers to pulling of individual hair shafts out of their follicles.

A related aspect concerns a method for hair removal from an area of a mammal comprising hair follicles, where the method involves applying to the area a composition that includes at least one double stranded nucleic acid molecule able to inhibit hairless mRNA translation in vitro.

In certain embodiments, the method also includes synchronizing hair growth cycles for hair follicles in the treated area, such as by hair extraction, e.g., using waxing; the mammal is a human; the mammal is a mouse; the mammal is a rat; the mammal is a bovine.

In another aspect, the invention provides a method of inhibiting expression of hairless protein in a mammal. The method involves administering a double stranded nucleic acid molecule to the mammal, where the double stranded nucleic acid molecule includes a sequence selected from the group consisting of oligonucleotides 1-5664 and their respective antisense sequences, or the species homology of such sequences, and a sequence complementary thereto.

As used in the context of this invention, the term “inhibiting expression” indicates that the level of mRNA and/or corresponding protein or rate of production of the corresponding protein in a cell that would otherwise produce the mRNA and/or protein is reduced as compared to a non-inhibited but otherwise equivalent cell. Reduction in the rate of production can be at various levels, including stopping such production.

The term “species homolog” refers to a form of a gene, or corresponding nucleic acid molecule, or polypeptide from a particular species that is sufficiently similar in sequence to the gene, corresponding nucleic acid, or polypeptide from a reference species that one skilled in the art recognizes a common evolutionary origin.

Thus, as used in connection with a molecule or composition, the phrase “able to inhibit hairless mRNA translation” indicates that the molecule or composition has the property that when present in a cell that would translate hairless mRNA to produce protein in the absence of an inhibitor, the molecule or composition reduces the rate of biosynthesis of hairless protein (or even eliminate such biosynthesis). Such reduction can occur in various ways, for example, by reducing the amount of mRNA available for translation or by at least partially blocking translation of mRNA that is present.

Reference to Oligonucleotides by number utilizes the oligonucleotide numbering in Table 1, and therefore, specifies a nucleotide sequence.

In particular embodiments, the mammal is a human, a mouse, a rat, a bovine (such as a cow), an ovine (such as a sheep), a monkey, a porcine (such as domestic pig).

The term “bovine” is used conventionally to refer to cattle, oxen, and closely related ruminants.

Another aspect concerns a method for treating a human desirous of losing hair. The method involves administering to the human a composition that includes a double stranded nucleic acid molecule that includes a sequence of at least a portion of human hairless protein mRNA and a sequence complementary thereto.

As used herein, the phrase “desirous of losing hair” refers to an objective indication of consent or request for a process to remove hair from a body area in a manner reducing or eliminating future hair growth in that area for a period of time, e.g., at least 1 week, 2 weeks, 1 month, 2 months, or longer.

A further aspect concerns a method for marketing a composition for hair removal, which includes providing for sale to medical practitioners (e.g., doctors, nurse practitioners, doctor's assistants, and nurses) or to the public (e.g., spas and other body care businesses, and individuals) a packaged pharmaceutical composition that includes a double stranded nucleic acid molecule containing a sequence of at least a portion of human hairless protein mRNA and a sequence complementary thereto; and a package label or insert indicating that the pharmaceutical composition can be used for hair removal.

In particular embodiments, the pharmaceutical composition is approved by the U.S. Food and Drug Administration, and/or by an equivalent regulatory agency in Europe or Japan, for hair removal in humans; the pharmaceutical composition is packaged with a hair removal wax or other component adapted for hair removal.

The term “pharmaceutical composition” refers to a substance that contains at least one biologically active component. The composition typically also contains at least one pharmaceutically acceptable carrier or excipient.

As used herein, the term “packaged” means that the referenced material or composition is enclosed in a container or containers in a manner suitable for storage or transportation. For example, a pharmaceutical composition may be sealed in a vial, bottle, tube, or the like, which may itself be inside a box. Typically, a label on the container identifies the contents and may also provide instructions for use and/or cautions to prevent misuse.

The term “hair removal wax” refers to refer to a substance that is adapted for removal of hair by embedding hair in the substance and then pulling the material away, thereby pulling embedded hairs out of the hair follicles. The substance may be used with a backing material such as paper or cloth. Both hot and cold waxes are commonly available. Unless clearly indicated, the term is not limited to substances that are chemically waxes; for example, the term will generally include substances such as caramel-based substances that are used for “sugaring”.

The term “other component adapted for hair removal” refers to a material or device that can be used for physically removing hairs and is either generally recognized as suitable for such use, of instructions are provided indicating that the component can be used for physical hair removal or providing instructions on performing such removal.

Another aspect concerns an isolated double stranded nucleic acid molecule that includes a nucleotide sequence corresponding to 19-25 contiguous nucleotides from human hairless mRNA, where the nucleotide sequence contains a nucleotide sequence selected from the group consisting of oligonucleotides 1-5664; and a nucleotide sequence complementary thereto, where the double stranded nucleic acid molecule induces RNA interference in a human cell in vitro.

Indication that a molecule or material of interest “induces RNA interference in a human cell in vitro” means that when present in cultured cells that are capable of RNA interference and under conditions such that a molecule or molecules that will normally induce RNA interference do induce RNAi in the cell, the molecule or material of interest will induce such RNA interference.

Likewise, in another aspect the invention provides a pharmaceutical composition that includes a double stranded nucleic acid molecule that contains a nucleotide sequence corresponding to 14-50, 17-40, 17-30, 17-25, 19-30, 19-29, 19-28, 19-26, 19-25, 19-24, 19-23, 20-23, 20-22, or 21-22 contiguous nucleotides from human hairless mRNA including a nucleotide sequence selected from the group consisting of oligonucleotides 1-5664, and a sequence complementary thereto, wherein said double stranded nucleic acid molecule induces RNA interference in a human cell in vitro.

In yet another aspect, the invention provides a kit that includes a pharmaceutical composition that contains a double stranded nucleic acid molecule that includes a sequence of at least a portion of human hairless protein mRNA and a sequence complementary thereto; and a package label or insert indicating that said pharmaceutical composition can be used for hair removal.

In certain embodiments, the kit is approved by the U.S. Food and Drug Administration or equivalent regulatory agency in Europe or Japan, for human hair removal.

In certain embodiments of the above aspects or other aspects described herein, the double stranded nucleic acid includes at least one (i.e., one or two) 3′-overhang, e.g., a 1, 2, or 3 nucleotide overhang. In certain embodiments, such overhang includes one or more non-ribonucleotides; includes 1, 2, or 3 deoxynucleotide; includes a modified linkage; each strand has a 1, 2, or 3 nucleotide overhang.

In certain embodiments of the above aspects, at least one strand of the double stranded nucleic acid includes at least one nucleotide analog or internucleotidic linkage different from unmodified RNA; each strand includes at least one nucleotide analog or internucleotidic linkage different from unmodified RNA; at least one strand includes at least one modified nucleotide; each strand includes at least one modified nucleotide.

In certain embodiments of the above aspects, the double stranded nucleic acid molecule induces RNA interference in a cell in vitro and includes the RNA sense sequence of Oligonucleotide 131, namely 5′-CUCUCCAGACAUUUGGCAA-3′ (SEQ ID NO: 11329), and its complementary RNA sequence 5′-TTGCCAAATGTCTGGAGAG-3′ (SEQ ID NO:262); includes the RNA sense sequence of Oligonucleotide 1194, namely 5′-GUGCGGCCGAUCCGCGCCG-3′ (SEQ ID NO: 11330), and its complementary RNA sequence 5′-CGGCGCGGAUCGGCCGCAC-3′ (SEQ ID NO:11331); includes the RNA sense sequence of Oligonucleotide 1521, namely 5′-TGGGAGAAGACGGCCCCAG-3′ (SEQ ID NO:3041) its complementary RNA sequence 5′-CTGGGGCCGTCTTCTCCCA-3′ (SEQ ID NO: 3042); includes an RNA sense sequence and a complementary RNA antisense sequence selected from the group consisting of oligonucleotides 1-5664; is targeted to hairless mRNA corresponding to a site in the coding sequence (CDS) covering nucleotides 1482 to 5051; includes a nucleotide sequence corresponding to an oligonucleotide selected from Oligonucleotides 1482 to 5032; includes a nucleotide sequence corresponding to an oligonucleotide selected from Oligonucleotides 1482 to 4032; includes a nucleotide sequence corresponding to an oligonucleotide selected from Oligonucleotides 1482 to 3032; includes a nucleotide sequence corresponding to an oligonucleotide selected from Oligonucleotides 1482 to 2032; includes a nucleotide sequence corresponding to an oligonucleotide selected from Oligonucleotides 1582 to 1732.

In certain embodiments of the above aspects, in the double stranded nucleic acid molecule, the sense sequence and the antisense sequence each include 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.

In certain embodiments of the above aspects, chemically modified nucleic acids are used, e.g., chemically modified siRNAs (siNAs) as described in McSwiggen et al., PCT/US03/05346, WO 03/070918, which is incorporated herein by reference.

As used herein, the terms “siRNA” and “siNA” both refer to double stranded nucleic acid that induces RNAi, and includes unmodified RNA oligonucleotides and chemically modified oligonucleotides. When unmodified RNA is intended, the term “unmodified RNA” is expressly used.

The term “RNAi inducing oligonucleotide” or “RNA interference inducing oligonucleotide” refers to an oligonucleotide, generally a double stranded molecule (usually an siRNA molecule), that is able to induce RNA interference in a suitable cell.

In certain embodiments of the above aspects involving application of the present oligonucleotides to a mammal, the oligonucleotides are applied at 0.01 to 0.1 microgram/cm², 0.1 to 0.2 microgram/cm², 0.2 to 0.5 microgram/cm², 0.5 to 1.0 microgram/cm², 1.0 to 2.0 microgram/cm², 2.0 to 5.0 microgram/cm², or 5.0 to 10.0 microgram/cm²; a combination of different RNAi inducing oligonucleotides is applied, which application can be as a mixture or mixtures or separately, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different oligonucleotides; one or more different RNAi inducing oligonucleotides (e.g., all targeted to hairless, e.g., siRNA) is applied in combination (as a mixture or separately) with one or more different agents that inhibit hairless translation or hairless activity; one or more different RNAi inducing oligonucleotides is applied in combination with one or more other hair removal agents, such as chemical depilatories and/or enzymatic hair removal agents. In accordance with the preceding description of embodiments, certain of the present pharmaceutical compositions also include at least one hairless inhibiting agent different from an RNAi inducing agent, at least one chemical depilatory; at least one enzymatic hair removal agent.

In certain embodiments, the present RNAi inducing oligonucleotides are applied once; applied daily for at least 7 days; applied daily for at least 14 days; applied on at least 4 days within a one month period; applied on at least 7 days within a one month period; applied at least 4 days per week for at least a four week period.

In particular embodiments, the RNAi inducing oligonucleotide does not include the sequence of a siRNA as shown in the Examples; the RNAi oligonucleotide includes the sequence of an siRNA shown in the Examples and the method of use includes synchronizing hair cycles, e.g., as described herein.

In particular embodiments involving mammalian mRNAs, the RNAi inducing oligonucleotide (e.g., siRNA) includes a sequence 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length (or at least one of those lengths) of one of the sequences shown in Table 3, or a sequence complementary thereto; the RNAi inducing oligonucleotide targets a mammalian hairless mRNA sequence corresponding to a sequence shown in Table 3.

In particular embodiments, the RNAi inducing oligonucleotide (e.g., siRNA) targets a human hairless mRNA sequence as identified in Table 4; the RNAi inducing oligonucleotide contains a sequence of 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length (or at least one of those lengths).

In particular embodiments, the RNAi inducing oligonucleotide (e.g., siRNA) targets a mouse hairless mRNA sequence as identified in Table 5; the RNAi inducing oligonucleotide contains a sequence of 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length (or at least one of those lengths).

Additional embodiments will be apparent from the Detailed Description and from the claims.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. NM005144 (SEQ ID NO:11412)

FIG. 2. NM005144.3 (SEQ ID NO: 11413)

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention concerns methods for inhibiting hair growth, by inhibiting particular mRNAs using RNAi, e.g., using siRNA. In particular non-limiting embodiments, the present invention provides for siRNA molecules, e.g., double stranded RNA oligonucleotides (which optionally may be chemically modified and/or comprise at least one 3′ overhang, as set forth below), comprising a nucleotide sequence that is complementary to a target nucleotide sequence which may be 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length, where the siRNA contains a sequence 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 base pairs in length. Preferably, the hairless in RNA target nucleotide sequence comprises a 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotide portion of the human hairless mRNA sequence set forth in FIG. 1 (SEQ ID NO: 11412) and/or FIG. 2 (SEQ ID NO: 11413). Non-limiting examples of target sequences may be identified as loops identified in secondary mRNA structure using software designed for such purpose (e.g. RnaDraw, RnaMotif, Rnaview-RnaMLView, RnaViz, Vienna RNA Package, etc.).

A. RNAi and siRNA

RNA interference (RNAi) refers to the process of sequence-specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs) (Fire et al., 1998, Nature, 391, 806). The corresponding process in plants is commonly referred to as post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes and is commonly shared by diverse flora and phyla (Fire et al., 1999, Trends Genet., 15, 358). The presence of dsRNA in cells triggers the RNAi response though a mechanism that appears to be different from the interferon response that results from dsRNA-mediated activation of protein kinase PKR and 2′,5′-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.

The presence of long dsRNAs in cells stimulates the activity of the enzyme, dicer, a ribonuclease III. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs) (Berstein et al., 2001, Nature, 409, 363). The resulting RNAs are typically about 21 to about 23 nucleotides in length, with complementary sequences of about 19 base pairs. Dicer has also been implicated in the excision of 21- and 22-nucleotide small temporal RNAs (stRNAs) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner et al., 2001, Science, 293, 834). The RNAi response also involves an endonuclease complex, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex (Elbashir et al., 2001, Genes Dev., 15, 188).

RNAi has been studied in a variety of systems. Fire et al., 1998, Nature, 391, 806, described RNAi in C. elegans. Wianny and Goetz, 1999, Nature Cell Biol., 2, 70, describe RNAi mediated by dsRNA in mouse embryos. Hammond et al., 2000, Nature, 404, 293, describe RNAi in Drosophila cells transfected with dsRNA. Elbashir et al., 2001, Nature, 411, 494, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells.

Work in Drosophila embryonic lysates (Elbashir et al., 2001, EMBO J, 20, 6877) has revealed certain factors of siRNA length, structure, chemical composition, and sequence that are significantly affect efficient RNAi activity. These studies have shown that 21-nucleotide siRNA duplexes are most active when containing 3′-terminal nucleotide overhangs. Furthermore, complete substitution of one or both siRNA strands with 2′-deoxy (2′-H) or 2′-O-methyl nucleotides abolishes RNAi activity, whereas substitution of the 3′-terminal siRNA overhang nucleotides with 2′-deoxy nucleotides (2′-H) was shown to be tolerated. Single mismatch sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5′-end of the siRNA guide sequence rather than the 3′-end of the guide sequence (Elbashir et al., 2001, EMBO J., 20, 6877). Other studies have suggested that a 5′-phosphate on the target-complementary strand of a siRNA duplex is important for siRNA activity and that ATP is utilized to maintain the 5′-phosphate moiety on the siRNA (Nykanen et al., 2001, Cell, 107, 309).

Studies have shown that replacing the 3′-terminal nucleotide overhanging segments of a 21-mer siRNA duplex having two 2-nucleotide 3′-overhangs with deoxyribonucleotides does not have an adverse effect on RNAi activity. Replacing up to 4 nucleotides on each end of the siRNA with deoxyribonucleotides has been reported to be well-tolerated whereas complete substitution with deoxyribonucleotides results in no RNAi activity, but that substitution of siRNA with 2′-O-methyl nucleotides completely abolishes RNAi activity. (Elbashir et al., 2001, EMBO J., 20, 6877.)

Li et al., International PCT Publication No. WO 00/44914, and Beach et al., International PCT Publication No. WO 01/68836 both suggest that siRNA “may include modifications to either the phosphate-sugar backbone or the nucleoside . . . to include at least one of a nitrogen or sulfur heteroatom.”

Kreutzer and Limmer, Canadian Patent Application No. 2,359,180, also describe certain chemical modifications for use in dsRNA constructs in order to counteract activation of double-stranded RNA-dependent protein kinase PKR, specifically 2′-amino or 2′-O-methyl nucleotides, and nucleotides containing a 2′-O or 4′-C methylene bridge

Parrish et al., 2000, Molecular Cell, 6, 1977-1087, tested certain chemical modifications targeting the unc-22 gene in C. elegans using long (>25 nt) siRNA transcripts. The authors describe the introduction of thiophosphate residues into these siRNA transcripts by incorporating thiophosphate nucleotide analogs with T7 and T3 RNA polymerase and observed that “RNAs with two [phosphorothioate] modified bases also had substantial decreases in effectiveness as RNAi triggers (data not shown); [phosphorothioate] modification of more than two residues greatly destabilized the RNAs in vitro and we were not able to assay interference activities.” Id. at 1081. The authors also tested certain modifications at the 2′-position of the nucleotide sugar in the long siRNA transcripts and observed that substituting deoxynucleotides for ribonucleotides “produced a substantial decrease in interference activity,” especially in the case of Uridine to Thymidine and/or Cytidine to deoxy-Cytidine substitutions. Id. In addition, the authors tested certain base modifications, including substituting, in sense and antisense strands of the siRNA, 4-thiouracil, 5-bromouracil, 5-iodouracil, and 3-(aminoallyl)uracil for uracil, and inosine for guanosine. They found that whereas 4-thiouracil and 5-bromouracil were all well-tolerated, inosine “produced a substantial decrease in interference activity” when incorporated in either strand. Incorporation of 5-iodouracil and 3-(aminoallyl)uracil in the antisense strand resulted in substantial decrease in RNAi activity as well.

Beach et al., International PCT Publication No. WO 01/68836, describes specific methods for attenuating gene expression using endogenously-derived dsRNA.

Tuschl et al., International PCT Publication No. WO 01/75164, describe a Drosophila in vitro RNAi system and the use of specific siRNA molecules for certain functional genomic and certain therapeutic applications; although Tuschl, 2001, Chem. Biochem., 2, 239-245, doubts that RNAi can be used to cure genetic diseases or viral infection due “to the danger of activating interferon response.”

Li et al., International PCT Publication No. WO 00/44914, describe the use of specific dsRNAs for use in attenuating the expression of certain target genes.

Zernicka-Goetz et al., International PCT Publication No. WO 01/36646, describe certain methods for inhibiting the expression of particular genes in mammalian cells using certain dsRNA molecules.

Fire et al., International PCT Publication No. WO 99/32619, describe particular methods for introducing certain dsRNA molecules into cells for use in inhibiting gene expression.

Plaetinck et al., International PCT Publication No. WO 00/01846, describe certain methods for identifying specific genes responsible for conferring a particular phenotype in a cell using specific dsRNA molecules.

Mello et al., International PCT Publication No. WO 01/29058, describe the identification of specific genes involved in dsRNA-mediated RNAi.

Deschamps Depaillette et al., International PCT Publication No. WO 99/07409, describe specific compositions consisting of particular dsRNA molecules combined with certain anti-viral agents.

Waterhouse et al., International PCT Publication No. 99/53050, describe certain methods for decreasing the phenotypic expression of a nucleic acid in plant cells.

Driscoll et al., International PCT Publication No. WO 01/49844, describe specific DNA constructs for use in facilitating gene silencing in targeted organisms.

Parrish et al., 2000, Molecular Cell, 6, 1977-1087, describe specific chemically-modified siRNA constructs targeting the unc-22 gene of C. elegans.

Grossniklaus, International PCT Publication No. WO 01/38551, describes certain methods for regulating polycomb gene expression in plants.

Churikov et al., International PCT Publication No. WO 01/42443, describe certain methods for modifying genetic characteristics of an organism.

Cogoni et al., International PCT Publication No. WO 01/53475, describe certain methods for isolating a Neurospora silencing gene and uses thereof.

Reed et al., International PCT Publication No. WO 01/68836, describe certain methods for gene silencing in plants.

Honer et al., International PCT Publication No. WO 01/70944, describe certain methods of drug screening using transgenic nematodes as Parkinson's Disease models.

Deak et al., International PCT Publication No. WO 01/72774, describe certain Drosophila-derived gene products.

Arndt et al., International PCT Publication No. WO 01/92513, describe certain methods for mediating gene suppression by using factors that enhance RNAi.

Tuschl et al., International PCT Publication No. WO 02/44321, describe certain synthetic siRNA constructs.

Pachuk et al., International PCT Publication No. WO 00/63364, and Satishchandran et al., International PCT Publication No. WO 01/04313, describe certain methods and compositions for inhibiting the function of certain oligonucleotide sequences.

Echeverri et al., International PCT Publication No. WO 02/38805, describe certain C. elegans genes identified via RNAi.

Kreutzer et al., International PCT Publications Nos. WO 02/055692, WO 02/055693, and EP 1144623 B1 describes certain methods for inhibiting gene expression using RNAi.

Graham et al., International PCT Publications Nos. WO 99/49029 and WO 01/70949, and AU 4037501 describe certain vector expressed long double stranded RNA molecules.

McSwiggen et al., PCT/US03/05028, WO 03/074654 describes RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA), and provides a table listing thousands of mRNAs, which is believed to include hairless protein mRNA, as potential targets for such siNA.

McSwiggen et al., PCT/US03/05346, WO 03/070918 describes synthetic chemically modified small nucleic acid molecules capable of mediating RNA interference against target nucleic acid sequences. The reference reports that up to all of the nucleotides in the RNA strands can be replaced with moieties that are not ribonucleotides.

B. Hairless Protein mRNA

Applicant's have found that RNAi can be used to inhibit translation from hairless protein mRNA, resulting in hair removal. This hair removal is long term, or even permanent, thus providing cosmetic and therapeutic methods, as well as methods useful for laboratory experimental mammals, and for de-hairing in the leather industry.

The Hairless Protein gene is expressed during a narrow window during the hair cycle, just at the transition to catagen (the regression phase). (Panteleyev et al. 1998, Exp Dermatol. 7:249-67; Panteleyev et al. 2000, Am J Pathol. 157:1071-9). In both humans and mice with mutations in the hairless gene, the cardinal finding is a wave of hair shedding shortly after birth, and no subsequent hair growth throughout life. The phenotype results from permanent structural damage to the hair follicle, after which no further hair cycling can occur. In addition, humans and mice which are genetically deficient in hairless gene expression exhibit no other phenotypic manifestations or abnormalities that might be associated with a deleterious effect (Zlotogorski et al., 2002, J Invest Dermatol. 118:887-90), suggesting that hairless is specifically involved and indispensable in regulating the hair cycle, and that its functions elsewhere in the body (if any) are compensated by other factors.

As a result, hair removal using RNAi targeted to hairless mRNA provides an advantageous approach, as any inadvertent, non-localized inhibition of hairless mRNA will not adversely affect the subject.

C. Applications and Conditions to be Treated

As indicated above, the present invention concerns inhibition of hair growth, and consequent hair removal, and is applicable to a number of different therapeutic, cosmetic, and industrial applications. The methods can be readily adapted to any of the various mammals having hairless protein analogs, for example, human, mouse, rat, cattle (and other bovines), equines.

1. Long Term (Permanent) Hair Removal

Permanent, or at least long term, hair removal can involve inhibition of hairless protein. Such hair removal is useful for both cosmetic and therapeutic applications. Exemplary cosmetic applications can include, for example, back and chest hair for men and upper lip, eyebrow, leg, arm, underarm, and pubic hair for women.

In addition to cosmetic applications, permanent or long term hair removal is also useful in certain conditions, e.g., trachoma, the various forms of hypertrichosis, and hirsutism.

Hypertrichosis

Hypertrichosis describes all forms of hair growth that are excessive for the bodily location and age of an individual, and which do not result from androgen stimulation. The present invention can be used for the various forms and causes of hypertrichosis, e.g., those described herein.

Hypertrichosis is usually categorized on the basis of the age of onset (at birth or during later years), the extent of distribution (universal or localized), the site of involvement (elbows, anterior or posterior neck), and the cause (genetic or acquired).

Acquired hypertrichosis may result from the use of particular drugs, for example, oral minoxidil, phenyloin, and cyclosporin. Acquired hypertrichosis lanuginosa may also be a manifestation of an underlying malignancy. In the dermatological literature, this is known as “malignant down”. Additional causes of acquired hypertrichosis include hormonal imbalances, malnutrition, HIV and local inflammation.

In addition, some forms of hypertrichosis are clearly hereditary but the genes involved generally remain unknown. Genetic forms of hypertrichosis are very rare human disorders.

There are only a small number of human disorders that have generalized congenital hypertrichosis as the leading phenotypic feature. These include:

Hypertrichosis universalis (MIM145700)

Hypertrichosis universalis congenita, Ambras type (MIM145701)

Gingival fibromatosis with hypertrichosis (MIMI 35400)

Barber-Say syndrome (MIM209885)

Amaurosis congenita, cone-rod type, with hypertrichosis (MIM204110),

CAHMR syndrome (MIM21770)

Cantu syndrome (MIM239850)

Gingival fibromatosis with hypertrichosis and mental retardation MIM605400)

X-linked hypertrichosis (MIM307150)

Acromegaly and hypertrichosis (Irvine et al, 1996).

Of these, only Hypertrichosis universalis, Ambras type hypertrichosis, and X-linked hypertrichosis have excessive hair as the predominant feature. In all the other listed syndromes hypertrichosis is associated with additional more prominent abnormalities. The present invention can be used to treat hypertrichosis, e.g., in any of the conditions listed above, as well as in other conditions in which trichosis occurs.

Trachoma

Trachoma is the leading cause of blindness worldwide. The World Health Organization estimates that there are 146 million people with trachoma and that the disease has caused blindness in 5.9 million people, 15% of the world's blindness. Trachoma is caused by the gram-negative bacterium Chlamydia trachomatis, an intracellular parasite transmitted by fly infestation. In trachoma, the conjunctival lining of the eyelids becomes infected with the bacterium, which over the long term, causes an inflammatory response. The inflammation can lead to scarring, shortening of the lid and in-turning of the eyelashes. Trichiasis, the condition when eyelashes rub on the cornea, can lead to blindness. An estimated 10.6 million adults have inturned eyelashes that require surgery.

While it is advantageous of the Chlamydia infection is prevented, or treated before in-turning of the eyelashes, there is a need for non-surgical approaches to treatment that can at least reduce the corneal scarring. Thus, removal of the eyelash hairs (without leaving stubble) using the present invention can substantially slow, or even prevent such corneal damage, thereby preserving the individual's vision.

Trichiasis

In addition to trachoma, in-turned eyelashes (trichiasis) can have other causes, and are a common source of recurrent ocular irritation for some patients. The in-turned lash (or lashes) in contact with the conjunctiva and/or cornea may lead to a foreign body sensation, localized conjunctival injection, pain and photophobia.

Trichiasis is the term used for misdirection or aberrant placement of eyelashes along the eyelid margin resulting in lash growth toward the cornea. Trichiasis is an acquired condition that may be caused by the following inflammatory or traumatic processes involving the eyelids. The present invention can be used in all cases of trichiasis, including those in the following causal situations:

Chronic blepharitis with meibomianitis—chronic inflammatory changes within the tarsal plate and posterior eyelid margin may cause destruction and misdirection of lash follicles, resulting in chronic trichiasis.

Lid lacerations and thermal burns to the lid margin—may cause redirection of the lash roots with resultant trichiasis.

Previous surgery on eyelids—For example, lid adhesions (tarsorrhaphys) done to prevent exposure in some patients with seventh nerve palsies may cause misdirection of lashes. Similarly, in many reconstructive eyelid procedures, the new eyelid margin may contain fine skin hairs (lanugo-type) that rub on the cornea.

Mucocutaneous diseases—Stevens-Johnson syndrome and Ocular Cicatricial Pemphigoid result not only in the destruction of the eyelid margins and trichiasis but also in the formation of new lashes from the meibomian gland orifices (a condition referred to as distichiasis).

Other cicatricial conjunctival diseases—Herpes Simplex conjunctivitis and Herpes Zoster may cause a cicatrizing conjunctivitis with destruction of the lid margin and lash follicles. Trachoma may also cause a chronic tarsitis with cicatrizing conjunctivitis in the upper or lower eyelid and resultant trichiasis (as well as a cicatricial entropion).

Irradiation and chemical burns—Therapeutic irradiation for eyelid cancers or alkali burns may lead to a disruption of the normal eyelid margin anatomy and resultant misdirection of eyelashes. Both of these processes may also lead to metaplasia of squamous epithelium of the mucocutaneous margin of the eyelid with resultant keratinization, a source of ocular irritation. In addition, destruction of the goblet cells, accessory lacrimal glands, and lacrimal gland will disrupt the normal tear flow, compounding the above problems.

Other conditions in which eyelashes contact the cornea also exist, and the present invention can be used in those cases also. For example:

A condition similar to trichiasis is Eyelid entropion—True entropion (e.g. involutional type seen in the aging population) is characterized by a normal eyelid margin architecture: the eyelid inverts as a result of eyelid laxity, allowing the eyelashes to rub on the cornea. Several of the entities mentioned above (Ocular Pemphigoid, Stevens-Johnson Syndrome) may cause a cicatrization of the conjunctiva as well as the lid margin and create a cicatricial entropion with trichiasis (i.e. the eyelid is inverted due to a cicatricial process). In addition, eyelashes may be misdirected not only due to the lid position, but also due to the inflammatory process involving the actual lash follicles. Therefore, sometimes there may be two problems present (entropion and trichiasis) both of which may require treatment.

Epiblepharon—Epiblepharon is a congenital condition commonly seen in the lower Asian eyelid. A fold of skin and muscle roll upwards and presses the lashes toward the cornea. This does not represent true trichiasis.

Distichiasis—is an abnormality in which an aberrant second row of lashes, (usually from the meibomian gland orifices) grows behind the normal lash line. It may be congenital or acquired. Any process causing chronic inflammation of the lid margin and meibomian glands may transform the meibomian glands into pilosebaceous units capable of producing hair (e.g. chronic blepharitis).

Combined eyelid margin process—Several of the eyelid processes mentioned (Stevens-Johnson syndrome, Ocular Pemphigoid, irradiation, chemical burns) not only may cause entropion and trichiasis, but in addition may lead to squamous metaplasia and keratinization of the non-keratinizing squamous epithelium of the eyelid margin. Keratinized tissue is very irritating to the eye. Therefore, several factors may contribute to the ocular irritation, and as a result, several types of treatment could be required.

Marginal entropion—Is a subtle form of entropion that is seen only at the lid margin. Usually there is chronic inflammation at the eyelid margin with a mild cicatricial process that is starting to roll the lid margin inward. The eyelashes appear more vertical with some truly trichiatic lashes. The clinical clue is the meibomian gland orifices. Normally they should be vertical and not covered by conjunctival epithelium. If the openings are rolled inward and conjunctiva is growing over the opening, then marginal entropion is present in addition to trichiasis. It is important to distinguish this condition when considering treatment.

Hirsutism

Hirsutism is excessive hair growth on a female in a male growth pattern, typically excessive facial hair. Hirsutism is usually caused by an increased sensitivity of the skin to a group of hormones called androgens (testosterone and androstenedione) or increased production of these hormones. Androgen disorders (hyperandrogenism) affects between 5% to 10% of all women. Hair from this condition can be removed in full or part using the present invention.

Pseudofolliculitis barbae

Pseudofolliculitis barbae (razor bumps) is a common condition of the beard area occurring in African American men and other people with curly hair. The problem results when highly curved hairs grow back into the skin causing inflammation and a foreign body reaction. Over time, this can cause keloidal scarring which looks like hard bumps of the beard area and neck. Currently this is usually addressed by attempting to prevent the hair from curving back and growing into the skin with altered shaving practices and the like. The present invention can be used to eliminate hairs causing such difficulties.

Experimental Animals

Permanent hair removal as described herein can also be used with experimental animals to remove hair from all or a portion of the body of an experimental animal. Thus, for example, a hairless spot can be created on a mouse, rat, sheep, monkey, chimpanzee, rabbit or other animal for application over an extended period of time of topically applied pharmaceutical compounds or other materials. Thus, the present invention can be used for this purpose, either with or without shaving shaveing, waxing, or depilation, or other such treatment. In some cases, the hairless spot or area on the animal is initially created with shaving, waxing, or other hair removal method, and the present invention allows the bare area to be maintained (which may be after a sustained period of application of the present compositions, e.g., at least 2, 4, 7, or 10 days, or 2, 3, 4, 5, 6, 8, 10, 12, weeks or even longer).

Industrial Applications

In addition, permanent hair removal as described herein can also be useful to remove hair from mammals whose hides will be used for leather. Dehairing is one of the main initial steps in leather production. Five methods of dehairing are commonly used: i.e., (i) clipping process, (ii) scalding process, (iii) chemical process, (iv) sweating process, and (v) enzymatic process. Of these, the most commonly practiced method of dehairing of hides and skins is the chemical process using lime and sodium sulphide. However, the use of high concentrations of lime and sodium sulphide creates an extremely alkaline environment resulting in the pulping of hair and its subsequent removal, and presents substantial pollution problems. Thus, removal of hairs using the present invention allows hides to be prepared for leather production while eliminating or at least reducing the use of the pollution-causing methods.

D. Use of RNAi and Oligo Sequences

The use of RNAi to reduce or eliminate translation from a targeted mRNA has been described in a number of patents and published patent applications, e.g., as mentioned in the Background of the Invention. In the present invention, particular target sites in hairless protein mRNA can be identified experimentally and/or using software programs to identify accessible sites. For example, procedures such as those described below can be used to identify sites, and to select an optimal site and active oligonucleotide.

Identification of Potential RNAi (e.g., siRNA) Target Sites in any RNA Sequence

The sequence of an RNA target of interest, such as a viral or human mRNA transcript, is screened for target sites, for example by using a computer folding algorithm. In a non-limiting example, the sequence of a gene or RNA gene transcript derived from a database, such as Genbank, is used to generate siNA targets having complementarity to the target. Such sequences can be obtained from a database, or can be determined experimentally as known in the art. Target sites that are known, for example, those target sites determined to be effective target sites based on studies with other nucleic acid molecules, for example ribozymes or antisense, or those targets known to be associated with a disease or condition such as those sites containing mutations or deletions, can be used to design siNA molecules targeting those sites as well. Various parameters can be used to determine which sites are the most suitable target sites within the target RNA sequence. These parameters include but are not limited to secondary or tertiary RNA structure, the nucleotide base composition of the target sequence, the degree of homology between various regions of the target sequence, or the relative position of the target sequence within the RNA transcript. Based on these determinations, any number of target sites within the RNA transcript can be chosen to screen siNA molecules for efficacy, for example by using in vitro RNA cleavage assays, cell culture, or animal models. In a non-limiting example, anywhere from 1 to 1000 target sites are chosen within the transcript based on the size of the siNA construct to be used. High throughput screening assays can be developed for screening siNA molecules using methods known in the art, such as with multi-well or multi-plate assays or combinatorial/siNA library screening assays to determine efficient reduction in target gene expression.

Selection of siNA Molecule Target Sites in a RNA

The following non-limiting steps can be used to carry out the selection of siNAs targeting a given gene sequence or transcript.

-   -   1 The target sequence is parsed in silico into a list of all         fragments or subsequences of a particular length, for example 23         nucleotide fragments, contained within the target sequence. This         step is typically carried out using a custom Perl script, but         commercial sequence analysis programs such as Oligo, MacVector,         or the GCG Wisconsin Package can be employed as well.     -   2 In some instances the siNAs correspond to more than one target         sequence; such would be the case for example in targeting         different transcripts of the same gene, targeting different         transcripts of more than one gene, or for targeting both the         human gene and an animal homolog. In this case, a subsequence         list of a particular length is generated for each of the         targets, and then the lists are compared to find matching         sequences in each list. The subsequences are then ranked         according to the number of target sequences that contain the         given subsequence; the goal is to find subsequences that are         present in most or all of the target sequences. Alternately, the         ranking can identify subsequences that are unique to a target         sequence, such as a mutant target sequence. Such an approach         would enable the use of siNA to target specifically the mutant         sequence and not effect the expression of the normal sequence.     -   3 In some instances the siNA subsequences are absent in one or         more sequences while present in the desired target sequence;         such would be the case if the siNA targets a gene with a         paralogous family member that is to remain untargeted. As in         case 2 above, a subsequence list of a particular length is         generated for each of the targets, and then the lists are         compared to find sequences that are present in the target gene         but are absent in the untargeted paralog.     -   4 The ranked siNA subsequences can be further analyzed and         ranked according to GC content. A preference can be given to         sites containing 30-70% GC, with a further preference to sites         containing 40-60% GC.     -   5 The ranked siNA subsequences can be further analyzed and         ranked according to self-folding and internal hairpins. Weaker         internal folds are preferred; strong hairpin structures are to         be avoided.     -   6 The ranked siNA subsequences can be further analyzed and         ranked according to whether they have runs of GGG or CCC in the         sequence. GGG (or even more Gs) in either strand can make         oligonucleotide synthesis problematic and can potentially         interfere with RNAi activity, so it is avoided whenever better         sequences are available. CCC is searched in the target strand         because that will place GGG in the antisense strand.     -   7 The ranked siNA subsequences can be further analyzed and         ranked according to whether they have the dinucleotide UU         (uridine dinucleotide) on the 3′-end of the sequence, and/or AA         on the 5′-end of the sequence (to yield 3′ UU on the antisense         sequence). These sequences allow one to design siNA molecules         with terminal TT thymidine dinucleotides.     -   8 Four or five target sites are chosen from the ranked list of         subsequences as described above. For example, in subsequences         having 23 nucleotides, the right 21 nucleotides of each chosen         23-mer subsequence are then designed and synthesized for the         upper (sense) strand of the siNA duplex, while the reverse         complement of the left 21 nucleotides of each chosen 23-mer         subsequence are then designed and synthesized for the lower         (antisense) strand of the siNA duplex. If terminal TT residues         are desired for the sequence (as described in paragraph 7), then         the two 3′ terminal nucleotides of both the sense and antisense         strands are replaced by TT prior to synthesizing the oligos.     -   9 The siNA molecules are screened in an in vitro, cell culture         or animal model system to identify the most active siNA molecule         or the most preferred target site within the target RNA         sequence.

In an alternate approach, a pool of siNA constructs specific to a target sequence is used to screen for target sites in cells expressing target RNA, such as human lung HeLa cells. A non-limiting example of such as pool is a pool comprising sequences having antisense sequences complementary to the target RNA sequence and sense sequences complementary to the antisense sequences. Cells (e.g., HeLa cells) expressing the target gene are transfected with the pool of siNA constructs and cells that demonstrate a phenotype associated with gene silencing are sorted. The pool of siNA constructs can be chemically modified as described herein and synthesized, for example, in a high throughput manner. The siNA from cells demonstrating a positive phenotypic change (e.g., decreased target mRNA levels or target protein expression), are identified, for example by positional analysis within the assay, and are used to determine the most suitable target site(s) within the target RNA sequence based upon the complementary sequence to the corresponding siNA antisense strand identified in the assay.

Exemplary siNA Design

siNA target sites are chosen by analyzing sequences of the target RNA target and optionally prioritizing the target sites on the basis of folding (structure of any given sequence analyzed to determine siNA accessibility to the target), by using a library of siNA molecules as described, or alternately by using an in vitro siNA system as described herein. siNA molecules were designed that could bind each target and are optionally individually analyzed by computer folding to assess whether the siNA molecule can interact with the target sequence. Varying the length of the siNA molecules can be chosen to optimize activity. Generally, a sufficient number of complementary nucleotide bases are chosen to bind to, or otherwise interact with, the target RNA, but the degree of complementarity can be modulated to accommodate siNA duplexes or varying length or base composition. By using such methodologies, siNA molecules can be designed to target sites within any known RNA sequence, for example those RNA sequences corresponding to the any gene transcript.

Chemically modified siNA constructs are designed to provide nuclease stability for systemic administration in vivo and/or improved pharmacokinetic, localization, and delivery properties while preserving the ability to mediate RNAi activity. Chemical modifications as described herein are introduced synthetically using synthetic methods described herein and those generally known in the art. The synthetic siNA constructs are then assayed for nuclease stability in serum and/or cellular/tissue extracts (e.g. liver extracts). The synthetic siNA constructs are also tested in parallel for RNAi activity using an appropriate assay, such as a luciferase reporter assay as described herein or another suitable assay that can quantity RNAi activity. Synthetic siNA constructs that possess both nuclease stability and RNAi activity can be further modified and re-evaluated in stability and activity assays. The chemical modifications of the stabilized active siNA constructs can then be applied to any siNA sequence targeting any chosen RNA and used, for example, in target screening assays to pick lead siNA compounds for therapeutic development.

RNAi In Vitro Assay to Assess siNA Activity

An in vitro assay that recapitulates RNAi in a cell free system is used to evaluate siNA constructs specific to target RNA. The assay comprises the system described by Tuschl et al., 1999, Genes and Development, 13, 3191-3197 and Zamore et al., 2000, Cell, 101, 25-33 adapted for use with a specific target RNA. A Drosophila extract derived from syncytial blastoderm is used to reconstitute RNAi activity in vitro. Target RNA is generated via in vitro transcription from an appropriate plasmid using T7 RNA polymerase or via chemical synthesis as described herein. Sense and antisense siNA strands (for example 20 uM each) are annealed by incubation in buffer (such as 100 mM potassium acetate, 30 mM HEPES-KOH, pH 7.4, 2 mM magnesium acetate) for 1 min. at 90° C. followed by 1 hour at 37° C., then diluted in lysis buffer (for example 100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate). Annealing can be monitored by gel electrophoresis on an agarose gel in TBE buffer and stained with ethidium bromide. The Drosophila lysate is prepared using zero to two hour old embryos from Oregon R flies collected on yeasted molasses agar that are dechorionated and lysed. The lysate is centrifuged and the supernatant isolated. The assay comprises a reaction mixture containing 50% lysate [vol/vol], RNA (10-50 pM final concentration), and 10% [vol/vol] lysis buffer containing siNA (10 nM final concentration). The reaction mixture also contains 10 mM creatine phosphate, 10 ug.ml creatine phosphokinase, 100 um GTP, 100 uM UTP, 100 uM CTP, 500 uM ATP, 5 mM DTT, 0.1 U/uL RNasin (Promega), and 100 uM of each amino acid. The final concentration of potassium acetate is adjusted to 100 mM. The reactions are pre-assembled on ice and preincubated at 25° C. for 10 minutes before adding RNA, then incubated at 25° C. for an additional 60 minutes. Reactions are quenched with 4 volumes of 1.25× Passive Lysis Buffer (Promega). Target RNA cleavage is assayed by RT-PCR analysis or other methods known in the art and are compared to control reactions in which siNA is omitted from the reaction.

Alternately, internally-labeled target RNA for the assay is prepared by in vitro transcription in the presence of [a-³²P] CTP, passed over a G 50 Sephadex column by spin chromatography and used as target RNA without further purification. Optionally, target RNA is 5′-³²P-end labeled using T4 oligonucleotide kinase enzyme. Assays are performed as described above and target RNA and the specific RNA cleavage products generated by RNAi are visualized on an autoradiograph of a gel. The percentage of cleavage is determined by Phosphor Imager® quantitation of bands representing intact control RNA or RNA from control reactions without siNA and the cleavage products generated by the assay.

In one embodiment, this assay is used to determine target sites in the RNA target for siNA mediated RNAi cleavage, wherein a plurality of siNA constructs are screened for RNAi mediated cleavage of the RNA target, for example by analyzing the assay reaction by electrophoresis of labeled target RNA, or by northern blotting, as well as by other methodology well known in the art.

Specific hairless protein target sequences and the complementary sequences are provided as 19-mers in Table 1 following the Examples. In the table, the oligo number (first column on the left), e.g., 1, 2, 3, etc. matches the 1^(st) (5′) nucleotide in the reference sense cDNA sequence. Thus, Oligonucleotide 1 begins at nucleotide 1 in the reference hairless cDNA sequence, Oligonucleotide 2, begins at nucleotide 2 in the reference sequence, and so on. Thus, one skilled in the art recognizes that the nucleotide position of each nucleotide in each oligonucleotide in Table 1 is specified as if each nucleotide were marked with the respective number.

The sequences shown in Table 1 are provided as DNA sequences, but one skilled in the art understands that Table 1 also describes the matching RNA sequence. One skilled in the art understands that the RNA sequence has a U replacing each T shown in the DNA sequence. For example, for Oligonucleotide 1 in Table 1, the DNA sequence is 5′-TCTCCCGGGAGCCACTCCC-3′ (SEQ ID NO: 1), and the matching RNA sequence is 5′-UCUCCCGGGAGCCACUCCC-3′ (SEQ ID NO: 11332).

While oligonucleotides are shown in Table 1 as 19-mers, this description expressly includes the additional 20-mer, 21-mer, 22-mer, 23-mer, 24-mer, 25-mer, 26-mer, 27-mer, 28-mer, and 29-mer oligonucleotides as if they were included in the table. The sequence descriptions of those 20-29-mers is provided by taking a starting 19-mer that has the same 5′-nucleotide as the respective 20-29-mer, and adding the next 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 3′-nucleotides from the subsequent 19-mer oligonucleotides from the table. Thus, for example, the 19-mer sense RNA Oligonucleotide 4 has the sequence:

5′-CCCGGGAGCCACUCCCAUG-3′ (SEQ ID NO: 11333) and the complementary 19-mer RNA described has the sequence

5′-CAUGGGAGUGGCUCCCGGG-3′. (SEQ ID NO: 11334)

Further, a 20-mer RNA that includes the Oligonucleotide 4 sequence is described by the Oligo 4 sequence with the next nucleotide 3′, i.e., the 3′-terminal G from Oligo 5. Thus, the 20-mer RNA described has the sequence

5′-CCCGGGAGCCACUCCCAUGG-3′ (SEQ ID NO: 11335) and the complementary 20-mer RNA described has the sequence

5′-CCAUGGGAGUGGCUCCCGGG-3′. (SEQ ID NO: 11336)

Similarly, a 21-mer RNA that includes the Oligonucleotide 4 sequence is described by the Oligo 4 sequence with the next two nucleotides 3′, i.e., the 3′-terminal GG from Oligo 6. Thus, the 21-mer RNA described has the sequence

5′-CCCGGGAGCCACUCCCAUGGG-3′ (SEQ ID NO: 11337) and the complementary 21-mer RNA described has the sequence

5′-CCCAUGGGAGUGGCUCCCGGG-3′. (SEQ ID NO: 11338)

As the next oligonucleotide described, a 22-mer RNA that includes the Oligonucleotide 4 sequence is described by the Oligo 4 sequence with the next three nucleotides 3′, i.e., the 3′-terminal GGC from Oligo 7. Thus, the 22-mer RNA described has the sequence

5′-CCCGGGAGCCACUCCCAUGGGC-3′ ((SEQ ID NO: 11339) and the complementary 22-mer RNA described has the sequence

5′-GCCCAUGGGAGUGGCUCCCGGG-3′. (SEQ ID NO: 11340)

A 23-mer RNA that includes the Oligonucleotide 4 sequence is described by the Oligo 4 sequence with the next four nucleotides 3′, i.e., the 3′-terminal GGCG from Oligo 8. Thus, the 23-mer RNA described has the sequence

5′-CCCGGGAGCCACUCCCAUGGGCG-3′ (SEQ ID NO: 11341) and the complementary 23-mer RNA described has the sequence

5′-CGCCCAUGGGAGUGGCUCCCGGG-3′. (SEQ ID NO: 11342)

A 24-mer RNA that includes the Oligonucleotide 4 sequence is described by the Oligo 4 sequence with the next five nucleotides 3′, i.e., the 3′-terminal GGCGC from Oligo 9. Thus, the 24-mer RNA described has the sequence

5′-CCCGGGAGCCACUCCCAUGGGCGC-3′ (SEQ ID NO: 11343) and the complementary 24-mer RNA described has the sequence

5′-GCGCCCAUGGGAGUGGCUCCCGGG-3′. (SEQ ID NO: 11344)

In similar fashion, a 25-mer that includes the Oligonucleotide 4 sequence is described as

5′-CCCGGGAGCCACUCCCAUGGGCGCC-3′ (SEQ ID NO: 11345) and the complementary 25-mer RNA described has the sequence

5′-GGCGCCCAUGGGAGUGGCUCCCGGG-3′. (SEQ ID NO: 11346)

A 26-mer that includes the Oligonucleotide 4 sequence is described as

5′-CCCGGGAGCCACUCCCAUGGGCGCCU-3′ (SEQ ID NO: 11347) and the complementary 26-mer RNA described has the sequence

(SEQ ID NO: 11348) 5′-AGGCGCCCAUGGGAGUGGCUCCCGGG-3′.

A 27-mer that includes the Oligonucleotide 4 sequence is described as

(SEQ ID NO: 11349) 5′-CCCGGGAGCCACUCCCAUGGGCGCCUC-3′ and the complementary 27-mer RNA described has the sequence

(SEQ ID NO: 11350) 5′-GAGGCGCCCAUGGGAGUGGCUCCCGGG-3′.

A 28-mer that includes the Oligonucleotide 4 sequence is described as

(SEQ ID NO: 11351) 5′-CCCGGGAGCCACUCCCAUGGGCGCCUCU-3′ and the complementary 28-mer RNA described has the sequence

(SEQ ID NO: 11352) 5′-AGAGGCGCCCAUGGGAGUGGCUCCCGGG-3′.

A 29-mer that includes the Oligonucleotide 4 sequence is described as

(SEQ ID NO: 11353) 5′-CCCGGGAGCCACUCCCAUGGGCGCCUCUC-3′ and the complementary 29-mer RNA described has the sequence

(SEQ ID NO: 11354) 5′-GAGAGGCGCCCAUGGGAGUGGCUCCCGGG-3′.

Thus, Table 1 describes each of the 19-mers shown in Table 1 as DNA and RNA, and the corresponding 20-mers and longer.

In addition, the Table describes double stranded oligonucleotides with the sense and antisense oligonucleotide strands hybridized, as well as such double stranded oligonucleotides with one or both strands having a 3′-overhang. Such an overhang consists of one or more 3′-terminal nucleotides of an oligonucleotide strand in a double stranded molecule that are not hybridized with the complementary strand. In the present case, such overhang nucleotides often match the corresponding nucleotides from the target mRNA sequence, but can be different.

Table 1 also describes oligonucleotides that contain known polymorphisms. Those polymorphic sites are described in Table 2 along with the replacement nucleotide. Thus, Table 1 with Table 2 describes the oligonucleotides with the alternate nucleotides at a polymorphic site.

Chemical Modifications

As indicated above, for many applications it is advantageous to use chemically modified oligonucleotides rather than unmodified RNA for RNAi (e.g., siRNA). Such modification can dramatically increase the cellular and/or serum lifetime of the modified oligonucleotide compared to the unmodified form.

Description of such chemical modification is provided in McSwiggen et al., PCT/US03/05346, WO 03/070918. Thus, the introduction of chemically modified nucleotides into nucleic acid molecules assists in overcoming potential limitations of in vivo stability and bioavailability inherent to native RNA molecules that are delivered exogenously. For example, the use of chemically modified nucleic acid molecules can enable a lower dose of a particular nucleic acid molecule for a given therapeutic effect since chemically modified nucleic acid molecules tend to have a longer half-life in serum. Furthermore, certain chemical modifications can improve the bioavailability of nucleic acid molecules by targeting particular cells or tissues and/or improving cellular uptake of the nucleic acid molecule. Therefore, even if the activity of a chemically modified nucleic acid molecule is reduced as compared to a native nucleic acid molecule, for example when compared to an all RNA nucleic acid molecule, the overall activity of the modified nucleic acid molecule can be greater than the native molecule due to improved stability and/or delivery of the molecule. Unlike native unmodified siRNA, chemically modified siNA can also minimize the possibility of activating interferon activity in humans.

Thus, in some embodiments of the present invention, the nucleic acid molecules that act as mediators of the RNA interference gene silencing response are chemically modified double stranded nucleic acid molecules, generally about 19-29 nucleotides in length. The most active siRNA molecules are thought to have such duplexes with overhanging ends of 1-3 nucleotides, for example 21 nucleotide duplexes with 19 base pairs and 2 nucleotide 3′-overhangs. These overhanging segments are readily hydrolyzed by endonucleases in vivo. Studies have shown that replacing the 3′-overhanging segments of a 21-mer siRNA duplex having 2 nucleotide 3′ overhangs with deoxyribonucleotides does not have an adverse effect on RNAi activity. Replacing up to 4 nucleotides on each end of the siRNA with deoxyribonucleotides has been reported to be well tolerated whereas complete substitution with deoxyribonucleotides results in no RNAi activity (Elbashir et al., 2001, EMBO J., 20, 6877). In addition, Elbashir et al. also report that full substitution of siRNA with 2′-O-methyl nucleotides completely abolishes RNAi activity.

In some embodiments, the chemically modified siNA constructs having specificity for target nucleic acid molecules in a cell. Non-limiting examples of such chemical modifications include without limitation phosphorothioate internucleotide linkages, 2′-O-methyl ribonucleotides, 2′-deoxy-2′-fluoro ribonucleotides, “universal base” nucleotides, 5-C-methyl nucleotides, and inverted deoxyabasic residue incorporation. These chemical modifications, when used in various siNA constructs, are shown to preserve RNAi activity in cells while at the same time, dramatically increasing the serum stability of these compounds. Furthermore, contrary to the data published by Parrish et al., supra, applicant demonstrates that multiple (greater than one) phosphorothioate substitutions are well-tolerated and confer substantial increases in serum stability for modified siNA constructs.

In one embodiment, a siNA molecule of the invention comprises modified nucleotides while maintaining the ability to mediate RNAi. The modified nucleotides can be used to improve in vitro or in vivo characteristics such as stability, activity, and/or bioavailability. For example, a siNA molecule of the invention can comprise modified nucleotides as a percentage of the total number of nucleotides present in the siNA molecule. As such, a siNA molecule of the invention can generally comprise modified nucleotides at between 5 and 100% of the nucleotide positions (e.g., 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the nucleotide positions). The actual percentage of modified nucleotides present in a given siNA molecule will depend on the total number of nucleotides present in the siNA. If the siNA molecule is single stranded, the percent modification can be based upon the total number of nucleotides present in the single stranded siNA molecules. Likewise, if the siNA molecule is double stranded, the percent modification can be based upon the total number of nucleotides present in the sense strand, antisense strand, or both the sense and antisense strands. In addition, the actual percentage of modified nucleotides present in a given siNA molecule can also depend on the total number of purine and pyrimidine nucleotides present in the siNA, for example wherein all pyrimidine nucleotides and/or all purine nucleotides present in the siNA molecule are modified.

In a non-limiting example, the introduction of chemically-modified nucleotides into nucleic acid molecules will provide a powerful tool in overcoming potential limitations of in vivo stability and bioavailability inherent to native RNA molecules that are delivered exogenously. For example, the use of chemically-modified nucleic acid molecules can enable a lower dose of a particular nucleic acid molecule for a given therapeutic effect since chemically-modified nucleic acid molecules tend to have a longer half-life in serum. Furthermore, certain chemical modifications can improve the bioavailability of nucleic acid molecules by targeting particular cells or tissues and/or improving cellular uptake of the nucleic acid molecule. Therefore, even if the activity of a chemically-modified nucleic acid molecule is reduced as compared to a native nucleic acid molecule, for example when compared to an all-RNA nucleic acid molecule, the overall activity of the modified nucleic acid molecule can be greater than that of the native molecule due to improved stability and/or delivery of the molecule. Unlike native unmodified siNA, chemically-modified siNA can also minimize the possibility of activating interferon activity in humans.

The antisense region of a siNA molecule of the invention can comprise a phosphorothioate internucleotide linkage at the 3′-end of said antisense region. The antisense region can comprise between about one and about five phosphorothioate internucleotide linkages at the 5′-end of said antisense region. The 3′-terminal nucleotide overhangs of a siNA molecule of the invention can comprise ribonucleotides or deoxyribonucleotides that are chemically-modified at a nucleic acid sugar, base, or backbone. The 3′-terminal nucleotide overhangs can comprise one or more universal base ribonucleotides. The 3′-terminal nucleotide overhangs can comprise one or more acyclic nucleotides.

In certain embodiments, the chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, includes one or more chemically modified nucleotides (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) comprising a backbone modified internucleotide linkage having Formula I:

wherein each R1 and R2 is independently any nucleotide, non-nucleotide, or oligonucleotide which can be naturally-occurring or chemically-modified, each X and Y is independently O, S, N, alkyl, or substituted alkyl, each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl, and wherein W, X, Y, and Z are optionally not all O.

The chemically-modified internucleotide linkages having Formula I, for example wherein any Z, W, X, and/or Y independently comprises a sulphur atom, can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) chemically-modified internucleotide linkages having Formula I at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified internucleotide linkages having Formula I at the 5′-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine nucleotides with chemically-modified internucleotide linkages having Formula I in the sense strand, the antisense strand, or both strands. In yet another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine nucleotides with chemically-modified internucleotide linkages having Formula I in the sense strand, the antisense strand, or both strands. In another embodiment, a siNA molecule of the invention having internucleotide linkage(s) of Formula I also comprises a chemically-modified nucleotide or non-nucleotide having any of Formulae I-VII.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or non-nucleotides having Formula II:

wherein each R3, R4, R5, R6, R7, R8, R10, R1 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalklylamino, substituted silyl, or group having Formula I; R9 is O, S, CH2, S═O, CHF, or CF2, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be complementary or non-complementary to target RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or any other non-naturally occurring universal base that can be complementary or non-complementary to target RNA.

The chemically-modified nucleotide or non-nucleotide of Formula II can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more chemically-modified nucleotide or non-nucleotide of Formula II at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotides or non-nucleotides of Formula II at the 5′-end of the sense strand, the antisense strand, or both strands. In anther non-limiting example, an exemplary siNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotides or non-nucleotides of Formula II at the 3′-end of the sense strand, the antisense strand, or both strands.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or non-nucleotides having Formula III:

wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalklylamino, substituted silyl, or group having Formula I; R9 is O, S, CH2, S═O, CHF, or CF2, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be employed to be complementary or non-complementary to target RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or any other non-naturally occurring universal base that can be complementary or non-complementary to target RNA.

The chemically-modified nucleotide or non-nucleotide of Formula III can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more chemically-modified nucleotide or non-nucleotide of Formula III at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotide(s) or non-nucleotide(s) of Formula III at the 5′-end of the sense strand, the antisense strand, or both strands. In anther non-limiting example, an exemplary siNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotide or non-nucleotide of Formula III at the 3′-end of the sense strand, the antisense strand, or both strands.

In another embodiment, a siNA molecule of the invention comprises a nucleotide having Formula II or III, wherein the nucleotide having Formula II or III is in an inverted configuration. For example, the nucleotide having Formula II or III is connected to the siNA construct in a 3′-3′,3′-2′,2′-3′, or 5′-5′ configuration, such as at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of one or both siNA strands.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein the chemical modification comprises a 5′-terminal phosphate group having Formula IV:

wherein each X and Y is independently O, S, N, alkyl, substituted alkyl, or alkylhalo; wherein each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, aralkyl, or alkylhalo; and wherein W, X, Y and Z are not all O.

In one embodiment, the invention features a siNA molecule having a 5′-terminal phosphate group having Formula IV on the target-complementary strand, for example a strand complementary to a target RNA, wherein the siNA molecule comprises an all RNA siNA molecule. In another embodiment, the invention features a siNA molecule having a 5′-terminal phosphate group having Formula IV on the target-complementary strand wherein the siNA molecule also comprises about 1-3 (e.g., about 1, 2, or 3) nucleotide 3′-terminal nucleotide overhangs having between about 1 and about 4 (e.g., about 1, 2, 3, or 4) deoxyribonucleotides on the 3′-end of one or both strands. In another embodiment, a 5′-terminal phosphate group having Formula IV is present on the target-complementary strand of a siNA molecule of the invention, for example a siNA molecule having chemical modifications having any of Formulae I-VII.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more phosphorothioate internucleotide linkages. For example, in a non-limiting example, the invention features a chemically-modified short interfering nucleic acid (siNA) having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in one siNA strand. In yet another embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) individually having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in both siNA strands. The phosphorothioate internucleotide linkages can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more phosphorothioate internucleotide linkages at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) consecutive phosphorothioate internucleotide linkages at the 5′-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine phosphorothioate internucleotide linkages in the sense strand, the antisense strand, or both strands. In yet another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine phosphorothioate internucleotide linkages in the sense strand, the antisense strand, or both strands.

In one embodiment, the invention features a siNA molecule, wherein the sense strand comprises one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′ end, the 5′-end, or both of the 3′- and 5′-ends of the sense strand; and wherein the antisense strand comprises any of between 1 and 10 or more, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2′-deoxy, 2′-O-methyl and/or 2′-deoxy-2′-fluoro nucleotides, with or without one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends, being present in the same or different strand.

In another embodiment, the invention features a siNA molecule, wherein the sense strand comprises between about 1 and about 5, specifically about 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3-end, the 5′-end, or both of the 3′- and 5′-ends of the sense strand; and wherein the antisense strand comprises any of between about 1 and about 5 or more, specifically about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2′-deoxy, 2′-O-methyl and/or 2′-deoxy-2′-fluoro nucleotides, with or without between about 1 and about 5 or more, for example about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends, being present in the same or different strand.

In one embodiment, the invention features a siNA molecule, wherein the antisense strand comprises one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or between one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the sense strand; and wherein the antisense strand comprises any of between about 1 and about 10, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2′-deoxy, 2′-O-methyl and/or 2′-deoxy-2′-fluoro nucleotides, with or without one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends, being present in the same or different strand.

In another embodiment, the invention features a siNA molecule, wherein the antisense strand comprises between about 1 and about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the sense strand; and wherein the antisense strand comprises any of between about 1 and about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2′-deoxy, 2′-O-methyl and/or 2′-deoxy-2′-fluoro nucleotides, with or without between about 1 and about 5, for example about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends, being present in the same or different strand.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule having between about 1 and about 5, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages in each strand of the siNA molecule.

In another embodiment, the invention features a siNA molecule comprising 2′-5′ internucleotide linkages. The 2′-5′ internucleotide linkage(s) can be at the 3′-end, the 5′-end, or both of the 3′- and 5′-ends of one or both siNA sequence strands. In addition, the 2′-5′ internucleotide linkage(s) can be present at various other positions within one or both siNA sequence strands, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a pyrimidine nucleotide in one or both strands of the siNA molecule can comprise a 2′-5′ internucleotide linkage, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a purine nucleotide in one or both strands of the siNA molecule can comprise a 2′-5′ internucleotide linkage.

In another embodiment, a chemically-modified siNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically-modified, wherein each strand is between about 18 and about 27 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27) nucleotides in length, wherein the duplex has between about 18 and about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the chemical modification comprises a structure having any of Formulae I-VII. For example, an exemplary chemically-modified siNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein each strand consists of about 21 nucleotides, each having a 2-nucleotide 3′-terminal nucleotide overhang, and wherein the duplex has about 19 base pairs. In another embodiment, a siNA molecule of the invention comprises a single stranded hairpin structure, wherein the siNA is between about 36 and about 70 (e.g., about 36, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having between about 18 and about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siNA can include a chemical modification comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a linear oligonucleotide having between about 42 and about 50 (e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein the linear oligonucleotide forms a hairpin structure having about 19 base pairs and a 2-nucleotide 3′-terminal nucleotide overhang. In another embodiment, a linear hairpin siNA molecule of the invention contains a stem loop motif, wherein the loop portion of the siNA molecule is biodegradable. For example, a linear hairpin siNA molecule of the invention is designed such that degradation of the loop portion of the siNA molecule in vivo can generate a double-stranded siNA molecule with 3′-terminal overhangs, such as 3′-terminal nucleotide overhangs comprising about 2 nucleotides.

In another embodiment, a siNA molecule of the invention comprises a circular nucleic acid molecule, wherein the siNA is between about 38 and about 70 (e.g., about 38, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having between about 18 and about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siNA can include a chemical modification, which comprises a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a circular oligonucleotide having between about 42 and about 50 (e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein the circular oligonucleotide forms a dumbbell shaped structure having about 19 base pairs and 2 loops.

In another embodiment, a circular siNA molecule of the invention contains two loop motifs, wherein one or both loop portions of the siNA molecule is biodegradable. For example, a circular siNA molecule of the invention is designed such that degradation of the loop portions of the siNA molecule in vivo can generate a double-stranded siNA molecule with 3′-terminal overhangs, such as 3′-terminal nucleotide overhangs comprising about 2 nucleotides.

In one embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) abasic moiety, for example a compound having Formula V:

wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalklylamino, substituted silyl, or group having Formula I; R9 is O, S, CH2, S═O, CHF, or CF2.

In one embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) inverted abasic moiety, for example a compound having Formula VI:

wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalklylamino, substituted silyl, or group having Formula I; R9 is O, S, CH2, S═O, CHF, or CF2, and either R2, R3, R8 or R13 serve as points of attachment to the siNA molecule of the invention.

In another embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) substituted polyalkyl moieties, for example a compound having Formula VII:

wherein each n is independently an integer from 1 to 12, each R1, R2 and R3 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalklylamino, substituted silyl, or a group having Formula I, and R1, R2 or R3 serves as points of attachment to the siNA molecule of the invention.

In another embodiment, the invention features a compound having Formula VII, wherein R1 and R2 are hydroxyl (OH) groups, n=1, and R3 comprises O and is the point of attachment to the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of one or both strands of a double-stranded siNA molecule of the invention or to a single-stranded siNA molecule of the invention. This modification is referred to herein as “glyceryl”.

In another embodiment, a moiety having any of Formula V, VI or VII of the invention is at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of a siNA molecule of the invention. For example, a moiety having Formula V, VI or VII can be present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the antisense strand, the sense strand, or both antisense and sense strands of the siNA molecule. In addition, a moiety having Formula VII can be present at the 3′-end or the 5′-end of a hairpin siNA molecule as described herein.

In another embodiment, a siNA molecule of the invention comprises an abasic residue having Formula V or VI, wherein the abasic residue having Formula VI or VI is connected to the siNA construct in a 3′-3′,3′-2′,2′-3′, or 5′-5′ configuration, such as at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of one or both siNA strands.

In one embodiment, a siNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) locked nucleic acid (LNA) nucleotides, for example at the 5′-end, the 3′-end, both of the 5′ and 3′-ends, or any combination thereof, of the siNA molecule.

In another embodiment, a siNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) acyclic nucleotides, for example at the 5′-end, the 3′-end, both of the 5′ and 3′-ends, or any combination thereof, of the siNA molecule.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises a sense region, where any (e.g., one or more or all) pyrimidine nucleotides present in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and where any (e.g., one or more or all) purine nucleotides present in the sense region are 2′-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2′-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2′-deoxy purine nucleotides).

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises a sense region, where any (e.g., one or more or all) pyrimidine nucleotides present in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and where any (e.g., one or more or all) purine nucleotides present in the sense region are 2′-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2′-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2′-deoxy purine nucleotides), wherein any nucleotides comprising a 3′-terminal nucleotide overhang that are present in said sense region are 2′-deoxy nucleotides.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises an antisense region, where any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides).

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises an antisense region, where any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides), wherein any nucleotides comprising a 3′-terminal nucleotide overhang that are present in said antisense region are 2′-deoxy nucleotides.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises an antisense region, where any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and where any (e.g., one or more or all) purine nucleotides present in the antisense region are 2′-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2′-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2′-deoxy purine nucleotides).

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein the chemically-modified siNA comprises a sense region, where one or more pyrimidine nucleotides present in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and where one or more purine nucleotides present in the sense region are 2′-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2′-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2′-deoxy purine nucleotides), and inverted deoxy abasic modifications that are optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the sense region, the sense region optionally further comprising a 3′-terminal overhang having between about 1 and about 4 (e.g, about 1, 2, 3, or 4) 2′-deoxyribonucleotides; and wherein the chemically-modified short interfering nucleic acid molecule comprises an antisense region, where one or more pyrimidine nucleotides present in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein one or more purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides), and a terminal cap modification, such as any modification described herein, that is optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the antisense sequence, the antisense region optionally further comprising a 3′-terminal nucleotide overhang having between about 1 and about 4 (e.g, about 1, 2, 3, or 4) 2′-deoxynucleotides, wherein the overhang nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein the siNA comprises a sense region, where one or more pyrimidine nucleotides present in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and where one or more purine nucleotides present in the sense region are purine ribonucleotides (e.g., wherein all purine nucleotides are purine ribonucleotides or alternately a plurality of purine nucleotides are purine ribonucleotides), and inverted deoxy abasic modifications that are optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the sense region, the sense region optionally further comprising a 3′-terminal overhang having between about 1 and about 4 (e.g, about 1, 2, 3, or 4) 2′-deoxyribonucleotides; and wherein the siNA comprises an antisense region, where one or more pyrimidine nucleotides present in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides), and a terminal cap modification, such as any modification described herein, that is optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the antisense sequence, the antisense region optionally further comprising a 3′-terminal nucleotide overhang having between about 1 and about 4 (e.g, about 1, 2, 3, or 4) 2′-deoxynucleotides, wherein the overhang nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein the chemically-modified siNA comprises a sense region, where one or more pyrimidine nucleotides present in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and for example where one or more purine nucleotides present in the sense region are selected from the group consisting of 2′-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2′-methoxyethyl nucleotides, 4′-thionucleotides, and 2′-O-methyl nucleotides (e.g., wherein all purine nucleotides are selected from the group consisting of 2′-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2′-methoxyethyl nucleotides, 4′-thionucleotides, and 2′-O-methyl nucleotides or alternately a plurality of purine nucleotides are selected from the group consisting of 2′-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2′-methoxyethyl nucleotides, 4′-thionucleotides, and 2′-O-methyl nucleotides), and wherein inverted deoxy abasic modifications are optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the sense region, the sense region optionally further comprising a 3′-terminal overhang having between about 1 and about 4 (e.g, about 1, 2, 3, or 4) 2′-deoxyribonucleotides; and wherein the chemically-modified short interfering nucleic acid molecule comprises an antisense region, where one or more pyrimidine nucleotides present in the antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein one or more purine nucleotides present in the antisense region are selected from the group consisting of 2′-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2′-methoxyethyl nucleotides, 4′-thionucleotides, and 2′-O-methyl nucleotides (e.g., wherein all purine nucleotides are selected from the group consisting of 2′-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2′-methoxyethyl nucleotides, 4′-thionucleotides, and 2′-O-methyl nucleotides or alternately a plurality of purine nucleotides are selected from the group consisting of 2′-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2′-methoxyethyl nucleotides, 4′-thionucleotides, and 2′-O-methyl nucleotides), and a terminal cap modification, that is optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the antisense sequence, the antisense region optionally further comprising a 3′-terminal nucleotide overhang having between about 1 and about 4 (e.g, about 1, 2, 3, or 4) 2′-deoxynucleotides, wherein the overhang nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages.

In another embodiment, any modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides. For example, the invention features siNA molecules including modified nucleotides having a Northern conformation (e.g., Northern pseudorotation cycle, see for example Saenger, Principles of Nucleic Acid Structure, Springer-Verlag ed., 1984). As such, chemically modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, are preferably resistant to nuclease degradation while at the same time maintaining the capacity to mediate RNAi. Non-limiting examples of nucleotides having a northern configuration include locked nucleic acid (LNA) nucleotides (e.g., 2′-O,4′-C-methylene-(D-ribofuranosyl) nucleotides); 2′-methoxyethoxy (MOE) nucleotides; 2′-deoxy-2′-fluoro nucleotides, 2′-deoxy-2′-chloro nucleotides, 2′-azido nucleotides, and 2′-O-methyl nucleotides.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid molecule (siNA) capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein the chemical modification comprises one or more conjugates covalently attached to the chemically-modified siNA molecule. In another embodiment, the conjugate is covalently attached to the chemically-modified siNA molecule via a biodegradable linker. In one embodiment, the conjugate molecule is attached at the 3′-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule. In another embodiment, the conjugate molecule is attached at the 5′-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule. In yet another embodiment, the conjugate molecule is attached both the 3′-end and 5′-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule, or any combination thereof. In one embodiment, a conjugate molecule of the invention comprises a molecule that facilitates delivery of a chemically-modified siNA molecule into a biological system such as a cell. In another embodiment, the conjugate molecule attached to the chemically-modified siNA molecule is a poly ethylene glycol, human serum albumin, or a ligand for a cellular receptor that can mediate cellular uptake. Examples of specific conjugate molecules contemplated by the instant invention that can be attached to chemically-modified siNA molecules are described in Vargeese et al., U.S. Ser. No. 60/311,865, incorporated by reference herein. The type of conjugates used and the extent of conjugation of siNA molecules of the invention can be evaluated for improved pharmacokinetic profiles, bioavailability, and/or stability of siNA constructs while at the same time maintaining the ability of the siNA to mediate RNAi activity. As such, one skilled in the art can screen siNA constructs that are modified with various conjugates to determine whether the siNA conjugate complex possesses improved properties while maintaining the ability to mediate RNAi, for example in animal models as are generally known in the art.

In one embodiment, the invention features a short interfering nucleic acid (siNA) molecule of the invention, wherein the siNA further comprises a nucleotide, non-nucleotide, or mixed nucleotide/non-nucleotide linker that joins the sense region of the siNA to the antisense region of the siNA. In another embodiment, a nucleotide linker of the invention can be a linker of ≧2 nucleotides in length, for example 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In yet another embodiment, the nucleotide linker can be a nucleic acid aptamer. By “aptamer” or “nucleic acid aptamer” as used herein is meant a nucleic acid molecule that binds specifically to a target molecule wherein the nucleic acid molecule has sequence that is comprises a sequence recognized by the target molecule in its natural setting. Alternately, an aptamer can be a nucleic acid molecule that binds to a target molecule where the target molecule does not naturally bind to a nucleic acid. The target molecule can be any molecule of interest. For example, the aptamer can be used to bind to a ligand-binding domain of a protein, thereby preventing interaction of the naturally occurring ligand with the protein. This is a non-limiting example and those in the art will recognize that other embodiments can be readily generated using techniques generally known in the art, see for example Gold et al., 1995, Annu. Rev. Biochem., 64, 763; Brody and Gold, 2000, J. Biotechnol., 74, 5; Sun, 2000, Curr. Opin. Mol. Ther., 2, 100; Kusser, 2000, J. Biotechnol., 74, 27; Hermann and Patel, 2000, Science, 287, 820; and Jayasena, 1999, Clinical Chemistry, 45, 1628.

In yet another embodiment, a non-nucleotide linker of the invention comprises abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or other polymeric compounds (e.g. polyethylene glycols such as those having between 2 and 100 ethylene glycol units). Specific examples include those described by Seela and Kaiser, Nucleic Acids Res. 1990, 18:6353 and Nucleic Acids Res. 1987, 15:3113; Cload and Schepartz, J. Am. Chem. Soc. 1991, 113:6324; Richardson and Schepartz, J. Am. Chem. Soc. 1991, 113:5109; Ma et al., Nucleic Acids Res. 1993, 21:2585 and Biochemistry 1993, 32:1751; Durand et al., Nucleic Acids Res. 1990, 18:6353; McCurdy et al., Nucleosides & Nucleotides 1991, 10:287; Jschke et al., Tetrahedron Lett. 1993, 34:301; Ono et al., Biochemistry 1991, 30:9914; Arnold et al., International Publication No. WO 89/02439; Usman et al., International Publication No. WO 95/06731; Dudycz et al., International Publication No. WO 95/11910 and Ferentz and Verdine, J. Am. Chem. Soc. 1991, 113:4000, all hereby incorporated by reference herein. A “non-nucleotide” further means any group or compound that can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound can be abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine, for example at the C1 position of the sugar.

In one embodiment, the invention features a short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein one or both strands of the siNA molecule that are assembled from two separate oligonucleotides do not comprise any ribonucleotides. All positions within the siNA can include chemically modified nucleotides and/or non-nucleotides such as nucleotides and or non-nucleotides having Formula I, II, III, IV, V, VI, or VII or any combination thereof to the extent that the ability of the siNA molecule to support RNAi activity in a cell is maintained.

In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein the siNA molecule comprises a single stranded oligonucleotide having complementarity to a target nucleic acid sequence. In another embodiment, the single stranded siNA molecule of the invention comprises a 5′-terminal phosphate group. In another embodiment, the single stranded siNA molecule of the invention comprises a 5′-terminal phosphate group and a 3′-terminal phosphate group (e.g., a 2′,3′-cyclic phosphate). In another embodiment, the single stranded siNA molecule of the invention comprises between 19 and 29 nucleotides. In yet another embodiment, the single stranded siNA molecule of the invention comprises one or more chemically modified nucleotides or non-nucleotides described herein. For example, all the positions within the siNA molecule can include chemically-modified nucleotides such as nucleotides having any of Formulae I-VII, or any combination thereof to the extent that the ability of the siNA molecule to support RNAi activity in a cell is maintained.

In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein the siNA molecule comprises a single stranded oligonucleotide having complementarity to a target nucleic acid sequence, and wherein one or more pyrimidine nucleotides present in the siNA are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are 2′-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-O-methyl purine nucleotides), and a terminal cap modification, such as any modification described herein, that is optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the antisense sequence, the siNA optionally further comprising between about 1 and about 4 (e.g, about 1, 2, 3, or 4) terminal 2′-deoxynucleotides at the 3′-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5′-terminal phosphate group.

In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein the siNA molecule comprises a single stranded oligonucleotide having complementarity to a target nucleic acid sequence, and wherein one or more pyrimidine nucleotides present in the siNA are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are 2′-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2′-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2′-deoxy purine nucleotides), and a terminal cap modification, such as any modification described herein, that is optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the antisense sequence, the siNA optionally further comprising between about 1 and about 4 (e.g, about 1, 2, 3, or 4) terminal 2′-deoxynucleotides at the 3′-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5′-terminal phosphate group.

In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein the siNA molecule comprises a single stranded oligonucleotide having complementarity to a target nucleic acid sequence, and wherein one or more pyrimidine nucleotides present in the siNA are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are locked nucleic acid (LNA) nucleotides (e.g., wherein all purine nucleotides are LNA nucleotides or alternately a plurality of purine nucleotides are LNA nucleotides), and a terminal cap modification, such as any modification described herein, that is optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the antisense sequence, the siNA optionally further comprising between about 1 and about 4 (e.g, about 1, 2, 3, or 4) terminal 2′-deoxynucleotides at the 3′-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5′-terminal phosphate group.

In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein the siNA molecule comprises a single stranded oligonucleotide having complementarity to a target nucleic acid sequence, and wherein one or more pyrimidine nucleotides present in the siNA are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are 2′-methoxyethyl purine nucleotides (e.g., wherein all purine nucleotides are 2′-methoxyethyl purine nucleotides or alternately a plurality of purine nucleotides are 2′-methoxyethyl purine nucleotides), and a terminal cap modification, such as any modification described herein, that is optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the antisense sequence, the siNA optionally further comprising between about 1 and about 4 (e.g, about 1, 2, 3, or 4) terminal 2′-deoxynucleotides at the 3′-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5′-terminal phosphate group.

In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein the siNA molecule comprises a single stranded oligonucleotide having complementarity to a target nucleic acid sequence, and wherein one or more pyrimidine nucleotides present in the siNA are 2′-deoxy-2′-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2′-deoxy-2′-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are purine ribonucleotides (e.g., wherein all purine nucleotides are purine ribonucleotides or alternately a plurality of purine nucleotides are purine ribonucleotides), and a terminal cap modification, such as any modification described herein, that is optionally present at the 3′-end, the 5′-end, or both of the 3′ and 5′-ends of the antisense sequence, the siNA optionally further comprising between about 1 and about 4 (e.g, about 1, 2, 3, or 4) terminal 2′-deoxynucleotides at the 3′-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5′-terminal phosphate group.

In another embodiment, any modified nucleotides present in the single stranded siNA molecules of the invention comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides. For example, the invention features siNA molecules including modified nucleotides having a Northern conformation (e.g., Northern pseudorotation cycle, see for example Saenger, Principles of Nucleic Acid Structure, Springer-Verlag ed., 1984). As such, chemically modified nucleotides present in the single stranded siNA molecules of the invention are preferably resistant to nuclease degradation while at the same time maintaining the capacity to mediate RNAi.

E. Preparation of Oligonucleotides

The present oligonucleotides can be prepared by methods available to those skilled in the art. For example, unmodified RNA can be prepared by transcription, e.g., in vitro, using methods and constructs available in the art. The sequence for the particular target, and its complementary sequence can be inserted into a selected vector, and transcribed to produce the desired oligonucleotides by conventional methods.

In many cases, it will be desirable to chemically synthesize the oligonucleotides, e.g., for chemically modified oligonucleotides. Such syntheses are known in the art, and are described, for example, below.

Thus, siNA molecules can be designed to interact with various sites in the RNA message, for example target sequences within the RNA sequences described herein. The sequence of one strand of the siNA molecule(s) is complementary to the target site sequences described above. The siNA molecules can be chemically synthesized using methods described herein. Inactive siNA molecules that are used as control sequences can be synthesized by scrambling the sequence of the siNA molecules such that it is not complementary to the target sequence. Generally, siNA constructs can by synthesized using solid phase oligonucleotide synthesis methods as described herein (see for example Usman et al., U.S. Pat. Nos. 5,804,683; 5,831,071; 5,998,203; 6,117,657; 6,353,098; 6,362,323; 6,437,117; 6,469,158; Scaringe et al., U.S. Pat. Nos. 6,111,086; 6,008,400; 6,111,086). Modification of synthesis conditions can be used to optimize coupling efficiency, for example by using differing coupling times, differing reagent/phosphoramidite concentrations, differing contact times, differing solid supports and solid support linker chemistries depending on the particular chemical composition of the siNA to be synthesized. Deprotection and purification of the siNA can be performed as is generally described in Vargeese et al., U.S. Ser. No. 10/194,875, incorporated by reference herein in its entirety. Additionally, deprotection conditions can be modified to provide the best possible yield and purity of siNA constructs. For example, applicant has observed that oligonucleotides comprising 2′-deoxy-2′-fluoro nucleotides can degrade under inappropriate deprotection conditions. Such oligonucleotides are deprotected using aqueous methylamine at about 35° C. for 30 minutes. If the 2′-deoxy-2′-fluoro containing oligonucleotide also comprises ribonucleotides, after deprotection with aqueous methylamine at about 35° C. for 30 minutes, TEA-HF is added and the reaction maintained at about 65° C. for an additional 15 minutes.

Synthesis of Nucleic Acid Molecules

In greater detail, synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs, “small” refers to nucleic acid motifs no more than 100 nucleotides in length, preferably no more than 80 nucleotides in length, and most preferably no more than 50 nucleotides in length; e.g., individual siNA oligonucleotide sequences or siNA sequences synthesized in tandem) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of protein and/or RNA structure. Exemplary molecules of the instant invention are chemically synthesized, and others can similarly be synthesized.

Oligonucleotides (e.g., certain modified oligonucleotides or portions of oligonucleotides lacking ribonucleotides) are synthesized using protocols known in the art, for example as described in Caruthers et al., 1992, Methods in Enzymology 211, 3-19, Thompson et al., International PCT Publication No. WO 99/54459, Wincott et al., 1995, Nucleic Acids Res. 23, 2677-2684, Wincott et al., 1997, Methods Mol. Bio., 74, 59, Brennan et al., 1998, Biotechnol Bioeng., 61, 33-45, and Brennan, U.S. Pat. No. 6,001,311. All of these references are incorporated herein by reference. The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μmol scale protocol with a 2.5 min coupling step for 2′-O-methylated nucleotides and a 45 sec coupling step for 2′-deoxy nucleotides or 2′-deoxy-2′-fluoro nucleotides. Alternatively, syntheses at the 0.2 μmol scale can be performed on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, Calif.) with minimal modification to the cycle. A 33-fold excess (60 μL of 0.11 M=6.6 μmol) of 2′-O-methyl phosphoramidite and a 105-fold excess of S-ethyl tetrazole (60 μL of 0.25 M=15 μmol) can be used in each coupling cycle of 2′-O-methyl residues relative to polymer-bound 5′-hydroxyl. A 22-fold excess (40 μL of 0.11 M=4.4 μmol) of deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40 μL of 0.25 M=10 μmol) can be used in each coupling cycle of deoxy residues relative to polymer-bound 5′-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); and oxidation solution is 16.9 mM I₂, 49 mM pyridine, 9% water in THF (PERSEPTIVE™). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in acetonitrile) is used.

Deprotection of the DNA-based oligonucleotides is performed as follows: the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65° C. for 10 min. After cooling to −20° C., the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H2O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder.

The method of synthesis used for RNA including certain siNA molecules of the invention follows the procedure as described in Usman et al., 1987, J. Am. Chem. Soc., 109, 7845; Scaringe et al., 1990, Nucleic Acids Res., 18, 5433; and Wincott et al., 1995, Nucleic Acids Res. 23, 2677-2684 Wincott et al., 1997, Methods Mol. Bio., 74, 59, and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μmol scale protocol with a 7.5 min coupling step for alkylsilyl protected nucleotides and a 2.5 min coupling step for 2′-O-methylated nucleotides. Alternatively, syntheses at the 0.2 μmol scale can be done on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, Calif.) with minimal modification to the cycle. A 33-fold excess (60 μL of 0.11 M=6.6 μmol) of 2′-O-methyl phosphoramidite and a 75-fold excess of S-ethyl tetrazole (60 μL of 0.25 M=15 μmol) can be used in each coupling cycle of 2′-O-methyl residues relative to polymer-bound 5′-hydroxyl. A 66-fold excess (120 μL of 0.11 M=13.2 μmol) of alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess of S-ethyl tetrazole (120 μL of 0.25 M=30 μmol) can be used in each coupling cycle of ribo residues relative to polymer-bound 5′-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution is 16.9 mM I₂, 49 mM pyridine, 9% water in THF (PERSEPTIVE™). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide 0.05 M in acetonitrile) is used.

Deprotection of the RNA is performed using either a two-pot or one-pot protocol. For the two-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65° C. for 10 min. After cooling to −20° C., the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H2O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The base deprotected oligoribonucleotide is resuspended in anhydrous TEA/HF/NMP solution (300 μL of a solution of 1.5 mL N-methylpyrrolidinone, 750 μL TEA and 1 mL TEA•3HF to provide a 1.4 M HF concentration) and heated to 65° C. After 1.5 h, the oligomer is quenched with 1.5 M NH₄HCO₃.

Alternatively, for the one-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 33% ethanolic methylamine/DMSO: 1/1 (0.8 mL) at 65° C. for 15 min. The vial is brought to r.t. TEA•3HF (0.1 mL) is added and the vial is heated at 65° C. for 15 min. The sample is cooled at −20° C. and then quenched with 1.5 M NH₄HCO₃.

For purification of the trityl-on oligomers, the quenched NH₄HCO₃ solution is loaded onto a C-18 containing cartridge that had been prewashed with acetonitrile followed by 50 mM TEAA. After washing the loaded cartridge with water, the RNA is detritylated with 0.5% TFA for 13 min. The cartridge is then washed again with water, salt exchanged with 1 M NaCl and washed with water again. The oligonucleotide is then eluted with 30% acetonitrile.

The average stepwise coupling yields are typically >98% (Wincott et al., 1995 Nucleic Acids Res. 23, 2677-2684). Those of ordinary skill in the art will recognize that the scale of synthesis can be adapted to be larger or smaller than the example described above including but not limited to 96-well format.

Alternatively, the nucleic acid molecules of the present invention can be synthesized separately and joined together post-synthetically, for example, by ligation (Moore et al., 1992, Science 256, 9923; Draper et al., International PCT publication No. WO 93/23569; Shabarova et al., 1991, Nucleic Acids Research 19, 4247; Bellon et al., 1997, Nucleosides & Nucleotides, 16, 951; Bellon et al., 1997, Bioconjugate Chem. 8, 204), or by hybridization following synthesis and/or deprotection.

The siNA molecules of the invention can also be synthesized via a tandem synthesis methodology as described below, where both siNA strands are synthesized as a single contiguous oligonucleotide fragment or strand separated by a cleavable linker which is subsequently cleaved to provide separate siNA fragments or strands that hybridize and permit purification of the siNA duplex. The linker can be a oligonucleotide linker or a non-nucleotide linker. The tandem synthesis of siNA as described herein can be readily adapted to both multiwell/multiplate synthesis platforms such as 96 well or similarly larger multi-well platforms. The tandem synthesis of siNA as described herein can also be readily adapted to large scale synthesis platforms employing batch reactors, synthesis columns and the like.

A siNA molecule can also be assembled from two distinct nucleic acid strands or fragments wherein one fragment includes the sense region and the second fragment includes the antisense region of the RNA molecule.

The nucleic acid molecules of the present invention can be modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2′-amino, 2′-C-allyl, 2′-fluoro, 2′-O-methyl, 2′-H (for a review see Usman and Cedergren, 1992, TIBS 17, 34; Usman et al., 1994, Nucleic Acids Symp. Ser. 31, 163). siNA constructs can be purified by gel electrophoresis using general methods or can be purified by high pressure liquid chromatography (HPLC; see Wincott et al., supra, the totality of which is hereby incorporated herein by reference) and re-suspended in water.

In another aspect of the invention, siNA molecules of the invention are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the siNA molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of siNA molecules.

Tandem Synthesis of siNA Constructs

Exemplary siNA molecules are synthesized in tandem using a cleavable linker, for example a succinyl-based linker. Tandem synthesis as described herein is followed by a one-step purification process that provides RNAi molecules in high yield. This approach is highly amenable to siNA synthesis in support of high throughput RNAi screening, and can be readily adapted to multi-column or multi-well synthesis platforms.

After completing a tandem synthesis of an siNA oligo and its complement in which the 5′-terminal dimethoxytrityl (5′-O-DMT) group remains intact (trityl on synthesis), the oligonucleotides are deprotected as described above. Following deprotection, the siNA sequence strands are allowed to spontaneously hybridize. This hybridization yields a duplex in which one strand has retained the 5′-O-DMT group while the complementary strand comprises a terminal 5′-hydroxyl. The newly formed duplex behaves as a single molecule during routine solid-phase extraction purification (Trityl-On purification) even though only one molecule has a dimethoxytrityl group. Because the strands form a stable duplex, this dimethoxytrityl group (or an equivalent group, such as other trityl groups or other hydrophobic moieties) is all that is required to purify the pair of oligos, for example by using a C18 cartridge.

Standard phosphoramidite synthesis chemistry is used up to point of introducing a tandem linker, such as an inverted deoxy abasic succinate or glyceryl succinate linker or an equivalent cleavable linker. A non-limiting example of linker coupling conditions that can be used includes a hindered base such as diisopropylethylamine (DIPA) and/or DMAP in the presence of an activator reagent such as Bromotripyrrolidinophosphoniumhexafluororophosphate (PyBrOP). After the linker is coupled, standard synthesis chemistry is utilized to complete synthesis of the second sequence leaving the terminal the 5′-O-DMT intact. Following synthesis, the resulting oligonucleotide is deprotected according to the procedures described herein and quenched with a suitable buffer, for example with 50 mM NaOAc or 1.5M NH₄H₂CO₃.

Purification of the siNA duplex can be readily accomplished using solid phase extraction, for example using a Waters C18 SepPak 1 g cartridge conditioned with 1 column volume (CV) of acetonitrile, 2 CV H2O, and 2 CV 50 mM NaOAc: The sample is loaded and then washed with 1 CV H2O or 50 mM NaOAc. Failure sequences are eluted with 1 CV 14% ACN (Aqueous with 50 mM NaOAc and 50 mM NaCl). The column is then washed, for example with 1 CV H2O followed by on-column detritylation, for example by passing 1 CV of 1% aqueous trifluoroacetic acid (TFA) over the column, then adding a second CV of 1% aqueous TFA to the column and allowing to stand for approx. 10 minutes. The remaining TFA solution is removed and the column washed with H2O followed by 1 CV 1 M NaCl and additional H2O. The siNA duplex product is then eluted, for example using 1 CV 20% aqueous CAN.

Optimizing Activity of the Nucleic Acid Molecules.

Chemically synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) can prevent their degradation by serum ribonucleases, which can increase their potency (see e.g., Eckstein et al., International Publication No. WO 92/07065; Perrault et al., 1990 Nature 344, 565; Pieken et al., 1991, Science 253, 314; Usman and Cedergren, 1992, Trends in Biochem. Sci. 17, 334; Usman et al., International Publication No. WO 93/15187; and Rossi et al., International Publication No. WO 91/03162; Sproat, U.S. Pat. No. 5,334,711; Gold et al., U.S. Pat. No. 6,300,074; and Burgin et al., supra; all of which are incorporated by reference herein). All of the above references describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of the nucleic acid molecules described herein. Modifications that enhance their efficacy in cells, and removal of bases from nucleic acid molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired.

There are several examples in the art describing sugar, base and phosphate modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2′-amino, 2′-C-allyl, 2′-fluoro, 2′-O-methyl, 2′-O-allyl, 2′-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992, TIBS. 17, 34; Usman et al., 1994, Nucleic Acids Symp. Ser. 31, 163; Burgin et al., 1996, Biochemistry, 35, 14090). Sugar modification of nucleic acid molecules have been extensively described in the art (see Eckstein et al., International Publication PCT No. WO 92/07065; Perrault et al. Nature, 1990, 344, 565-568; Pieken et al. Science, 1991, 253, 314-317; Usman and Cedergren, Trends in Biochem. Sci., 1992, 17, 334-339; Usman et al. International Publication PCT No. WO 93/15187; Sproat, U.S. Pat. No. 5,334,711 and Beigelman et al., 1995, J. Biol. Chem., 270, 25702; Beigelman et al., International PCT publication No. WO 97/26270; Beigelman et al., U.S. Pat. No. 5,716,824; Usman et al., U.S. Pat. No. 5,627,053; Woolf et al., International PCT Publication No. WO 98/13526; Thompson et al., U.S. Ser. No. 60/082,404 which was filed on Apr. 20, 1998; Karpeisky et al., 1998, Tetrahedron Lett., 39, 1131; Earnshaw and Gait, 1998, Biopolymers (Nucleic Acid Sciences), 48, 39-55; Verma and Eckstein, 1998, Annu. Rev. Biochem., 67, 99-134; and Burlina et al., 1997, Bioorg. Med. Chem., 5, 1999-2010; all of the references are hereby incorporated in their totality by reference herein). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into nucleic acid molecules without modulating catalysis, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein to modify the siNA nucleic acid molecules of the instant invention so long as the ability of siNA to promote RNAi is cells is not significantly inhibited.

While chemical modification of oligonucleotide internucleotide linkages with phosphorothioate, phosphorodithioate, and/or 5′-methylphosphonate linkages improves stability, excessive modifications can cause some toxicity or decreased activity. Therefore, when designing nucleic acid molecules, the amount of these internucleotide linkages should be minimized. The reduction in the concentration of these linkages should lower toxicity, resulting in increased efficacy and higher specificity of these molecules.

Short interfering nucleic acid (siNA) molecules having chemical modifications that maintain or enhance activity are provided. Such a nucleic acid is also generally more resistant to nucleases than an unmodified nucleic acid. Accordingly, the in vitro and/or in vivo activity should not be significantly lowered. In cases in which modulation is the goal, therapeutic nucleic acid molecules delivered exogenously should optimally be stable within cells until translation of the target RNA has been modulated long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Improvements in the chemical synthesis of RNA and DNA (Wincott et al., 1995, Nucleic Acids Res. 23, 2677; Caruthers et al., 1992, Methods in Enzymology 211, 3-19 (incorporated by reference herein)) have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability, as described above.

In one embodiment, nucleic acid molecules of the invention include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) G-clamp nucleotides. A G-clamp nucleotide is a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine within a duplex, see for example Lin and Matteucci, 1998, J. Am. Chem. Soc., 120, 8531-8532. A single G-clamp analog substitution within an oligonucleotide can result in substantially enhanced helical thermal stability and mismatch discrimination when hybridized to complementary oligonucleotides. The inclusion of such nucleotides in nucleic acid molecules of the invention results in both enhanced affinity and specificity to nucleic acid targets, complementary sequences, or template strands. In another embodiment, nucleic acid molecules of the invention include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) LNA “locked nucleic acid” nucleotides such as a 2′,4′-C mythylene bicyclo nucleotide (see for example Wengel et al., International PCT Publication No. WO 00/66604 and WO 99/14226).

In another embodiment, the invention features conjugates and/or complexes of siNA molecules of the invention. Such conjugates and/or complexes can be used to facilitate delivery of siNA molecules into a biological system, such as a cell. The conjugates and complexes provided by the instant invention can impart therapeutic activity by transferring therapeutic compounds across cellular membranes, altering the pharmacokinetics, and/or modulating the localization of nucleic acid molecules of the invention. The present invention encompasses the design and synthesis of novel conjugates and complexes for the delivery of molecules, including, but not limited to, small molecules, lipids, phospholipids, nucleosides, nucleotides, nucleic acids, antibodies, toxins, negatively charged polymers and other polymers, for example proteins, peptides, hormones, carbohydrates, polyethylene glycols, or polyamines, across cellular membranes. In general, the transporters described are designed to be used either individually or as part of a multi-component system, with or without degradable linkers. These compounds are expected to improve delivery and/or localization of nucleic acid molecules of the invention into a number of cell types originating from different tissues, in the presence or absence of serum (see Sullenger and Cech, U.S. Pat. No. 5,854,038). Conjugates of the molecules described herein can be attached to biologically active molecules via linkers that are biodegradable, such as biodegradable nucleic acid linker molecules.

The term “biodegradable linker” as used herein, refers to a nucleic acid or non-nucleic acid linker molecule that is designed as a biodegradable linker to connect one molecule to another molecule, for example, a biologically active molecule to a siNA molecule of the invention or the sense and antisense strands of a siNA molecule of the invention. The biodegradable linker is designed such that its stability can be modulated for a particular purpose, such as delivery to a particular tissue or cell type. The stability of a nucleic acid-based biodegradable linker molecule can be modulated by using various chemistries, for example combinations of ribonucleotides, deoxyribonucleotides, and chemically-modified nucleotides, such as 2′-O-methyl, 2′-fluoro, 2′-amino, 2′-O-amino, 2′-C-allyl, 2′-O-allyl, and other 2′-modified or base modified nucleotides. The biodegradable nucleic acid linker molecule can be a dimer, trimer, tetramer or longer nucleic acid molecule, for example, an oligonucleotide of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length, or can comprise a single nucleotide with a phosphorus-based linkage, for example, a phosphoramidate or phosphodiester linkage. The biodegradable nucleic acid linker molecule can also comprise nucleic acid backbone, nucleic acid sugar, or nucleic acid base modifications.

The term “biodegradable” as used herein, refers to degradation in a biological system, for example enzymatic degradation or chemical degradation.

The term “biologically active molecule” as used herein, refers to compounds or molecules that are capable of eliciting or modifying a biological response in a system. Non-limiting examples of biologically active siNA molecules either alone or in combination with other molecules contemplated by the instant invention include therapeutically active molecules such as antibodies, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, siNA, dsRNA, allozymes, aptamers, decoys and analogs thereof. Biologically active molecules of the invention also include molecules capable of modulating the pharmacokinetics and/or pharmacodynamics of other biologically active molecules, for example, lipids and polymers such as polyamines, polyamides, polyethylene glycol and other polyethers.

The term “phospholipid” as used herein, refers to a hydrophobic molecule comprising at least one phosphorus group. For example, a phospholipid can comprise a phosphorus-containing group and saturated or unsaturated alkyl group, optionally substituted with OH, COOH, oxo, amine, or substituted or unsubstituted aryl groups.

Therapeutic nucleic acid molecules (e.g., siNA molecules) delivered exogenously optimally are stable within cells until reverse transcription of the RNA has been modulated long enough to reduce the levels of the RNA transcript. The nucleic acid molecules are resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of nucleic acid molecules described in the instant invention and in the art have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above.

In yet another embodiment, siNA molecules having chemical modifications that maintain or enhance enzymatic activity of proteins involved in RNAi are provided. Such nucleic acids are also generally more resistant to nucleases than unmodified nucleic acids. Thus, in vitro and/or in vivo the activity should not be significantly lowered.

Use of the nucleic acid-based molecules of the invention will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple siNA molecules targeted to different genes; nucleic acid molecules coupled with known small molecule modulators; or intermittent treatment with combinations of molecules, including different motifs and/or other chemical or biological molecules). The treatment of subjects with siNA molecules can also include combinations of different types of nucleic acid molecules, such as enzymatic nucleic acid molecules (ribozymes), allozymes, antisense, 2,5-A oligoadenylate, decoys, and aptamers.

In another aspect a siNA molecule of the invention comprises one or more 5′ and/or a 3′-cap structure, for example on only the sense siNA strand, the antisense siNA strand, or both siNA strands.

By “cap structure” is meant chemical modifications, which have been incorporated at either terminus of the oligonucleotide (see, for example, Adamic et al., U.S. Pat. No. 5,998,203, incorporated by reference herein). These terminal modifications protect the nucleic acid molecule from exonuclease degradation, and may help in delivery and/or localization within a cell. The cap may be present at the 5′-terminus (5′-cap) or at the 3′-terminal (3′-cap) or may be present on both termini. In non-limiting examples: the 5′-cap is selected from the group comprising glyceryl, inverted deoxy abasic residue (moiety); 4′,5′-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide, 4′-thio nucleotide; carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3′-3′-inverted nucleotide moiety; 3′-3′-inverted abasic moiety; 3′-2′-inverted nucleotide moiety; 3′-2′-inverted abasic moiety; 1,4-butanediol phosphate; 3′-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3′-phosphate; 3′-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety.

In yet another embodiment, the 3′-cap is selected from a group comprising glyceryl, inverted deoxy abasic residue (moiety), 4′,5′-methylene nucleotide; I-(beta-D-erythrofuranosyl) nucleotide; 4′-thio nucleotide, carbocyclic nucleotide; 5′-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate; 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5′-5′-inverted nucleotide moiety; 5′-5′-inverted abasic moiety; 5′-phosphoramidate; 5′-phosphorothioate; 1,4-butanediol phosphate; 5′-amino; bridging and/or non-bridging 5′-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5′-mercapto moieties (for more details see Beaucage and Iyer, 1993, Tetrahedron 49, 1925; incorporated by reference herein).

By the term “non-nucleotide” is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine and therefore lacks a base at the 1′-position.

An “alkyl” group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, ═O, ═S, NO₂ or N(CH₃)₂, amino, or SH. The term also includes alkenyl groups that are unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably, it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, ═O, ═S, NO₂, halogen, N(CH₃)₂, amino, or SH. The term “alkyl” also includes alkynyl groups that have an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably, it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, ═O, ═S, NO₂ or N(CH₃)₂, amino or SH.

Such alkyl groups can also include aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester groups. An “aryl” group refers to an aromatic group that has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The preferred substituent(s) of aryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups. An “alkylaryl” group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above). Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted. Heterocyclic aryl groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted. An “amide” refers to an —C(O)—NH—R, where R is either alkyl, aryl, alkylaryl or hydrogen. An “ester” refers to an —C(O)—OR′, where R is either alkyl, aryl, alkylaryl or hydrogen.

By “nucleotide” as used herein is as recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1′ position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other; see, for example, Usman and McSwiggen, supra; Eckstein et al., International PCT Publication No. WO 92/07065; Usman et al., International PCT Publication No. WO 93/15187; Uhlman & Peyman, supra, all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach et al., 1994, Nucleic Acids Res. 22, 2183. Some of the non-limiting examples of base modifications that can be introduced into nucleic acid molecules include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2,4,6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, and others (Burgin et al., 1996, Biochemistry, 35, 14090; Uhlman & Peyman, supra). By “modified bases” in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1′ position or their equivalents.

In one embodiment, the invention features modified siNA molecules, with phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/or alkylsilyl, substitutions. For a review of oligonucleotide backbone modifications, see Hunziker and Leumann, 1995, Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods, VCH, 331-417, and Mesmaeker et al., 1994, Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research, ACS, 24-39.

By “abasic” is meant sugar moieties lacking a base or having other chemical groups in place of a base at the 1′ position, see for example Adamic et al., U.S. Pat. No. 5,998,203.

By “unmodified nucleoside” is meant one of the bases adenine, cytosine, guanine, thymine, or uracil joined to the 1′ carbon of β-D-ribo-furanose.

By “modified nucleoside” is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate. Non-limiting examples of modified nucleotides are shown by Formulae I-VII and/or other modifications described herein.

In connection with 2′-modified nucleotides as described for the present invention, by “amino” is meant 2′—NH₂ or 2′-O—NH₂, which may be modified or unmodified. Such modified groups are described, for example, in Eckstein et al., U.S. Pat. No. 5,672,695 and Matulic-Adamic et al., U.S. Pat. No. 6,248,878, which are both incorporated by reference in their entireties.

Various modifications to nucleic acid siNA structure can be made to enhance the utility of these molecules. Such modifications will enhance shelf-life, half-life in vitro, stability, and ease of introduction of such oligonucleotides to the target site, e.g., to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.

F. Compositions for Administration

Suitable pharmaceutical compositions containing the present RNAi inducing oligonucleotides can be prepared in many different forms. In most cases, it is desirable to apply the active oligonucleotide topically to one or more hair producing skin areas on a subject. For these applications, a composition that flows, or is spreadable or sprayable is advantageous. Examples of such compositions include, for example, solutions, suspensions, emulsions, lotions, creams, gels, ointments, liposome preparations, and the like. Preparation of such pharmaceutical compositions is well-known in the art, and can be utilized for the present invention.

Thus, the oligonucleotide formulations useful in the present invention will generally include the oligonucleotide(s) and a pharmaceutically acceptable carrier, e.g., any liquid or nonliquid carrier, gel, cream, ointment, lotion, paste, emulsifier, solvent, liquid diluent, powder, or the like, which is stable with respect to all components of the topical pharmaceutical formulation and which is suitable for topical administration of oligonucleotides according to the method of the invention. Such carriers are well known in the art.

A topical carrier, as noted above, is one which is generally suited to topical drug administration and includes any such materials known in the art. The topical carrier is selected so as to provide the composition in the desired form, e.g., as a liquid, lotion, cream, paste, gel, or ointment, and may be comprised of a material of either naturally occurring or synthetic origin. It is essential, clearly, that the selected carrier not adversely affect the oligonucleotide or other components of the topical formulation. Examples of suitable topical carriers for use herein include water, alcohols and other nontoxic organic solvents, glycerin, mineral oil, silicone, petroleum jelly, lanolin, fatty acids, vegetable oils, waxes, and the like. Particularly preferred formulations herein are colorless, odorless ointments, lotions, creams and gels.

Ointments, which are semisolid preparations, are typically based on petrolatum or other petroleum derivatives. As will be appreciated by the ordinarily skilled artisan, the specific ointment base to be used is one that provides for optimum oligonucleotide delivery, and, preferably, provides for other desired characteristics as well, e.g., emolliency or the like. As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and nonsensitizing. As explained in Remington: The Science and Practice of Pharmacy, 19th Ed. (Easton, Pa.: Mack Publishing Co., 1995), at pages 1399-1404, ointment bases may be grouped in four classes: oleaginous bases; emulsifiable bases; emulsion bases; and water-soluble bases. Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semisolid hydrocarbons obtained from petroleum. Emulsifiable ointment bases, also known as absorbent ointment bases, contain little or no water and include, for example, hydroxystearin sulfate, anhydrous lanolin and hydrophilic petrolatum. Emulsion ointment bases are either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin and stearic acid. Preferred water-soluble ointment bases are prepared from polyethylene glycols of varying molecular weight; again, reference may be had to Remington: The Science and Practice of Pharmacy for further information.

Lotions, which are preparations that are to be applied to the skin surface without friction, are typically liquid or semiliquid preparations in which solid particles, including the oligonucleotide, are present in a water or alcohol base. Lotions are usually suspensions of solids, and preferably, for the present purpose, comprise a liquid oily emulsion of the oil-in-water type. Lotions are preferred formulations for oligonucleotide delivery to large body areas, because of the ease of applying a more fluid composition. It is generally necessary that the insoluble matter in a lotion be finely divided. Lotions will typically contain suspending agents to produce better dispersions as well as compounds useful for localizing and holding the active agent in contact with the skin, e.g., methylcellulose, sodium carboxymethyl-cellulose, or the like.

Creams containing a oligonucleotide for delivery according to the method of the invention are viscous liquid or semisolid emulsions, either oil-in-water or water-in-oil. Cream bases are water-washable, and contain an oil phase, an emulsifier and an aqueous phase. The oil phase, also sometimes called the “internal” phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation, as explained in Remington, supra, is generally a nonionic, anionic, cationic or amphoteric surfactant.

Gel formulations can also be used in connection with the present invention. As will be appreciated by those working in the field of topical drug formulation, gels are semisolid, suspension-type systems. Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the carrier liquid, which is typically aqueous, but also, preferably, contain an alcohol and, optionally, an oil.

The oligonucleotide formulations useful in the invention also encompass sprays, that generally provide the oligonucleotide in an aqueous solution which can be misted onto the skin for delivery. Such sprays include those formulated to provide for concentration of the oligonucleotide solution at the site of administration following delivery, e.g., the spray solution can be primarily composed of alcohol or other like volatile liquid in which the oligonucleotide can be dissolved. Upon delivery to the skin, the alcohol carrier evaporates, leaving concentrated oligonucleotide at the site of administration.

The oligonucleotide formulations useful in the invention can also contain other optional such as opacifiers, anti-oxidants, gelling agents, thickening agents, stabilizers, and the like. Other agents may also be added, such as antimicrobial agents, antifungal agents, antibiotics and anti-inflammatory agents such as steroids.

The oligonucleotide formulations can include other components that, while not necessary for delivery of oligonucleotides to the skin, may enhance such delivery. For example, although it is not necessary to the practice of the invention, the oligonucleotide formulations may also contain a skin permeation enhancer. Suitable enhancers are well know in the art and include, for example, dimethylsulfoxide (DMSO), dimethyl formamide (DMF), N,N-dimethylacetamide (DMA), decylmethylsulfoxide (C.sub.10 MSO), C.sub.2-C.sub.6 alkanediols, and the 1-substituted azacycloheptan-2-ones, particularly 1-n-dodecylcyclazacycloheptan-2-one (available under the trademark Azone® from Whitby Research Incorporated, Richmond, Va.), alcohols, and the like. Preferably, the oligonucleotides delivered are substantially free of such permeation enhancers.

The additional components should not substantially interfere with the integrity or biological activity of the oligonucleotide or the formulation in which it is provided, i.e., the additional components do not adversely affect the uptake of the oligonucleotide by skin cells or chemically modify the oligonucleotide in an undesirable manner.

It will be recognized by those skilled in the art that the optimal quantity and spacing of individual dosages of oligonucleotides will be determined by the precise form and components of the oligonucleotide formulation to be delivered, the site of administration, the use to which the delivery device is applied (e.g., immunization, treatment of a condition, production of transgenic animals, etc.), and the particular subject to which the oligonucleotide formulation is to be delivered, and that such optimums can be determined by conventional techniques. It will also be appreciated by one skilled in the art that the optimal dosing regimen, i.e., the number of doses of oligonucleotides, can be ascertained using conventional methods, e.g., course of treatment determination tests. Generally, a dosing regimen will involve administration of the selected oligonucleotide formulation at least once daily, and may be one to four times daily or more.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of drug formulation, particularly topical drug formulation, which are within the skill of the art. Such techniques are fully explained in the literature. See Remington: The Science and Practice of Pharmacy, cited supra, as well as Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. (New York: McGraw-Hill, 1996).

Dosage Forms of the Oligonucleotide Formulations

The oligonucleotides can be prepared in unit dosage form (e.g., in ampules), or in multidose form. The oligonucleotides may be present in such forms as suspensions, solutions, gels, or creams, preferably in an aqueous vehicle (e.g., in a buffered solution). Alternatively, the oligonucleotide salt may be in lyophilized form for reconstitution, at the time of delivery, with a suitable vehicle, such as sterile pyrogen-free water or phosphate-buffered saline (PBS). Both liquid as well as lyophilized forms that are to be reconstituted preferably comprise agents, preferably buffers, in amounts necessary to suitably adjust the pH of the solution. Nonionic materials, such as sugars, are preferred for adjusting tonicity, and sucrose is particularly preferred. Any of these forms may further comprise suitable formulatory agents, such as starch or sugar, glycerol or saline. The compositions per unit dosage, whether liquid, gel, cream, or solid, may contain from 0.1% to 99% of oligonucleotide material.

Delivery Devices

The oligonucleotide formulation can administered using and be provided within, a delivery device (e.g., a patch, bandage, etc.) that provides for both maintenance of contact between the skin of the subject and the oligonucleotide formulation and substantially uninhibited movement of the oligonucleotide into the skin. The delivery device generally does not in and of itself facilitate movement of the oligonucleotide contained therein into the skin, but rather primarily acts to ensure that the oligonucleotide formulation is in contact with the skin for a time sufficient to allow genetic alteration of skin cells. The delivery device comprises a delivery means, or “reservoir,” which is saturated with a formulation that comprises an amount of oligonucleotide sufficient to genetic alteration of skin cells to which it is to be delivered and sufficient to elicit the desired biological effect. For example, where the delivery device is to be used to deliver a oligonucleotide for genetic immunization of a human, the delivery means of the device preferably contains an amount of oligonucleotide ranging from about 10 .mu.g to about 1,000 .mu.g, preferably from about 100 .mu.g to about 500 .mu.g.

Suitable delivery means of the delivery devices of the invention include, but are not limited to, sponges, hydrogels, and absorptive materials (e.g., gauze) that allow for retention of the oligonucleotide formulation at the site of oligonucleotide administration without substantially interfering with the delivery of oligonucleotide to the skin. It is important that, upon contact of the delivery means with the skin, the oligonucleotides contained in the delivery means diffuse or otherwise pass from the delivery means into the skin at a rate and in an amount suitable to accomplish the desired effect.

In general, the delivery means has at least two surfaces: a first surface that serves as a skin-contacting surface; and a second surface opposite the skin-contacting surface. Preferably, the second surface is in contact with a liquid-impermeable coating that substantially prevents movement of the oligonucleotide out of the delivery means through the second surface (e.g., in a direction away from the first skin-contacting surface). Preferably, the liquid-impermeable coating also decreases the rate of dehydration of the oligonucleotide formulation contained in the delivery means. In one embodiment, the first skin-contacting surface of the delivery means is associated with a liquid-impermeable, removable layer (e.g., release liner), which layer is removed just prior to placement of the first surface on the skin of a subject for administration of the oligonucleotide.

The delivery device preferably comprises an adhesive means, which can be a polymeric matrix of a pharmaceutically acceptable contact adhesive material, which serves to affix the system to the skin during drug delivery. The adhesive means facilitates retention of the delivery means on the skin at the desired site of administration. Preferably, the adhesive means comprises an adhesive substance that allows for retention of the delivery means at the desired site for a selected amount of time, but additionally allows for easy removal of the delivery means without substantially adversely affecting the skin with which the adhesive substance was in contact.

The adhesive substance used must be biocompatible with the skin of the subject, and should not substantially interfere with the delivery of oligonucleotide to the subject. Examples of suitable skin contact adhesive materials include, but are not limited to, polyethylenes, polysiloxanes, polyisobutylenes, polyacrylates, polyurethanes, and the like. The particular polymeric adhesive selected will depend on the particular oligonucleotide formulation, vehicle, etc., i.e., the adhesive must be compatible with all components of the oligonucleotide formulation.

In one embodiment, the delivery means and skin contact adhesive are present as separate and distinct layers of the delivery device, with the adhesive underlying the delivery means which, in this case, may be either a polymeric matrix as described above, or it may be a liquid or hydrogel reservoir, or may take some other form. In another embodiment, the delivery means is an adhesive bandage. Exemplary delivery devices suitable for use in the invention include, but are not limited to, those devices described in U.S. Pat. No. 5,160,328; U.S. Pat. No. 5,254,346; U.S. Pat. No. 5,714,162; U.S. Pat. No. 5,667,798; U.S. Pat. No. 5,230,896; and U.S. Pat. No. 5,260,066. Methods for preparation of suitable delivery means and other elements associated with the delivery means, such as an adhesive means are well known in the art.

In another embodiment, the oligonucleotide formulation of the invention is provided as a patch, wherein the drug composition is contained within, for example, a laminated structure that serves as a drug delivery device to be affixed to the skin. In such a structure, the oligonucleotide composition is contained within a delivery means, or “reservoir,” which lies beneath an upper backing layer. The laminated structure may contain a single reservoir, or it may contain multiple reservoirs.

The backing layer in the laminates of the patch, which serves as the upper surface of the delivery device, functions as the primary structural element of the laminated structure and provides the device with much of its flexibility. The material selected for the backing material should be selected so that it is substantially impermeable to oligonucleotide and, preferably, to other components of the oligonucleotide formulation, thus preventing loss of any components through the upper surface of the device, and preferably substantially impeding dehydration of the composition in the reservoir. The backing layer may be either occlusive or nonocclusive, depending on whether it is desired that the skin become hydrated during drug delivery. The backing is preferably made of a sheet or film of a preferably flexible elastomeric material. Examples of polymers that are suitable for the backing layer include polyethylene, polypropylene, polyesters, and the like.

During storage and prior to use, the laminated structure includes a release liner. Immediately prior to use, this layer is removed from the device to expose the skin-contacting surface of the device, which as noted above may be either the reservoir itself or a separate contact adhesive layer, so that the system may be affixed to the skin. The release liner is preferably made of a material that is substantially impermeable to the oligonucleotide and other components in the oligonucleotide formulation.

Delivery devices suitable for use in the present invention may be fabricated using conventional techniques, known in the art, for example by casting a fluid admixture of adhesive, oligonucleotide, and carrier/vehicle onto the backing layer, followed by lamination of the release liner. Similarly, the adhesive mixture may be cast onto the release liner, followed by lamination of the backing layer. Alternatively, the oligonucleotide reservoir may be prepared in the absence of oligonucleotide formulation or excipient, and then loaded by “soaking” in a drug/vehicle mixture.

As with the topical formulations of the invention, the oligonucleotide formulation contained within the delivery means of the delivery devices may contain a number of components. Furthermore, such delivery devices can be used in connection with administration of any of the oligonucleotide formulations described herein, e.g., naked oligonucleotide formulations, or lipid- or liposome-comprising oligonucleotide formulations. Regardless of the specific basic components of the oligonucleotide formulation, the oligonucleotide formulation will generally dissolved, dispersed or suspended in a suitable pharmaceutically acceptable vehicle, typically an aqueous solution or gel. Other components that may be present include preservatives, stabilizers, and the like.

Packaging of the Oligonucleotide Formulations and Delivery Devices

The units dosage ampules, multidose containers, and/or delivery devices (e.g., patches) in which the oligonucleotides are packaged prior to use may comprise an hermetically sealed container enclosing an amount of oligonucleotide or oligonucleotide formulation containing a oligonucleotide suitable for a pharmaceutically effective dose thereof, or multiples of an effective dose. The oligonucleotide is preferably packaged as a sterile formulation, and the hermetically sealed container is designed to preserve sterility of the formulation until use. Where the oligonucleotides are provided in a patch-style delivery device, the patches may be contained in a strip of individually separable packaged patches for ease in dispensing.

The container in which the oligonucleotide formulation and/or delivery device is packaged is labeled, and the label bears a notice in the form prescribed by any appropriate governmental agency. For example, where the oligonucleotides are to be administered to humans, the package comprises a notice that reflects approval by the Food and Drug Administration under the applicable federal law, of the manufacture, use, or sale of the oligonucleotide material therein for human administration. Federal law requires that the use of pharmaceutical agents in the therapy of humans be approved by an agency of the Federal government. Responsibility for enforcement is the responsibility of the Food and Drug Administration, which issues appropriate regulations for securing such approval, detailed in 21 U.S.C. 301-392. Regulation for biologic material, comprising products made from the tissues of animals is provided under 42 U.S.C 262. Similar approval is required by most foreign countries. Regulations vary from country to country, but the individual procedures are well known to those in the art.

Introduction of Oligonucleotides into Skin Cells According to the Method of the Invention

Application of the Oligonucleotide to Skin

Administration of the oligonucleotide is accomplished by contacting a oligonucleotide-comprising formulation (e.g., a buffered salt solution comprising the oligonucleotide) with an area of skin for a time sufficient to allow genetic alteration of skin cells. Preferably, the oligonucleotide is applied to hirsute skin. The oligonucleotide can be applied to skin without substantial pretreatment or with pretreatment, preferably without pretreatment of the skin. “Pretreatment” can generally encompass removal of hair from the skin, increasing skin permeability by mechanical means (e.g, abrasion), increasing skin permeability by application of a chemical agent to the site either before or during oligonucleotide administration, and application of an irritant or other like chemical agent to elicit a non-specific immune response or an immune response toward the irritant (e.g., by application of a keratinolytic agent). Administration of the oligonucleotide can be accomplished according to the invention without the application of an electric field or electric pulse (e.g., as in iontophoresis), without breaking the skin (e.g., by abrasion or through use of a needle), and without application of pressure to the site of administration (e.g., via jet propulsion, pressurized air, etc.). Furthermore, oligonucleotide administration can be accomplished using a oligonucleotide formulation that is substantially free of permeabilizing agents, detergents, or other chemical agents that facilitate entry of the oligonucleotide into the skin.

Once the oligonucleotide-comprising formulation is brought into contact with skin, contact is maintained for a time sufficient to allow movement of the oligonucleotide from the formulation into skin and into skin cells. In general, the time of contact between the oligonucleotide and the skin will be at least about 1 min to about 1 hr or more, preferably at least about 30 min. Because there is substantially no toxicity associated with contacting the oligonucleotide with the skin, the time of contact maintained between the oligonucleotide and the skin to which the oligonucleotide is to be delivered is limited only by such factors as the ability to keep the oligonucleotide in a suitable delivery form (e.g., a time during which the oligonucleotide-comprising solution can be prevented from dehydrating) and the ability to physically maintain contact between the oligonucleotide and the site of delivery (e.g., maintenance of a patch comprising the oligonucleotide(s) on the skin). Therefore, the time of contact of a single dose can be as long as several hours to several days, and may be weeks or more. Furthermore, the time of delivery can be further extended by additional subsequent applications of the oligonucleotide to the same or different delivery site on the skin.

While an ethanolic/propylene glycol solution of anti-hairless oligonucleotide as found to deliver beneficial amounts of oligonucleotide to the hair follicle and result in inhibition of hairless, other formulations can also advantageously be used. In particular, liposome compositions can be advantageous. Liposomes were introduced first in about 1980 for topical drug delivery and have since attracted considerable interest due to their potential utility both as a drug carrier and a reservoir for controlled release of drugs within various layers of the skin and the hair follicle. In addition to reducing the undesirable high systemic absorption of topically applied drugs, the major advantage of liposomes compared to other formulations such as ointments or creams, is based on their ability to create a depot, from which the drug is slowly released. The delivery agents also provide advantages in that they protect oligonucleotides against degradation, increase cellular uptake, and may target the drug to specific cells or tissue compartment. Thus, a delivery system allowing the controlled and sustained release of oligonucleotides in vivo can greatly increase the efficacy of gene inhibition technology.

One of the most favored sites of liposome penetration is into the hair follicle, since the hair canal opens directly onto the surface of the skin. Liposomes applied to cultured hair follicles are easily detected in cells lining the inner root sheath. (Li et al., 1992b, In Vitro Cell Dev Biol 28A:679-681.) Liposomes also find their way into the pilosebaceous unit once traveling down the root sheath. (Lieb et al. 1992, J Invest Dermatol 99:108-113.) Liposomes have been shown to direct compounds into the sebaceous gland, when they would otherwise be trapped in the stratum corneum. (Bernard et al., 1997, J Pharm Sci 86:573-578.) Liposomes function both as a controlled release system and as a delivery system transporting encapsulated substances into cells. After topical application, and upon drying, the liposomes develop into a structured film that fills the follicular openings, intimately mixing with the follicular contents, and fostering drug diffusion to the depths of the follicles.

A number of different compositions of liposomes have been tested for in vivo oligonucleotide delivery. For example, three different lipids were compared: N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride (DOTMA), 2,3-dioleyloxy-N-[2(sperminecarboxamido) ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA) and N-(1-(2,3-dimyristyloxypropyl)-N,N dimethyl-(2-hydroxyethyl) ammonium bromide (DMRIE). The macrophages incorporated tenfold more oligonucleotide when delivered in conjunction with DOSPA than with the other cationic lipids.

Liposome preparation and encapsulation of oligonucleotides are available from commercial manufacturer, e.g., BioZone Laboratories, Inc. Pittsburg, Calif., which manufactures a wide range of topically applied LipoCeutical products that include cationic lipids.

In addition to cationic lipid liposomes, other types of liposomes can also be used, e.g. pH-sensitive liposomes. The cellular uptake of liposomes passes mainly through an endocytic pathway, and occasionally, liposomes and their contents inadvertently arrive in the lysosomes where they are degraded. The quantity of oligonucleotides that can avoid degradation and reach their nuclear or cytoplasmic target is probably very low. To overcome lysosomal degradation and in order to increase the efficiency of delivery, pH sensitive fusogenic liposomes have been used. These consist of a non-bilayer-forming lipid such as dioleylphosphatidylethanolamine (DOPE) and a titratable acidic amphiphile such as oleic acid (OA) or cholesterylhemisuccinate (CHEMS). (DeOliveira et al., 1998, Biochim. Biophys. Acta Biomembr. 1372:301-310.) At pH 7, the amphiphile maintains the lipid mix in a bilayer (liposome) structure. However, as the complex moves through the endosomes, the pH drops and the amphiphile becomes protonated. This causes the liposome to collapse resulting in fusion with the endosomal membrane and release of the liposome contents into the cytoplasm. However, the anionic nature of pH-sensitive liposomes may lead to poor encapsulation of ODNs. (Hughes et al., 2000, Methods Enzymol 313:342-358.).

As one alternative to liposomes, other carriers/delivery agents can be used, such as cationic polymers. The most widely studied polymers are polylactides and co-polymers of lactic acid and glycolic acid P(LA-GA) and both of these have been evaluated for the use for delivery of oligonucleotides. (Lewis et al., 1998, J Drug Target 5:291-302; Hudson et al., 1999, Int J Pharm 182:49-58.)

In addition to the above, certain patents have described methods for delivery that can be used in the present invention. Examples include the following.

Li and Lishko, U.S. Pat. No. 5,914,126 (incorporated herein by reference in its entirety) describes methods to deliver macromolecules to hair follicles, where the method involves applying to the skin a formulation that includes a macromolecule, such as a nucleic acid, in a liposomal formulation, such that the liposomes target the macromolecule selectively into hair follicle cells by transfer into the follicle without entry into the circulation of the adjacent skin tissue.

Khavari et al., U.S. Pat. No. 6,087,341 (incorporated herein by reference in its entirety) describes methods and compositions for introduction of nucleic acid into skin cells by topical application.

Li and Baranov, U.S. Pat. No. 6,080,127 (incorporated herein by reference in its entirety) describes a skin vibration method for topical targeted delivery of beneficial agents into hair follicles. The vibration frequency can, for example, be about 1 Hz to 100 Hz.

In some applications, it may be useful to include transdermal penetration enhancers, for example, as described in Karande et al., 2004, Nature Biotech. 192-197. As described, two types of compositions were particularly effective. One included sodium laureth sulfate (SLA) with phenyl piperazine (PP). In a particular composition the SLA:PP was as 0.5% (w/v) with the weight ration of SLA=0.7 in the combination. The second included N-lauroyl sarcosine (NLS) with sorbitan monolaurate (S20). In a particular composition, the combination was at 1.0% (w/v) with the weight ration of NLS=0.6.

G. Administration

The present compositions can be administered in various ways, e.g., depending on the condition to be treated, and the type of composition to be used. In many cases, topical administration will be used. This mode of administration is particularly suitable for local hair removal.

In some applications, hair removal is desired in only a portion of the skin area of a subject. In those cases, the composition can be applied locally.

Exemplary Topical Application Methods

Spreading

In most cases, the composition containing the RNAi inducing oligonucleotides will be spread or wiped on the treatment area to form a thin film. Thus, for example, for any of the forms of liquid suspension or solution, cream, lotion, gel, or ointment, a quantity of the composition is spread on the treatment surface or surfaces of the subject, and left for a time to allow oligonucleotides (which may be in a carrier species such as in liposomes, to migrate to the hair follicles.

Spraying

For compositions that are sufficiently liquid, the composition can be sprayed on the treatment site, either with or without protection against overspray on surrounding areas. For spray applications, it may be desirable to protect against inhalation of sprayed material, e.g., by using masks that will filter out the relevant sized aerosol particles.

Injection

In some applications, it will be desirable to remove only specific hairs. Thus, rather than contacting a particular area, a composition will be delivered to one or more particular hair follicles. Such individual follicle delivery can be accomplished in various ways. For example, a drop of liquid containing the active oligonucleotide(s) can be deposited on the hair shaft, and allowed to migrate down the shaft to the follicle. In another approach, a needle can be inserted in the hair channel, and liquid or other composition deposited at or near the follicle.

Application Site Preparation and Hair Cycle Synchronization

In some cases, the present compositions can be applied without any special preparation of the application site. In other cases, however, it is advantageous to prepare the site, e.g., by preliminary removal of hair from the site and/or to combine the present invention with a supplementary method of hair removal. Such removal can be beneficial in several different ways. For example, such removal can reduce the amount of active agent required for the present invention because the material will not be lost by adhering to the hair, and instead will be available for absorption/migration to the hair follicles.

Such removal can also be beneficially be used to supplement the present invention by removing residual hairs. Depending on the manner and amount of RNAi inducing oligonucleotide delivered to the hair follicles, some of the follicles may not be sufficiently inhibited, such that some hairs may grow in the treated area and/or some hairs may be reduced in thickness or length but still present. In such cases, a supplementary method of hair removal can be used to produce a desired level of hair removal, e.g., shaving, chemical depilation, enzymatic hair removal; laser treatment; electrolysis. Certain embodiments of the present invention include such an supplemental method.

It can also be advantageous to synchronize hair cycles in the treatment area. Such synchronization can advantageously be done prior to application of the present compositions, or during an interval of treatment with the present compositions, or in an interval between two occasions or intervals of application of the present compositions.

Such synchronization can be accomplished, for example, by pulling hairs from the follicles (either individually or in larger numbers). Examples of methods for pulling the hairs include plucking and waxing. In some circumstances it will be necessary/desirable to induce follicle synchrony by molecular means. In these instances, skin is treated with a known follicle growth inducer such as cyclosporin A, TPA, Noggin, estrogen receptor agonist, and the like.

In general, if a hair is pulled from a follicle in anagen, that follicle goes into catagen; if a hair is pulled from a follicle in telogen, the follicle is stimulated to produce hair, and thus goes into anagen. Thus, for a more extensive effect using the present invention, a distribution of hairs in anagen, catagen, and telogen can be synchronized in catagen, with one pulling to push anagen follicles to catagen, and two pullings to stimulate telegen follicles to anagen, and then push the newly anagen follicles to catagen. Depending on the reaction of the follicles, such procedure can produce a single phase synchrony, or a two phase synchrony.

EXAMPLE 1 In Vitro siRNA Inhibition of Hairless mRNA

siRNAs were commercially obtained from Ambion, Inc. for human and mouse hairless genes. These are validated, chemically synthesized siRNAs, that are HPLC purified, annealed and ready to use, and guaranteed to reduce target gene expression by 70% or more. For both human and mouse transcripts, two different siRNAs were used. The sequence of the hairless siRNAs is given in the following table. In this and the subsequent tables in this example, upper case letter are used to refer to the human homologs, and lower case letter refer to the mouse homologs of the specified genes.

List of Pre-Designed siRNAs Used for Gene Silencing Experiments.

siRNA Sense Sequence Antisense Sequence HR#1 5′-GGACAUGCUCCCACUUGUGtt-3′ 5′-CACAAGUGGGAGCAUGUCCtt-3′ (SEQ ID NO: 11355) (SEQ ID NO: 11356) HR#2 5′-GGAGGCCAUGCUUACCCAUtt-3′ 5′-AUGGGUAAGCAUGGCCUCCtt-3′ (SEQ ID NO: 11357) (SEQ ID NO: 11358) hr#1 5′-GGACACACUCUCACUGGUGtt-3′ 5′-CACCAGUGAGAGUGUGUCCtt-3′ (SEQ ID NO: 11359) (SEQ ID NO: 11360) hr#2 5′-GGGCUUUUACCACAAGGAUtt-3′ 5′-AUCCUUGUGGUAAAAGCCCtt-3′ (SEQ ID NO: 11361) (SEQ ID NO: 11362)

We also used siRNAs for the mouse glyceraldehyde-3-phosphate dehydrogenase (gapdh) gene, Silencer™ GAPDH siRNA (Cat no. 4605, Ambion, Inc. Austin, Tex.) as controls to monitor and optimize siRNA experiments.

Human HaCaT, HeLa and mouse NIH 3T3 cells were used in siRNA transfection experiments. Cells were plated on 6-well tissue culture plates in Dulbecco's Modified Eagle Media (D-MEM, Cat no. 10569-010, Invitrogen Corp., Carlsbad, Calif.) with 10% Fetal Bovine Serum (Cat no. 16000-044, Invitrogen, Corp.) so that they were 30-50% confluent at the time of transfection. Immediately before the transfection, the cells were washed in Opti-MEM I Reduced Serum Medium (Cat no. 31985-070, Invitrogen, Inc.). We used 200 μmol of short interfering RNA (siRNA) for each well and the Oligofectamine™ reagent. The transfections were performed according to the manufacturer's instructions (Cat no. 12252-011, Invitrogen, Inc).

Total RNA was isolated 24 and 48 hours post-transfection using the RNeasy Mini Kit (Cat no. 74104, QIAGEN, Inc., Valencia, Calif.) according to the manufacturer's instructions. cDNA synthesis was performed using the SuperScript First-Strand Synthesis System for RT-PCR kit (Cat no. 11904-018, Invitrogen, Corp.) and oligo (dT) primers. Gene activity was determined by the Real-Time quantitative RT-PCR (qRT-PCR) technique.

Real Time Quantitative RT-PCR (qRT-PCR)

Real-Time qRT-PCR was performed using MJ Research Opticon 2 continuous fluorescence detector. For qRT-PCR 40 ng of cDNA obtained from cultured HaCaT, HeLa, and NIH3T3 cells (siRNA treated and untreated), was amplified using the MJ Research DyNAmo Hot Start SYBR Green qPCR kit (Cat no. F-410L, MJ Research, Inc., Waltham, Mass. The DyNAmo Hot Start SYBR Green qPCR kit is a master mix of a modified hot start DNA polymerase with SYBR Green I and the appropriate buffers, all of which have been optimized for real-time quantitative analysis with the MJ Research Opticon 2. PCR amplification of cDNA samples was performed in 96 well optical plates under the following conditions:

1. Incubate at 95.0 C. tor 00:10:00 2. Incubate at 95.0 C. for 00:00:20 3. Incubate at 55.0 C. for 00:00:30 4. Incubate at 72.0 C. for 00:00:40 5. Plate Read 6. Incubate at 77.0 C. for 00:00:01 7. Plate Read 8. Go to line 3 for 39 more times 9. Incubate at 72.0 C. for 00:05:00 10. Melting Curve from 65.0 C. to 95.0 C. read every 0.2 C. hold 00:00:01 11. Incubate at 72.0 C. for 00:05:00 END

The list of PCR primers used for Real Time PCR amplifications is given in the following table.

PCR primers used for Real-Time RT-PCR amplifications of mouse and human hairless, mouse glyceraldehyde-3-phosphate dehydrogenase gene, and hypoxanthine guanine phosphoriboxyltransferase 1 (hprt). (HPRT was used as a normalizing internal control in mouse cells the same way GAPDH was used for the human cell lines.)

Gene Forward primer Reverse primer Hr 5′-TTCTACCGCGGTCAAACTCT-3′ 5′-TTGGTGTCAGGGATCCAAAG-3′ (SEQ ID NO: 11363) (SEQ ID NO: 11364) GAPDH 5′-AGCCACATCGCTCAGAACAC-3′ 5′-GAGGCATTGCTGATGATCTTG-3′ (SEQ ID NO: 11365) (SEQ ID NO: 11366) hr 5′-ACATCAAAGAAGAGACCCCAG-3′ 5′-TTCGCACTGGTGACAATGGAA-3′ (SEQ ID NO: 11367) (SEQ ID NO: 11368) gapdh 5′-GTGAACGGATTTGGCCGTATT-3′ 5′-TTTTGGCTCCACCCTTCAAGT-3′ (SEQ ID NO: 11369) (SEQ ID NO: 11370) hplt 5′-CCCTGGTTAAGCAGTACAGC-3′ 5′-CAGGACTAGAACACCTGCTAA-3′ (SEQ ID NO: 11371) (SEQ ID NO: 11372)

Plate readings for fluorescence levels are taken at two steps, 5 and 7. These values indicate the relative amounts of amplicon per well at a particular cycle. The raw numbers obtained from these readings were used to determine the PCR amplification efficiency. This is the measurement of fold amplification per PCR cycle, and is expressed as a fraction or percentage relative to perfect doubling. A PCR resulting in perfect doubling would exhibit 100% amplification efficiency. All of the calculations are done using the LinRegPCR program by J. M. Ruijter and C. Ramakers. The crossing threshold for the experiment is determined manually and is defined at the cycle at which amplification for all samples becomes logarithmic. The relative fold for each amplicon is then determined using the amplification efficiency and crossing threshold for that particular amplicon and normalizing it against the relative starting amounts, which is determined by the GAPDH amplification efficiency and crossing threshold that corresponds to that sample. This is done using parameters and equations set by Lui and Saint (Analytical Biochemistry 302, 52-59 (2002)). The final values can then be used to compare the fold differences in gene expression of a particular gene across several different samples or conditions.

This technique and analysis can be applied to determine the levels of hairless expression, or more specifically, the efficiency of gene silencing using hairless siRNA through comparison of the treated and untreated cell populations.

The following table shows the percentage of gene silencing observed following siRNA treatment of human HeLa and HaCaT cells. Total RNA was collected 48 hours following transfection with siRNAs for hairless (Hr) gene. Gene activity was assayed by real-time quantitative RT-PCR (qRT-PCR) technique. Percent knockdown is calculated by obtaining the ratio of the normalized level of Hr expression in treated and untreated cell populations and subtracting this value from 1 (100% expression).

Gene Expression Cell Percent RNA isolation siRNA Tested Type Knockdown time point HR#1 Hr HeLa 97.3% 48 hours HR#2 Hr HeLa 98.7% 48 hours HR#2 Hr HaCaT 95.8% 48 hours

The following table shows the percentage of gene silencing observed following siRNA treatment of mouse NIH3T3 cells. Total RNA was collected 48 hours following transfection with siRNAs for hairless (hr) and glyceraldehyde-3-phosphate dehydrogenase (gpdh) genes. Gene activity was assayed by real-time quantitative RT-PCR (qRT-PCR) technique. Percent knockdown is calculated by obtaining the ratio of the normalized level of hr and gapdh expression in treated and untreated cell populations and subtracting this value from 1 (100% expression).

Gene Expression Cell Percent RNA isolation siRNA Tested Type Knockdown time point hr#1 Hr NIH3T3 99.3% 48 hours hr#2 Hr NIH3T3 99.17% 48 hours Gapdh Gapdh NIH3T3 99.3% 48 hours

EXAMPLE 2 In Vivo Testing: A Phase 1 Clinical Trial of Anti-Hairless siRNA

The goal of this study is to establish the safety of topical application of anti-hairless siRNA (Trichozyme) in healthy human subjects at a dose of 10 μg daily, administered over a period of 3 months.

Inhibition of gene expression using or siRNA technology is a recently developing area of therapy. Several recent studies indicate the usefulness of such therapeutic strategies in a number of different conditions. Our preliminary in vivo studies demonstrated the inhibition of hairless mRNA can be used to permanently inhibit hair growth in experimental animals. Briefly, they inhibit translation from the mRNA transcript originating from the human hairless gene, the first known gene participating in the regulation of the human hair cycle as identified by our group earlier, preventing the synthesis of functional hairless protein. Presence of hairless protein is necessary for uninterrupted hair cycling, and lack of hairless gene expression due to a deleterious mutation or temporary inhibition leads to a permanent inhibition of hair growth and the involution of hair follicles as evidenced by our own in vivo trials in animal models. The successful translation of the result of animal studies to human application leads to a strategy to obtain permanent inhibition of hair growth by temporary topical treatment with Trichozyme.

Study Design

This will be an open label, uncontrolled, safety study. Monitoring for side effects, alterations in hematology, serum chemistries and urine analysis will continue during the 3 month treatment period as well as during the 6 month follow up period after the application is stopped. Subjects will be seen daily by Study personnel during the treatment period and monthly during the follow-up period. The Study will not offer treatment of any side effects that develop.

We will enlist 20 subjects, 10 of which will be treated with the siRNA in an isopropranol or liposomal based vehicle, the other 10 subject will receive treatment with vehicle only. Hair from the dorsal surface of the left forearm will be removed by waxing before applying treatment during the first 30 days of the study. Treatment will consist of topical application of an isopropranol based solution alone or containing anti-hairless siRNA over a 15 cm² area of the dorsal surface of the left forearm using a glass rod. Ample time will be left for absorption.

Subjective side effects, alterations in serum chemistry, hematology and urine analysis will be monitored as well as serum and urine isopropranol level and presence of Trichozymes in serum and urine samples. Photography of the treatment area and hair count will be performed during the initial visit and weekly afterwards during the treatment period of the study then monthly during the follow-up period of the study.

Study Procedures

Before entering in the study subjects will sign an informed consent for disclosure of medical records. A screening questionnaire will be completed as well as a review of medical records to exclude any preexisting medical conditions affecting hair growth or other preexisting diseases listed as exclusion criteria.

Laboratory evaluation—Fasting blood and urine samples will be obtained for the following tests: (a) Hematology—hemoglobin and hematocrit, CBC with differential and platelet count, (b) Serum Chemistry—sodium, total bilirubin, potassium, glucose, chloride, alkaline phosphatase, calcium, AST, ALT, inorganic phosphorus, BUN, creatinine, bicarbonate; (c) urinalysis—protein, glucose, pH, Ketones, nitrates, blood (d.) pregnancy test.

Screening/Baseline Visit—Informed consent for study participation signed. Complete history (including record of systemic and topical medication, both prescription and non-prescription). Physical exam—Comprehensive skin exam and photography of the treatment area and hair count. (e) Review criteria for inclusion/exclusion and determine eligibility.

Daily Clinic Visits for treatment—waxing of the treatment area (for first 30 days only) followed by topical application of Treatment. Blood and urine samples for Hematology, Serum chemistry, Urine analysis, Isporopranol serum/urine level and siRNA detection in serum/urine will be obtained monthly. Photography of the treatment area and hair count will be performed weekly. Subjects will be interviewed for subjective side effects weekly.

Monthly Clinic Visits for follow-up—Blood and urine samples for Hematology, Serum chemistry, Urine analysis, Isporopranol serum/urine level and siRNA detection in serum/urine will be obtained. Photography of the treatment area and hair count. Subjects will be interviewed for subjective side effects.

Study Site—Subjects will be seen at the clinical facilities for the study.

Study Drugs

siRNAs for the study are are oligonucleotides with RNAi activity that is specific to mRNA sequences present in the human hairless mRNA. This study will utilize a mixture of 8-10 different siRNAs. To date there is no data available of topical cutaneous application of any deoxy-ribozymes. The siRNAs to be used in this study will be provided by a manufacturer offering custom synthesized human grade oligonucleotides.

Study Questionnaires

All subjects will complete study questionnaires at baseline.

Study Subjects

Criteria—Inclusion—(i) Study subjects must be 18 to 35 years of age, female of Hispanic ethnicity. (ii) Have no previous medical history of hair growth abnormalities or endocrine, renal, autoimmune, cardiac, pulmonary, hematological or psychiatric disorders. (iii) Other inclusion criteria: (iv) The subject has provided written informed consent prior to administration of any study-related procedures. (v) The subject has been using adequate contraception since her last menses and will use adequate contraception during the study, is not lactating, and has a documented negative serum pregnancy test within 14 days prior to the first dose of study medication. (vi) The subject is willing to abstain from any voluntary alteration of body hair of the treated area. (vii) The subject is willing to abstain from application of prescription and over the counter topical medications for the duration of the study, including moisturizers, emollients and sunscreens. (viii) The subject is willing to return for scheduled follow-up visits for the duration of the study. (ix) The subject must meet the following laboratory criteria during a time not to exceed 8 weeks prior to randomization: 1) hemoglobin level of greater than 12.0 (women) or 13.0 (men); 2) WBC count greater than 3000/mm³; 3) platelet count greater than 125,000; 4) BUN within normal limits; 5) electrolytes within normal limits; 6) creatinine≦1.5×ULN; 7) AST≦1.5×ULN; 8) ALT≦1.5×ULN; 9) total bilirubin within normal limits; and 10) creatinin clearance within normal limits.

Exclusion—(i) existence of any medical conditions listed above. (ii) any laboratory values that do not meet the criteria listed above. (iii) Pregnancy or lactation. (iv) Invasive cancer or anticipated hormonal, chemo-, or radiotherapy while participating in the study. (v) Any medical or psychosocial condition that, in the opinion of the investigator, could jeopardize subject's participation in this study.

Recruitment of Subjects

Potential subjects for this Study will be recruited from among residents in proximity to the study site because of the daily visit requirements. Subjects with Hispanic ethnicity will be recruited to avoid inter-ethnicity variations of hair density and follicle site as well as blonde hair that is less appropriate for complete hair count and photography.

EXAMPLE 3 Hair Removal Using In Vivo Knockdown of Hairless mRNA

It was demonstrated that inhibiting the expression of hairless mRNA in an animal model system created essentially a hairless condition. This exemplary test was conducted using ribozymes targeting the hairless mRNA, and is described in Cserhalmi-Friedman et al., Exp Dermatol., 2004 March; 13(3):155-62, which is incorporated herein by reference in its entirety.

Short Term Results in Newborn Mice

The mice, who were gender-matched littermates, were sacrificed after four weeks of treatment that started immediately after the animals were born. All treated mice demonstrated a variable degree of visible sparseness of hair at the treated area of the back, which was not observed in the control animals treated with nonspecific deoxyribozymes. The specimens taken from the control animal show the presence of large number of hair follicles in anagen V stage, corresponding to the clinical appearance. In contrast, the samples taken from the treated mice demonstrate the presence of smaller hair follicles with morphological features similar to those observed in anagen III stage (i.e.: hair shaft did not reach the level of the sebaceous gland). A large portion of the hair follicles in the treated region showed delayed anagen development as well as significant dilatation of the hair canal, reminiscent of utricles characteristic of the hairless phenotype. In these samples, we observed several large cysts filled with keratinous material and remnants of coiled and degraded hair follicles. These dermal cysts are believed to be the result of hair follicle disintegration and abnormal hair shaft formation. Importantly, dermal cysts are hallmark features of the hairless phenotype and usually contain either keratinous mass or a degraded hair shaft, as seen in the sample taken from the skin of a hairless mouse. The inhibition of hair growth, formation of the utriculi, and appearance of dermal cysts were present in all treated mice, but were not detected in any control animals.

b. Long Term Results in Newborn Mice

Another group of littermates of identical gender was sacrificed after seven weeks of treatment that started immediately after the animals were born. A noticeable decrease in the density of hair was present in the treated animals as compared to the control mice treated with on specific deoxyribozymes. The sample from the control animals showed the presence of regularly spaced telogen hair follicles. In the treated area, we observed a significantly decreased number of follicles with large areas of the skin devoid of any hair follicles at all. In the treated area, we detected the presence of large cysts filled with amorphous keratin material, corresponding to dermal cysts, which are characteristics of the hairless phenotype. Histopathology of the treated area showed the presence of small dense groups of cells with condensed nuclei in the deep dermis. These cell groups were reminiscent of detached dermal papillae, which are typically found in hairless mice. The lack of hair follicles, the presence of dermal cysts and the detached dermal papillae were present in every treated animal, while all the control animals showed the presence of evenly spaced telogen follicles.

c. Results in Depilated Animals

This group of eight week old female littermates was wax-depilated and subsequently sacrificed after four weeks of treatment that began immediately after the depilation. Clinically, the control animals showed active hair regrowth in the depilated area.

In contrast, the hair regrowth was of lesser magnitude in the treated mice, and the hair became sparse (not shown). Histopathology of the control mouse skin shows the presence of a large number of hair follicles in advanced anagen. In the samples taken from the treated animals, the treated regions could be easily identified by the lack of depilation-induced hair regrowth. These untreated hair follicles were identical to those observed in the control animals treated with nonspecific deoxyribozymes. On histology, the treated area with small telogen hair follicles could be easily distinguished from neighboring untreated area with hair follicles at advanced anagen stages, suggesting that in the treated portion of skin the hair follicles were not able to enter depilation-induced anagen at all, or exhibited much lower growth rates compare to control skin.

All patents and other references cited in the specification are indicative of the level of skill of those skilled in the art to which the invention pertains, and are incorporated by reference in their entireties, including any tables and figures, to the same extent as if each reference had been incorporated by reference in its entirety individually.

One skilled in the art would readily appreciate that the present invention is well adapted to obtain the ends and advantages mentioned, as well as those inherent therein. The methods, variances, and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. For example, variations can be made to the number, length, and chemical modifications in the dsRNA. Thus, such additional embodiments are within the scope of the present invention and the following claims.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

Also, unless indicated to the contrary, where various numerical values are provided for embodiments, additional embodiments are described by taking any 2 different values as the endpoints of a range. Such ranges are also within the scope of the described invention.

Thus, additional embodiments are within the scope of the invention and within the following claims.

TABLE 1 cDNA Human Hairless 19-mer Target Sequences and Complement Referenced to NM_005144- Homo sapiens hairless homolog (mouse) (HR), transcript variant 1, complete mRNA (1-5699 bp). (SEQ ID NO: for Sense equals (2X − 1) SEQ ID NO: for Antisense equals (2X), (e.g. where X = 1 Sense has SEQ ID NO: 1 and Antisense has SEQ ID NO: 2) X Sense (5′-3′) Antisense (5′-3′) 1 TCTCCCGGGAGCCACTCCC GGGAGTGGCTCCCGGGAGA 2 CTCCCGGGAGCCACTCCCA TGGGAGTGGCTCCCGGGAG 3 TCCCGGGAGCCACTCCCAT ATGGGAGTGGCTCCCGGGA 4 CCCGGGAGCCACTCCCATG CATGGGAGTGGCTCCCGGG 5 CCGGGAGCCACTCCCATGG CCATGGGAGTGGCTCCCGG 6 CGGGAGCCACTCCCATGGG CCCATGGGAGTGGCTCCCG 7 GGGAGCCACTCCCATGGGC GCCCATGGGAGTGGCTCCC 8 GGAGCCACTCCCATGGGCG CGCCCATGGGAGTGGCTCC 9 GAGCCACTCCCATGGGCGC GCGCCCATGGGAGTGGCTC 10 AGCCACTCCCATGGGCGCC GGCGCCCATGGGAGTGGCT 11 GCCACTCCCATGGGCGCCT AGGCGCCCATGGGAGTGGC 12 CCACTCCCATGGGCGCCTC GAGGCGCCCATGGGAGTGG 13 CACTCCCATGGGCGCCTCT AGAGGCGCCCATGGGAGTG 14 ACTCCCATGGGCGCCTCTC GAGAGGCGCCCATGGGAGT 15 CTCCCATGGGCGCCTCTCC GGAGAGGCGCCCATGGGAG 16 TCCCATGGGCGCCTCTCCA TGGAGAGGCGCCCATGGGA 17 CCCATGGGCGCCTCTCCAG CTGGAGAGGCGCCCATGGG 18 CCATGGGCGCCTCTCCAGC GCTGGAGAGGCGCCCATGG 19 CATGGGCGCCTCTCCAGCC GGCTGGAGAGGCGCCCATG 20 ATGGGCGCCTCTCCAGCCC GGGCTGGAGAGGCGCCGAT 21 TGGGCGCCTCTCCAGCCCC GGGGCTGGAGAGGCGCCCA 22 GGGCGCCTCTCCAGCCCCT AGGGGCTGGAGAGGCGCCC 23 GGCGCCTCTCCAGCCCCTG CAGGGGCTGGAGAGGCGCC 24 GCGCCTCTCCAGCCCCTGG CCAGGGGCTGGAGAGGCGC 25 CGCCTCTCCAGCCCCTGGC GCCAGGGGCTGGAGAGGCG 26 GCCTCTCCAGCCCCTGGCC GGCCAGGGGCTGGAGAGGC 27 CCTCTCCAGCCCCTGGCCT AGGCCAGGGGCTGGAGAGG 28 CTCTCCAGCCCCTGGCCTG CAGGCCAGGGGCTGGAGAG 29 TCTCCAGCCCCTGGCCTGG CCAGGCCAGGGGCTGGAGA 30 CTCCAGCCCCTGGCCTGGA TCCAGGCCAGGGGCTGGAG 31 TCCAGCCCCTGGCCTGGAA TTCCAGGCCAGGGGCTGGA 32 CCAGCCCCTGGCCTGGAAG CTTCCAGGCCAGGGGCTGG 33 CAGCCCCTGGCCTGGAAGC GCTTCCAGGCCAGGGGCTG 34 AGCCCCTGGCCTGGAAGCA TGCTTCCAGGCCAGGGGCT 35 GCCCCTGGCCTGGAAGCAC GTGCTTCCAGGCCAGGGGC 36 CCCCTGGCCTGGAAGCACC GGTGCTTCCAGGCCAGGGG 37 CCCTGGCCTGGAAGCACCA TGGTGCTTCCAGGCCAGGG 38 CCTGGCCTGGAAGCACCAG CTGGTGCTTCCAGGCCAGG 39 CTGGCCTGGAAGCACCAGG CCTGGTGCTTCCAGGCCAG 40 TGGCCTGGAAGCACCAGGA TCCTGGTGCTTCCAGGCCA 41 GGCCTGGAAGCACCAGGAA TTCCTGGTGCTTCCAGGCC 42 GCCTGGAAGCACCAGGAAC GTTCCTGGTGCTTCCAGGC 43 CCTGGAAGCACCAGGAACC GGTTCCTGGTGCTTCCAGG 44 CTGGAAGCACCAGGAACCC GGGTTCCTGGTGCTTCCAG 45 TGGAAGCACCAGGAACCCT AGGGTTCCTGGTGCTTCCA 46 GGAAGCACCAGGAACCCTG CAGGGTTCCTGGTGCTTCC 47 GAAGCACCAGGAACCCTGG CCAGGGTTCCTGGTGCTTC 48 AAGCACCAGGAACCCTGGG CCCAGGGTTCCTGGTGCTT 49 AGCACCAGGAACCCTGGGG CCCCAGGGTTCCTGGTGCT 50 GCACCAGGAACCCTGGGGA TCCCCAGGGTTCCTGGTGC 51 CACCAGGAACCCTGGGGAT ATCCCCAGGGTTCCTGGTG 52 ACCAGGAACCCTGGGGATG CATCCCCAGGGTTCCTGGT 53 CCAGGAACCCTGGGGATGG CCATCCCCAGGGTTCCTGG 54 CAGGAACCCTGGGGATGGG CCCATCCCCAGGGTTCCTG 55 AGGAACCCTGGGGATGGGG CCCCATCCCCAGGGTTCCT 56 GGAACCCTGGGGATGGGGC GCCCCATCCCCAGGGTTCC 57 GAACCCTGGGGATGGGGCA TGCCCCATCCCCAGGGTTC 58 AACCCTGGGGATGGGGCAG CTGCCCCATCCCCAGGGTT 59 ACCCTGGGGATGGGGCAGA TCTGCCCCATCCCCAGGGT 60 CCCTGGGGATGGGGCAGAC GTCTGCCCCATCCCCAGGG 61 CCTGGGGATGGGGCAGACC GGTCTGCCCCATCCCCAGG 62 CTGGGGATGGGGCAGACCC GGGTCTGCCCCATCCCCAG 63 TGGGGATGGGGCAGACCCT AGGGTCTGCCCCATCCCCA 64 GGGGATGGGGCAGACCCTC GAGGGTCTGCCCCATCCCC 65 GGGATGGGGCAGACCCTCA TGAGGGTCTGCCCCATCCC 66 GGATGGGGCAGACCCTCAC GTGAGGGTCTGCCCCATCC 67 GATGGGGCAGACCCTCACA TGTGAGGGTCTGCCCCATC 68 ATGGGGCAGACCCTCACAG CTGTGAGGGTCTGCCCCAT 69 TGGGGCAGACCCTCACAGC GCTGTGAGGGTCTGCCCCA 70 GGGGCAGACCCTCACAGCC GGCTGTGAGGGTCTGCCCC 71 GGGCAGACCCTCACAGCCC GGGCTGTGAGGGTCTGCCC 72 GGCAGACCCTCACAGCCCG CGGGCTGTGAGGGTCTGCC 73 GCAGACCCTCACAGCCCGG CCGGGCTGTGAGGGTCTGC 74 CAGACCCTCACAGCCCGGG CCCGGGCTGTGAGGGTCTG 75 AGACCCTCACAGCCCGGGG CCCCGGGCTGTGAGGGTCT 76 GACCCTCACAGCCCGGGGT ACCCCGGGCTGTGAGGGTC 77 ACCCTCACAGCCCGGGGTC GACCCCGGGCTGTGAGGGT 78 CCCTCACAGCCCGGGGTCT AGACCCCGGGCTGTGAGGG 79 CCTCACAGCCCGGGGTCTG CAGACCCCGGGCTGTGAGG 80 CTCACAGCCCGGGGTCTGG CCAGACCCCGGGCTGTGAG 81 TCACAGCCCGGGGTCTGGA TCCAGACCCCGGGCTGTGA 82 CACAGCCCGGGGTCTGGAG CTCCAGACCCCGGGCTGTG 83 ACAGCCCGGGGTCTGGAGC GCTCCAGACCCCGGGCTGT 84 CAGCCCGGGGTCTGGAGCC GGCTCCAGACCCCGGGCTG 85 AGCCCGGGGTCTGGAGCCG CGGCTCCAGACCCCGGGCT 86 GCCCGGGGTCTGGAGCCGG CCGGCTCCAGACCCCGGGC 87 CCCGGGGTCTGGAGCCGGT ACCGGCTCCAGACCCCGGG 88 CCGGGGTCTGGAGCCGGTG CACCGGCTCCAGACCCCGG 89 CGGGGTCTGGAGCCGGTGT ACACCGGCTCCAGACCCCG 90 GGGGTCTGGAGCCGGTGTC GACACCGGCTCCAGACCCC 91 GGGTCTGGAGCCGGTGTCG CGACACCGGCTCCAGACCC 92 GGTCTGGAGCCGGTGTCGG CCGACACCGGCTCCAGACC 93 GTCTGGAGCCGGTGTCGGA TCCGACACCGGCTCCAGAC 94 TCTGGAGCCGGTGTCGGAG CTCCGACACCGGCTCCAGA 95 CTGGAGCCGGTGTCGGAGC GCTCCGACACCGGCTCCAG 96 TGGAGCCGGTGTCGGAGCT AGCTCCGACACCGGCTCCA 97 GGAGCCGGTGTCGGAGCTC GAGCTCCGACACCGGCTCC 98 GAGCCGGTGTCGGAGCTCA TGAGCTCCGACACCGGCTC 99 AGCCGGTGTCGGAGCTCAT ATGAGCTCCGACACCGGCT 100 GCCGGTGTCGGAGCTCATC GATGAGCTCCGACACCGGC 101 CCGGTGTCGGAGCTCATCT AGATGAGCTCCGACACCGG 102 CGGTGTCGGAGCTCATCTG CAGATGAGCTCCGACACCG 103 GGTGTCGGAGCTCATCTGG CCAGATGAGCTCCGACACC 104 GTGTCGGAGCTCATCTGGG CCCAGATGAGCTCCGACAC 105 TGTCGGAGCTCATCTGGGC GCCCAGATGAGCTCCGACA 106 GTCGGAGCTCATCTGGGCC GGCCCAGATGAGCTCCGAC 107 TCGGAGCTCATCTGGGCCC GGGCCCAGATGAGCTCCGA 108 CGGAGCTCATCTGGGCCCA TGGGCCCAGATGAGCTCCG 109 GGAGCTCATCTGGGCCCAT ATGGGCCCAGATGAGCTCC 110 GAGCTCATCTGGGCCCATG CATGGGCCCAGATGAGCTC 111 AGCTCATCTGGGCCCATGA TCATGGGCCCAGATGAGCT 112 GCTCATCTGGGCCCATGAC GTCATGGGCCCAGATGAGC 113 CTCATCTGGGCCCATGACC GGTCATGGGCCCAGATGAG 114 TCATCTGGGCCCATGACCT AGGTCATGGGCCCAGATGA 115 CATCTGGGCCCATGACCTC GAGGTCATGGGCCCAGATG 116 ATCTGGGCCCATGACCTCT AGAGGTCATGGGCCCAGAT 117 TCTGGGCCCATGACCTCTC GAGAGGTCATGGGCCCAGA 118 CTGGGCCCATGACCTCTCC GGAGAGGTCATGGGCCCAG 119 TGGGCCCATGACCTCTCCA TGGAGAGGTCATGGGCCCA 120 GGGCCCATGACCTCTCCAG CTGGAGAGGTCATGGGCCC 121 GGCCCATGACCTCTCCAGA TCTGGAGAGGTCATGGGCC 122 GCCCATGACCTCTCCAGAC GTCTGGAGAGGTCATGGGC 123 CCCATGACCTCTCCAGACA TGTCTGGAGAGGTCATGGG 124 CCATGACCTCTCCAGACAT ATGTCTGGAGAGGTCATGG 125 CATGACCTCTCCAGACATT AATGTCTGGAGAGGTCATG 126 ATGACCTCTCCAGACATTT AAATGTCTGGAGAGGTCAT 127 TGACCTCTCCAGACATTTG CAAATGTCTGGAGAGGTCA 128 GACCTCTCCAGACATTTGG CCAAATGTCTGGAGAGGTC 129 ACCTCTCCAGACATTTGGC GCCAAATGTCTGGAGAGGT 130 CCTCTCCAGACATTTGGCA TGCCAAATGTCTGGAGAGG 131 CTCTCCAGACATTTGGCAA TTGCCAAATGTCTGGAGAG 132 TCTCCAGACATTTGGCAAA TTTGCCAAATGTCTGGAGA 133 CTCCAGACATTTGGCAAAA TTTTGCCAAATGTCTGGAG 134 TCCAGACATTTGGCAAAAT ATTTTGCCAAATGTCTGGA 135 CCAGACATTTGGCAAAATC GATTTTGCCAAATGTCTGG 136 CAGACATTTGGCAAAATCA TGATTTTGCCAAATGTCTG 137 AGACATTTGGCAAAATCAA TTGATTTTGCCAAATGTCT 138 GACATTTGGCAAAATCAAG CTTGATTTTGCCAAATGTC 139 ACATTTGGCAAAATCAAGG CCTTGATTTTGCCAAATGT 140 CATTTGGCAAAATCAAGGC GCCTTGATTTTGCCAAATG 141 ATTTGGCAAAATCAAGGCC GGCCTTGATTTTGCCAAAT 142 TTTGGCAAAATCAAGGCCC GGGCCTTGATTTTGCCAAA 143 TTGGCAAAATCAAGGCCCT AGGGCCTTGATTTTGCCAA 144 TGGCAAAATCAAGGCCCTT AAGGGCCTTGATTTTGCCA 145 GGCAAAATCAAGGCCCTTA TAAGGGCCTTGATTTTGCC 146 GCAAAATCAAGGCCCTTAG CTAAGGGCCTTGATTTTGC 147 CAAAATCAAGGCCCTTAGA TCTAAGGGCCTTGATTTTG 148 AAAATCAAGGCCCTTAGAC GTCTAAGGGCCTTGATTTT 149 AAATCAAGGCCCTTAGACC GGTCTAAGGGCCTTGATTT 150 AATCAAGGCCCTTAGACCA TGGTCTAAGGGCCTTGATT 151 ATCAAGGCCCTTAGACCAG CTGGTCTAAGGGCCTTGAT 152 TCAAGGCCCTTAGACCAGG CCTGGTCTAAGGGCCTTGA 153 CAAGGCCCTTAGACCAGGG CCCTGGTCTAAGGGCCTTG 154 AAGGCCCTTAGACCAGGGA TCCCTGGTCTAAGGGCCTT 155 AGGCCCTTAGACCAGGGAC GTCCCTGGTCTAAGGGCCT 156 GGCCCTTAGACCAGGGACA TGTCCCTGGTCTAAGGGCC 157 GCCCTTAGACCAGGGACAG CTGTCCCTGGTCTAAGGGC 158 CCCTTAGACCAGGGACAGA TCTGTCCCTGGTCTAAGGG 159 CCTTAGACCAGGGACAGAC GTCTGTCCCTGGTCTAAGG 160 CTTAGACCAGGGACAGACC GGTCTGTCCCTGGTCTAAG 161 TTAGACCAGGGACAGACCC GGGTCTGTCCCTGGTCTAA 162 TAGACCAGGGACAGACCCA TGGGTCTGTCCCTGGTCTA 163 AGACCAGGGACAGACCCAA TTGGGTCTGTCCCTGGTCT 164 GACCAGGGACAGACCCAAG CTTGGGTCTGTCCCTGGTC 165 ACCAGGGACAGACCCAAGC GCTTGGGTCTGTCCCTGGT 166 CCAGGGACAGACCCAAGCC GGCTTGGGTCTGTCCCTGG 167 CAGGGACAGACCCAAGCCC GGGCTTGGGTCTGTCCCTG 168 AGGGACAGACCCAAGCCCA TGGGCTTGGGTCTGTCCCT 169 GGGACAGACCCAAGCCCAG CTGGGCTTGGGTCTGTCCC 170 GGACAGACCCAAGCCCAGG CCTGGGCTTGGGTCTGTCC 171 GACAGACCCAAGCCCAGGC GCCTGGGCTTGGGTCTGTC 172 ACAGACCCAAGCCCAGGCC GGCCTGGGCTTGGGTCTGT 173 CAGACCCAAGCCCAGGCCC GGGCCTGGGCTTGGGTCTG 174 AGACCCAAGCCCAGGCCCT AGGGCCTGGGCTTGGGTCT 175 GACCCAAGCCCAGGCCCTC GAGGGCCTGGGCTTGGGTC 176 ACCCAAGCCCAGGCCCTCC GGAGGGCCTGGGCTTGGGT 177 CCCAAGCCCAGGCCCTCCC GGGAGGGCCTGGGCTTGGG 178 CCAAGCCCAGGCCCTCCCA TGGGAGGGCCTGGGCTTGG 179 CAAGCCCAGGCCCTCCCAG CTGGGAGGGCCTGGGCTTG 180 AAGCCCAGGCCCTCCCAGA TCTGGGAGGGCCTGGGCTT 181 AGCCCAGGCCCTCCCAGAG CTCTGGGAGGGCCTGGGCT 182 GCCCAGGCCCTCCCAGAGG CCTCTGGGAGGGCCTGGGC 183 CCCAGGCCCTCCCAGAGGT ACCTCTGGGAGGGCCTGGG 184 CCAGGCCCTCCCAGAGGTC GACCTCTGGGAGGGCCTGG 185 CAGGCCCTCCCAGAGGTCC GGACCTCTGGGAGGGCCTG 186 AGGCCCTCCCAGAGGTCCT AGGACCTCTGGGAGGGCCT 187 GGCCCTCCCAGAGGTCCTA TAGGACCTCTGGGAGGGCC 188 GCCCTCCCAGAGGTCCTAG CTAGGACCTCTGGGAGGGC 189 CCCTCCCAGAGGTCCTAGG CCTAGGACCTCTGGGAGGG 190 CCTCCCAGAGGTCCTAGGA TCCTAGGACCTCTGGGAGG 191 CTCCCAGAGGTCCTAGGAC GTCCTAGGACCTCTGGGAG 192 TCCCAGAGGTCCTAGGACG CGTCCTAGGACCTCTGGGA 193 CCCAGAGGTCCTAGGACGC GCGTCCTAGGACCTCTGGG 194 CCAGAGGTCCTAGGACGCA TGCGTCCTAGGACCTCTGG 195 CAGAGGTCCTAGGACGCAA TTGCGTCCTAGGACCTCTG 196 AGAGGTCCTAGGACGCAAC GTTGCGTCCTAGGACCTCT 197 GAGGTCCTAGGACGCAACC GGTTGCGTCCTAGGACCTC 198 AGGTCCTAGGACGCAACCC GGGTTGCGTCCTAGGACCT 199 GGTCCTAGGACGCAACCCT AGGGTTGCGTCCTAGGACC 200 GTCCTAGGACGCAACCCTT AAGGGTTGCGTCCTAGGAC 201 TCCTAGGACGCAACCCTTT AAAGGGTTGCGTCCTAGGA 202 CCTAGGACGCAACCCTTTG CAAAGGGTTGCGTCCTAGG 203 CTAGGACGCAACCCTTTGT ACAAAGGGTTGCGTCCTAG 204 TAGGACGCAACCCTTTGTG CACAAAGGGTTGCGTCCTA 205 AGGACGCAACCCTTTGTGC GCACAAAGGGTTGCGTCCT 206 GGACGCAACCCTTTGTGCC GGCACAAAGGGTTGCGTCC 207 GACGCAACCCTTTGTGCCC GGGCACAAAGGGTTGCGTC 208 ACGCAACCCTTTGTGCCCT AGGGCACAAAGGGTTGCGT 209 CGCAACCCTTTGTGCCCTT AAGGGCACAAAGGGTTGCG 210 GCAACCCTTTGTGCCCTTG CAAGGGCACAAAGGGTTGC 211 CAACCCTTTGTGCCCTTGG CCAAGGGCACAAAGGGTTG 212 AACCCTTTGTGCCCTTGGG CCCAAGGGCACAAAGGGTT 213 ACCCTTTGTGCCCTTGGGC GCCCAAGGGCACAAAGGGT 214 CCCTTTGTGCCCTTGGGCT AGCCCAAGGGCACAAAGGG 215 CCTTTGTGCCCTTGGGCTC GAGCCCAAGGGCACAAAGG 216 CTTTGTGCCCTTGGGCTCT AGAGCCCAAGGGCACAAAG 217 TTTGTGCCCTTGGGCTCTG CAGAGCCCAAGGGCACAAA 218 TTGTGCCCTTGGGCTCTGG CCAGAGCCCAAGGGCACAA 219 TGTGCCCTTGGGCTCTGGA TCCAGAGCCCAAGGGCACA 220 GTGCCCTTGGGCTCTGGAA TTCCAGAGCCCAAGGGCAC 221 TGCCCTTGGGCTCTGGAAG CTTCCAGAGCCCAAGGGCA 222 GCCCTTGGGCTCTGGAAGA TCTTCCAGAGCCCAAGGGC 223 CCCTTGGGCTCTGGAAGAG CTCTTCCAGAGCCCAAGGG 224 CCTTGGGCTCTGGAAGAGG CCTCTTCCAGAGCCCAAGG 225 CTTGGGCTCTGGAAGAGGT ACCTCTTCCAGAGCCCAAG 226 TTGGGCTCTGGAAGAGGTT AACCTCTTCCAGAGCCCAA 227 TGGGCTCTGGAAGAGGTTT AAACCTCTTCCAGAGCCCA 228 GGGCTCTGGAAGAGGTTTG CAAACCTCTTCCAGAGCCC 229 GGCTCTGGAAGAGGTTTGG CCAAACCTCTTCCAGAGCC 230 GCTCTGGAAGAGGTTTGGG CCCAAACCTCTTCCAGAGC 231 CTCTGGAAGAGGTTTGGGA TCCCAAACCTCTTCCAGAG 232 TCTGGAAGAGGTTTGGGAA TTCCCAAACCTCTTCCAGA 233 CTGGAAGAGGTTTGGGAAG CTTCCCAAACCTCTTCCAG 234 TGGAAGAGGTTTGGGAAGG CCTTCCCAAACCTCTTCCA 235 GGAAGAGGTTTGGGAAGGG CCCTTCCCAAACCTCTTCC 236 GAAGAGGTTTGGGAAGGGT ACCCTTCCCAAACCTCTTC 237 AAGAGGTTTGGGAAGGGTT AACCCTTCCCAAACCTCTT 238 AGAGGTTTGGGAAGGGTTT AAACCCTTCCCAAACCTCT 239 GAGGTTTGGGAAGGGTTTG CAAACCCTTCCCAAACCTC 240 AGGTTTGGGAAGGGTTTGG CCAAACCCTTCCCAAACCT 241 GGTTTGGGAAGGGTTTGGG CCCAAACCCTTCCCAAACC 242 GTTTGGGAAGGGTTTGGGG CCCCAAACCCTTCCCAAAC 243 TTTGGGAAGGGTTTGGGGT ACCCCAAACCCTTCCCAAA 244 TTGGGAAGGGTTTGGGGTG CACCCCAAACCCTTCCCAA 245 TGGGAAGGGTTTGGGGTGG CCACCCCAAACCCTTCCCA 246 GGGAAGGGTTTGGGGTGGA TCCACCCCAAACCCTTCCC 247 GGAAGGGTTTGGGGTGGAA TTCCACCCCAAACCCTTCC 248 GAAGGGTTTGGGGTGGAAG CTTCCACCCCAAACCCTTC 249 AAGGGTTTGGGGTGGAAGA TCTTCCACCCCAAACCCTT 250 AGGGTTTGGGGTGGAAGAT ATCTTCCACCCCAAACCCT 251 GGGTTTGGGGTGGAAGATG CATCTTCCACCCCAAACCC 252 GGTTTGGGGTGGAAGATGG CCATCTTCCACCCCAAACC 253 GTTTGGGGTGGAAGATGGC GCCATCTTCCACCCCAAAC 254 TTTGGGGTGGAAGATGGCA TGCCATCTTCCACCCCAAA 255 TTGGGGTGGAAGATGGCAA TTGCCATCTTCCACCCCAA 256 TGGGGTGGAAGATGGCAAA TTTGCCATCTTCCACCCCA 257 GGGGTGGAAGATGGCAAAG CTTTGCCATCTTCCACCCC 258 GGGTGGAAGATGGCAAAGA TCTTTGCCATCTTCCACCC 259 GGTGGAAGATGGCAAAGAG CCTCTTTGCCATCTTCCACC 260 GTGGAAGATGGCAAAGAGC GCTCTTTGCCATCTTCCAC 261 TGGAAGATGGCAAAGAGCA TGCTCTTTGCCATCTTCCA 262 GGAAGATGGCAAAGAGCAG CTGCTCTTTGCCATCTTCC 263 GAAGATGGCAAAGAGCAGC GCTGCTCTTTGCCATCTTC 264 AAGATGGCAAAGAGCAGCT AGCTGCTCTTTGCCATCTT 265 AGATGGCAAAGAGCAGCTT AAGCTGCTCTTTGCCATCT 266 GATGGCAAAGAGCAGCTTG CAAGCTGCTCTTTGCCATC 267 ATGGCAAAGAGCAGCTTGG CCAAGCTGCTCTTTGCCAT 268 TGGCAAAGAGCAGCTTGGC GCCAAGCTGCTCTTTGCCA 269 GGCAAAGAGCAGCTTGGCC GGCCAAGCTGCTCTTTGCC 270 GCAAAGAGCAGCTTGGCCA TGGCCAAGCTGCTCTTTGC 271 CAAAGAGCAGCTTGGCCAG CTGGCCAAGCTGCTCTTTG 272 AAAGAGCAGCTTGGCCAGG CCTGGCCAAGCTGCTCTTT 273 AAGAGCAGCTTGGCCAGGT ACCTGGCCAAGCTGCTCTT 274 AGAGCAGCTTGGCCAGGTG CACCTGGCCAAGCTGCTCT 275 GAGCAGCTTGGCCAGGTGA TCACCTGGCCAAGCTGCTC 276 AGCAGCTTGGCCAGGTGAG CTCACCTGGCCAAGCTGCT 277 GCAGCTTGGCCAGGTGAGG CCTCACCTGGCCAAGCTGC 278 CAGCTTGGCCAGGTGAGGA TCCTCACCTGGCCAAGCTG 279 AGCTTGGCCAGGTGAGGAT ATCCTCACCTGGCCAAGCT 280 GCTTGGCCAGGTGAGGATG CATCCTCACCTGGCCAAGC 281 CTTGGCCAGGTGAGGATGA TCATCCTCACCTGGCCAAG 282 TTGGCCAGGTGAGGATGAG CTCATCCTCACCTGGCCAA 283 TGGCCAGGTGAGGATGAGG CCTCATCCTCACCTGGCCA 284 GGCCAGGTGAGGATGAGGC GCCTCATCCTCACCTGGCC 285 GCCAGGTGAGGATGAGGCA TGCCTCATCCTCACCTGGC 286 CCAGGTGAGGATGAGGCAG CTGCCTCATCCTCACCTGG 287 CAGGTGAGGATGAGGCAGG CCTGCCTCATCCTCACCTG 288 AGGTGAGGATGAGGCAGGG CCCTGCCTCATCCTCACCT 289 GGTGAGGATGAGGCAGGGC GCCCTGCCTCATCCTCACC 290 GTGAGGATGAGGCAGGGCA TGCCCTGCCTCATCCTCAC 291 TGAGGATGAGGCAGGGCAG CTGCCCTGCCTCATCCTCA 292 GAGGATGAGGCAGGGCAGA TCTGCCCTGCCTCATCCTC 293 AGGATGAGGCAGGGCAGAC GTCTGCCCTGCCTCATCCT 294 GGATGAGGCAGGGCAGACA TGTCTGCCCTGCCTCATCC 295 GATGAGGCAGGGCAGACAC GTGTCTGCCCTGCCTCATC 296 ATGAGGCAGGGCAGACACA TGTGTCTGCCCTGCCTCAT 297 TGAGGCAGGGCAGACACAG CTGTGTCTGCCCTGCCTCA 298 GAGGCAGGGCAGACACAGG CCTGTGTCTGCCCTGCCTC 299 AGGCAGGGCAGACACAGGC GCCTGTGTCTGCCCTGCCT 300 GGCAGGGCAGACACAGGCC GGCCTGTGTCTGCCCTGCC 301 GCAGGGCAGACACAGGCCA TGGCCTGTGTCTGCCCTGC 302 CAGGGCAGACACAGGCCAG CTGGCCTGTGTCTGCCCTG 303 AGGGCAGACACAGGCCAGT ACTGGCCTGTGTCTGCCCT 304 GGGCAGACACAGGCCAGTG CACTGGCCTGTGTCTGCCC 305 GGCAGACAGAGGCCAGTGG CCACTGGCCTGTGTCTGCC 306 GCAGACACAGGCCAGTGGG CCCACTGGCCTGTGTCTGC 307 CAGACACAGGCCAGTGGGG CCCCACTGGCCTGTGTCTG 308 AGACACAGGCCAGTGGGGC GCCCCACTGGCCTGTGTCT 309 GACACAGGCCAGTGGGGCG CGCCCCACTGGCCTGTGTC 310 ACACAGGCCAGTGGGGCGT ACGCCCCACTGGCCTGTGT 311 CACAGGCCAGTGGGGCGTG CACGCCCCACTGGCCTGTG 312 ACAGGCCAGTGGGGCGTGC GCACGCCCCACTGGCCTGT 313 CAGGCCAGTGGGGCGTGCC GGCACGCCCCACTGGCCTG 314 AGGCCAGTGGGGCGTGCCA TGGCACGCCCCACTGGCCT 315 GGCCAGTGGGGCGTGCCAT ATGGCACGCCCCACTGGCC 316 GCCAGTGGGGCGTGCCATG CATGGCACGCCCCACTGGC 317 CCAGTGGGGCGTGCCATGT ACATGGCACGCCCCACTGG 318 CAGTGGGGCGTGCCATGTG CACATGGCACGCCCCACTG 319 AGTGGGGCGTGCCATGTGC GCACATGGCACGCCCCACT 320 GTGGGGCGTGCCATGTGCC GGCACATGGCACGCCCCAC 321 TGGGGCGTGCCATGTGCCA TGGCACATGGCACGCCCCA 322 GGGGCGTGCCATGTGCCAC GTGGCACATGGCACGCCCC 323 GGGCGTGCCATGTGCCACA TGTGGCACATGGCACGCCC 324 GGCGTGCCATGTGCCACAG CTGTGGCACATGGCACGCC 325 GCGTGCCATGTGCCACAGA TCTGTGGCACATGGCACGC 326 CGTGCCATGTGCCACAGAT ATCTGTGGCACATGGCACG 327 GTGCCATGTGCCACAGATG CATCTGTGGCACATGGCAC 328 TGCCATGTGCCACAGATGG CCATCTGTGGCACATGGCA 329 GCCATGTGCCACAGATGGA TCCATCTGTGGCACATGGC 330 CCATGTGCCACAGATGGAG CTCCATCTGTGGCACATGG 331 CATGTGCCACAGATGGAGA TCTCCATCTGTGGCACATG 332 ATGTGCCACAGATGGAGAG CTCTCCATCTGTGGCACAT 333 TGTGCCACAGATGGAGAGG CCTCTCCATCTGTGGCACA 334 GTGCCACAGATGGAGAGGA TCCTCTCCATCTGTGGCAC 335 TGCCACAGATGGAGAGGAC GTCCTCTCCATCTGTGGCA 336 GCCACAGATGGAGAGGACC GGTCCTCTCCATCTGTGGC 337 CCACAGATGGAGAGGACCA TGGTCCTCTCCATCTGTGG 338 CACAGATGGAGAGGACCAG CTGGTCCTCTCCATCTGTG 339 ACAGATGGAGAGGACCAGG CCTGGTCCTCTCCATCTGT 340 CAGATGGAGAGGACCAGGA TCCTGGTCCTCTCCATCTG 341 AGATGGAGAGGACCAGGAG CTCCTGGTCCTCTCCATCT 342 GATGGAGAGGACCAGGAGC GCTCCTGGTCCTCTCCATC 343 ATGGAGAGGACCAGGAGCC GGCTCCTGGTCCTCTCCAT 344 TGGAGAGGACCAGGAGCCA TGGCTCCTGGTCCTCTCCA 345 GGAGAGGACCAGGAGCCAG CTGGCTCCTGGTCCTCTCC 346 GAGAGGACCAGGAGCCAGT ACTGGCTCCTGGTCCTCTC 347 AGAGGACCAGGAGCCAGTG CACTGGCTCCTGGTCCTCT 348 GAGGACCAGGAGCCAGTGG CCACTGGCTCCTGGTCCTC 349 AGGACCAGGAGCCAGTGGC GCCACTGGCTCCTGGTCCT 350 GGACCAGGAGCCAGTGGCC GGCCACTGGCTCCTGGTCC 351 GACCAGGAGCCAGTGGCCC GGGCCACTGGCTCCTGGTC 352 ACCAGGAGCCAGTGGCCCG CGGGCCACTGGCTCCTGGT 353 CCAGGAGCCAGTGGCCCGG CCGGGCCACTGGCTCCTGG 354 CAGGAGCCAGTGGCCCGGC GCCGGGCCACTGGCTCCTG 355 AGGAGCCAGTGGCCCGGCA TGCCGGGCCACTGGCTCCT 356 GGAGCCAGTGGCCCGGCAG CTGCCGGGCCACTGGCTCC 357 GAGCCAGTGGCCCGGCAGG CCTGCCGGGCCACTGGCTC 358 AGCCAGTGGCCCGGCAGGC GCCTGCCGGGCCACTGGCT 359 GCCAGTGGCCCGGCAGGCA TGCCTGCCGGGCCACTGGC 360 CCAGTGGCCCGGCAGGCAC GTGCCTGCCGGGCCACTGG 361 CAGTGGCCCGGCAGGCACA TGTGCCTGCCGGGCCACTG 362 AGTGGCCCGGCAGGCACAG CTGTGCCTGCCGGGCCACT 363 GTGGCCCGGCAGGCACAGC GCTGTGCCTGCCGGGCCAC 364 TGGCCCGGCAGGCACAGCC GGCTGTGCCTGCCGGGCCA 365 GGCCCGGCAGGCACAGCCC GGGCTGTGCCTGCCGGGCC 366 GCCCGGCAGGCACAGCCCG CGGGCTGTGCCTGCCGGGC 367 CCCGGCAGGCACAGCCCGG CCGGGCTGTGCCTGCCGGG 368 CCGGCAGGCACAGCCCGGT ACCGGGCTGTGCCTGCCGG 369 CGGCAGGCACAGCCCGGTT AACCGGGCTGTGCCTGCCG 370 GGCAGGCACAGCCCGGTTG CAACCGGGCTGTGCCTGCC 371 GCAGGCACAGCCCGGTTGG CCAACCGGGCTGTGCCTGC 372 CAGGCACAGCCCGGTTGGC GCCAACCGGGCTGTGCCTG 373 AGGCACAGCCCGGTTGGCG CGCCAACCGGGCTGTGCCT 374 GGCACAGCCCGGTTGGCGT ACGCCAACCGGGCTGTGCC 375 GCACAGCCCGGTTGGCGTG CACGCCAACCGGGCTGTGC 376 CACAGCCCGGTTGGCGTGG CCACGCCAACCGGGCTGTG 377 ACAGCCCGGTTGGCGTGGG CCCACGCCAACCGGGCTGT 378 CAGCCCGGTTGGCGTGGGC GCCCACGCCAACCGGGCTG 379 AGCCCGGTTGGCGTGGGCC GGCCCACGCCAACCGGGCT 380 GCCCGGTTGGCGTGGGCCA TGGCCCACGCCAACCGGGC 381 CCCGGTTGGCGTGGGCCAG CTGGCCCACGCCAACCGGG 382 CCGGTTGGCGTGGGCCAGA TCTGGCCCACGCCAACCGG 383 CGGTTGGCGTGGGCCAGAG CTCTGGCCCACGCCAACCG 384 GGTTGGCGTGGGCCAGAGC GCTCTGGCCCACGCCAACC 385 GTTGGCGTGGGCCAGAGCG CGCTCTGGCCCACGCCAAC 386 TTGGCGTGGGCCAGAGCGC GCGCTCTGGCCCACGCCAA 387 TGGCGTGGGCCAGAGCGCC GGCGCTCTGGCCCACGCCA 388 GGCGTGGGCCAGAGCGCCC GGGCGCTCTGGCCCACGCC 389 GCGTGGGCCAGAGCGCCCA TGGGCGCTCTGGCCCACGC 390 CGTGGGCCAGAGCGCCCAT ATGGGCGCTCTGGCCCACG 391 GTGGGCCAGAGCGCCCATC GATGGGCGCTCTGGCCCAC 392 TGGGCCAGAGCGCCCATCA TGATGGGCGCTCTGGCCCA 393 GGGCCAGAGCGCCCATCAC GTGATGGGCGCTCTGGCCC 394 GGCCAGAGCGCCCATCACT AGTGATGGGCGCTCTGGCC 395 GCCAGAGCGCCCATCACTG CAGTGATGGGCGCTCTGGC 396 CCAGAGCGCCCATCACTGA TCAGTGATGGGCGCTCTGG 397 CAGAGCGCCCATCACTGAC GTCAGTGATGGGCGCTCTG 398 AGAGCGCCCATCACTGACC GGTCAGTGATGGGCGCTCT 399 GAGCGCCCATCACTGACCC GGGTCAGTGATGGGCGCTC 400 AGCGCCCATCACTGACCCG CGGGTCAGTGATGGGCGCT 401 GCGCCCATCACTGACCCGT ACGGGTCAGTGATGGGCGC 402 CGCCCATCACTGACCCGTG CACGGGTCAGTGATGGGCG 403 GCCCATCACTGACCCGTGA TCACGGGTCAGTGATGGGC 404 CCCATCACTGACCCGTGAG CTCACGGGTCAGTGATGGG 405 CCATCACTGACCCGTGAGA TCTCACGGGTCAGTGATGG 406 CATCACTGACCCGTGAGAA TTCTCACGGGTCAGTGATG 407 ATCACTGACCCGTGAGAAC GTTCTCACGGGTCAGTGAT 408 TCACTGACCCGTGAGAACT AGTTCTCACGGGTCAGTGA 409 CACTGACCCGTGAGAACTC GAGTTCTCACGGGTCAGTG 410 ACTGACCCGTGAGAACTCG CGAGTTCTCACGGGTCAGT 411 CTGACCCGTGAGAACTCGA TCGAGTTCTCACGGGTCAG 412 TGACCCGTGAGAACTCGAC GTCGAGTTCTCACGGGTCA 413 GACCCGTGAGAACTCGACT AGTCGAGTTCTCACGGGTC 414 ACCCGTGAGAACTCGACTG CAGTCGAGTTCTCACGGGT 415 CCCGTGAGAACTCGACTGC GCAGTCGAGTTCTCACGGG 416 CCGTGAGAACTCGACTGCC GGCAGTCGAGTTCTCACGG 417 CGTGAGAACTCGACTGCCC GGGCAGTCGAGTTCTCACG 418 GTGAGAACTCGACTGCCCC GGGGCAGTCGAGTTCTCAC 419 TGAGAACTCGACTGCCCCT AGGGGCAGTCGAGTTCTCA 420 GAGAACTCGACTGCCCCTG CAGGGGCAGTCGAGTTCTC 421 AGAACTCGACTGCCCCTGC GCAGGGGCAGTCGAGTTCT 422 GAACTCGACTGCCCCTGCC GGCAGGGGCAGTCGAGTTC 423 AACTCGACTGCCCCTGCCA TGGCAGGGGCAGTCGAGTT 424 ACTCGACTGCCCCTGCCAG CTGGCAGGGGCAGTCGAGT 425 CTCGACTGCCCCTGCCAGC GCTGGCAGGGGCAGTCGAG 426 TCGACTGCCCCTGCCAGCT AGCTGGCAGGGGCAGTCGA 427 CGACTGCCCCTGCCAGCTC GAGCTGGCAGGGGCAGTCG 428 GACTGCCCCTGCCAGCTCT AGAGCTGGCAGGGGCAGTC 429 ACTGCCCCTGCCAGCTCTG CAGAGCTGGCAGGGGCAGT 430 CTGCCCCTGCCAGCTCTGG CCAGAGCTGGCAGGGGCAG 431 TGCCCCTGCCAGCTCTGGC GCCAGAGCTGGCAGGGGCA 432 GCCCCTGCCAGCTCTGGCA TGCCAGAGCTGGCAGGGGC 433 CCCCTGCCAGCTCTGGCAC GTGCCAGAGCTGGCAGGGG 434 CCCTGCCAGCTCTGGCACT AGTGCCAGAGCTGGCAGGG 435 CCTGCCAGCTCTGGCACTG CAGTGCCAGAGCTGGCAGG 436 CTGCCAGCTCTGGCACTGC GCAGTGCCAGAGCTGGCAG 437 TGCCAGCTCTGGCACTGCC GGCAGTGCCAGAGCTGGCA 438 GCCAGCTCTGGCACTGCCC GGGCAGTGCCAGAGCTGGC 439 CCAGCTCTGGCACTGCCCC GGGGCAGTGCCAGAGCTGG 440 CAGCTCTGGCACTGCCCCC GGGGGCAGTGCCAGAGCTG 441 AGCTCTGGCACTGCCCCCT AGGGGGCAGTGCCAGAGCT 442 GCTCTGGCACTGCCCCCTC GAGGGGGCAGTGCCAGAGC 443 CTCTGGCACTGCCCCCTCC GGAGGGGGCAGTGCCAGAG 444 TCTGGCACTGCCCCCTCCC GGGAGGGGGCAGTGCCAGA 445 CTGGCACTGCCCCCTCCCA TGGGAGGGGGCAGTGCCAG 446 TGGCACTGCCCCCTCCCAG CTGGGAGGGGGCAGTGCCA 447 GGCACTGCCCCCTCCCAGC GCTGGGAGGGGGCAGTGCC 448 GCACTGCCCCCTCCCAGCC GGCTGGGAGGGGGCAGTGC 449 CACTGCCCCCTCCCAGCCG CGGCTGGGAGGGGGCAGTG 450 ACTGCCCCCTCCCAGCCGC GCGGCTGGGAGGGGGCAGT 451 CTGCCCCCTCCCAGCCGCC GGCGGCTGGGAGGGGGCAG 452 TGCCCCCTCCCAGCCGCCC GGGCGGCTGGGAGGGGGCA 453 GCCCCCTCCCAGCCGCCCC GGGGCGGCTGGGAGGGGGC 454 CCCCCTCCCAGCCGCCCCG CGGGGCGGCTGGGAGGGGG 455 CCCCTCCCAGCCGCCCCGC GCGGGGCGGCTGGGAGGGG 456 CCCTCCCAGCCGCCCCGCC GGCGGGGCGGCTGGGAGGG 457 CCTCCCAGCCGCCCCGCCC GGGCGGGGCGGCTGGGAGG 458 CTCCCAGCCGCCCCGCCCT AGGGCGGGGCGGCTGGGAG 459 TCCCAGCCGCCCCGCCCTA TAGGGCGGGGCGGCTGGGA 460 CCCAGCCGCCCCGCCCTAG CTAGGGCGGGGCGGCTGGG 461 CCAGCCGCCCCGCCCTAGC GCTAGGGCGGGGCGGCTGG 462 CAGCCGCCCCGCCCTAGCA TGCTAGGGCGGGGCGGCTG 463 AGCCGCCCCGCCCTAGCAC GTGCTAGGGCGGGGCGGCT 464 GCCGCCCCGCCCTAGCACC GGTGCTAGGGCGGGGCGGC 465 CCGCCCCGCCCTAGCACCC GGGTGCTAGGGCGGGGCGG 466 CGCCCCGCCCTAGCACCCT AGGGTGCTAGGGCGGGGCG 467 GCCCCGCCCTAGCACCCTG CAGGGTGCTAGGGCGGGGC 468 CCCCGCCCTAGCACCCTGG CCAGGGTGCTAGGGCGGGG 469 CCCGCCCTAGCACCCTGGG CCCAGGGTGCTAGGGCGGG 470 CCGCCCTAGCACCCTGGGG CCCCAGGGTGCTAGGGCGG 471 CGCCCTAGCACCCTGGGGG CCCCCAGGGTGCTAGGGCG 472 GCCCTAGCACCCTGGGGGG CCCCCCAGGGTGCTAGGGC 473 CCCTAGCACCCTGGGGGGC GCCCCCCAGGGTGCTAGGG 474 CCTAGCACCCTGGGGGGCA TGCCCCCCAGGGTGCTAGG 475 CTAGCACCCTGGGGGGCAC GTGCCCCCCAGGGTGCTAG 476 TAGCACCCTGGGGGGCACC GGTGCCCCCCAGGGTGCTA 477 AGCACCCTGGGGGGCACCC GGGTGCCCCCCAGGGTGCT 478 GCACCCTGGGGGGCACCCC GGGGTGCCCCCCAGGGTGC 479 CACCCTGGGGGGCACCCCG CGGGGTGCCCCCCAGGGTG 480 ACCCTGGGGGGCACCCCGC GCGGGGTGCCCCCCAGGGT 481 CCCTGGGGGGCACCCCGCC GGCGGGGTGCCCCCCAGGG 482 CCTGGGGGGCACCCCGCCC GGGCGGGGTGCCCCCCAGG 483 CTGGGGGGCACCCCGCCCA TGGGCGGGGTGCCCCCCAG 484 TGGGGGGCACCCCGCCCAA TTGGGCGGGGTGCCCCCCA 485 GGGGGGCACCCCGCCCAAC GTTGGGCGGGGTGCCCCCC 486 GGGGGCACCCCGCCCAACC GGTTGGGCGGGGTGCCCCC 487 GGGGCACCCCGCCCAACCG CGGTTGGGCGGGGTGCCCC 488 GGGCACCCCGCCCAACCGT ACGGTTGGGCGGGGTGCCC 489 GGCACCCCGCCCAACCGTG CACGGTTGGGCGGGGTGCC 490 GCACCCCGCCCAACCGTGG CCACGGTTGGGCGGGGTGC 491 CACCCCGCCCAACCGTGGC GCCACGGTTGGGCGGGGTG 492 ACCCCGCCCAACCGTGGCC GGCCACGGTTGGGCGGGGT 493 CCCCGCCCAACCGTGGCCT AGGCCACGGTTGGGCGGGG 494 CCCGCCCAACCGTGGCCTG CAGGCCACGGTTGGGCGGG 495 CCGCCCAACCGTGGCCTGG CCAGGCCACGGTTGGGCGG 496 CGCCCAACCGTGGCCTGGT ACCAGGCCACGGTTGGGCG 497 GCCCAACCGTGGCCTGGTC GACCAGGCCACGGTTGGGC 498 CCCAACCGTGGCCTGGTCC GGACCAGGCCACGGTTGGG 499 CCAACCGTGGCCTGGTCCG CGGACCAGGCCACGGTTGG 500 CAACCGTGGCCTGGTCCGG CCGGACCAGGCCACGGTTG 501 AACCGTGGCCTGGTCCGGC GCCGGACCAGGCCACGGTT 502 ACCGTGGCCTGGTCCGGCC GGCCGGACCAGGCCACGGT 503 CCGTGGCCTGGTCCGGCCC GGGCCGGACCAGGCCACGG 504 CGTGGCCTGGTCCGGCCCC GGGGCCGGACCAGGCCACG 505 GTGGCCTGGTCCGGCCCCT AGGGGCCGGACCAGGCCAC 506 TGGCCTGGTCCGGCCCCTC GAGGGGCCGGACCAGGCCA 507 GGCCTGGTCCGGCCCCTCC GGAGGGGCCGGACCAGGCC 508 GCCTGGTCCGGCCCCTCCC GGGAGGGGCCGGACCAGGC 509 CCTGGTCCGGCCCCTCCCG CGGGAGGGGCCGGACCAGG 510 CTGGTCCGGCCCCTCCCGC GCGGGAGGGGCCGGACCAG 511 TGGTCCGGCCCCTCCCGCC GGCGGGAGGGGCCGGACCA 512 GGTCCGGCCCCTCCCGCCC GGGCGGGAGGGGCCGGACC 513 GTCCGGCCCCTCCCGCCCT AGGGCGGGAGGGGCCGGAC 514 TCCGGCCCCTCCCGCCCTT AAGGGCGGGAGGGGCCGGA 515 CCGGCCCCTCCCGCCCTTT AAAGGGCGGGAGGGGCCGG 516 CGGCCCCTCCCGCCCTTTG CAAAGGGCGGGAGGGGCCG 517 GGCCCCTCCCGCCCTTTGC GCAAAGGGCGGGAGGGGCC 518 GCCCCTCCCGCCCTTTGCT AGCAAAGGGCGGGAGGGGC 519 CCCCTCCCGCCCTTTGCTC GAGCAAAGGGCGGGAGGGG 520 CCCTCCCGCCCTTTGCTCC GGAGCAAAGGGCGGGAGGG 521 CCTCCCGCCCTTTGCTCCA TGGAGCAAAGGGCGGGAGG 522 CTCCCGCCCTTTGCTCCAG CTGGAGCAAAGGGCGGGAG 523 TCCCGCCCTTTGCTCCAGT ACTGGAGCAAAGGGCGGGA 524 CCCGCCCTTTGCTCCAGTT AACTGGAGCAAAGGGCGGG 525 CCGCCCTTTGCTCCAGTTC GAACTGGAGCAAAGGGCGG 526 CGCCCTTTGCTCCAGTTCC GGAACTGGAGCAAAGGGCG 527 GCCCTTTGCTCCAGTTCCC GGGAACTGGAGCAAAGGGC 528 CCCTTTGCTCCAGTTCCCG CGGGAACTGGAGCAAAGGG 529 CCTTTGCTCCAGTTCCCGG CCGGGAACTGGAGCAAAGG 530 CTTTGCTCCAGTTCCCGGG CCCGGGAACTGGAGCAAAG 531 TTTGCTCCAGTTCCCGGGC GCCCGGGAACTGGAGCAAA 532 TTGCTCCAGTTCCCGGGCT AGCCCGGGAACTGGAGCAA 533 TGCTCCAGTTCCCGGGCTT AAGCCCGGGAACTGGAGCA 534 GCTCCAGTTCCCGGGCTTG CAAGCCCGGGAACTGGAGC 535 CTCCAGTTCCCGGGCTTGG CCAAGCCCGGGAACTGGAG 536 TCCAGTTCCCGGGCTTGGC GCCAAGCCCGGGAACTGGA 537 CCAGTTCCCGGGCTTGGCA TGCCAAGCCCGGGAACTGG 538 CAGTTCCCGGGCTTGGCAC GTGCCAAGCCCGGGAACTG 539 AGTTCCCGGGCTTGGCACC GGTGCCAAGCCCGGGAACT 540 GTTCCCGGGCTTGGCACCT AGGTGCCAAGCCCGGGAAC 541 TTCCCGGGCTTGGCACCTA TAGGTGCCAAGCCCGGGAA 542 TCCCGGGCTTGGCACCTAT ATAGGTGCCAAGCCCGGGA 543 CCCGGGCTTGGCACCTATA TATAGGTGCCAAGCCCGGG 544 CCGGGCTTGGCACCTATAG CTATAGGTGCCAAGCCCGG 545 CGGGCTTGGCACCTATAGT ACTATAGGTGCCAAGCCCG 546 GGGCTTGGCACCTATAGTG CACTATAGGTGCCAAGCCC 547 GGCTTGGCACCTATAGTGG CCACTATAGGTGCCAAGCC 548 GCTTGGCACCTATAGTGGG CCCACTATAGGTGCCAAGC 549 CTTGGCACCTATAGTGGGG CCCCACTATAGGTGCCAAG 550 TTGGCACCTATAGTGGGGG CCCCCACTATAGGTGCCAA 551 TGGCACCTATAGTGGGGGT ACCCCCACTATAGGTGCCA 552 GGCACCTATAGTGGGGGTG CACCCCCACTATAGGTGCC 553 GCACCTATAGTGGGGGTGC GCACCCCCACTATAGGTGC 554 CACCTATAGTGGGGGTGCC GGCACCCCCACTATAGGTG 555 ACCTATAGTGGGGGTGCCG CGGCACCCCCACTATAGGT 556 CCTATAGTGGGGGTGCCGC GCGGCACCCCCACTATAGG 557 CTATAGTGGGGGTGCCGCC GGCGGCACCCCCACTATAG 558 TATAGTGGGGGTGCCGCCC GGGCGGCACCCCCACTATA 559 ATAGTGGGGGTGCCGCCCG CGGGCGGCACCCCCACTAT 560 TAGTGGGGGTGCCGCCCGC GCGGGCGGCACCCCCACTA 561 AGTGGGGGTGCCGCCCGCC GGCGGGCGGCACCCCCACT 562 GTGGGGGTGCCGCCCGCCT AGGCGGGCGGCACCCCCAC 563 TGGGGGTGCCGCCCGCCTG CAGGCGGGCGGCACCCCCA 564 GGGGGTGCCGCCCGCCTGC GCAGGCGGGCGGCACCCCC 565 GGGGTGCCGCCCGCCTGCC GGCAGGCGGGCGGCACCCC 566 GGGTGCCGCCCGCCTGCCA TGGCAGGCGGGCGGCACCC 567 GGTGCCGCCCGCCTGCCAG CTGGCAGGCGGGCGGCACC 568 GTGCCGCCCGCCTGCCAGG CCTGGCAGGCGGGCGGCAC 569 TGCCGCCCGCCTGCCAGGC GCCTGGCAGGCGGGCGGCA 570 GCCGCCCGCCTGCCAGGCT AGCCTGGCAGGCGGGCGGC 571 CCGCCCGCCTGCCAGGCTC GAGCCTGGCAGGCGGGCGG 572 CGCCCGCCTGCCAGGCTCC GGAGCCTGGCAGGCGGGCG 573 GCCCGCCTGCCAGGCTCCG CGGAGCCTGGCAGGCGGGC 574 CCCGCCTGCCAGGCTCCGG CCGGAGCCTGGCAGGCGGG 575 CCGCCTGCCAGGCTCCGGG CCCGGAGCCTGGCAGGCGG 576 CGCCTGCCAGGCTCCGGGG CCCCGGAGCCTGGCAGGCG 577 GCCTGCCAGGCTCCGGGGC GCCCCGGAGCCTGGCAGGC 578 CCTGCCAGGCTCCGGGGCC GGCCCCGGAGCCTGGCAGG 579 CTGCCAGGCTCCGGGGCCG CGGCCCCGGAGCCTGGCAG 580 TGCCAGGCTCCGGGGCCGG CCGGCCCCGGAGCCTGGCA 581 GCCAGGCTCCGGGGCCGGG CCCGGCCCCGGAGCCTGGC 582 CCAGGCTCCGGGGCCGGGC GCCCGGCCCCGGAGCCTGG 583 CAGGCTCCGGGGCCGGGCC GGCCCGGCCCCGGAGCCTG 584 AGGCTCCGGGGCCGGGCCC GGGCCCGGCCCCGGAGCCT 585 GGCTCCGGGGCCGGGCCCA TGGGCCCGGCCCCGGAGCC 586 GCTCCGGGGCCGGGCCCAC GTGGGCCCGGCCCCGGAGC 587 CTCCGGGGCCGGGCCCACG CGTGGGCCCGGCCCCGGAG 588 TCCGGGGCCGGGCCCACGG CCGTGGGCCCGGCCCCGGA 589 CCGGGGCCGGGCCCACGGG CCCGTGGGCCCGGCCCCGG 590 CGGGGCCGGGCCCACGGGA TCCCGTGGGCCCGGCCCCG 591 GGGGCCGGGCCCACGGGAG CTCCCGTGGGCCCGGCCCC 592 GGGCCGGGCCCACGGGAGG CCTCCCGTGGGCCCGGCCC 593 GGCCGGGCCCACGGGAGGG CCCTCCCGTGGGCCCGGCC 594 GCCGGGCCCACGGGAGGGT ACCCTCCCGTGGGCCCGGC 595 CCGGGCCCACGGGAGGGTG CACCCTCCCGTGGGCCCGG 596 CGGGCCCACGGGAGGGTGG CCACCCTCCCGTGGGCCCG 597 GGGCCCACGGGAGGGTGGG CCCACCCTCCCGTGGGCCC 598 GGCCCACGGGAGGGTGGGG CCCCACCCTCCCGTGGGCC 599 GCCCACGGGAGGGTGGGGC GCCCCACCCTCCCGTGGGC 600 CCCACGGGAGGGTGGGGCG CGCCCCACCCTCCCGTGGG 601 CCACGGGAGGGTGGGGCGG CCGCCCCACCCTCCCGTGG 602 CACGGGAGGGTGGGGCGGC GCCGCCCCACCCTCCCGTG 603 ACGGGAGGGTGGGGCGGCT AGCCGCCCCACCCTCCCGT 604 CGGGAGGGTGGGGCGGCTG CAGCCGCCCCACCCTCCCG 605 GGGAGGGTGGGGCGGCTGG CCAGCCGCCCCACCCTCCC 606 GGAGGGTGGGGCGGCTGGG CCCAGCCGCCCCACCCTCC 607 GAGGGTGGGGCGGCTGGGA TCCCAGCCGCCCCACCCTC 608 AGGGTGGGGCGGCTGGGAA TTCCCAGCCGCCCCACCCT 609 GGGTGGGGCGGCTGGGAAG CTTCCCAGCCGCCCCACCC 610 GGTGGGGCGGCTGGGAAGC GCTTCCCAGCCGCCCCACC 611 GTGGGGCGGCTGGGAAGCT AGCTTCCCAGCCGCCCCAC 612 TGGGGCGGCTGGGAAGCTG CAGCTTCCCAGCCGCCCCA 613 GGGGCGGCTGGGAAGCTGG CCAGCTTCCCAGCCGCCCC 614 GGGCGGCTGGGAAGCTGGC GCCAGCTTCCCAGCCGCCC 615 GGCGGCTGGGAAGCTGGCA TGCCAGCTTCCCAGCCGCC 616 GCGGCTGGGAAGCTGGCAC GTGCCAGCTTCCCAGCCGC 617 CGGCTGGGAAGCTGGCACG CGTGCCAGCTTCCCAGCCG 618 GGCTGGGAAGCTGGCACGC GCGTGCCAGCTTCCCAGCC 619 GCTGGGAAGCTGGCACGCT AGCGTGCCAGCTTCCCAGC 620 CTGGGAAGCTGGCACGCTG CAGCGTGCCAGCTTCCCAG 621 TGGGAAGCTGGCACGCTGC GCAGCGTGCCAGCTTCCCA 622 GGGAAGCTGGCACGCTGCC GGCAGCGTGCCAGCTTCCC 623 GGAAGCTGGCACGCTGCCC GGGCAGCGTGCCAGCTTCC 624 GAAGCTGGCACGCTGCCCC GGGGCAGCGTGCCAGCTTC 625 AAGCTGGCACGCTGCCCCG CGGGGCAGCGTGCCAGCTT 626 AGCTGGCACGCTGCCCCGG CCGGGGCAGCGTGCCAGCT 627 GCTGGCACGCTGCCCCGGG CCCGGGGCAGCGTGCCAGC 628 CTGGCACGCTGCCCCGGGG CCCCGGGGCAGCGTGCCAG 629 TGGCACGCTGCCCCGGGGG CCCCCGGGGCAGCGTGCCA 630 GGCACGCTGCCCCGGGGGA TCCCCCGGGGCAGCGTGCC 631 GCACGCTGCCCCGGGGGAG CTCCCCCGGGGCAGCGTGC 632 CACGCTGCCCCGGGGGAGC GCTCCCCCGGGGCAGCGTG 633 ACGCTGCCCCGGGGGAGCC GGCTCCCCCGGGGCAGCGT 634 CGCTGCCCCGGGGGAGCCT AGGCTCCCCCGGGGCAGCG 635 GCTGCCCCGGGGGAGCCTC GAGGCTCCCCCGGGGCAGC 636 CTGCCCCGGGGGAGCCTCT AGAGGCTCCCCCGGGGCAG 637 TGCCCCGGGGGAGCCTCTC GAGAGGCTCCCCCGGGGCA 638 GCCCCGGGGGAGCCTCTCT AGAGAGGCTCCCCCGGGGC 639 CCCCGGGGGAGCCTCTCTC GAGAGAGGCTCCCCCGGGG 640 CCCGGGGGAGCCTCTCTCG CGAGAGAGGCTCCCCCGGG 641 CCGGGGGAGCCTCTCTCGG CCGAGAGAGGCTCCCCCGG 642 CGGGGGAGCCTCTCTCGGC GCCGAGAGAGGCTCCCCCG 643 GGGGGAGCCTCTCTCGGCA TGCCGAGAGAGGCTCCCCC 644 GGGGAGCCTCTCTCGGCAG CTGCCGAGAGAGGCTCCCC 645 GGGAGCCTCTCTCGGCAGG CCTGCCGAGAGAGGCTCCC 646 GGAGCCTCTCTCGGCAGGC GCCTGCCGAGAGAGGCTCC 647 GAGCCTCTCTCGGCAGGCG CGCCTGCCGAGAGAGGCTC 648 AGCCTCTCTCGGCAGGCGC GCGCCTGCCGAGAGAGGCT 649 GCCTCTCTCGGCAGGCGCC GGCGCCTGCCGAGAGAGGC 650 CCTCTCTCGGCAGGCGCCC GGGCGCCTGCCGAGAGAGG 651 CTCTCTCGGCAGGCGCCCG CGGGCGCCTGCCGAGAGAG 652 TCTCTCGGCAGGCGCCCGG CCGGGCGCCTGCCGAGAGA 653 CTCTCGGCAGGCGCCCGGG CCCGGGCGCCTGCCGAGAG 654 TCTCGGCAGGCGCCCGGGT ACCCGGGCGCCTGCCGAGA 655 CTCGGCAGGCGCCCGGGTG CACCCGGGCGCCTGCCGAG 656 TCGGCAGGCGCCCGGGTGC GCACCCGGGCGCCTGCCGA 657 CGGCAGGCGCCCGGGTGCC GGCACCCGGGCGCCTGCCG 658 GGCAGGCGCCCGGGTGCCG CGGCACCCGGGCGCCTGCC 659 GCAGGCGCCCGGGTGCCGC GCGGCACCCGGGCGCCTGC 660 CAGGCGCCCGGGTGCCGCG CGCGGCACCCGGGCGCCTG 661 AGGCGCCCGGGTGCCGCGG CCGCGGCACCCGGGCGCCT 662 GGCGCCCGGGTGCCGCGGG CCCGCGGCACCCGGGCGCC 663 GCGCCCGGGTGCCGCGGGG CCCCGCGGCACCCGGGCGC 664 CGCCCGGGTGCCGCGGGGG CCCCCGCGGCACCCGGGCG 665 GCCCGGGTGCCGCGGGGGG CCCCCCGCGGCACCCGGGC 666 CCCGGGTGCCGCGGGGGGG CCCCCCCGCGGCACCCGGG 667 CCGGGTGCCGCGGGGGGGA TCCCCCCCGCGGCACCCGG 668 CGGGTGCCGCGGGGGGGAG CTCCCCCCCGCGGCACCCG 669 GGGTGCCGCGGGGGGGAGG CCTCCCCCCCGCGGCACCC 670 GGTGCCGCGGGGGGGAGGG CCCTCCCCCCCGCGGCACC 671 GTGCCGCGGGGGGGAGGGG CCCCTCCCCCCCGCGGCAC 672 TGCCGCGGGGGGGAGGGGG CCCCCTCCCCCCCGCGGCA 673 GCCGCGGGGGGGAGGGGGA TCCCCCTCCCCCCCGCGGC 674 CCGCGGGGGGGAGGGGGAA TTCCCCCTCCCCCCCGCGG 675 CGCGGGGGGGAGGGGGAAC GTTCCCCCTCCCCCCCGCG 676 GCGGGGGGGAGGGGGAACA TGTTCCCCCTCCCCCCCGC 677 CGGGGGGGAGGGGGAACAA TTGTTCCCCCTCCCCCCCG 678 GGGGGGGAGGGGGAACAAA TTTGTTCCCCCTCCCCCCC 679 GGGGGGAGGGGGAACAAAG CTTTGTTCCCCCTCCCCCC 680 GGGGGAGGGGGAACAAAGG CCTTTGTTCCCCCTCCCCC 681 GGGGAGGGGGAACAAAGGG CCCTTTGTTCCCCCTCCCC 682 GGGAGGGGGAACAAAGGGC GCCCTTTGTTCCCCCTCCC 683 GGAGGGGGAACAAAGGGCT AGCCCTTTGTTCCCCCTCC 684 GAGGGGGAACAAAGGGCTC GAGCCCTTTGTTCCCCCTC 685 AGGGGGAACAAAGGGCTCA TGAGCCCTTTGTTCCCCCT 686 GGGGGAACAAAGGGCTCAT ATGAGCCCTTTGTTCCCCC 687 GGGGAACAAAGGGCTCATT AATGAGCCCTTTGTTCCCC 688 GGGAACAAAGGGCTCATTC GAATGAGCCCTTTGTTCCC 689 GGAACAAAGGGCTCATTCT AGAATGAGCCCTTTGTTCC 690 GAACAAAGGGCTCATTCTC GAGAATGAGCCCTTTGTTC 691 AACAAAGGGCTCATTCTCC GGAGAATGAGCCCTTTGTT 692 ACAAAGGGCTCATTCTCCC GGGAGAATGAGCCCTTTGT 693 CAAAGGGCTCATTCTCCCC GGGGAGAATGAGCCCTTTG 694 AAAGGGCTCATTCTCCCCG CGGGGAGAATGAGCCCTTT 695 AAGGGCTCATTCTCCCCGT ACGGGGAGAATGAGCCCTT 696 AGGGCTCATTCTCCCCGTG CACGGGGAGAATGAGCCCT 697 GGGCTCATTCTCCCCGTGC GCACGGGGAGAATGAGCCC 698 GGCTCATTCTCCCCGTGCG CGCACGGGGAGAATGAGCC 699 GCTCATTCTCCCCGTGCGC GCGCACGGGGAGAATGAGC 700 CTCATTCTCCCCGTGCGCA TGCGCACGGGGAGAATGAG 701 TCATTCTCCCCGTGCGCAG CTGCGCACGGGGAGAATGA 702 CATTCTCCCCGTGCGCAGC GCTGCGCACGGGGAGAATG 703 ATTCTCCCCGTGCGCAGCC GGCTGCGCACGGGGAGAAT 704 TTCTCCCCGTGCGCAGCCG CGGCTGCGCACGGGGAGAA 705 TCTCCCCGTGCGCAGCCGG CCGGCTGCGCACGGGGAGA 706 CTCCCCGTGCGCAGCCGGT ACCGGCTGCGCACGGGGAG 707 TCCCCGTGCGCAGCCGGTG CACCGGCTGCGCACGGGGA 708 CCCCGTGCGCAGCCGGTGG CCACCGGCTGCGCACGGGG 709 CCCGTGCGCAGCCGGTGGC GCCACCGGCTGCGCACGGG 710 CCGTGCGCAGCCGGTGGCA TGCCACCGGCTGCGCACGG 711 CGTGCGCAGCCGGTGGCAT ATGCCACCGGCTGCGCACG 712 GTGCGCAGCCGGTGGCATC GATGCCACCGGCTGCGCAC 713 TGCGCAGCCGGTGGCATCG CGATGCCACCGGCTGCGCA 714 GCGCAGCCGGTGGCATCGC GCGATGCCACCGGCTGCGC 715 CGCAGCCGGTGGCATCGCC GGCGATGCCACCGGCTGCG 716 GCAGCCGGTGGCATCGCCG CGGCGATGCCACCGGCTGC 717 CAGCCGGTGGCATCGCCGG CCGGCGATGCCACCGGCTG 718 AGCCGGTGGCATCGCCGGG CCCGGCGATGCCACCGGCT 719 GCCGGTGGCATCGCCGGGG CCCCGGCGATGCCACCGGC 720 CCGGTGGCATCGCCGGGGC GCCCCGGCGATGCCACCGG 721 CGGTGGCATCGCCGGGGCG CGCCCCGGCGATGCCACCG 722 GGTGGCATCGCCGGGGCGT ACGCCCCGGCGATGCCACC 723 GTGGCATCGCCGGGGCGTT AACGCCCCGGCGATGCCAC 724 TGGCATCGCCGGGGCGTTG CAACGCCCCGGCGATGCCA 725 GGCATCGCCGGGGCGTTGG CCAACGCCCCGGCGATGCC 726 GCATCGCCGGGGCGTTGGC GCCAACGCCCCGGCGATGC 727 CATCGCCGGGGCGTTGGCG CGCCAACGCCCCGGCGATG 728 ATCGCCGGGGCGTTGGCGG CCGCCAACGCCCCGGCGAT 729 TCGCCGGGGCGTTGGCGGA TCCGCCAACGCCCCGGCGA 730 CGCCGGGGCGTTGGCGGAA TTCCGCCAACGCCCCGGCG 731 GCCGGGGCGTTGGCGGAAG CTTCCGCCAACGCCCCGGC 732 CCGGGGCGTTGGCGGAAGC GCTTCCGCCAACGCCCCGG 733 CGGGGCGTTGGCGGAAGCC GGCTTCCGCCAACGCCCCG 734 GGGGCGTTGGCGGAAGCCC GGGCTTCCGCCAACGCCCC 735 GGGCGTTGGCGGAAGCCCC GGGGCTTCCGCCAACGCCC 736 GGCGTTGGCGGAAGCCCCC GGGGGCTTCCGCCAACGCC 737 GCGTTGGCGGAAGCCCCCG CGGGGGCTTCCGCCAACGC 738 CGTTGGCGGAAGCCCCCGG CCGGGGGCTTCCGCCAACG 739 GTTGGCGGAAGCCCCCGGG CCCGGGGGCTTCCGCCAAC 740 TTGGCGGAAGCCCCCGGGG CCCCGGGGGCTTCCGCCAA 741 TGGCGGAAGCCCCCGGGGC GCCCCGGGGGCTTCCGCCA 742 GGCGGAAGCCCCCGGGGCC GGCCCCGGGGGCTTCCGCC 743 GCGGAAGCCCCCGGGGCCC GGGCCCCGGGGGCTTCCGC 744 CGGAAGCCCCCGGGGCCCG CGGGCCCCGGGGGCTTCCG 745 GGAAGCCCCCGGGGCCCGG CCGGGCCCCGGGGGCTTCC 746 GAAGCCCCCGGGGCCCGGG CCCGGGCCCCGGGGGCTTC 747 AAGCCCCCGGGGCCCGGGA TCCCGGGCCCCGGGGGCTT 748 AGCCCCCGGGGCCCGGGAG CTCCCGGGCCCCGGGGGCT 749 GCCCCCGGGGCCCGGGAGG CCTCCCGGGCCCCGGGGGC 750 CCCCCGGGGCCCGGGAGGG CCCTCCCGGGCCCCGGGGG 751 CCCCGGGGCCCGGGAGGGG CCCCTCCCGGGCCCCGGGG 752 CCCGGGGCCCGGGAGGGGG CCCCCTCCCGGGCCCCGGG 753 CCGGGGCCCGGGAGGGGGC GCCCCCTCCCGGGCCCCGG 754 CGGGGCCCGGGAGGGGGCA TGCCCCCTCCCGGGCCCCG 755 GGGGCCCGGGAGGGGGCAG CTGCCCCCTCCCGGGCCCC 756 GGGCCCGGGAGGGGGCAGG CCTGCCCCCTCCCGGGCCC 757 GGCCCGGGAGGGGGCAGGC GCCTGCCCCCTCCCGGGCC 758 GCCCGGGAGGGGGCAGGCC GGCCTGCCCCCTCCCGGGC 759 CCCGGGAGGGGGCAGGCCC GGGCCTGCCCCCTCCCGGG 760 CCGGGAGGGGGCAGGCCCA TGGGCCTGCCCCCTCCCGG 761 CGGGAGGGGGCAGGCCCAG CTGGGCCTGCCCCCTCCCG 762 GGGAGGGGGCAGGCCCAGG CCTGGGCCTGCCCCCTCCC 763 GGAGGGGGCAGGCCCAGGC GCCTGGGCCTGCCCCCTCC 764 GAGGGGGCAGGCCCAGGCG CGCCTGGGCCTGCCCCCTC 765 AGGGGGCAGGCCCAGGCGC GCGCCTGGGCCTGCCCCCT 766 GGGGGCAGGCCCAGGCGCG CGCGCCTGGGCCTGCCCCC 767 GGGGCAGGCCCAGGCGCGG CCGCGCCTGGGCCTGCCCC 768 GGGCAGGCCCAGGCGCGGC GCCGCGCCTGGGCCTGCCC 769 GGCAGGCCCAGGCGCGGCC GGCCGCGCCTGGGCCTGCC 770 GCAGGCCCAGGCGCGGCCG CGGCCGCGCCTGGGCCTGC 771 CAGGCCCAGGCGCGGCCGC GCGGCCGCGCCTGGGCCTG 772 AGGCCCAGGCGCGGCCGCC GGCGGCCGCGCCTGGGCCT 773 GGCCCAGGCGCGGCCGCCG CGGCGGCCGCGCCTGGGCC 774 GCCCAGGCGCGGCCGCCGA TCGGCGGCCGCGCCTGGGC 775 CCCAGGCGCGGCCGCCGAA TTCGGCGGCCGCGCCTGGG 776 CCAGGCGCGGCCGCCGAAT ATTCGGCGGCCGCGCCTGG 777 CAGGCGCGGCCGCCGAATC GATTCGGCGGCCGCGCCTG 778 AGGCGCGGCCGCCGAATCA TGATTCGGCGGCCGCGCCT 779 GGCGCGGCCGCCGAATCAC GTGATTCGGCGGCCGCGCC 780 GCGCGGCCGCCGAATCACG CGTGATTCGGCGGCCGCGC 781 CGCGGCCGCCGAATCACGG CCGTGATTCGGCGGCCGCG 782 GCGGCCGCCGAATCACGGG CCCGTGATTCGGCGGCCGC 783 CGGCCGCCGAATCACGGGC GCCCGTGATTCGGCGGCCG 784 GGCCGCCGAATCACGGGCT AGCCCGTGATTCGGCGGCC 785 GCCGCCGAATCACGGGCTC GAGCCCGTGATTCGGCGGC 786 CCGCCGAATCACGGGCTCC GGAGCCCGTGATTCGGCGG 787 CGCCGAATCACGGGCTCCT AGGAGCCCGTGATTCGGCG 788 GCCGAATCACGGGCTCCTG CAGGAGCCCGTGATTCGGC 789 CCGAATCACGGGCTCCTGT ACAGGAGCCCGTGATTCGG 790 CGAATCACGGGCTCCTGTT AACAGGAGCCCGTGATTCG 791 GAATCACGGGCTCCTGTTT AAACAGGAGCCCGTGATTC 792 AATCACGGGCTCCTGTTTC GAAACAGGAGCCCGTGATT 793 ATCACGGGCTCCTGTTTCC GGAAACAGGAGCCCGTGAT 794 TCACGGGCTCCTGTTTCCC GGGAAACAGGAGCCCGTGA 795 CACGGGCTCCTGTTTCCCG CGGGAAACAGGAGCCCGTG 796 ACGGGCTCCTGTTTCCCGC GCGGGAAACAGGAGCCCGT 797 CGGGCTCCTGTTTCCCGCA TGCGGGAAACAGGAGCCCG 798 GGGCTCCTGTTTCCCGCAG CTGCGGGAAACAGGAGCCC 799 GGCTCCTGTTTCCCGCAGG CCTGCGGGAAACAGGAGCC 800 GCTCCTGTTTCCCGCAGGG CCCTGCGGGAAACAGGAGC 801 CTCCTGTTTCCCGCAGGGT ACCCTGCGGGAAACAGGAG 802 TCCTGTTTCCCGCAGGGTG CACCCTGCGGGAAACAGGA 803 CCTGTTTCCCGCAGGGTGC GCACCCTGCGGGAAACAGG 804 CTGTTTCCCGCAGGGTGCT AGCACCCTGCGGGAAACAG 805 TGTTTCCCGCAGGGTGCTG CAGCACCCTGCGGGAAACA 806 GTTTCCCGCAGGGTGCTGG CCAGCACCCTGCGGGAAAC 807 TTTCCCGCAGGGTGCTGGA TCCAGCACCCTGCGGGAAA 808 TTCCCGCAGGGTGCTGGAG CTCCAGCACCCTGCGGGAA 809 TCCCGCAGGGTGCTGGAGG CCTCCAGCACCCTGCGGGA 810 CCCGCAGGGTGCTGGAGGA TCCTCCAGCACCCTGCGGG 811 CCGCAGGGTGCTGGAGGAG CTCCTCCAGCACCCTGCGG 812 CGCAGGGTGCTGGAGGAGG CCTCCTCCAGCACCCTGCG 813 GCAGGGTGCTGGAGGAGGA TCCTCCTCCAGCACCCTGC 814 CAGGGTGCTGGAGGAGGAA TTCCTCCTCCAGCACCCTG 815 AGGGTGCTGGAGGAGGAAA TTTCCTCCTCCAGCACCCT 816 GGGTGCTGGAGGAGGAAAC GTTTCCTCCTCCAGCACCC 817 GGTGCTGGAGGAGGAAACC GGTTTCCTCCTCCAGCACC 818 GTGCTGGAGGAGGAAACCG CGGTTTCCTCCTCCAGCAC 819 TGCTGGAGGAGGAAACCGG CCGGTTTCCTCCTCCAGCA 820 GCTGGAGGAGGAAACCGGC GCCGGTTTCCTCCTCCAGC 821 CTGGAGGAGGAAACCGGCG CGCCGGTTTCCTCCTCCAG 822 TGGAGGAGGAAACCGGCGG CCGCCGGTTTCCTCCTCCA 823 GGAGGAGGAAACCGGCGGA TCCGCCGGTTTCCTCCTCC 824 GAGGAGGAAACCGGCGGAG CTCCGCCGGTTTCCTCCTC 825 AGGAGGAAACCGGCGGAGC GCTCCGCCGGTTTCCTCCT 826 GGAGGAAACCGGCGGAGCA TGCTCCGCCGGTTTCCTCC 827 GAGGAAACCGGCGGAGCAG CTGCTCCGCCGGTTTCCTC 828 AGGAAACCGGCGGAGCAGC GCTGCTCCGCCGGTTTCCT 829 GGAAACCGGCGGAGCAGCT AGCTGCTCCGCCGGTTTCC 830 GAAACCGGCGGAGCAGCTT AAGCTGCTCCGCCGGTTTC 831 AAACCGGCGGAGCAGCTTC GAAGCTGCTCCGCCGGTTT 832 AACCGGCGGAGCAGCTTCC GGAAGCTGCTCCGCCGGTT 833 ACCGGCGGAGCAGCTTCCC GGGAAGCTGCTCCGCCGGT 834 CCGGCGGAGCAGCTTCCCC GGGGAAGCTGCTCCGCCGG 835 CGGCGGAGCAGCTTCCCCA TGGGGAAGCTGCTCCGCCG 836 GGCGGAGCAGCTTCCCCAC GTGGGGAAGCTGCTCCGCC 837 GCGGAGCAGCTTCCCCACT AGTGGGGAAGCTGCTCCGC 838 CGGAGCAGCTTCCCCACTC GAGTGGGGAAGCTGCTCCG 839 GGAGCAGCTTCCCCACTCT AGAGTGGGGAAGCTGCTCC 840 GAGCAGCTTCCCCACTCTC GAGAGTGGGGAAGCTGCTC 841 AGCAGCTTCCCCACTCTCA TGAGAGTGGGGAAGCTGCT 842 GCAGCTTCCCCACTCTCAG CTGAGAGTGGGGAAGCTGC 843 CAGCTTCCCCACTCTCAGT ACTGAGAGTGGGGAAGCTG 844 AGCTTCCCCACTCTCAGTT AACTGAGAGTGGGGAAGCT 845 GCTTCCCCACTCTCAGTTG CAACTGAGAGTGGGGAAGC 846 CTTCCCCACTCTCAGTTGC GCAACTGAGAGTGGGGAAG 847 TTCCCCACTCTCAGTTGCG CGCAACTGAGAGTGGGGAA 848 TCCCCACTCTCAGTTGCGC GCGCAACTGAGAGTGGGGA 849 CCCCACTCTCAGTTGCGCT AGCGCAACTGAGAGTGGGG 850 CCCACTCTCAGTTGCGCTT AAGCGCAACTGAGAGTGGG 851 CCACTCTCAGTTGCGCTTC GAAGCGCAACTGAGAGTGG 852 CACTCTCAGTTGCGCTTCT AGAAGCGCAACTGAGAGTG 853 ACTCTCAGTTGCGCTTCTG CAGAAGCGCAACTGAGAGT 854 CTCTCAGTTGCGCTTCTGG CCAGAAGCGCAACTGAGAG 855 TCTCAGTTGCGCTTCTGGC GCCAGAAGCGCAACTGAGA 856 CTCAGTTGCGCTTCTGGCG CGCCAGAAGCGCAACTGAG 857 TCAGTTGCGCTTCTGGCGA TCGCCAGAAGCGCAACTGA 858 CAGTTGCGCTTCTGGCGAT ATCGCCAGAAGCGCAACTG 859 AGTTGCGCTTCTGGCGATG CATCGCCAGAAGCGCAACT 860 GTTGCGCTTCTGGCGATGG CCATCGCCAGAAGCGCAAC 861 TTGCGCTTCTGGCGATGGC GCCATCGCCAGAAGCGCAA 862 TGCGCTTCTGGCGATGGCG CGCCATCGCCAGAAGCGCA 863 GCGCTTCTGGCGATGGCGA TCGCCATCGCCAGAAGCGC 864 CGCTTCTGGCGATGGCGAT ATCGCCATCGCCAGAAGCG 865 GCTTCTGGCGATGGCGATC GATCGCCATCGCCAGAAGC 866 CTTCTGGCGATGGCGATCA TGATCGCCATCGCCAGAAG 867 TTCTGGCGATGGCGATCAG CTGATCGCCATCGCCAGAA 868 TCTGGCGATGGCGATCAGA TCTGATCGCCATCGCCAGA 869 CTGGCGATGGCGATCAGAG CTCTGATCGCCATCGCCAG 870 TGGCGATGGCGATCAGAGG CCTCTGATCGCCATCGCCA 871 GGCGATGGCGATCAGAGGT ACCTCTGATCGCCATCGCC 872 GCGATGGCGATCAGAGGTC GACCTCTGATCGCCATCGC 873 CGATGGCGATCAGAGGTCC GGACCTCTGATCGCCATCG 874 GATGGCGATCAGAGGTCCT AGGACCTCTGATCGCCATC 875 ATGGCGATCAGAGGTCCTG CAGGACCTCTGATCGCCAT 876 TGGCGATCAGAGGTCCTGC GCAGGACCTCTGATCGCCA 877 GGCGATCAGAGGTCCTGCT AGCAGGACCTCTGATCGCC 878 GCGATCAGAGGTCCTGCTG CAGCAGGACCTCTGATCGC 879 CGATCAGAGGTCCTGCTGC GCAGCAGGACCTCTGATCG 880 GATCAGAGGTCCTGCTGCG CGCAGCAGGACCTCTGATC 881 ATCAGAGGTCCTGCTGCGC GCGCAGCAGGACCTCTGAT 882 TCAGAGGTCCTGCTGCGCT AGCGCAGCAGGACCTCTGA 883 CAGAGGTCCTGCTGCGCTC GAGCGCAGCAGGACCTCTG 884 AGAGGTCCTGCTGCGCTCT AGAGCGCAGCAGGACCTCT 885 GAGGTCCTGCTGCGCTCTC GAGAGCGCAGCAGGACCTC 886 AGGTCCTGCTGCGCTCTCC GGAGAGCGCAGCAGGACCT 887 GGTCCTGCTGCGCTCTCCG CGGAGAGCGCAGCAGGACC 888 GTCCTGCTGCGCTCTCCGC GCGGAGAGCGCAGCAGGAC 889 TCCTGCTGCGCTCTCCGCC GGCGGAGAGCGCAGCAGGA 890 CCTGCTGCGCTCTCCGCCG CGGCGGAGAGCGCAGCAGG 891 CTGCTGCGCTCTCCGCCGC GCGGCGGAGAGCGCAGCAG 892 TGCTGCGCTCTCCGCCGCG CGCGGCGGAGAGCGCAGCA 893 GCTGCGCTCTCCGCCGCGC GCGCGGCGGAGAGCGCAGC 894 CTGCGCTCTCCGCCGCGCT AGCGCGGCGGAGAGCGCAG 895 TGCGCTCTCCGCCGCGCTC GAGCGCGGCGGAGAGCGCA 896 GCGCTCTCCGCCGCGCTCT AGAGCGCGGCGGAGAGCGC 897 CGCTCTCCGCCGCGCTCTA TAGAGCGCGGCGGAGAGCG 898 GCTCTCCGCCGCGCTCTAC GTAGAGCGCGGCGGAGAGC 899 CTCTCCGCCGCGCTCTACC GGTAGAGCGCGGCGGAGAG 900 TCTCCGCCGCGCTCTACCT AGGTAGAGCGCGGCGGAGA 901 CTCCGCCGCGCTCTACCTC GAGGTAGAGCGCGGCGGAG 902 TCCGCCGCGCTCTACCTCC GGAGGTAGAGCGCGGCGGA 903 CCGCCGCGCTCTACCTCCA TGGAGGTAGAGCGCGGCGG 904 CGCCGCGCTCTACCTCCAT ATGGAGGTAGAGCGCGGCG 905 GCCGCGCTCTACCTCCATT AATGGAGGTAGAGCGCGGC 906 CCGCGCTCTACCTCCATTA TAATGGAGGTAGAGCGCGG 907 CGCGCTCTACCTCCATTAG CTAATGGAGGTAGAGCGCG 908 GCGCTCTACCTCCATTAGC GCTAATGGAGGTAGAGCGC 909 CGCTCTACCTCCATTAGCC GGCTAATGGAGGTAGAGCG 910 GCTCTACCTCCATTAGCCG CGGCTAATGGAGGTAGAGC 911 CTCTACCTCCATTAGCCGC GCGGCTAATGGAGGTAGAG 912 TCTACCTCCATTAGCCGCG CGCGGCTAATGGAGGTAGA 913 CTACCTCCATTAGCCGCGC GCGCGGCTAATGGAGGTAG 914 TACCTCCATTAGCCGCGCT AGCGCGGCTAATGGAGGTA 915 ACCTCCATTAGCCGCGCTG CAGCGCGGCTAATGGAGGT 916 CCTCCATTAGCCGCGCTGC GCAGCGCGGCTAATGGAGG 917 CTCCATTAGCCGCGCTGCG CGCAGCGCGGCTAATGGAG 918 TCCATTAGCCGCGCTGCGC GCGCAGCGCGGCTAATGGA 919 CCATTAGCCGCGCTGCGCG CGCGCAGCGCGGCTAATGG 920 CATTAGCCGCGCTGCGCGG CCGCGCAGCGCGGCTAATG 921 ATTAGCCGCGCTGCGCGGT ACCGCGCAGCGCGGCTAAT 922 TTAGCCGCGCTGCGCGGTG CACCGCGCAGCGCGGCTAA 923 TAGCCGCGCTGCGCGGTGC GCACCGCGCAGCGCGGCTA 924 AGCCGCGCTGCGCGGTGCT AGCACCGCGCAGCGCGGCT 925 GCCGCGCTGCGCGGTGCTG CAGCACCGCGCAGCGCGGC 926 CCGCGCTGCGCGGTGCTGC GCAGCACCGCGCAGCGCGG 927 CGCGCTGCGCGGTGCTGCG CGCAGCACCGCGCAGCGCG 928 GCGCTGCGCGGTGCTGCGC GCGCAGCACCGCGCAGCGC 929 CGCTGCGCGGTGCTGCGCC GGCGCAGCACCGCGCAGCG 930 GCTGCGCGGTGCTGCGCCC GGGCGCAGCACCGCGCAGC 931 CTGCGCGGTGCTGCGCCCT AGGGCGCAGCACCGCGCAG 932 TGCGCGGTGCTGCGCCCTC GAGGGCGCAGCACCGCGCA 933 GCGCGGTGCTGCGCCCTCG CGAGGGCGCAGCACCGCGC 934 CGCGGTGCTGCGCCCTCGC GCGAGGGCGCAGCACCGCG 935 GCGGTGCTGCGCCCTCGCC GGCGAGGGCGCAGCACCGC 936 CGGTGCTGCGCCCTCGCCG CGGCGAGGGCGCAGCACCG 937 GGTGCTGCGCCCTCGCCGG CCGGCGAGGGCGCAGCACC 938 GTGCTGCGCCCTCGCCGGT ACCGGCGAGGGCGCAGCAC 939 TGCTGCGCCCTCGCCGGTG CACCGGCGAGGGCGCAGCA 940 GCTGCGCCCTCGCCGGTGC GCACCGGCGAGGGCGCAGC 941 CTGCGCCCTCGCCGGTGCC GGCACCGGCGAGGGCGCAG 942 TGCGCCCTCGCCGGTGCCT AGGCACCGGCGAGGGCGCA 943 GCGCCCTCGCCGGTGCCTC GAGGCACCGGCGAGGGCGC 944 CGCCCTCGCCGGTGCCTCT AGAGGCACCGGCGAGGGCG 945 GCCCTCGCCGGTGCCTCTC GAGAGGCACCGGCGAGGGC 946 CCCTCGCCGGTGCCTCTCT AGAGAGGCACCGGCGAGGG 947 CCTCGCCGGTGCCTCTCTC GAGAGAGGCACCGGCGAGG 948 CTCGCCGGTGCCTCTCTCC GGAGAGAGGCACCGGCGAG 949 TCGCCGGTGCCTCTCTCCT AGGAGAGAGGCACCGGCGA 950 CGCCGGTGCCTCTCTCCTG CAGGAGAGAGGCACCGGCG 951 GCCGGTGCCTCTCTCCTGG CCAGGAGAGAGGCACCGGC 952 CCGGTGCCTCTCTCCTGGG CCCAGGAGAGAGGCACCGG 953 CGGTGCCTCTCTCCTGGGT ACCCAGGAGAGAGGCACCG 954 GGTGCCTCTCTCCTGGGTC GACCCAGGAGAGAGGCACC 955 GTGCCTCTCTCCTGGGTCC GGACCCAGGAGAGAGGCAC 956 TGCCTCTCTCCTGGGTCCC GGGACCCAGGAGAGAGGCA 957 GCCTCTCTCCTGGGTCCCA TGGGACCCAGGAGAGAGGC 958 CCTCTCTCCTGGGTCCCAG CTGGGACCCAGGAGAGAGG 959 CTCTCTCCTGGGTCCCAGG CCTGGGACCCAGGAGAGAG 960 TCTCTCCTGGGTCCCAGGA TCCTGGGACCCAGGAGAGA 961 CTCTCCTGGGTCCCAGGAT ATCCTGGGACCCAGGAGAG 962 TCTCCTGGGTCCCAGGATC GATCCTGGGACCCAGGAGA 963 CTCCTGGGTCCCAGGATCG CGATCCTGGGACCCAGGAG 964 TCCTGGGTCCCAGGATCGG CCGATCCTGGGACCCAGGA 965 CCTGGGTCCCAGGATCGGC GCCGATCCTGGGACCCAGG 966 CTGGGTCCCAGGATCGGCC GGCCGATCCTGGGACCCAG 967 TGGGTCCCAGGATCGGCCC GGGCCGATCCTGGGACCCA 968 GGGTCCCAGGATCGGCCCC GGGGCCGATCCTGGGACCC 969 GGTCCCAGGATCGGCCCCC GGGGGCCGATCCTGGGACC 970 GTCCCAGGATCGGCCCCCA TGGGGGCCGATCCTGGGAC 971 TCCCAGGATCGGCCCCCAC GTGGGGGCCGATCCTGGGA 972 CCCAGGATCGGCCCCCACC GGTGGGGGCCGATCCTGGG 973 CCAGGATCGGCCCCCACCA TGGTGGGGGCCGATCCTGG 974 CAGGATCGGCCCCCACCAT ATGGTGGGGGCCGATCCTG 975 AGGATCGGCCCCCACCATC GATGGTGGGGGCCGATCCT 976 GGATCGGCCCCCACCATCC GGATGGTGGGGGCCGATCC 977 GATCGGCCCCCACCATCCA TGGATGGTGGGGGCCGATC 978 ATCGGCCCCCACCATCCAG CTGGATGGTGGGGGCCGAT 979 TCGGCCCCCACCATCCAGG CCTGGATGGTGGGGGCCGA 980 CGGCCCCCACCATCCAGGC GCCTGGATGGTGGGGGCCG 981 GGCCCCCACCATCCAGGCA TGCCTGGATGGTGGGGGCC 982 GCCCCCACCATCCAGGCAC GTGCCTGGATGGTGGGGGC 983 CCCCCACCATCCAGGCACG CGTGCCTGGATGGTGGGGG 984 CCCCACCATCCAGGCACGA TCGTGCCTGGATGGTGGGG 985 CCCACCATCCAGGCACGAC GTCGTGCCTGGATGGTGGG 986 CCACCATCCAGGCACGACC GGTCGTGCCTGGATGGTGG 987 CACCATCCAGGCACGACCC GGGTCGTGCCTGGATGGTG 988 ACCATCCAGGCACGACCCC GGGGTCGTGCCTGGATGGT 989 CCATCCAGGCACGACCCCC GGGGGTCGTGCCTGGATGG 990 CATCCAGGCACGACCCCCT AGGGGGTCGTGCCTGGATG 991 ATCCAGGCACGACCCCCTT AAGGGGGTCGTGCCTGGAT 992 TCCAGGCACGACCCCCTTC GAAGGGGGTCGTGCCTGGA 993 CCAGGCACGACCCCCTTCC GGAAGGGGGTCGTGCCTGG 994 CAGGCACGACCCCCTTCCC GGGAAGGGGGTCGTGCCTG 995 AGGCACGACCCCCTTCCCC GGGGAAGGGGGTCGTGCCT 996 GGCACGACCCCCTTCCCCG CGGGGAAGGGGGTCGTGCC 997 GCACGACCCCCTTCCCCGG CCGGGGAAGGGGGTCGTGC 998 CACGACCCCCTTCCCCGGC GCCGGGGAAGGGGGTCGTG 999 ACGACCCCCTTCCCCGGCC GGCCGGGGAAGGGGGTCGT 1000 CGACCCCCTTCCCCGGCCC GGGCCGGGGAAGGGGGTCG 1001 GACCCCCTTCCCCGGCCCC GGGGCCGGGGAAGGGGGTC 1002 ACCCCCTTCCCCGGCCCCT AGGGGCCGGGGAAGGGGGT 1003 CCCCCTTCCCCGGCCCCTC GAGGGGCCGGGGAAGGGGG 1004 CCCCTTCCCCGGCCCCTCG CGAGGGGCCGGGGAAGGGG 1005 CCCTTCCCCGGCCCCTCGG CCGAGGGGCCGGGGAAGGG 1006 CCTTCCCCGGCCCCTCGGC GCCGAGGGGCCGGGGAAGG 1007 CTTCCCCGGCCCCTCGGCC GGCCGAGGGGCCGGGGAAG 1008 TTCCCCGGCCCCTCGGCCT AGGCCGAGGGGCCGGGGAA 1009 TCCCCGGCCCCTCGGCCTT AAGGCCGAGGGGCCGGGGA 1010 CCCCGGCCCCTCGGCCTTT AAAGGCCGAGGGGCCGGGG 1011 CCCGGCCCCTCGGCCTTTC GAAAGGCCGAGGGGCCGGG 1012 CCGGCCCCTCGGCCTTTCC GGAAAGGCCGAGGGGCCGG 1013 CGGCCCCTCGGCCTTTCCC GGGAAAGGCCGAGGGGCCG 1014 GGCCCCTCGGCCTTTCCCC GGGGAAAGGCCGAGGGGCC 1015 GCCCCTCGGCCTTTCCCCC GGGGGAAAGGCCGAGGGGC 1016 CCCCTCGGCCTTTCCCCCA TGGGGGAAAGGCCGAGGGG 1017 CCCTCGGCCTTTCCCCCAA TTGGGGGAAAGGCCGAGGG 1018 CCTCGGCCTTTCCCCCAAC GTTGGGGGAAAGGCCGAGG 1019 CTCGGCCTTTCCCCCAACT AGTTGGGGGAAAGGCCGAG 1020 TCGGCCTTTCCCCCAACTC GAGTTGGGGGAAAGGCCGA 1021 CGGCCTTTCCCCCAACTCG CGAGTTGGGGGAAAGGCCG 1022 GGCCTTTCCCCCAACTCGG CCGAGTTGGGGGAAAGGCC 1023 GCCTTTCCCCCAACTCGGC GCCGAGTTGGGGGAAAGGC 1024 CCTTTCCCCCAACTCGGCC GGCCGAGTTGGGGGAAAGG 1025 CTTTCCCCCAACTCGGCCA TGGCCGAGTTGGGGGAAAG 1026 TTTCCCCCAACTCGGCCAT ATGGCCGAGTTGGGGGAAA 1027 TTCCCCCAACTCGGCCATC GATGGCCGAGTTGGGGGAA 1028 TCCCCCAACTCGGCCATCT AGATGGCCGAGTTGGGGGA 1029 CCCCCAACTCGGCCATCTC GAGATGGCCGAGTTGGGGG 1030 CCCCAACTCGGCCATCTCC GGAGATGGCCGAGTTGGGG 1031 CCCAACTCGGCCATCTCCG CGGAGATGGCCGAGTTGGG 1032 CCAACTCGGCCATCTCCGA TCGGAGATGGCCGAGTTGG 1033 CAACTCGGCCATCTCCGAC GTCGGAGATGGCCGAGTTG 1034 AACTCGGCCATCTCCGACC GGTCGGAGATGGCCGAGTT 1035 ACTCGGCCATCTCCGACCC GGGTCGGAGATGGCCGAGT 1036 CTCGGCCATCTCCGACCCG CGGGTCGGAGATGGCCGAG 1037 TCGGCCATCTCCGACCCGG CCGGGTCGGAGATGGCCGA 1038 CGGCCATCTCCGACCCGGG CCCGGGTCGGAGATGGCCG 1039 GGCCATCTCCGACCCGGGG CCCCGGGTCGGAGATGGCC 1040 GCCATCTCCGACCCGGGGC GCCCCGGGTCGGAGATGGC 1041 CCATCTCCGACCCGGGGCG CGCCCCGGGTCGGAGATGG 1042 CATCTCCGACCCGGGGCGC GCGCCCCGGGTCGGAGATG 1043 ATCTCCGACCCGGGGCGCG CGCGCCCCGGGTCGGAGAT 1044 TCTCCGACCCGGGGCGCGT ACGCGCCCCGGGTCGGAGA 1045 CTCCGACCCGGGGCGCGTG CACGCGCCCCGGGTCGGAG 1046 TCCGACCCGGGGCGCGTGT ACACGCGCCCCGGGTCGGA 1047 CCGACCCGGGGCGCGTGTT AACACGCGCCCCGGGTCGG 1048 CGACCCGGGGCGCGTGTTC GAACACGCGCCCCGGGTCG 1049 GACCCGGGGCGCGTGTTCC GGAACACGCGCCCCGGGTC 1050 ACCCGGGGCGCGTGTTCCC GGGAACACGCGCCCCGGGT 1051 CCCGGGGCGCGTGTTCCCC GGGGAACACGCGCCCCGGG 1052 CCGGGGCGCGTGTTCCCCC GGGGGAACACGCGCCCCGG 1053 CGGGGCGCGTGTTCCCCCC GGGGGGAACACGCGCCCCG 1054 GGGGCGCGTGTTCCCCCCG CGGGGGGAACACGCGCCCC 1055 GGGCGCGTGTTCCCCCCGG CCGGGGGGAACACGCGCCC 1056 GGCGCGTGTTCCCCCCGGC GCCGGGGGGAACACGCGCC 1057 GCGCGTGTTCCCCCCGGCC GGCCGGGGGGAACACGCGC 1058 CGCGTGTTCCCCCCGGCCC GGGCCGGGGGGAACACGCG 1059 GCGTGTTCCCCCCGGCCCG CGGGCCGGGGGGAACACGC 1060 CGTGTTCCCCCCGGCCCGG CCGGGCCGGGGGGAACACG 1061 GTGTTCCCCCCGGCCCGGC GCCGGGCCGGGGGGAACAC 1062 TGTTCCCCCCGGCCCGGCG CGCCGGGCCGGGGGGAACA 1063 GTTCCCCCCGGCCCGGCGC GCGCCGGGCCGGGGGGAAC 1064 TTCCCCCCGGCCCGGCGCC GGCGCCGGGCCGGGGGGAA 1065 TCCCCCCGGCCCGGCGCCT AGGCGCCGGGCCGGGGGGA 1066 CCCCCCGGCCCGGCGCCTT AAGGCGCCGGGCCGGGGGG 1067 CCCCCGGCCCGGCGCCTTC GAAGGCGCCGGGCCGGGGG 1068 CCCCGGCCCGGCGCCTTCT AGAAGGCGCCGGGCCGGGG 1069 CCCGGCCCGGCGCCTTCTC GAGAAGGCGCCGGGCCGGG 1070 CCGGCCCGGCGCCTTCTCT AGAGAAGGCGCCGGGCCGG 1071 CGGCCCGGCGCCTTCTCTC GAGAGAAGGCGCCGGGCCG 1072 GGCCCGGCGCCTTCTCTCC GGAGAGAAGGCGCCGGGCC 1073 GCCCGGCGCCTTCTCTCCC GGGAGAGAAGGCGCCGGGC 1074 CCCGGCGCCTTCTCTCCCT AGGGAGAGAAGGCGCCGGG 1075 CCGGCGCCTTCTCTCCCTC GAGGGAGAGAAGGCGCCGG 1076 CGGCGCCTTCTCTCCCTCC GGAGGGAGAGAAGGCGCCG 1077 GGCGCCTTCTCTCCCTCCG CGGAGGGAGAGAAGGCGCC 1078 GCGCCTTCTCTCCCTCCGG CCGGAGGGAGAGAAGGCGC 1079 CGCCTTCTCTCCCTCCGGG CCCGGAGGGAGAGAAGGCG 1080 GCCTTCTCTCCCTCCGGGG CCCCGGAGGGAGAGAAGGC 1081 CCTTCTCTCCCTCCGGGGG CCCCCGGAGGGAGAGAAGG 1082 CTTCTCTCCCTCCGGGGGC GCCCCCGGAGGGAGAGAAG 1083 TTCTCTCCCTCCGGGGGCA TGCCCCCGGAGGGAGAGAA 1084 TCTCTCCCTCCGGGGGCAC GTGCCCCCGGAGGGAGAGA 1085 CTCTCCCTCCGGGGGCACC GGTGCCCCCGGAGGGAGAG 1086 TCTCCCTCCGGGGGCACCC GGGTGCCCCCGGAGGGAGA 1087 CTCCCTCCGGGGGCACCCG CGGGTGCCCCCGGAGGGAG 1088 TCCCTCCGGGGGCACCCGC GCGGGTGCCCCCGGAGGGA 1089 CCCTCCGGGGGCACCCGCT AGCGGGTGCCCCCGGAGGG 1090 CCTCCGGGGGCACCCGCTC GAGCGGGTGCCCCCGGAGG 1091 CTCCGGGGGCACCCGCTCC GGAGCGGGTGCCCCCGGAG 1092 TCCGGGGGCACCCGCTCCC GGGAGCGGGTGCCCCCGGA 1093 CCGGGGGCACCCGCTCCCT AGGGAGCGGGTGCCCCCGG 1094 CGGGGGCACCCGCTCCCTA TAGGGAGCGGGTGCCCCCG 1095 GGGGGCACCCGCTCCCTAG CTAGGGAGCGGGTGCCCCC 1096 GGGGCACCCGCTCCCTAGC GCTAGGGAGCGGGTGCCCC 1097 GGGCACCCGCTCCCTAGCC GGCTAGGGAGCGGGTGCCC 1098 GGCACCCGCTCCCTAGCCC GGGCTAGGGAGCGGGTGCC 1099 GCACCCGCTCCCTAGCCCC GGGGCTAGGGAGCGGGTGC 1100 CACCCGCTCCCTAGCCCCG CGGGGCTAGGGAGCGGGTG 1101 ACCCGCTCCCTAGCCCCGG CCGGGGCTAGGGAGCGGGT 1102 CCCGCTCCCTAGCCCCGGC GCCGGGGCTAGGGAGCGGG 1103 CCGCTCCCTAGCCCCGGCC GGCCGGGGCTAGGGAGCGG 1104 CGCTCCCTAGCCCCGGCCC GGGCCGGGGCTAGGGAGCG 1105 GCTCCCTAGCCCCGGCCCG CGGGCCGGGGCTAGGGAGC 1106 CTCCCTAGCCCCGGCCCGG CCGGGCCGGGGCTAGGGAG 1107 TCCCTAGCCCCGGCCCGGC GCCGGGCCGGGGCTAGGGA 1108 CCCTAGCCCCGGCCCGGCC GGCCGGGCCGGGGCTAGGG 1109 CCTAGCCCCGGCCCGGCCC GGGCCGGGCCGGGGCTAGG 1110 CTAGCCCCGGCCCGGCCCT AGGGCCGGGCCGGGGCTAG 1111 TAGCCCCGGCCCGGCCCTC GAGGGCCGGGCCGGGGCTA 1112 AGCCCCGGCCCGGCCCTCC GGAGGGCCGGGCCGGGGCT 1113 GCCCCGGCCCGGCCCTCCC GGGAGGGCCGGGCCGGGGC 1114 CCCCGGCCCGGCCCTCCCC GGGGAGGGCCGGGCCGGGG 1115 CCCGGCCCGGCCCTCCCCG CGGGGAGGGCCGGGCCGGG 1116 CCGGCCCGGCCCTCCCCGC GCGGGGAGGGCCGGGCCGG 1117 CGGCCCGGCCCTCCCCGCG CGCGGGGAGGGCCGGGCCG 1118 GGCCCGGCCCTCCCCGCGG CCGCGGGGAGGGCCGGGCC 1119 GCCCGGCCCTCCCCGCGGC GCCGCGGGGAGGGCCGGGC 1120 CCCGGCCCTCCCCGCGGCG CGCCGCGGGGAGGGCCGGG 1121 CCGGCCCTCCCCGCGGCGC GCGCCGCGGGGAGGGCCGG 1122 CGGCCCTCCCCGCGGCGCA TGCGCCGCGGGGAGGGCCG 1123 GGCCCTCCCCGCGGCGCAG CTGCGCCGCGGGGAGGGCC 1124 GCCCTCCCCGCGGCGCAGC GCTGCGCCGCGGGGAGGGC 1125 CCCTCCCCGCGGCGCAGCA TGCTGCGCCGCGGGGAGGG 1126 CCTCCCCGCGGCGCAGCAC GTGCTGCGCCGCGGGGAGG 1127 CTCCCCGCGGCGCAGCACG CGTGCTGCGCCGCGGGGAG 1128 TCCCCGCGGCGCAGCACGG CCGTGCTGCGCCGCGGGGA 1129 CCCCGCGGCGCAGCACGGA TCCGTGCTGCGCCGCGGGG 1130 CCCGCGGCGCAGCACGGAG CTCCGTGCTGCGCCGCGGG 1131 CCGCGGCGCAGCACGGAGT ACTCCGTGCTGCGCCGCGG 1132 CGCGGCGCAGCACGGAGTC GACTCCGTGCTGCGCCGCG 1133 GCGGCGCAGCACGGAGTCT AGACTCCGTGCTGCGCCGC 1134 CGGCGCAGCACGGAGTCTC GAGACTCCGTGCTGCGCCG 1135 GGCGCAGCACGGAGTCTCG CGAGACTCCGTGCTGCGCC 1136 GCGCAGCACGGAGTCTCGG CCGAGACTCCGTGCTGCGC 1137 CGCAGCACGGAGTCTCGGC GCCGAGACTCCGTGCTGCG 1138 GCAGCACGGAGTCTCGGCG CGCCGAGACTCCGTGCTGC 1139 CAGCACGGAGTCTCGGCGT ACGCCGAGACTCCGTGCTG 1140 AGCACGGAGTCTCGGCGTC GACGCCGAGACTCCGTGCT 1141 GCACGGAGTCTCGGCGTCC GGACGCCGAGACTCCGTGC 1142 CACGGAGTCTCGGCGTCCC GGGACGCCGAGACTCCGTG 1143 ACGGAGTCTCGGCGTCCCA TGGGACGCCGAGACTCCGT 1144 CGGAGTCTCGGCGTCCCAT ATGGGACGCCGAGACTCCG 1145 GGAGTCTCGGCGTCCCATG CATGGGACGCCGAGACTCC 1146 GAGTCTCGGCGTCCCATGG CCATGGGACGCCGAGACTC 1147 AGTCTCGGCGTCCCATGGC GCCATGGGACGCCGAGACT 1148 GTCTCGGCGTCCCATGGCG CGCCATGGGACGCCGAGAC 1149 TCTCGGCGTCCCATGGCGC GCGCCATGGGACGCCGAGA 1150 CTCGGCGTCCCATGGCGCA TGCGCCATGGGACGCCGAG 1151 TCGGCGTCCCATGGCGCAA TTGCGCCATGGGACGCCGA 1152 CGGCGTCCCATGGCGCAAC GTTGCGCCATGGGACGCCG 1153 GGCGTCCCATGGCGCAACC GGTTGCGCCATGGGACGCC 1154 GCGTCCCATGGCGCAACCT AGGTTGCGCCATGGGACGC 1155 CGTCCCATGGCGCAACCTA TAGGTTGCGCCATGGGACG 1156 GTCCCATGGCGCAACCTAC GTAGGTTGCGCCATGGGAC 1157 TCCCATGGCGCAACCTACG CGTAGGTTGCGCCATGGGA 1158 CCCATGGCGCAACCTACGG CCGTAGGTTGCGCCATGGG 1159 CCATGGCGCAACCTACGGC GCCGTAGGTTGCGCCATGG 1160 CATGGCGCAACCTACGGCC GGCCGTAGGTTGCGCCATG 1161 ATGGCGCAACCTACGGCCT AGGCCGTAGGTTGCGCCAT 1162 TGGCGCAACCTACGGCCTC GAGGCCGTAGGTTGCGCCA 1163 GGCGCAACCTACGGCCTCG CGAGGCCGTAGGTTGCGCC 1164 GCGCAACCTACGGCCTCGG CCGAGGCCGTAGGTTGCGC 1165 CGCAACCTACGGCCTCGGC GCCGAGGCCGTAGGTTGCG 1166 GCAACCTACGGCCTCGGCC GGCCGAGGCCGTAGGTTGC 1167 CAACCTACGGCCTCGGCCC GGGCCGAGGCCGTAGGTTG 1168 AACCTACGGCCTCGGCCCA TGGGCCGAGGCCGTAGGTT 1169 ACCTACGGCCTCGGCCCAG CTGGGCCGAGGCCGTAGGT 1170 CCTACGGCCTCGGCCCAGA TCTGGGCCGAGGCCGTAGG 1171 CTACGGCCTCGGCCCAGAA TTCTGGGCCGAGGCCGTAG 1172 TACGGCCTCGGCCCAGAAG CTTCTGGGCCGAGGCCGTA 1173 ACGGCCTCGGCCCAGAAGC GCTTCTGGGCCGAGGCCGT 1174 CGGCCTCGGCCCAGAAGCT AGCTTCTGGGCCGAGGCCG 1175 GGCCTCGGCCCAGAAGCTG CAGCTTCTGGGCCGAGGCC 1176 GCCTCGGCCCAGAAGCTGG CCAGCTTCTGGGCCGAGGC 1177 CCTCGGCCCAGAAGCTGGT ACCAGCTTCTGGGCCGAGG 1178 CTCGGCCCAGAAGCTGGTG CACCAGCTTCTGGGCCGAG 1179 TCGGCCCAGAAGCTGGTGC GCACCAGCTTCTGGGCCGA 1180 CGGCCCAGAAGCTGGTGCG CGCACCAGCTTCTGGGCCG 1181 GGCCCAGAAGCTGGTGCGG CCGCACCAGCTTCTGGGCC 1182 GCCCAGAAGCTGGTGCGGC GCCGCACCAGCTTCTGGGC 1183 CCCAGAAGCTGGTGCGGCC GGCCGCACCAGCTTCTGGG 1184 CCAGAAGCTGGTGCGGCCG CGGCCGCACCAGCTTCTGG 1185 CAGAAGCTGGTGCGGCCGA TCGGCCGCACCAGCTTCTG 1186 AGAAGCTGGTGCGGCCGAT ATCGGCCGCACCAGCTTCT 1187 GAAGCTGGTGCGGCCGATC GATCGGCCGCACCAGCTTC 1188 AAGCTGGTGCGGCCGATCC GGATCGGCCGCACCAGCTT 1189 AGCTGGTGCGGCCGATCCG CGGATCGGCCGCACCAGCT 1190 GCTGGTGCGGCCGATCCGC GCGGATCGGCCGCACCAGC 1191 CTGGTGCGGCCGATCCGCG CGCGGATCGGCCGCACCAG 1192 TGGTGCGGCCGATCCGCGC GCGCGGATCGGCCGCACCA 1193 GGTGCGGCCGATCCGCGCC GGCGCGGATCGGCCGCACC 1194 GTGCGGCCGATCCGCGCCG CGGCGCGGATCGGCCGCAC 1195 TGCGGCCGATCCGCGCCGT ACGGCGCGGATCGGCCGCA 1196 GCGGCCGATCCGCGCCGTG CACGGCGCGGATCGGCCGC 1197 CGGCCGATCCGCGCCGTGT ACACGGCGCGGATCGGCCG 1198 GGCCGATCCGCGCCGTGTG CACACGGCGCGGATCGGCC 1199 GCCGATCCGCGCCGTGTGC GCACACGGCGCGGATCGGC 1200 CCGATCCGCGCCGTGTGCC GGCACACGGCGCGGATCGG 1201 CGATCCGCGCCGTGTGCCG CGGCACACGGCGCGGATCG 1202 GATCCGCGCCGTGTGCCGC GCGGCACACGGCGCGGATC 1203 ATCCGCGCCGTGTGCCGCA TGCGGCACACGGCGCGGAT 1204 TCCGCGCCGTGTGCCGCAT ATGCGGCACACGGCGCGGA 1205 CCGCGCCGTGTGCCGCATC GATGCGGCACACGGCGCGG 1206 CGCGCCGTGTGCCGCATCC GGATGCGGCACACGGCGCG 1207 GCGCCGTGTGCCGCATCCT AGGATGCGGCACACGGCGC 1208 CGCCGTGTGCCGCATCCTG CAGGATGCGGCACACGGCG 1209 GCCGTGTGCCGCATCCTGC GCAGGATGCGGCACACGGC 1210 CCGTGTGCCGCATCCTGCA TGCAGGATGCGGCACACGG 1211 CGTGTGCCGCATCCTGCAG CTGCAGGATGCGGCACACG 1212 GTGTGCCGCATCCTGCAGA TCTGCAGGATGCGGCACAC 1213 TGTGCCGCATCCTGCAGAT ATCTGCAGGATGCGGCACA 1214 GTGCCGCATCCTGCAGATC GATCTGCAGGATGCGGCAC 1215 TGCCGCATCCTGCAGATCC GGATCTGCAGGATGCGGCA 1216 GCCGCATCCTGCAGATCCC GGGATCTGCAGGATGCGGC 1217 CCGCATCCTGCAGATCCCG CGGGATCTGCAGGATGCGG 1218 CGCATCCTGCAGATCCCGG CCGGGATCTGCAGGATGCG 1219 GCATCCTGCAGATCCCGGA TCCGGGATCTGCAGGATGC 1220 CATCCTGCAGATCCCGGAG CTCCGGGATCTGCAGGATG 1221 ATCCTGCAGATCCCGGAGT ACTCCGGGATCTGCAGGAT 1222 TCCTGCAGATCCCGGAGTC GACTCCGGGATCTGCAGGA 1223 CCTGCAGATCCCGGAGTCC GGACTCCGGGATCTGCAGG 1224 CTGCAGATCCCGGAGTCCG CGGACTCCGGGATCTGCAG 1225 TGCAGATCCCGGAGTCCGA TCGGACTCCGGGATCTGCA 1226 GCAGATCCCGGAGTCCGAC GTCGGACTCCGGGATCTGC 1227 CAGATCCCGGAGTCCGACC GGTCGGACTCCGGGATCTG 1228 AGATCCCGGAGTCCGACCC GGGTCGGACTCCGGGATCT 1229 GATCCCGGAGTCCGACCCC GGGGTCGGACTCCGGGATC 1230 ATCCCGGAGTCCGACCCCT AGGGGTCGGACTCCGGGAT 1231 TCCCGGAGTCCGACCCCTC GAGGGGTCGGACTCCGGGA 1232 CCCGGAGTCCGACCCCTCC GGAGGGGTCGGACTCCGGG 1233 CCGGAGTCCGACCCCTCCA TGGAGGGGTCGGACTCCGG 1234 CGGAGTCCGACCCCTCCAA TTGGAGGGGTCGGACTCCG 1235 GGAGTCCGACCCCTCCAAC GTTGGAGGGGTCGGACTCC 1236 GAGTCCGACCCCTCCAACC GGTTGGAGGGGTCGGACTC 1237 AGTCCGACCCCTCCAACCT AGGTTGGAGGGGTCGGACT 1238 GTCCGACCCCTCCAACCTG CAGGTTGGAGGGGTCGGAC 1239 TCCGACCCCTCCAACCTGC GCAGGTTGGAGGGGTCGGA 1240 CCGACCCCTCCAACCTGCG CGCAGGTTGGAGGGGTCGG 1241 CGACCCCTCCAACCTGCGG CCGCAGGTTGGAGGGGTCG 1242 GACCCCTCCAACCTGCGGC GCCGCAGGTTGGAGGGGTC 1243 ACCCCTCCAACCTGCGGCC GGCCGCAGGTTGGAGGGGT 1244 CCCCTCCAACCTGCGGCCC GGGCCGCAGGTTGGAGGGG 1245 CCCTCCAACCTGCGGCCCT AGGGCCGCAGGTTGGAGGG 1246 CCTCCAACCTGCGGCCCTA TAGGGCCGCAGGTTGGAGG 1247 CTCCAACCTGCGGCCCTAG CTAGGGCCGCAGGTTGGAG 1248 TCCAACCTGCGGCCCTAGA TCTAGGGCCGCAGGTTGGA 1249 CCAACCTGCGGCCCTAGAG CTCTAGGGCCGCAGGTTGG 1250 CAACCTGCGGCCCTAGAGC GCTCTAGGGCCGCAGGTTG 1251 AACCTGCGGCCCTAGAGCG CGCTCTAGGGCCGCAGGTT 1252 ACCTGCGGCCCTAGAGCGC GCGCTCTAGGGCCGCAGGT 1253 CCTGCGGCCCTAGAGCGCC GGCGCTCTAGGGCCGCAGG 1254 CTGCGGCCCTAGAGCGCCC GGGCGCTCTAGGGCCGCAG 1255 TGCGGCCCTAGAGCGCCCC GGGGCGCTCTAGGGCCGCA 1256 GCGGCCCTAGAGCGCCCCC GGGGGCGCTCTAGGGCCGC 1257 CGGCCCTAGAGCGCCCCCG CGGGGGCGCTCTAGGGCCG 1258 GGCCCTAGAGCGCCCCCGC GCGGGGGCGCTCTAGGGCC 1259 GCCCTAGAGCGCCCCCGCC GGCGGGGGCGCTCTAGGGC 1260 CCCTAGAGCGCCCCCGCCG CGGCGGGGGCGCTCTAGGG 1261 CCTAGAGCGCCCCCGCCGC GCGGCGGGGGCGCTCTAGG 1262 CTAGAGCGCCCCCGCCGCC GGCGGCGGGGGCGCTCTAG 1263 TAGAGCGCCCCCGCCGCCC GGGCGGCGGGGGCGCTCTA 1264 AGAGCGCCCCCGCCGCCCC GGGGCGGCGGGGGCGCTCT 1265 GAGCGCCCCCGCCGCCCCG CGGGGCGGCGGGGGCGCTC 1266 AGCGCCCCCGCCGCCCCGG CCGGGGCGGCGGGGGCGCT 1267 GCGCCCCCGCCGCCCCGGG CCCGGGGCGGCGGGGGCGC 1268 CGCCCCCGCCGCCCCGGGG CCCCGGGGCGGCGGGGGCG 1269 GCCCCCGCCGCCCCGGGGG CCCCCGGGGCGGCGGGGGC 1270 CCCCCGCCGCCCCGGGGGA TCCCCCGGGGCGGCGGGGG 1271 CCCCGCCGCCCCGGGGGAA TTCCCCCGGGGCGGCGGGG 1272 CCCGCCGCCCCGGGGGAAG CTTCCCCCGGGGCGGCGGG 1273 CCGCCGCCCCGGGGGAAGG CCTTCCCCCGGGGCGGCGG 1274 CGCCGCCCCGGGGGAAGGA TCCTTCCCCCGGGGCGGCG 1275 GCCGCCCCGGGGGAAGGAG CTCCTTCCCCCGGGGCGGC 1276 CCGCCCCGGGGGAAGGAGA TCTCCTTCCCCCGGGGCGG 1277 CGCCCCGGGGGAAGGAGAG CTCTCCTTCCCCCGGGGCG 1278 GCCCCGGGGGAAGGAGAGC GCTCTCCTTCCCCCGGGGC 1279 CCCCGGGGGAAGGAGAGCG CGCTCTCCTTCCCCCGGGG 1280 CCCGGGGGAAGGAGAGCGC GCGCTCTCCTTCCCCCGGG 1281 CCGGGGGAAGGAGAGCGCG CGCGCTCTCCTTCCCCCGG 1282 CGGGGGAAGGAGAGCGCGA TCGCGCTCTCCTTCCCCCG 1283 GGGGGAAGGAGAGCGCGAG CTCGCGCTCTCCTTCCCCC 1284 GGGGAAGGAGAGCGCGAGC GCTCGCGCTCTCCTTCCCC 1285 GGGAAGGAGAGCGCGAGCG CGCTCGCGCTCTCCTTCCC 1286 GGAAGGAGAGCGCGAGCGC GCGCTCGCGCTCTCCTTCC 1287 GAAGGAGAGCGCGAGCGCG CGCGCTCGCGCTCTCCTTC 1288 AAGGAGAGCGCGAGCGCGC GCGCGCTCGCGCTCTCCTT 1289 AGGAGAGCGCGAGCGCGCT AGCGCGCTCGCGCTCTCCT 1290 GGAGAGCGCGAGCGCGCTG CAGCGCGCTCGCGCTCTCC 1291 GAGAGCGCGAGCGCGCTGA TCAGCGCGCTCGCGCTCTC 1292 AGAGCGCGAGCGCGCTGAG CTCAGCGCGCTCGCGCTCT 1293 GAGCGCGAGCGCGCTGAGC GCTCAGCGCGCTCGCGCTC 1294 AGCGCGAGCGCGCTGAGCA TGCTCAGCGCGCTCGCGCT 1295 GCGCGAGCGCGCTGAGCAG CTGCTCAGCGCGCTCGCGC 1296 CGCGAGCGCGCTGAGCAGA TCTGCTCAGCGCGCTCGCG 1297 GCGAGCGCGCTGAGCAGAC GTCTGCTCAGCGCGCTCGC 1298 CGAGCGCGCTGAGCAGACA TGTCTGCTCAGCGCGCTCG 1299 GAGCGCGCTGAGCAGACAG CTGTCTGCTCAGCGCGCTC 1300 AGCGCGCTGAGCAGACAGA TCTGTCTGCTCAGCGCGCT 1301 GCGCGCTGAGCAGACAGAG CTCTGTCTGCTCAGCGCGC 1302 CGCGCTGAGCAGACAGAGC GCTCTGTCTGCTCAGCGCG 1303 GCGCTGAGCAGACAGAGCG CGCTCTGTCTGCTCAGCGC 1304 CGCTGAGCAGACAGAGCGG CCGCTCTGTCTGCTCAGCG 1305 GCTGAGCAGACAGAGCGGG CCCGCTCTGTCTGCTCAGC 1306 CTGAGCAGACAGAGCGGGA TCCCGCTCTGTCTGCTCAG 1307 TGAGCAGACAGAGCGGGAG CTCCCGCTCTGTCTGCTCA 1308 GAGCAGACAGAGCGGGAGA TCTCCCGCTCTGTCTGCTC 1309 AGCAGACAGAGCGGGAGAA TTCTCCCGCTCTGTCTGCT 1310 GCAGACAGAGCGGGAGAAC GTTCTCCCGCTCTGTCTGC 1311 CAGACAGAGCGGGAGAACG CGTTCTCCCGCTCTGTCTG 1312 AGACAGAGCGGGAGAACGC GCGTTCTCCCGCTCTGTCT 1313 GACAGAGCGGGAGAACGCG CGCGTTCTCCCGCTCTGTC 1314 ACAGAGCGGGAGAACGCGT ACGCGTTCTCCCGCTCTGT 1315 CAGAGCGGGAGAACGCGTC GACGCGTTCTCCCGCTCTG 1316 AGAGCGGGAGAACGCGTCC GGACGCGTTCTCCCGCTCT 1317 GAGCGGGAGAACGCGTCCT AGGACGCGTTCTCCCGCTC 1318 AGCGGGAGAACGCGTCCTC GAGGACGCGTTCTCCCGCT 1319 GCGGGAGAACGCGTCCTCG CGAGGACGCGTTCTCCCGC 1320 CGGGAGAACGCGTCCTCGC GCGAGGACGCGTTCTCCCG 1321 GGGAGAACGCGTCCTCGCC GGCGAGGACGCGTTCTCCC 1322 GGAGAACGCGTCCTCGCCC GGGCGAGGACGCGTTCTCC 1323 GAGAACGCGTCCTCGCCCG CGGGCGAGGACGCGTTCTC 1324 AGAACGCGTCCTCGCCCGC GCGGGCGAGGACGCGTTCT 1325 GAACGCGTCCTCGCCCGCC GGCGGGCGAGGACGCGTTC 1326 AACGCGTCCTCGCCCGCCG CGGCGGGCGAGGACGCGTT 1327 ACGCGTCCTCGCCCGCCGG CCGGCGGGCGAGGACGCGT 1328 CGCGTCCTCGCCCGCCGGC GCCGGCGGGCGAGGACGCG 1329 GCGTCCTCGCCCGCCGGCC GGCCGGCGGGCGAGGACGC 1330 CGTCCTCGCCCGCCGGCCG CGGCCGGCGGGCGAGGACG 1331 GTCCTCGCCCGCCGGCCGG CCGGCCGGCGGGCGAGGAC 1332 TCCTCGCCCGCCGGCCGGG CCCGGCCGGCGGGCGAGGA 1333 CCTCGCCCGCCGGCCGGGA TCCCGGCCGGCGGGCGAGG 1334 CTCGCCCGCCGGCCGGGAG CTCCCGGCCGGCGGGCGAG 1335 TCGCCCGCCGGCCGGGAGG CCTCCCGGCCGGCGGGCGA 1336 CGCCCGCCGGCCGGGAGGC GCCTCCCGGCCGGCGGGCG 1337 GCCCGCCGGCCGGGAGGCC GGCCTCCCGGCCGGCGGGC 1338 CCCGCCGGCCGGGAGGCCC GGGCCTCCCGGCCGGCGGG 1339 CCGCCGGCCGGGAGGCCCC GGGGCCTCCCGGCCGGCGG 1340 CGCCGGCCGGGAGGCCCCG CGGGGCCTCCCGGCCGGCG 1341 GCCGGCCGGGAGGCCCCGG CCGGGGCCTCCCGGCCGGC 1342 CCGGCCGGGAGGCCCCGGA TCCGGGGCCTCCCGGCCGG 1343 CGGCCGGGAGGCCCCGGAG CTCCGGGGCCTCCCGGCCG 1344 GGCCGGGAGGCCCCGGAGC GCTCCGGGGCCTCCCGGCC 1345 GCCGGGAGGCCCCGGAGCT AGCTCCGGGGCCTCCCGGC 1346 CCGGGAGGCCCCGGAGCTG CAGCTCCGGGGCCTCCCGG 1347 CGGGAGGCCCCGGAGCTGG CCAGCTCCGGGGCCTCCCG 1348 GGGAGGCCCCGGAGCTGGC GCCAGCTCCGGGGCCTCCC 1349 GGAGGCCCCGGAGCTGGCC GGCCAGCTCCGGGGCCTCC 1350 GAGGCCCCGGAGCTGGCCC GGGCCAGCTCCGGGGCCTC 1351 AGGCCCCGGAGCTGGCCCA TGGGCCAGCTCCGGGGCCT 1352 GGCCCCGGAGCTGGCCCAT ATGGGCCAGCTCCGGGGCC 1353 GCCCCGGAGCTGGCCCATG CATGGGCCAGCTCCGGGGC 1354 CCCCGGAGCTGGCCCATGG CCATGGGCCAGCTCCGGGG 1355 CCCGGAGCTGGCCCATGGG CCCATGGGCCAGCTCCGGG 1356 CCGGAGCTGGCCCATGGGG CCCCATGGGCCAGCTCCGG 1357 CGGAGCTGGCCCATGGGGA TCCCCATGGGCCAGCTCCG 1358 GGAGCTGGCCCATGGGGAG CTCCCCATGGGCCAGCTCC 1359 GAGCTGGCCCATGGGGAGC GCTCCCCATGGGCCAGCTC 1360 AGCTGGCCCATGGGGAGCA TGCTCCCCATGGGCCAGCT 1361 GCTGGCCCATGGGGAGCAG CTGCTCCCCATGGGCCAGC 1362 CTGGCCCATGGGGAGCAGG CCTGCTCCCCATGGGCCAG 1363 TGGCCCATGGGGAGCAGGC GCCTGCTCCCCATGGGCCA 1364 GGCCCATGGGGAGCAGGCG CGCCTGCTCCCCATGGGCC 1365 GCCCATGGGGAGCAGGCGC GCGCCTGCTCCCCATGGGC 1366 CCCATGGGGAGCAGGCGCC GGCGCCTGCTCCCCATGGG 1367 CCATGGGGAGCAGGCGCCC GGGCGCCTGCTCCCCATGG 1368 CATGGGGAGCAGGCGCCCG CGGGCGCCTGCTCCCCATG 1369 ATGGGGAGCAGGCGCCCGG CCGGGCGCCTGCTCCCCAT 1370 TGGGGAGCAGGCGCCCGGT ACCGGGCGCCTGCTCCCCA 1371 GGGGAGCAGGCGCCCGGTG CACCGGGCGCCTGCTCCCC 1372 GGGAGCAGGCGCCCGGTGC GCACCGGGCGCCTGCTCCC 1373 GGAGCAGGCGCCCGGTGCC GGCACCGGGCGCCTGCTCC 1374 GAGCAGGCGCCCGGTGCCG CGGCACCGGGCGCCTGCTC 1375 AGCAGGCGCCCGGTGCCGG CCGGCACCGGGCGCCTGCT 1376 GCAGGCGCCCGGTGCCGGC GCCGGCACCGGGCGCCTGC 1377 CAGGCGCCCGGTGCCGGCC GGCCGGCACCGGGCGCCTG 1378 AGGCGCCCGGTGCCGGCCA TGGCCGGCACCGGGCGCCT 1379 GGCGCCCGGTGCCGGCCAC GTGGCCGGCACCGGGCGCC 1380 GCGCCCGGTGCCGGCCACG CGTGGCCGGCACCGGGCGC 1381 CGCCCGGTGCCGGCCACGA TCGTGGCCGGCACCGGGCG 1382 GCCCGGTGCCGGCCACGAC GTCGTGGCCGGCACCGGGC 1383 CCCGGTGCCGGCCACGACG CGTCGTGGCCGGCACCGGG 1384 CCGGTGCCGGCCACGACGA TCGTCGTGGCCGGCACCGG 1385 CGGTGCCGGCCACGACGAC GTCGTCGTGGCCGGCACCG 1386 GGTGCCGGCCACGACGACC GGTCGTCGTGGCCGGCACC 1387 GTGCCGGCCACGACGACCG CGGTCGTCGTGGCCGGCAC 1388 TGCCGGCCACGACGACCGC GCGGTCGTCGTGGCCGGCA 1389 GCCGGCCACGACGACCGCC GGCGGTCGTCGTGGCCGGC 1390 CCGGCCACGACGACCGCCA TGGCGGTCGTCGTGGCCGG 1391 CGGCCACGACGACCGCCAC GTGGCGGTCGTCGTGGCCG 1392 GGCCACGACGACCGCCACC GGTGGCGGTCGTCGTGGCC 1393 GCCACGACGACCGCCACCG CGGTGGCGGTCGTCGTGGC 1394 CCACGACGACCGCCACCGC GCGGTGGCGGTCGTCGTGG 1395 CACGACGACCGCCACCGCC GGCGGTGGCGGTCGTCGTG 1396 ACGACGACCGCCACCGCCC GGGCGGTGGCGGTCGTCGT 1397 CGACGACCGCCACCGCCCG CGGGCGGTGGCGGTCGTCG 1398 GACGACCGCCACCGCCCGC GCGGGCGGTGGCGGTCGTC 1399 ACGACCGCCACCGCCCGCG CGCGGGCGGTGGCGGTCGT 1400 CGACCGCCACCGCCCGCGC GCGCGGGCGGTGGCGGTCG 1401 GACCGCCACCGCCCGCGCC GGCGCGGGCGGTGGCGGTC 1402 ACCGCCACCGCCCGCGCCG CGGCGCGGGCGGTGGCGGT 1403 CCGCCACCGCCCGCGCCGC GCGGCGCGGGCGGTGGCGG 1404 CGCCACCGCCCGCGCCGCG CGCGGCGCGGGCGGTGGCG 1405 GCCACCGCCCGCGCCGCGA TCGCGGCGCGGGCGGTGGC 1406 CCACCGCCCGCGCCGCGAC GTCGCGGCGCGGGCGGTGG 1407 CACCGCCCGCGCCGCGACC GGTCGCGGCGCGGGCGGTG 1408 ACCGCCCGCGCCGCGACCG CGGTCGCGGCGCGGGCGGT 1409 CCGCCCGCGCCGCGACCGG CCGGTCGCGGCGCGGGCGG 1410 CGCCCGCGCCGCGACCGGC GCCGGTCGCGGCGCGGGCG 1411 GCCCGCGCCGCGACCGGCC GGCCGGTCGCGGCGCGGGC 1412 CCCGCGCCGCGACCGGCCG CGGCCGGTCGCGGCGCGGG 1413 CCGCGCCGCGACCGGCCGG CCGGCCGGTCGCGGCGCGG 1414 CGCGCCGCGACCGGCCGGT ACCGGCCGGTCGCGGCGCG 1415 GCGCCGCGACCGGCCGGTG CACCGGCCGGTCGCGGCGC 1416 CGCCGCGACCGGCCGGTGA TCACCGGCCGGTCGCGGCG 1417 GCCGCGACCGGCCGGTGAA TTCACCGGCCGGTCGCGGC 1418 CCGCGACCGGCCGGTGAAG CTTCACCGGCCGGTCGCGG 1419 CGCGACCGGCCGGTGAAGC GCTTCACCGGCCGGTCGCG 1420 GCGACCGGCCGGTGAAGCC GGCTTCACCGGCCGGTCGC 1421 CGACCGGCCGGTGAAGCCC GGGCTTCACCGGCCGGTCG 1422 GACCGGCCGGTGAAGCCCA TGGGCTTCACCGGCCGGTC 1423 ACCGGCCGGTGAAGCCCAG CTGGGCTTCACCGGCCGGT 1424 CCGGCCGGTGAAGCCCAGG CCTGGGCTTCACCGGCCGG 1425 CGGCCGGTGAAGCCCAGGG CCCTGGGCTTCACCGGCCG 1426 GGCCGGTGAAGCCCAGGGA TCCCTGGGCTTCACCGGCC 1427 GCCGGTGAAGCCCAGGGAC GTCCCTGGGCTTCACCGGC 1428 CCGGTGAAGCCCAGGGACC GGTCCCTGGGCTTCACCGG 1429 CGGTGAAGCCCAGGGACCC GGGTCCCTGGGCTTCACCG 1430 GGTGAAGCCCAGGGACCCC GGGGTCCCTGGGCTTCACC 1431 GTGAAGCCCAGGGACCCCC GGGGGTCCCTGGGCTTCAC 1432 TGAAGCCCAGGGACCCCCC GGGGGGTCCCTGGGCTTCA 1433 GAAGCCCAGGGACCCCCCT AGGGGGGTCCCTGGGCTTC 1434 AAGCCCAGGGACCCCCCTC GAGGGGGGTCCCTGGGCTT 1435 AGCCCAGGGACCCCCCTCT AGAGGGGGGTCCCTGGGCT 1436 GCCCAGGGACCCCCCTCTG CAGAGGGGGGTCCCTGGGC 1437 CCCAGGGACCCCCCTCTGG CCAGAGGGGGGTCCCTGGG 1438 CCAGGGACCCCCCTCTGGG CCCAGAGGGGGGTCCCTGG 1439 CAGGGACCCCCCTCTGGGA TCCCAGAGGGGGGTCCCTG 1440 AGGGACCCCCCTCTGGGAG CTCCCAGAGGGGGGTCCCT 1441 GGGACCCCCCTCTGGGAGA TCTCCCAGAGGGGGGTCCC 1442 GGACCCCCCTCTGGGAGAG CTCTCCCAGAGGGGGGTCC 1443 GACCCCCCTCTGGGAGAGC GCTCTCCCAGAGGGGGGTC 1444 ACCCCCCTCTGGGAGAGCC GGCTCTCCCAGAGGGGGGT 1445 CCCCCCTCTGGGAGAGCCC GGGCTCTCCCAGAGGGGGG 1446 CCCCCTCTGGGAGAGCCCC GGGGCTCTCCCAGAGGGGG 1447 CCCCTCTGGGAGAGCCCCA TGGGGCTCTCCCAGAGGGG 1448 CCCTCTGGGAGAGCCCCAT ATGGGGCTCTCCCAGAGGG 1449 CCTCTGGGAGAGCCCCATG CATGGGGCTCTCCCAGAGG 1450 CTCTGGGAGAGCCCCATGA TCATGGGGCTCTCCCAGAG 1451 TCTGGGAGAGCCCCATGAG CTCATGGGGCTCTCCCAGA 1452 CTGGGAGAGCCCCATGAGG CCTCATGGGGCTCTCCCAG 1453 TGGGAGAGCCCCATGAGGG CCCTCATGGGGCTCTCCCA 1454 GGGAGAGCCCCATGAGGGC GCCCTCATGGGGCTCTCCC 1455 GGAGAGCCCCATGAGGGCA TGCCCTCATGGGGCTCTCC 1456 GAGAGCCCCATGAGGGCAG CTGCCCTCATGGGGCTCTC 1457 AGAGCCCCATGAGGGCAGG CCTGCCCTCATGGGGCTCT 1458 GAGCCCCATGAGGGCAGGA TCCTGCCCTCATGGGGCTC 1459 AGCCCCATGAGGGCAGGAG CTCCTGCCCTCATGGGGCT 1460 GCCCCATGAGGGCAGGAGA TCTCCTGCCCTCATGGGGC 1461 CCCCATGAGGGCAGGAGAG CTCTCCTGCCCTCATGGGG 1462 CCCATGAGGGCAGGAGAGT ACTCTCCTGCCCTCATGGG 1463 CCATGAGGGCAGGAGAGTG CACTCTCCTGCCCTCATGG 1464 CATGAGGGCAGGAGAGTGA TCACTCTCCTGCCCTCATG 1465 ATGAGGGCAGGAGAGTGAT ATCACTCTCCTGCCCTCAT 1466 TGAGGGCAGGAGAGTGATG CATCACTCTCCTGCCCTCA 1467 GAGGGCAGGAGAGTGATGG CCATCACTCTCCTGCCCTC 1468 AGGGCAGGAGAGTGATGGA TCCATCACTCTCCTGCCCT 1469 GGGCAGGAGAGTGATGGAG CTCCATCACTCTCCTGCCC 1470 GGCAGGAGAGTGATGGAGA TCTCCATCACTCTCCTGCC 1471 GCAGGAGAGTGATGGAGAG CTCTCCATCACTCTCCTGC 1472 CAGGAGAGTGATGGAGAGT ACTCTCCATCACTCTCCTG 1473 AGGAGAGTGATGGAGAGTA TACTCTCCATCACTCTCCT 1474 GGAGAGTGATGGAGAGTAC GTACTCTCCATCACTCTCC 1475 GAGAGTGATGGAGAGTACG CGTACTCTCCATCACTCTC 1476 AGAGTGATGGAGAGTACGC GCGTACTCTCCATCACTCT 1477 GAGTGATGGAGAGTACGCC GGCGTACTCTCCATCACTC 1478 AGTGATGGAGAGTACGCCC GGGCGTACTCTCCATCACT 1479 GTGATGGAGAGTACGCCCA TGGGCGTACTCTCCATCAC 1480 TGATGGAGAGTACGCCCAG CTGGGCGTACTCTCCATCA 1481 GATGGAGAGTACGCCCAGC GCTGGGCGTACTCTCCATC 1482 ATGGAGAGTACGCCCAGCT AGCTGGGCGTACTCTCCAT 1483 TGGAGAGTACGCCCAGCTT AAGCTGGGCGTACTCTCCA 1484 GGAGAGTACGCCCAGCTTC GAAGCTGGGCGTACTCTCC 1485 GAGAGTACGCCCAGCTTCC GGAAGCTGGGCGTACTCTC 1486 AGAGTACGCCCAGCTTCCT AGGAAGCTGGGCGTACTCT 1487 GAGTACGCCCAGCTTCCTG CAGGAAGCTGGGCGTACTC 1488 AGTACGCCCAGCTTCCTGA TCAGGAAGCTGGGCGTACT 1489 GTACGCCCAGCTTCCTGAA TTCAGGAAGCTGGGCGTAC 1490 TACGCCCAGCTTCCTGAAG CTTCAGGAAGCTGGGCGTA 1491 ACGCCCAGCTTCCTGAAGG CCTTCAGGAAGCTGGGCGT 1492 CGCCCAGCTTCCTGAAGGG CCCTTCAGGAAGCTGGGCG 1493 GCCCAGCTTCCTGAAGGGC GCCCTTCAGGAAGCTGGGC 1494 CCCAGCTTCCTGAAGGGCA TGCCCTTCAGGAAGCTGGG 1495 CCAGCTTCCTGAAGGGCAC GTGCCCTTCAGGAAGCTGG 1496 CAGCTTCCTGAAGGGCACC GGTGCCCTTCAGGAAGCTG 1497 AGCTTCCTGAAGGGCACCC GGGTGCCCTTCAGGAAGCT 1498 GCTTCCTGAAGGGCACCCC GGGGTGCCCTTCAGGAAGC 1499 CTTCCTGAAGGGCACCCCA TGGGGTGCCCTTCAGGAAG 1500 TTCCTGAAGGGCACCCCAA TTGGGGTGCCCTTCAGGAA 1501 TCCTGAAGGGCACCCCAAC GTTGGGGTGCCCTTCAGGA 1502 CCTGAAGGGCACCCCAACC GGTTGGGGTGCCCTTCAGG 1503 CTGAAGGGCACCCCAACCT AGGTTGGGGTGCCCTTCAG 1504 TGAAGGGCACCCCAACCTG CAGGTTGGGGTGCCCTTCA 1505 GAAGGGCACCCCAACCTGG CCAGGTTGGGGTGCCCTTC 1506 AAGGGCACCCCAACCTGGG CCCAGGTTGGGGTGCCCTT 1507 AGGGCACCCCAACCTGGGA TCCCAGGTTGGGGTGCCCT 1508 GGGCACCCCAACCTGGGAG CTCCCAGGTTGGGGTGCCC 1509 GGCACCCCAACCTGGGAGA TCTCCCAGGTTGGGGTGCC 1510 GCACCCCAACCTGGGAGAA TTCTCCCAGGTTGGGGTGC 1511 CACCCCAACCTGGGAGAAG CTTCTCCCAGGTTGGGGTG 1512 ACCCCAACCTGGGAGAAGA TCTTCTCCCAGGTTGGGGT 1513 CCCCAACCTGGGAGAAGAC GTCTTCTCCCAGGTTGGGG 1514 CCCAACCTGGGAGAAGACG CGTCTTCTCCCAGGTTGGG 1515 CCAACCTGGGAGAAGACGG CCGTCTTCTCCCAGGTTGG 1516 CAACCTGGGAGAAGACGGC GCCGTCTTCTCCCAGGTTG 1517 AACCTGGGAGAAGACGGCC GGCCGTCTTCTCCCAGGTT 1518 ACCTGGGAGAAGACGGCCC GGGCCGTCTTCTCCCAGGT 1519 CCTGGGAGAAGACGGCCCC GGGGCCGTCTTCTCCCAGG 1520 CTGGGAGAAGACGGCCCCA TGGGGCCGTCTTCTCCCAG 1521 TGGGAGAAGACGGCCCCAG CTGGGGCCGTCTTCTCCCA 1522 GGGAGAAGACGGCCCCAGA TCTGGGGCCGTCTTCTCCC 1523 GGAGAAGACGGCCCCAGAG CTCTGGGGCCGTCTTCTCC 1524 GAGAAGACGGGGCCAGAGA TCTCTGGGGCCGTCTTCTC 1525 AGAAGACGGCCCCAGAGAA TTCTCTGGGGCCGTCTTCT 1526 GAAGACGGCCCCAGAGAAC GTTCTCTGGGGCCGTCTTC 1527 AAGACGGCCCCAGAGAACG CGTTCTCTGGGGCCGTCTT 1528 AGACGGCCCCAGAGAACGG CCGTTCTCTGGGGCCGTCT 1529 GACGGCCCCAGAGAACGGC GCCGTTCTCTGGGGCCGTC 1530 ACGGCCCCAGAGAACGGCA TGCCGTTCTCTGGGGCCGT 1531 CGGCCCCAGAGAACGGCAT ATGCCGTTCTCTGGGGCCG 1532 GGCCCCAGAGAACGGCATC GATGCCGTTCTCTGGGGCC 1533 GCCCCAGAGAACGGCATCG CGATGCCGTTCTCTGGGGC 1534 CCCCAGAGAACGGCATCGT ACGATGCCGTTCTCTGGGG 1535 CCCAGAGAACGGCATCGTG CACGATGCCGTTCTCTGGG 1536 CCAGAGAACGGCATCGTGA TCACGATGCCGTTCTCTGG 1537 CAGAGAACGGCATCGTGAG CTCACGATGCCGTTCTCTG 1538 AGAGAACGGCATCGTGAGA TCTCACGATGCCGTTCTCT 1539 GAGAACGGCATCGTGAGAC GTCTCACGATGCCGTTCTC 1540 AGAACGGCATCGTGAGACA TGTCTCACGATGCCGTTCT 1541 GAACGGCATCGTGAGACAG CTGTCTCACGATGCCGTTC 1542 AACGGCATCGTGAGACAGG CCTGTCTCACGATGCCGTT 1543 ACGGCATCGTGAGACAGGA TCCTGTCTCACGATGCCGT 1544 CGGCATCGTGAGACAGGAG CTCCTGTCTCACGATGCCG 1545 GGCATCGTGAGACAGGAGC GCTCCTGTCTCACGATGCC 1546 GCATCGTGAGACAGGAGCC GGCTCCTGTCTCACGATGC 1547 CATCGTGAGACAGGAGCCC GGGCTCCTGTCTCACGATG 1548 ATCGTGAGACAGGAGCCCG CGGGCTCCTGTCTCACGAT 1549 TCGTGAGACAGGAGCCCGG CCGGGCTCCTGTCTCACGA 1550 CGTGAGACAGGAGCCCGGC GCCGGGCTCCTGTCTCACG 1551 GTGAGACAGGAGCCCGGCA TGCCGGGCTCCTGTCTCAC 1552 TGAGACAGGAGCCCGGCAG CTGCCGGGCTCCTGTCTCA 1553 GAGACAGGAGCCCGGCAGC GCTGCCGGGCTCCTGTCTC 1554 AGACAGGAGCCCGGCAGCC GGCTGCCGGGCTCCTGTCT 1555 GACAGGAGCCCGGCAGCCC GGGCTGCCGGGCTCCTGTC 1556 ACAGGAGCCCGGCAGCCCG CGGGCTGCCGGGCTCCTGT 1557 CAGGAGCCCGGCAGCCCGC GCGGGCTGCCGGGCTCCTG 1558 AGGAGCCCGGCAGCCCGCC GGCGGGCTGCCGGGCTCCT 1559 GGAGCCCGGCAGCCCGCCT AGGCGGGCTGCCGGGCTCC 1560 GAGCCCGGCAGCCCGCCTC GAGGCGGGCTGCCGGGCTC 1561 AGCCCGGCAGCCCGCCTCG CGAGGCGGGCTGCCGGGCT 1562 GCCCGGCAGCCCGCCTCGA TCGAGGCGGGCTGCCGGGC 1563 CCCGGCAGCCCGCCTCGAG CTCGAGGCGGGCTGCCGGG 1564 CCGGCAGCCCGCCTCGAGA TCTCGAGGCGGGCTGCCGG 1565 CGGCAGCCCGCCTCGAGAT ATCTCGAGGCGGGCTGCCG 1566 GGCAGCCCGCCTCGAGATG CATCTCGAGGCGGGCTGCC 1567 GCAGCCCGCCTCGAGATGG CCATCTCGAGGCGGGCTGC 1568 CAGCCCGCCTCGAGATGGA TCCATCTCGAGGCGGGCTG 1569 AGCCCGCCTCGAGATGGAC GTCCATCTCGAGGCGGGCT 1570 GCCCGCCTCGAGATGGACT AGTCCATCTCGAGGCGGGC 1571 CCCGCCTCGAGATGGACTG CAGTCCATCTCGAGGCGGG 1572 CCGCCTCGAGATGGACTGC GCAGTCCATCTCGAGGCGG 1573 CGCCTCGAGATGGACTGCA TGCAGTCCATCTCGAGGCG 1574 GCCTCGAGATGGACTGCAC GTGCAGTCCATCTCGAGGC 1575 CCTCGAGATGGACTGCACC GGTGCAGTCCATCTCGAGG 1576 CTCGAGATGGACTGCACCA TGGTGCAGTCCATCTCGAG 1577 TCGAGATGGACTGCACCAT ATGGTGCAGTCCATCTCGA 1578 CGAGATGGACTGCACCATG CATGGTGCAGTCCATCTCG 1579 GAGATGGACTGCACCATGG CCATGGTGCAGTCCATCTC 1580 AGATGGACTGCACCATGGG CCCATGGTGCAGTCCATCT 1581 GATGGACTGCACCATGGGC GCCCATGGTGCAGTCCATC 1582 ATGGACTGCACCATGGGCC GGCCCATGGTGCAGTCCAT 1583 TGGACTGCACCATGGGCCG CGGCCCATGGTGCAGTCCA 1584 GGACTGCACCATGGGCCGC GCGGCCCATGGTGCAGTCC 1585 GACTGCACCATGGGCCGCT AGCGGCCCATGGTGCAGTC 1586 ACTGCACCATGGGCCGCTG CAGCGGCCCATGGTGCAGT 1587 CTGCACCATGGGCCGCTGT ACAGCGGCCCATGGTGCAG 1588 TGCACCATGGGCCGCTGTG CACAGCGGCCCATGGTGCA 1589 GCACCATGGGCCGCTGTGC GCACAGCGGCCCATGGTGC 1590 CACCATGGGCCGCTGTGCC GGCACAGCGGCCCATGGTG 1591 ACCATGGGCCGCTGTGCCT AGGCACAGCGGCCCATGGT 1592 CCATGGGCCGCTGTGCCTG CAGGCACAGCGGCCCATGG 1593 CATGGGCCGCTGTGCCTGG CCAGGCACAGCGGCCCATG 1594 ATGGGCCGCTGTGCCTGGG CCCAGGCACAGCGGCCCAT 1595 TGGGCCGCTGTGCCTGGGA TCCCAGGCACAGCGGCCCA 1596 GGGCCGCTGTGCCTGGGAG CTCCCAGGCACAGCGGCCC 1597 GGCCGCTGTGCCTGGGAGA TCTCCCAGGCACAGCGGCC 1598 GCCGCTGTGCCTGGGAGAG CTCTCCCAGGCACAGCGGC 1599 CCGCTGTGCCTGGGAGAGC GCTCTCCCAGGCACAGCGG 1600 CGCTGTGCCTGGGAGAGCC GGCTCTCCCAGGCACAGCG 1601 GCTGTGCCTGGGAGAGCCT AGGCTCTCCCAGGCACAGC 1602 CTGTGCCTGGGAGAGCCTG CAGGCTCTCCCAGGCACAG 1603 TGTGCCTGGGAGAGCCTGC GCAGGCTCTCCCAGGCACA 1604 GTGCCTGGGAGAGCCTGCT AGCAGGCTCTCCCAGGCAC 1605 TGCCTGGGAGAGCCTGCTC GAGCAGGCTCTCCCAGGCA 1606 GCCTGGGAGAGCCTGCTCC GGAGCAGGCTCTCCCAGGC 1607 CCTGGGAGAGCCTGCTCCC GGGAGCAGGCTCTCCCAGG 1608 CTGGGAGAGCCTGCTCCCT AGGGAGCAGGCTCTCCCAG 1609 TGGGAGAGCCTGCTCCCTT AAGGGAGCAGGCTCTCCCA 1610 GGGAGAGCCTGCTCCCTTT AAAGGGAGCAGGCTCTCCC 1611 GGAGAGCCTGCTCCCTTTT AAAAGGGAGCAGGCTCTCC 1612 GAGAGCCTGCTCCCTTTTG CAAAAGGGAGCAGGCTCTC 1613 AGAGCCTGCTCCCTTTTGG CCAAAAGGGAGCAGGCTCT 1614 GAGCCTGCTCCCTTTTGGA TCCAAAAGGGAGCAGGCTC 1615 AGCCTGCTCCCTTTTGGAG CTCCAAAAGGGAGCAGGCT 1616 GCCTGCTCCCTTTTGGAGG CCTCCAAAAGGGAGCAGGC 1617 CCTGCTCCCTTTTGGAGGG CCCTCCAAAAGGGAGCAGG 1618 CTGCTCCCTTTTGGAGGGG CCCCTCCAAAAGGGAGCAG 1619 TGCTCCCTTTTGGAGGGGC GCCCCTCCAAAAGGGAGCA 1620 GCTCCCTTTTGGAGGGGCG CGCCCCTCCAAAAGGGAGC 1621 CTCCCTTTTGGAGGGGCGT ACGCCCCTCCAAAAGGGAG 1622 TCCCTTTTGGAGGGGCGTC GACGCCCCTCCAAAAGGGA 1623 CCCTTTTGGAGGGGCGTCC GGACGCCCCTCCAAAAGGG 1624 CCTTTTGGAGGGGCGTCCT AGGACGCCCCTCCAAAAGG 1625 CTTTTGGAGGGGCGTCCTG CAGGACGCCCCTCCAAAAG 1626 TTTTGGAGGGGCGTCCTGA TCAGGACGCCCCTCCAAAA 1627 TTTGGAGGGGCGTCCTGAG CTCAGGACGCCCCTCCAAA 1628 TTGGAGGGGCGTCCTGAGC GCTCAGGACGCCCCTCCAA 1629 TGGAGGGGCGTCCTGAGCA TGCTCAGGACGCCCCTCCA 1630 GGAGGGGCGTCCTGAGCAC GTGCTCAGGACGCCCCTCC 1631 GAGGGGCGTCCTGAGCACC GGTGCTCAGGACGCCCCTC 1632 AGGGGCGTCCTGAGCACCC GGGTGCTCAGGACGCCCCT 1633 GGGGCGTCCTGAGCACCCC GGGGTGCTCAGGACGCCCC 1634 GGGCGTCCTGAGCACCCCA TGGGGTGCTCAGGACGCCC 1635 GGCGTCCTGAGCACCCCAG CTGGGGTGCTCAGGACGCC 1636 GCGTCCTGAGCACCCCAGA TCTGGGGTGCTCAGGACGC 1637 CGTCCTGAGCACCCCAGAC GTCTGGGGTGCTCAGGACG 1638 GTCCTGAGCACCCCAGACT AGTCTGGGGTGCTCAGGAC 1639 TCCTGAGCACCCCAGACTC GAGTCTGGGGTGCTCAGGA 1640 CCTGAGCACCCCAGACTCC GGAGTCTGGGGTGCTCAGG 1641 CTGAGCACCCCAGACTCCT AGGAGTCTGGGGTGCTCAG 1642 TGAGCACCCCAGACTCCTG CAGGAGTCTGGGGTGCTCA 1643 GAGCACCCCAGACTCCTGG CCAGGAGTCTGGGGTGCTC 1644 AGCACCCCAGACTCCTGGC GCCAGGAGTCTGGGGTGCT 1645 GCACCCCAGACTCCTGGCT AGCCAGGAGTCTGGGGTGC 1646 CACCCCAGACTCCTGGCTT AAGCCAGGAGTCTGGGGTG 1647 ACCCCAGACTCCTGGCTTC GAAGCCAGGAGTCTGGGGT 1648 CCCCAGACTCCTGGCTTCC GGAAGCCAGGAGTCTGGGG 1649 CCCAGACTCCTGGCTTCCC GGGAAGCCAGGAGTCTGGG 1650 CCAGACTCCTGGCTTCCCC GGGGAAGCCAGGAGTCTGG 1651 CAGACTCCTGGCTTCCCCC GGGGGAAGCCAGGAGTCTG 1652 AGACTCCTGGCTTCCCCCT AGGGGGAAGCCAGGAGTCT 1653 GACTCCTGGCTTCCCCCTG CAGGGGGAAGCCAGGAGTC 1654 ACTCCTGGCTTCCCCCTGG CCAGGGGGAAGCCAGGAGT 1655 CTCCTGGCTTCCCCCTGGC GCCAGGGGGAAGCCAGGAG 1656 TCCTGGCTTCCCCCTGGCT AGCCAGGGGGAAGCCAGGA 1657 CCTGGCTTCCCCCTGGCTT AAGCCAGGGGGAAGCCAGG 1658 CTGGCTTCCCCCTGGCTTC GAAGCCAGGGGGAAGCCAG 1659 TGGCTTCCCCCTGGCTTCC GGAAGCCAGGGGGAAGCCA 1660 GGCTTCCCCCTGGCTTCCC GGGAAGCCAGGGGGAAGCC 1661 GCTTCCCCCTGGCTTCCCC GGGGAAGCCAGGGGGAAGC 1662 CTTCCCCCTGGCTTCCCCC GGGGGAAGCCAGGGGGAAG 1663 TTCCCCCTGGCTTCCCCCA TGGGGGAAGCCAGGGGGAA 1664 TCCCCCTGGCTTCCCCCAG CTGGGGGAAGCCAGGGGGA 1665 CCCCCTGGCTTCCCCCAGG CCTGGGGGAAGCCAGGGGG 1666 CCCCTGGCTTCCCCCAGGG CCCTGGGGGAAGCCAGGGG 1667 CCCTGGCTTCCCCCAGGGC GCCCTGGGGGAAGCCAGGG 1668 CCTGGCTTCCCCCAGGGCC GGCCCTGGGGGAAGCCAGG 1669 CTGGCTTCCCCCAGGGCCC GGGCCCTGGGGGAAGCCAG 1670 TGGCTTCCCCCAGGGCCCC GGGGCCCTGGGGGAAGCCA 1671 GGCTTCCCCCAGGGCCCCA TGGGGCCCTGGGGGAAGCC 1672 GCTTCCCCCAGGGCCCCAA TTGGGGCCCTGGGGGAAGC 1673 CTTCCCCCAGGGCCCCAAG CTTGGGGCCCTGGGGGAAG 1674 TTCCCCCAGGGCCCCAAGG CCTTGGGGCCCTGGGGGAA 1675 TCCCCCAGGGCCCCAAGGA TCCTTGGGGCCCTGGGGGA 1676 CCCCCAGGGCCCCAAGGAC GTCCTTGGGGCCCTGGGGG 1677 CCCCAGGGCCCCAAGGACA TGTCCTTGGGGCCCTGGGG 1678 CCCAGGGCCCCAAGGACAT ATGTCCTTGGGGCCCTGGG 1679 CCAGGGCCCCAAGGACATG CATGTCCTTGGGGCCCTGG 1680 CAGGGCCCCAAGGACATGC GCATGTCCTTGGGGCCCTG 1681 AGGGCCCCAAGGACATGCT AGCATGTCCTTGGGGCCCT 1682 GGGCCCCAAGGACATGCTC GAGCATGTCCTTGGGGCCC 1683 GGCCCCAAGGACATGCTCC GGAGCATGTCCTTGGGGCC 1684 GCCCCAAGGACATGCTCCC GGGAGCATGTCCTTGGGGC 1685 CCCCAAGGACATGCTCCCA TGGGAGCATGTCCTTGGGG 1686 CCCAAGGACATGCTCCCAC GTGGGAGCATGTCCTTGGG 1687 CCAAGGACATGCTCCCACT AGTGGGAGCATGTCCTTGG 1688 CAAGGACATGCTCCCACTT AAGTGGGAGCATGTCCTTG 1689 AAGGACATGCTCCCACTTG CAAGTGGGAGCATGTCCTT 1690 AGGACATGCTCCCACTTGT ACAAGTGGGAGCATGTCCT 1691 GGACATGCTCCCACTTGTG CACAAGTGGGAGCATGTCC 1692 GACATGCTCCCACTTGTGG CCACAAGTGGGAGCATGTC 1693 ACATGCTCCCACTTGTGGA TCCACAAGTGGGAGCATGT 1694 CATGCTCCCACTTGTGGAG CTCCACAAGTGGGAGCATG 1695 ATGCTCCCACTTGTGGAGG CCTCCACAAGTGGGAGCAT 1696 TGCTCCCACTTGTGGAGGG CCCTCCACAAGTGGGAGCA 1697 GCTCCCACTTGTGGAGGGC GCCCTCCACAAGTGGGAGC 1698 CTCCCACTTGTGGAGGGCG CGCCCTCCACAAGTGGGAG 1699 TCCCACTTGTGGAGGGCGA TCGCCCTCCACAAGTGGGA 1700 CCCACTTGTGGAGGGCGAG CTCGCCCTCCACAAGTGGG 1701 CCACTTGTGGAGGGCGAGG CCTCGCCCTCCACAAGTGG 1702 CACTTGTGGAGGGCGAGGG CCCTCGCCCTCCACAAGTG 1703 ACTTGTGGAGGGCGAGGGC GCCCTCGCCCTCCACAAGT 1704 CTTGTGGAGGGCGAGGGCC GGCCCTCGCCCTCCACAAG 1705 TTGTGGAGGGCGAGGGCCC GGGCCCTCGCCCTCCACAA 1706 TGTGGAGGGCGAGGGCCCC GGGGCCCTCGCCCTCCACA 1707 GTGGAGGGCGAGGGCCCCC GGGGGCCCTCGCCCTCCAC 1708 TGGAGGGCGAGGGCCCCCA TGGGGGCCCTCGCCCTCCA 1709 GGAGGGCGAGGGCCCCCAG CTGGGGGCCCTCGCCCTCC 1710 GAGGGCGAGGGCCCCCAGA TCTGGGGGCCCTCGCCCTC 1711 AGGGCGAGGGCCCCCAGAA TTCTGGGGGCCCTCGCCCT 1712 GGGCGAGGGCCCCCAGAAT ATTCTGGGGGCCCTCGCCC 1713 GGCGAGGGCCCCCAGAATG CATTCTGGGGGCCCTCGCC 1714 GCGAGGGCCCCCAGAATGG CCATTCTGGGGGCCCTCGC 1715 CGAGGGCCCCCAGAATGGG CCCATTCTGGGGGCCCTCG 1716 GAGGGCCCCCAGAATGGGG CCCCATTCTGGGGGCCCTC 1717 AGGGCCCCCAGAATGGGGA TCCCCATTCTGGGGGCCCT 1718 GGGCCCCCAGAATGGGGAG CTCCCCATTCTGGGGGCCC 1719 GGCCCCCAGAATGGGGAGA TCTCCCCATTCTGGGGGCC 1720 GCCCCCAGAATGGGGAGAG CTCTCCCCATTCTGGGGGC 1721 CCCCCAGAATGGGGAGAGG CCTCTCCCCATTCTGGGGG 1722 CCCCAGAATGGGGAGAGGA TCCTCTCCCCATTCTGGGG 1723 CCCAGAATGGGGAGAGGAA TTCCTCTCCCCATTCTGGG 1724 CCAGAATGGGGAGAGGAAG CTTCCTCTCCCCATTCTGG 1725 CAGAATGGGGAGAGGAAGG CCTTCCTCTCCCCATTCTG 1726 AGAATGGGGAGAGGAAGGT ACCTTCCTCTCCCCATTCT 1727 GAATGGGGAGAGGAAGGTC GACCTTCCTCTCCCCATTC 1728 AATGGGGAGAGGAAGGTCA TGACCTTCCTCTCCCCATT 1729 ATGGGGAGAGGAAGGTCAA TTGACCTTCCTCTCCCCAT 1730 TGGGGAGAGGAAGGTCAAC GTTGACCTTCCTCTCCCCA 1731 GGGGAGAGGAAGGTCAACT AGTTGACCTTCCTCTCCCC 1732 GGGAGAGGAAGGTCAACTG CAGTTGACCTTCCTCTCCC 1733 GGAGAGGAAGGTCAACTGG CCAGTTGACCTTCCTCTCC 1734 GAGAGGAAGGTCAACTGGC GCCAGTTGACCTTCCTCTC 1735 AGAGGAAGGTCAACTGGCT AGCCAGTTGACCTTCCTCT 1736 GAGGAAGGTCAACTGGCTG CAGCCAGTTGACCTTCCTC 1737 AGGAAGGTCAACTGGCTGG CCAGCCAGTTGACCTTCCT 1738 GGAAGGTCAACTGGCTGGG CCCAGCCAGTTGACCTTCC 1739 GAAGGTCAACTGGCTGGGC GCCCAGCCAGTTGACCTTC 1740 AAGGTCAACTGGCTGGGCA TGCCCAGCCAGTTGACCTT 1741 AGGTCAACTGGCTGGGCAG CTGCCCAGCCAGTTGACCT 1742 GGTCAACTGGCTGGGCAGC GCTGCCCAGCCAGTTGACC 1743 GTCAACTGGCTGGGCAGCA TGCTGCCCAGCCAGTTGAC 1744 TCAACTGGCTGGGCAGCAA TTGCTGCCCAGCCAGTTGA 1745 CAACTGGCTGGGCAGCAAA TTTGCTGCCCAGCCAGTTG 1746 AACTGGCTGGGCAGCAAAG CTTTGCTGCCCAGCCAGTT 1747 ACTGGCTGGGCAGCAAAGA TCTTTGCTGCCCAGCCAGT 1748 CTGGCTGGGCAGCAAAGAG CTCTTTGCTGCCCAGCCAG 1749 TGGCTGGGCAGCAAAGAGG CCTCTTTGCTGCCCAGCCA 1750 GGCTGGGCAGCAAAGAGGG CCCTCTTTGCTGCCCAGCC 1751 GCTGGGCAGCAAAGAGGGA TCCCTCTTTGCTGCCCAGC 1752 CTGGGCAGCAAAGAGGGAC GTCCCTCTTTGCTGCCCAG 1753 TGGGCAGCAAAGAGGGACT AGTCCCTCTTTGCTGCCCA 1754 GGGCAGCAAAGAGGGACTG CAGTCCCTCTTTGCTGCCC 1755 GGCAGCAAAGAGGGACTGC GCAGTCCCTCTTTGCTGCC 1756 GCAGCAAAGAGGGACTGCG CGCAGTCCCTCTTTGCTGC 1757 CAGCAAAGAGGGACTGCGC GCGCAGTCCCTCTTTGCTG 1758 AGCAAAGAGGGACTGCGCT AGCGCAGTCCCTCTTTGCT 1759 GCAAAGAGGGACTGCGCTG CAGCGCAGTCCCTCTTTGC 1760 CAAAGAGGGACTGCGCTGG CCAGCGCAGTCCCTCTTTG 1761 AAAGAGGGACTGCGCTGGA TCCAGCGCAGTCCCTCTTT 1762 AAGAGGGACTGCGCTGGAA TTCCAGCGCAGTCCCTCTT 1763 AGAGGGACTGCGCTGGAAG CTTCCAGCGCAGTCCCTCT 1764 GAGGGACTGCGCTGGAAGG CCTTCCAGCGCAGTCCCTC 1765 AGGGACTGCGCTGGAAGGA TCCTTCCAGCGCAGTCCCT 1766 GGGACTGCGCTGGAAGGAG CTCCTTCCAGCGCAGTCCC 1767 GGACTGCGCTGGAAGGAGG CCTCCTTCCAGCGCAGTCC 1768 GACTGCGCTGGAAGGAGGC GCCTCCTTCCAGCGCAGTC 1769 ACTGCGCTGGAAGGAGGCC GGCCTCCTTCCAGCGCAGT 1770 CTGCGCTGGAAGGAGGCCA TGGCCTCCTTCCAGCGCAG 1771 TGCGCTGGAAGGAGGCCAT ATGGCCTCCTTCCAGCGCA 1772 GCGCTGGAAGGAGGCCATG CATGGCCTCCTTCCAGCGC 1773 CGCTGGAAGGAGGCCATGC GCATGGCCTCCTTCCAGCG 1774 GCTGGAAGGAGGCCATGCT AGCATGGCCTCCTTCCAGC 1775 CTGGAAGGAGGCCATGCTT AAGCATGGCCTCCTTCCAG 1776 TGGAAGGAGGCCATGCTTA TAAGCATGGCCTCCTTCCA 1777 GGAAGGAGGCCATGCTTAC GTAAGCATGGCCTCCTTCC 1778 GAAGGAGGCCATGCTTACC GGTAAGCATGGCCTCCTTC 1779 AAGGAGGCCATGCTTACCC GGGTAAGCATGGCCTCCTT 1780 AGGAGGCCATGCTTACCCA TGGGTAAGCATGGCCTCCT 1781 GGAGGCCATGCTTACCCAT ATGGGTAAGCATGGCCTCC 1782 GAGGCCATGCTTACCCATC GATGGGTAAGCATGGCCTC 1783 AGGCCATGCTTACCCATCC GGATGGGTAAGCATGGCCT 1784 GGCCATGCTTACCCATCCG CGGATGGGTAAGCATGGCC 1785 GCCATGCTTACCCATCCGC GCGGATGGGTAAGCATGGC 1786 CCATGCTTACCCATCCGCT AGCGGATGGGTAAGCATGG 1787 CATGCTTACCCATCCGCTG CAGCGGATGGGTAAGCATG 1788 ATGCTTACCCATCCGCTGG CCAGCGGATGGGTAAGCAT 1789 TGCTTACCCATCCGCTGGC GCCAGCGGATGGGTAAGCA 1790 GCTTACCCATCCGCTGGCA TGCCAGCGGATGGGTAAGC 1791 CTTACCCATCCGCTGGCAT ATGCCAGCGGATGGGTAAG 1792 TTACCCATCCGCTGGCATT AATGCCAGCGGATGGGTAA 1793 TACCCATCCGCTGGCATTC GAATGCCAGCGGATGGGTA 1794 ACCCATCCGCTGGCATTCT AGAATGCCAGCGGATGGGT 1795 CCCATCCGCTGGCATTCTG CAGAATGCCAGCGGATGGG 1796 CCATCCGCTGGCATTCTGC GCAGAATGCCAGCGGATGG 1797 CATCCGCTGGCATTCTGCG CGCAGAATGCCAGCGGATG 1798 ATCCGCTGGCATTCTGCGG CCGCAGAATGCCAGCGGAT 1799 TCCGCTGGCATTCTGCGGG CCCGCAGAATGCCAGCGGA 1800 CCGCTGGCATTCTGCGGGC GCCCGCAGAATGCCAGCGG 1801 CGCTGGCATTCTGCGGGCC GGCCCGCAGAATGCCAGCG 1802 GCTGGCATTCTGCGGGCCA TGGCCCGCAGAATGCCAGC 1803 CTGGCATTCTGCGGGCCAG CTGGCCCGCAGAATGCCAG 1804 TGGCATTCTGCGGGCCAGC GCTGGCCCGCAGAATGCCA 1805 GGCATTCTGCGGGCCAGCG CGCTGGCCCGCAGAATGCC 1806 GCATTCTGCGGGCCAGCGT ACGCTGGCCCGCAGAATGC 1807 CATTCTGCGGGCCAGCGTG CACGCTGGCCCGCAGAATG 1808 ATTCTGCGGGCCAGCGTGC GCACGCTGGCCCGCAGAAT 1809 TTCTGCGGGCCAGCGTGCC GGCACGCTGGCCCGCAGAA 1810 TCTGCGGGCCAGCGTGCCC GGGCACGCTGGCCCGCAGA 1811 CTGCGGGCCAGCGTGCCCA TGGGCACGCTGGCCCGCAG 1812 TGCGGGCCAGCGTGCCCAC GTGGGCACGCTGGCCCGCA 1813 GCGGGCCAGCGTGCCCACC GGTGGGCACGCTGGCCCGC 1814 CGGGCCAGCGTGCCCACCT AGGTGGGCACGCTGGCCCG 1815 GGGCCAGCGTGCCCACCTC GAGGTGGGCACGCTGGCCC 1816 GGCCAGCGTGCCCACCTCG CGAGGTGGGCACGCTGGCC 1817 GCCAGCGTGCCCACCTCGC GCGAGGTGGGCACGCTGGC 1818 CCAGCGTGCCCACCTCGCT AGCGAGGTGGGCACGCTGG 1819 CAGCGTGCCCACCTCGCTG CAGCGAGGTGGGCACGCTG 1820 AGCGTGCCCACCTCGCTGT ACAGCGAGGTGGGCACGCT 1821 GCGTGCCCACCTCGCTGTG CACAGCGAGGTGGGCACGC 1822 CGTGCCCACCTCGCTGTGG CCACAGCGAGGTGGGCACG 1823 GTGCCCACCTCGCTGTGGC GCCACAGCGAGGTGGGCAC 1824 TGCCCACCTCGCTGTGGCC GGCCACAGCGAGGTGGGCA 1825 GCCCACCTCGCTGTGGCCC GGGCCACAGCGAGGTGGGC 1826 CCCACCTCGCTGTGGCCCC GGGGCCACAGCGAGGTGGG 1827 CCACCTCGCTGTGGCCCCC GGGGGCCACAGCGAGGTGG 1828 CACCTCGCTGTGGCCCCCT AGGGGGCCACAGCGAGGTG 1829 ACCTCGCTGTGGCCCCCTG CAGGGGGCCACAGCGAGGT 1830 CCTCGCTGTGGCCCCCTGA TCAGGGGGCCACAGCGAGG 1831 CTCGCTGTGGCCCCCTGAT ATCAGGGGGCCACAGCGAG 1832 TCGCTGTGGCCCCCTGATG CATCAGGGGGCCACAGCGA 1833 CGCTGTGGCCCCCTGATGC GCATCAGGGGGCCACAGCG 1834 GCTGTGGCCCCCTGATGCC GGCATCAGGGGGCCACAGC 1835 CTGTGGCCCCCTGATGCCT AGGCATCAGGGGGCCACAG 1836 TGTGGCCCCCTGATGCCTG CAGGCATCAGGGGGCCACA 1837 GTGGCCCCCTGATGCCTGA TCAGGCATCAGGGGGCCAC 1838 TGGCCCCCTGATGCCTGAG CTCAGGCATCAGGGGGCCA 1839 GGCCCCCTGATGCCTGAGC GCTCAGGCATCAGGGGGCC 1840 GCCCCCTGATGCCTGAGCA TGCTCAGGCATCAGGGGGC 1841 CCCCCTGATGCCTGAGCAT ATGCTCAGGCATCAGGGGG 1842 CCCCTGATGCCTGAGCATA TATGCTCAGGCATCAGGGG 1843 CCCTGATGCCTGAGCATAG CTATGCTCAGGCATCAGGG 1844 CCTGATGCCTGAGCATAGT ACTATGCTCAGGCATCAGG 1845 CTGATGCCTGAGCATAGTG CACTATGCTCAGGCATCAG 1846 TGATGCCTGAGCATAGTGG CCACTATGCTCAGGCATCA 1847 GATGCCTGAGCATAGTGGT ACCACTATGCTCAGGCATC 1848 ATGCCTGAGCATAGTGGTG CACCACTATGCTCAGGCAT 1849 TGCCTGAGCATAGTGGTGG CCACCACTATGCTCAGGCA 1850 GCCTGAGCATAGTGGTGGC GCCACCACTATGCTCAGGC 1851 CCTGAGCATAGTGGTGGCC GGCCACCACTATGCTCAGG 1852 CTGAGCATAGTGGTGGCCA TGGCCACCACTATGCTCAG 1853 TGAGCATAGTGGTGGCCAT ATGGCCACCACTATGCTCA 1854 GAGCATAGTGGTGGCCATC GATGGCCACCACTATGCTC 1855 AGCATAGTGGTGGCCATCT AGATGGCCACCACTATGCT 1856 GCATAGTGGTGGCCATCTC GAGATGGCCACCACTATGC 1857 CATAGTGGTGGCCATCTCA TGAGATGGCCACCACTATG 1858 ATAGTGGTGGCCATCTCAA TTGAGATGGCCACCACTAT 1859 TAGTGGTGGCCATCTCAAG CTTGAGATGGCCACCACTA 1860 AGTGGTGGCCATCTCAAGA TCTTGAGATGGCCACCACT 1861 GTGGTGGCCATCTCAAGAG CTCTTGAGATGGCCACCAC 1862 TGGTGGCCATCTCAAGAGT ACTCTTGAGATGGCCACCA 1863 GGTGGCCATCTCAAGAGTG CACTCTTGAGATGGCCACC 1864 GTGGCCATCTCAAGAGTGA TCACTCTTGAGATGGCCAC 1865 TGGCCATCTCAAGAGTGAC GTCACTCTTGAGATGGCCA 1866 GGCCATCTCAAGAGTGACC GGTCACTCTTGAGATGGCC 1867 GCCATCTCAAGAGTGACCC GGGTCACTCTTGAGATGGC 1868 CCATCTCAAGAGTGACCCT AGGGTCACTCTTGAGATGG 1869 CATCTCAAGAGTGACCCTG CAGGGTCACTCTTGAGATG 1870 ATCTCAAGAGTGACCCTGT ACAGGGTCACTCTTGAGAT 1871 TCTCAAGAGTGACCCTGTG CACAGGGTCACTCTTGAGA 1872 CTCAAGAGTGACCCTGTGG CCACAGGGTCACTCTTGAG 1873 TCAAGAGTGACCCTGTGGC GCCACAGGGTCACTCTTGA 1874 CAAGAGTGACCCTGTGGCC GGCCACAGGGTCACTCTTG 1875 AAGAGTGACCCTGTGGCCT AGGCCACAGGGTCACTCTT 1876 AGAGTGACCCTGTGGCCTT AAGGCCACAGGGTCACTCT 1877 GAGTGACCCTGTGGCCTTC GAAGGCCACAGGGTCACTC 1878 AGTGACCCTGTGGCCTTCC GGAAGGCCACAGGGTCACT 1879 GTGACCCTGTGGCCTTCCG CGGAAGGCCACAGGGTCAC 1880 TGACCCTGTGGCCTTCCGG CCGGAAGGCCACAGGGTCA 1881 GACCCTGTGGCCTTCCGGC GCCGGAAGGCCACAGGGTC 1882 ACCCTGTGGCCTTCCGGCC GGCCGGAAGGCCACAGGGT 1883 CCCTGTGGCCTTCCGGCCC GGGCCGGAAGGCCACAGGG 1884 CCTGTGGCCTTCCGGCCCT AGGGCCGGAAGGCCACAGG 1885 CTGTGGCCTTCCGGCCCTG CAGGGCCGGAAGGCCACAG 1886 TGTGGCCTTCCGGCCCTGG CCAGGGCCGGAAGGCCACA 1887 GTGGCCTTCCGGCCCTGGC GCCAGGGCCGGAAGGCCAC 1888 TGGCCTTCCGGCCCTGGCA TGCCAGGGCCGGAAGGCCA 1889 GGCCTTCCGGCCCTGGCAC GTGCCAGGGCCGGAAGGCC 1890 GCCTTCCGGCCCTGGCACT AGTGCCAGGGCCGGAAGGC 1891 CCTTCCGGCCCTGGCACTG CAGTGCCAGGGCCGGAAGG 1892 CTTCCGGCCCTGGCACTGC GCAGTGCCAGGGCCGGAAG 1893 TTCCGGCCCTGGCACTGCC GGCAGTGCCAGGGCCGGAA 1894 TCCGGCCCTGGCACTGCCC GGGCAGTGCCAGGGCCGGA 1895 CCGGCCCTGGCACTGCCCT AGGGCAGTGCCAGGGCCGG 1896 CGGCCCTGGCACTGCCCTT AAGGGCAGTGCCAGGGCCG 1897 GGCCCTGGCACTGCCCTTT AAAGGGCAGTGCCAGGGCC 1898 GCCCTGGCACTGCCCTTTC GAAAGGGCAGTGCCAGGGC 1899 CCCTGGCACTGCCCTTTCC GGAAAGGGCAGTGCCAGGG 1900 CCTGGCACTGCCCTTTCCT AGGAAAGGGCAGTGCCAGG 1901 CTGGCACTGCCCTTTCCTT AAGGAAAGGGCAGTGCCAG 1902 TGGCACTGCCCTTTCCTTC GAAGGAAAGGGCAGTGCCA 1903 GGCACTGCCCTTTCCTTCT AGAAGGAAAGGGCAGTGCC 1904 GCACTGCCCTTTCCTTCTG CAGAAGGAAAGGGCAGTGC 1905 CACTGCCCTTTCCTTCTGG CCAGAAGGAAAGGGCAGTG 1906 ACTGCCCTTTCCTTCTGGA TCCAGAAGGAAAGGGCAGT 1907 CTGCCCTTTCCTTCTGGAG CTCCAGAAGGAAAGGGCAG 1908 TGCCCTTTCCTTCTGGAGA TCTCCAGAAGGAAAGGGCA 1909 GCCCTTTCCTTCTGGAGAC GTCTCCAGAAGGAAAGGGC 1910 CCCTTTCCTTCTGGAGACC GGTCTCCAGAAGGAAAGGG 1911 CCTTTCCTTCTGGAGACCA TGGTCTCCAGAAGGAAAGG 1912 CTTTCCTTCTGGAGACCAA TTGGTCTCCAGAAGGAAAG 1913 TTTCCTTCTGGAGACCAAG CTTGGTCTCCAGAAGGAAA 1914 TTCCTTCTGGAGACCAAGA TCTTGGTCTCCAGAAGGAA 1915 TCCTTCTGGAGACCAAGAT ATCTTGGTCTCCAGAAGGA 1916 CCTTCTGGAGACCAAGATC GATCTTGGTCTCCAGAAGG 1917 CTTCTGGAGACCAAGATCC GGATCTTGGTCTCCAGAAG 1918 TTCTGGAGACCAAGATCCT AGGATCTTGGTCTCCAGAA 1919 TCTGGAGACCAAGATCCTG CAGGATCTTGGTCTCCAGA 1920 CTGGAGACCAAGATCCTGG CCAGGATCTTGGTCTCCAG 1921 TGGAGACCAAGATCCTGGA TCCAGGATCTTGGTCTCCA 1922 GGAGACCAAGATCCTGGAG CTCCAGGATCTTGGTCTCC 1923 GAGACCAAGATCCTGGAGC GCTCCAGGATCTTGGTCTC 1924 AGACCAAGATCCTGGAGCG CGCTCCAGGATCTTGGTCT 1925 GACCAAGATCCTGGAGCGA TCGCTCCAGGATCTTGGTC 1926 ACCAAGATCCTGGAGCGAG CTCGCTCCAGGATCTTGGT 1927 CCAAGATCCTGGAGCGAGC GCTCGCTCCAGGATCTTGG 1928 CAAGATCCTGGAGCGAGCT AGCTCGCTCCAGGATCTTG 1929 AAGATCCTGGAGCGAGCTC GAGCTCGCTCCAGGATCTT 1930 AGATCCTGGAGCGAGCTCC GGAGCTCGCTCCAGGATCT 1931 GATCCTGGAGCGAGCTCCC GGGAGCTCGCTCCAGGATC 1932 ATCCTGGAGCGAGCTCCCT AGGGAGCTCGCTCCAGGAT 1933 TCCTGGAGCGAGCTCCCTT AAGGGAGCTCGCTCCAGGA 1934 CCTGGAGCGAGCTCCCTTC GAAGGGAGCTCGCTCCAGG 1935 CTGGAGCGAGCTCCCTTCT AGAAGGGAGCTCGCTCCAG 1936 TGGAGCGAGCTCCCTTCTG CAGAAGGGAGCTCGCTCCA 1937 GGAGCGAGCTCCCTTCTGG CCAGAAGGGAGCTCGCTCC 1938 GAGCGAGCTCCCTTCTGGG CCCAGAAGGGAGCTCGCTC 1939 AGCGAGCTCCCTTCTGGGT ACCCAGAAGGGAGCTCGCT 1940 GCGAGCTCCCTTCTGGGTG CACCCAGAAGGGAGCTCGC 1941 CGAGCTCCCTTCTGGGTGC GCACCCAGAAGGGAGCTCG 1942 GAGCTCCCTTCTGGGTGCC GGCACCCAGAAGGGAGCTC 1943 AGCTCCCTTCTGGGTGCCC GGGCACCCAGAAGGGAGCT 1944 GCTCCCTTCTGGGTGCCCA TGGGCACCCAGAAGGGAGC 1945 CTCCCTTCTGGGTGCCCAC GTGGGCACCCAGAAGGGAG 1946 TCCCTTCTGGGTGCCCACC GGTGGGCACCCAGAAGGGA 1947 CCCTTCTGGGTGCCCACCT AGGTGGGCACCCAGAAGGG 1948 CCTTCTGGGTGCCCACCTG CAGGTGGGCACCCAGAAGG 1949 CTTCTGGGTGCCCACCTGC GCAGGTGGGCACCCAGAAG 1950 TTCTGGGTGCCCACCTGCT AGCAGGTGGGCACCCAGAA 1951 TCTGGGTGCCCACCTGCTT AAGCAGGTGGGCACCCAGA 1952 CTGGGTGCCCACCTGCTTG CAAGCAGGTGGGCACCCAG 1953 TGGGTGCCCACCTGCTTGC GCAAGCAGGTGGGCACCCA 1954 GGGTGCCCACCTGCTTGCC GGCAAGCAGGTGGGCACCC 1955 GGTGCCCACCTGCTTGCCA TGGCAAGCAGGTGGGCACC 1956 GTGCCCACCTGCTTGCCAC GTGGCAAGCAGGTGGGCAC 1957 TGCCCACCTGCTTGCCACC GGTGGCAAGCAGGTGGGCA 1958 GCCCACCTGCTTGCCACCC GGGTGGCAAGCAGGTGGGC 1959 CCCACCTGCTTGCCACCCT AGGGTGGCAAGCAGGTGGG 1960 CCACCTGCTTGCCACCCTA TAGGGTGGCAAGCAGGTGG 1961 CACCTGCTTGCCACCCTAC GTAGGGTGGCAAGCAGGTG 1962 ACCTGCTTGCCACCCTACC GGTAGGGTGGCAAGCAGGT 1963 CCTGCTTGCCACCCTACCT AGGTAGGGTGGCAAGCAGG 1964 CTGCTTGCCACCCTACCTA TAGGTAGGGTGGCAAGCAG 1965 TGCTTGCCACCCTACCTAG CTAGGTAGGGTGGCAAGCA 1966 GCTTGCCACCCTACCTAGT ACTAGGTAGGGTGGCAAGC 1967 CTTGCCACCCTACCTAGTG CACTAGGTAGGGTGGCAAG 1968 TTGCCACCCTACCTAGTGT ACACTAGGTAGGGTGGCAA 1969 TGCCACCCTACCTAGTGTC GACACTAGGTAGGGTGGCA 1970 GCCACCCTACCTAGTGTCT AGACACTAGGTAGGGTGGC 1971 CCACCCTACCTAGTGTCTG CAGACACTAGGTAGGGTGG 1972 CACCCTACCTAGTGTCTGG CCAGACACTAGGTAGGGTG 1973 ACCCTACCTAGTGTCTGGC GCCAGACACTAGGTAGGGT 1974 CCCTACCTAGTGTCTGGCC GGCCAGACACTAGGTAGGG 1975 CCTACCTAGTGTCTGGCCT AGGCCAGACACTAGGTAGG 1976 CTACCTAGTGTCTGGCCTG CAGGCCAGACACTAGGTAG 1977 TACCTAGTGTCTGGCCTGC GCAGGCCAGACACTAGGTA 1978 ACCTAGTGTCTGGCCTGCC GGCAGGCCAGACACTAGGT 1979 CCTAGTGTCTGGCCTGCCC GGGCAGGCCAGACACTAGG 1980 CTAGTGTCTGGCCTGCCCC GGGGCAGGCCAGACACTAG 1981 TAGTGTCTGGCCTGCCCCC GGGGGCAGGCCAGACACTA 1982 AGTGTCTGGCCTGCCCCCA TGGGGGCAGGCCAGACACT 1983 GTGTCTGGCCTGCCCCCAG CTGGGGGCAGGCCAGACAC 1984 TGTCTGGCCTGCCCCCAGA TCTGGGGGCAGGCCAGACA 1985 GTCTGGCCTGCCCCCAGAG CTCTGGGGGCAGGCCAGAC 1986 TCTGGCCTGCCCCCAGAGC GCTCTGGGGGCAGGCCAGA 1987 CTGGCCTGCCCCCAGAGCA TGCTCTGGGGGCAGGCCAG 1988 TGGCCTGCCCCCAGAGCAT ATGCTCTGGGGGCAGGCCA 1989 GGCCTGCCCCCAGAGCATC GATGCTCTGGGGGCAGGCC 1990 GCCTGCCCCCAGAGCATCC GGATGCTCTGGGGGCAGGC 1991 CCTGCCCCCAGAGCATCCA TGGATGCTCTGGGGGCAGG 1992 CTGCCCCCAGAGCATCCAT ATGGATGCTCTGGGGGCAG 1993 TGCCCCCAGAGCATCCATG CATGGATGCTCTGGGGGCA 1994 GCCCCCAGAGCATCCATGT ACATGGATGCTCTGGGGGC 1995 CCCCCAGAGCATCCATGTG CACATGGATGCTCTGGGGG 1996 CCCCAGAGCATCCATGTGA TCACATGGATGCTCTGGGG 1997 CCCAGAGCATCCATGTGAC GTCACATGGATGCTCTGGG 1998 CCAGAGCATCCATGTGACT AGTCACATGGATGCTCTGG 1999 CAGAGCATCCATGTGACTG CAGTCACATGGATGCTCTG 2000 AGAGCATCCATGTGACTGG CCAGTCACATGGATGCTCT 2001 GAGCATCCATGTGACTGGC GCCAGTCACATGGATGCTC 2002 AGCATCCATGTGACTGGCC GGCCAGTCACATGGATGCT 2003 GCATCCATGTGACTGGCCC GGGCCAGTCACATGGATGC 2004 CATCCATGTGACTGGCCCC GGGGCCAGTCACATGGATG 2005 ATCCATGTGACTGGCCCCT AGGGGCCAGTCACATGGAT 2006 TCCATGTGACTGGCCCCTG CAGGGGCCAGTCACATGGA 2007 CCATGTGACTGGCCCCTGA TCAGGGGCCAGTCACATGG 2008 CATGTGACTGGCCCCTGAC GTCAGGGGCCAGTCACATG 2009 ATGTGACTGGCCCCTGACC GGTCAGGGGCCAGTCACAT 2010 TGTGACTGGCCCCTGACCC GGGTCAGGGGCCAGTCACA 2011 GTGACTGGCCCCTGACCCC GGGGTCAGGGGCCAGTCAC 2012 TGACTGGCCCCTGACCCCG CGGGGTCAGGGGCCAGTCA 2013 GACTGGCCCCTGACCCCGC GCGGGGTCAGGGGCCAGTC 2014 ACTGGCCCCTGACCCCGCA TGCGGGGTCAGGGGCCAGT 2015 CTGGCCCCTGACCCCGCAC GTGCGGGGTCAGGGGCCAG 2016 TGGCCCCTGACCCCGCACC GGTGCGGGGTCAGGGGCCA 2017 GGCCCCTGACCCCGCACCC GGGTGCGGGGTCAGGGGCC 2018 GCCCCTGACCCCGCACCCC GGGGTGCGGGGTCAGGGGC 2019 CCCCTGACCCCGCACCCCT AGGGGTGCGGGGTCAGGGG 2020 CCCTGACCCCGCACCCCTG CAGGGGTGCGGGGTCAGGG 2021 CCTGACCCCGCACCCCTGG CCAGGGGTGCGGGGTCAGG 2022 CTGACCCCGCACCCCTGGG CCCAGGGGTGCGGGGTCAG 2023 TGACCCCGCACCCCTGGGT ACCCAGGGGTGCGGGGTCA 2024 GACCCCGCACCCCTGGGTA TACCCAGGGGTGCGGGGTC 2025 ACCCCGCACCCCTGGGTAT ATACCCAGGGGTGCGGGGT 2026 CCCCGCACCCCTGGGTATA TATACCCAGGGGTGCGGGG 2027 CCCGCACCCCTGGGTATAC GTATACCCAGGGGTGCGGG 2028 CCGCACCCCTGGGTATACT AGTATACCCAGGGGTGCGG 2029 CGCACCCCTGGGTATACTC GAGTATACCCAGGGGTGCG 2030 GCACCCCTGGGTATACTCC GGAGTATACCCAGGGGTGC 2031 CACCCCTGGGTATACTCCG CGGAGTATACCCAGGGGTG 2032 ACCCCTGGGTATACTCCGG CCGGAGTATACCCAGGGGT 2033 CCCCTGGGTATACTCCGGG CCCGGAGTATACCCAGGGG 2034 CCCTGGGTATACTCCGGGG CCCCGGAGTATACCCAGGG 2035 CCTGGGTATACTCCGGGGG CCCCCGGAGTATACCCAGG 2036 CTGGGTATACTCCGGGGGC GCCCCCGGAGTATACCCAG 2037 TGGGTATACTCCGGGGGCC GGCCCCCGGAGTATACCCA 2038 GGGTATACTCCGGGGGCCA TGGCCCCCGGAGTATACCC 2039 GGTATACTCCGGGGGCCAG CTGGCCCCCGGAGTATACC 2040 GTATACTCCGGGGGCCAGC GCTGGCCCCCGGAGTATAC 2041 TATACTCCGGGGGCCAGCC GGCTGGCCCCCGGAGTATA 2042 ATACTCCGGGGGCCAGCCC GGGCTGGCCCCCGGAGTAT 2043 TACTCCGGGGGCCAGCCCA TGGGCTGGCCCCCGGAGTA 2044 ACTCCGGGGGCCAGCCCAA TTGGGCTGGCCCCCGGAGT 2045 CTCCGGGGGCCAGCCCAAA TTTGGGCTGGCCCCCGGAG 2046 TCCGGGGGCCAGCCCAAAG CTTTGGGCTGGCCCCCGGA 2047 CCGGGGGCCAGCCCAAAGT ACTTTGGGCTGGCCCCCGG 2048 CGGGGGCCAGCCCAAAGTG CACTTTGGGCTGGCCCCCG 2049 GGGGGCCAGCCCAAAGTGC GCACTTTGGGCTGGCCCCC 2050 GGGGCCAGCCCAAAGTGCC GGCACTTTGGGCTGGCCCC 2051 GGGCCAGCCCAAAGTGCCC GGGCACTTTGGGCTGGCCC 2052 GGCCAGCCCAAAGTGCCCT AGGGCACTTTGGGCTGGCC 2053 GCCAGCCCAAAGTGCCCTC GAGGGCACTTTGGGCTGGC 2054 CCAGCCCAAAGTGCCCTCT AGAGGGCACTTTGGGCTGG 2055 CAGCCCAAAGTGCCCTCTG CAGAGGGCACTTTGGGCTG 2056 AGCCCAAAGTGCCCTCTGC GCAGAGGGCACTTTGGGCT 2057 GCCCAAAGTGCCCTCTGCC GGCAGAGGGCACTTTGGGC 2058 CCCAAAGTGCCCTCTGCCT AGGCAGAGGGCACTTTGGG 2059 CCAAAGTGCCCTCTGCCTT AAGGCAGAGGGCACTTTGG 2060 CAAAGTGCCCTCTGCCTTC GAAGGCAGAGGGCACTTTG 2061 AAAGTGCCCTCTGCCTTCA TGAAGGCAGAGGGCACTTT 2062 AAGTGCCCTCTGCCTTCAG CTGAAGGCAGAGGGCACTT 2063 AGTGCCCTCTGCCTTCAGC GCTGAAGGCAGAGGGCACT 2064 GTGCCCTCTGCCTTCAGCT AGCTGAAGGCAGAGGGCAC 2065 TGCCCTCTGCCTTCAGCTT AAGCTGAAGGCAGAGGGCA 2066 GCCCTCTGCCTTCAGCTTA TAAGCTGAAGGCAGAGGGC 2067 CCCTCTGCCTTCAGCTTAG CTAAGCTGAAGGCAGAGGG 2068 CCTCTGCCTTCAGCTTAGG CCTAAGCTGAAGGCAGAGG 2069 CTCTGCCTTCAGCTTAGGC GCCTAAGCTGAAGGCAGAG 2070 TCTGCCTTCAGCTTAGGCA TGCCTAAGCTGAAGGCAGA 2071 CTGCCTTCAGCTTAGGCAG CTGCCTAAGCTGAAGGCAG 2072 TGCCTTCAGCTTAGGCAGC GCTGCCTAAGCTGAAGGCA 2073 GCCTTCAGCTTAGGCAGCA TGCTGCCTAAGCTGAAGGC 2074 CCTTCAGCTTAGGCAGCAA TTGCTGCCTAAGCTGAAGG 2075 CTTCAGCTTAGGCAGCAAG CTTGCTGCCTAAGCTGAAG 2076 TTCAGCTTAGGCAGCAAGG CCTTGCTGCCTAAGCTGAA 2077 TCAGCTTAGGCAGCAAGGG CCCTTGCTGCCTAAGCTGA 2078 CAGCTTAGGCAGCAAGGGC GCCCTTGCTGCCTAAGCTG 2079 AGCTTAGGCAGCAAGGGCT AGCCCTTGCTGCCTAAGCT 2080 GCTTAGGCAGCAAGGGCTT AAGCCCTTGCTGCCTAAGC 2081 CTTAGGCAGCAAGGGCTTT AAAGCCCTTGCTGCCTAAG 2082 TTAGGCAGCAAGGGCTTTT AAAAGCCCTTGCTGCCTAA 2083 TAGGCAGCAAGGGCTTTTA TAAAAGCCCTTGCTGCCTA 2084 AGGCAGCAAGGGCTTTTAC GTAAAAGCCCTTGCTGCCT 2085 GGCAGCAAGGGCTTTTACT AGTAAAAGCCCTTGCTGCC 2086 GCAGCAAGGGCTTTTACTA TAGTAAAAGCCCTTGCTGC 2087 CAGCAAGGGCTTTTACTAC GTAGTAAAAGCCCTTGCTG 2088 AGCAAGGGCTTTTACTACA TGTAGTAAAAGCCCTTGCT 2089 GCAAGGGCTTTTACTACAA TTGTAGTAAAAGCCCTTGC 2090 CAAGGGCTTTTACTACAAG CTTGTAGTAAAAGCCCTTG 2091 AAGGGCTTTTACTACAAGG CCTTGTAGTAAAAGCCCTT 2092 AGGGCTTTTACTACAAGGA TCCTTGTAGTAAAAGCCCT 2093 GGGCTTTTACTACAAGGAT ATCCTTGTAGTAAAAGCCC 2094 GGCTTTTACTACAAGGATC GATCCTTGTAGTAAAAGCC 2095 GCTTTTACTACAAGGATCC GGATCCTTGTAGTAAAAGC 2096 CTTTTACTACAAGGATCCG CGGATCCTTGTAGTAAAAG 2097 TTTTACTACAAGGATCCGA TCGGATCCTTGTAGTAAAA 2098 TTTACTACAAGGATCCGAG CTCGGATCCTTGTAGTAAA 2099 TTACTACAAGGATCCGAGC GCTCGGATCCTTGTAGTAA 2100 TACTACAAGGATCCGAGCA TGCTCGGATCCTTGTAGTA 2101 ACTACAAGGATCCGAGCAT ATGCTCGGATCCTTGTAGT 2102 CTACAAGGATCCGAGCATT AATGCTCGGATCCTTGTAG 2103 TACAAGGATCCGAGCATTC GAATGCTCGGATCCTTGTA 2104 ACAAGGATCCGAGCATTCC GGAATGCTCGGATCCTTGT 2105 CAAGGATCCGAGCATTCCC GGGAATGCTCGGATCCTTG 2106 AAGGATCCGAGCATTCCCA TGGGAATGCTCGGATCCTT 2107 AGGATCCGAGCATTCCCAG CTGGGAATGCTCGGATCCT 2108 GGATCCGAGCATTCCCAGG CCTGGGAATGCTCGGATCC 2109 GATCCGAGCATTCCCAGGT ACCTGGGAATGCTCGGATC 2110 ATCCGAGCATTCCCAGGTT AACCTGGGAATGCTCGGAT 2111 TCCGAGCATTCCCAGGTTG CAACCTGGGAATGCTCGGA 2112 CCGAGCATTCCCAGGTTGG CCAACCTGGGAATGCTCGG 2113 CGAGCATTCCCAGGTTGGC GCCAACCTGGGAATGCTCG 2114 GAGCATTCCCAGGTTGGCA TGCCAACCTGGGAATGCTC 2115 AGCATTCCCAGGTTGGCAA TTGCCAACCTGGGAATGCT 2116 GCATTCCCAGGTTGGCAAA TTTGCCAACCTGGGAATGC 2117 CATTCCCAGGTTGGCAAAG CTTTGCCAACCTGGGAATG 2118 ATTCCCAGGTTGGCAAAGG CCTTTGCCAACCTGGGAAT 2119 TTCCCAGGTTGGCAAAGGA TCCTTTGCCAACCTGGGAA 2120 TCCCAGGTTGGCAAAGGAG CTCCTTTGCCAACCTGGGA 2121 CCCAGGTTGGCAAAGGAGC GCTCCTTTGCCAACCTGGG 2122 CCAGGTTGGCAAAGGAGCC GGCTCCTTTGCCAACCTGG 2123 CAGGTTGGCAAAGGAGCCC GGGCTCCTTTGCCAACCTG 2124 AGGTTGGCAAAGGAGCCCT AGGGCTCCTTTGCCAACCT 2125 GGTTGGCAAAGGAGCCCTT AAGGGCTCCTTTGCCAACC 2126 GTTGGCAAAGGAGCCCTTG CAAGGGCTCCTTTGCCAAC 2127 TTGGCAAAGGAGCCCTTGG CCAAGGGCTCCTTTGCCAA 2128 TGGCAAAGGAGCCCTTGGC GCCAAGGGCTCCTTTGCCA 2129 GGCAAAGGAGCCCTTGGCA TGCCAAGGGCTCCTTTGCC 2130 GCAAAGGAGCCCTTGGCAG CTGCCAAGGGCTCCTTTGC 2131 CAAAGGAGCCCTTGGCAGC GCTGCCAAGGGCTCCTTTG 2132 AAAGGAGCCCTTGGCAGCT AGCTGCCAAGGGCTCCTTT 2133 AAGGAGCCCTTGGCAGCTG CAGCTGCCAAGGGCTCCTT 2134 AGGAGCCCTTGGCAGCTGC GCAGCTGCCAAGGGCTCCT 2135 GGAGCCCTTGGCAGCTGCG CGCAGCTGCCAAGGGCTCC 2136 GAGCCCTTGGCAGCTGCGG CCGCAGCTGCCAAGGGCTC 2137 AGCCCTTGGCAGCTGCGGA TCCGCAGCTGCCAAGGGCT 2138 GCCCTTGGCAGCTGCGGAA TTCCGCAGCTGCCAAGGGC 2139 CCCTTGGCAGCTGCGGAAC GTTCCGCAGCTGCCAAGGG 2140 CCTTGGCAGCTGCGGAACC GGTTCCGCAGCTGCCAAGG 2141 CTTGGCAGCTGCGGAACCT AGGTTCCGCAGCTGCCAAG 2142 TTGGCAGCTGCGGAACCTG CAGGTTCCGCAGCTGCCAA 2143 TGGCAGCTGCGGAACCTGG CCAGGTTCCGCAGCTGCCA 2144 GGCAGCTGCGGAACCTGGG CCCAGGTTCCGCAGCTGCC 2145 GCAGCTGCGGAACCTGGGT ACCCAGGTTCCGCAGCTGC 2146 CAGCTGCGGAACCTGGGTT AACCCAGGTTCCGCAGCTG 2147 AGCTGCGGAACCTGGGTTG CAACCCAGGTTCCGCAGCT 2148 GCTGCGGAACCTGGGTTGT ACAACCCAGGTTCCGCAGC 2149 CTGCGGAACCTGGGTTGTT AACAACCCAGGTTCCGCAG 2150 TGCGGAACCTGGGTTGTTT AAACAACCCAGGTTCCGCA 2151 GCGGAACCTGGGTTGTTTG CAAACAACCCAGGTTCCGC 2152 CGGAACCTGGGTTGTTTGG CCAAACAACCCAGGTTCCG 2153 GGAACCTGGGTTGTTTGGC GCCAAACAACCCAGGTTCC 2154 GAACCTGGGTTGTTTGGCT AGCCAAACAACCCAGGTTC 2155 AACCTGGGTTGTTTGGCTT AAGCCAAACAACCCAGGTT 2156 ACCTGGGTTGTTTGGCTTA TAAGCCAAACAACCCAGGT 2157 CCTGGGTTGTTTGGCTTAA TTAAGCCAAACAACCCAGG 2158 CTGGGTTGTTTGGCTTAAA TTTAAGCCAAACAACCCAG 2159 TGGGTTGTTTGGCTTAAAC GTTTAAGCCAAACAACCCA 2160 GGGTTGTTTGGCTTAAACT AGTTTAAGCCAAACAACCC 2161 GGTTGTTTGGCTTAAACTC GAGTTTAAGCCAAACAACC 2162 GTTGTTTGGCTTAAACTCT AGAGTTTAAGCCAAACAAC 2163 TTGTTTGGCTTAAACTCTG CAGAGTTTAAGCCAAACAA 2164 TGTTTGGCTTAAACTCTGG CCAGAGTTTAAGCCAAACA 2165 GTTTGGCTTAAACTCTGGT ACCAGAGTTTAAGCCAAAC 2166 TTTGGCTTAAACTCTGGTG CACCAGAGTTTAAGCCAAA 2167 TTGGCTTAAACTCTGGTGG CCACCAGAGTTTAAGCCAA 2168 TGGCTTAAACTCTGGTGGG CCCACCAGAGTTTAAGCCA 2169 GGCTTAAACTCTGGTGGGC GCCCACCAGAGTTTAAGCC 2170 GCTTAAACTCTGGTGGGCA TGCCCACCAGAGTTTAAGC 2171 CTTAAACTCTGGTGGGCAC GTGCCCACCAGAGTTTAAG 2172 TTAAACTCTGGTGGGCACC GGTGCCCACCAGAGTTTAA 2173 TAAACTCTGGTGGGCACCT AGGTGCCCACCAGAGTTTA 2174 AAACTCTGGTGGGCACCTG CAGGTGCCCACCAGAGTTT 2175 AACTCTGGTGGGCACCTGC GCAGGTGCCCACCAGAGTT 2176 ACTCTGGTGGGCACCTGCA TGCAGGTGCCCACCAGAGT 2177 CTCTGGTGGGCACCTGCAG CTGCAGGTGCCCACCAGAG 2178 TCTGGTGGGCACCTGCAGA TCTGCAGGTGCCCACCAGA 2179 CTGGTGGGCACCTGCAGAG CTCTGCAGGTGCCCACCAG 2180 TGGTGGGCACCTGCAGAGA TCTCTGCAGGTGCCCACCA 2181 GGTGGGCACCTGCAGAGAG CTCTCTGCAGGTGCCCACC 2182 GTGGGCACCTGCAGAGAGC GCTCTCTGCAGGTGCCCAC 2183 TGGGCACCTGCAGAGAGCC GGCTCTCTGCAGGTGCCCA 2184 GGGCACCTGCAGAGAGCCG CGGCTCTCTGCAGGTGCCC 2185 GGCACCTGCAGAGAGCCGG CCGGCTCTCTGCAGGTGCC 2186 GCACCTGCAGAGAGCCGGG CCCGGCTCTCTGCAGGTGC 2187 CACCTGCAGAGAGCCGGGG CCCCGGCTCTCTGCAGGTG 2188 ACCTGCAGAGAGCCGGGGA TCCCCGGCTCTCTGCAGGT 2189 CCTGCAGAGAGCCGGGGAG CTCCCCGGCTCTCTGCAGG 2190 CTGCAGAGAGCCGGGGAGG CCTCCCCGGCTCTCTGCAG 2191 TGCAGAGAGCCGGGGAGGC GCCTCCCCGGCTCTCTGCA 2192 GCAGAGAGCCGGGGAGGCC GGCCTCCCCGGCTCTCTGC 2193 CAGAGAGCCGGGGAGGCCG CGGCCTCCCCGGCTCTCTG 2194 AGAGAGCCGGGGAGGCCGA TCGGCCTCCCCGGCTCTCT 2195 GAGAGCCGGGGAGGCCGAA TTCGGCCTCCCCGGCTCTC 2196 AGAGCCGGGGAGGCCGAAC GTTCGGCCTCCCCGGCTCT 2197 GAGCCGGGGAGGCCGAACG CGTTCGGCCTCCCCGGCTC 2198 AGCCGGGGAGGCCGAACGC GCGTTCGGCCTCCCCGGCT 2199 GCCGGGGAGGCCGAACGCC GGCGTTCGGCCTCCCCGGC 2200 CCGGGGAGGCCGAACGCCC GGGCGTTCGGCCTCCCCGG 2201 CGGGGAGGCCGAACGCCCT AGGGCGTTCGGCCTCCCCG 2202 GGGGAGGCCGAACGCCCTT AAGGGCGTTCGGCCTCCCC 2203 GGGAGGCCGAACGCCCTTC GAAGGGCGTTCGGCCTCCC 2204 GGAGGCCGAACGCCCTTCA TGAAGGGCGTTCGGCCTCC 2205 GAGGCCGAACGCCCTTCAC GTGAAGGGCGTTCGGCCTC 2206 AGGCCGAACGCCCTTCACT AGTGAAGGGCGTTCGGCCT 2207 GGCCGAACGCCCTTCACTG CAGTGAAGGGCGTTCGGCC 2208 GCCGAACGCCCTTCACTGC GCAGTGAAGGGCGTTCGGC 2209 CCGAACGCCCTTCACTGCA TGCAGTGAAGGGCGTTCGG 2210 CGAACGCCCTTCACTGCAC GTGCAGTGAAGGGCGTTCG 2211 GAACGCCCTTCACTGCACC GGTGCAGTGAAGGGCGTTC 2212 AACGCCCTTCACTGCACCA TGGTGCAGTGAAGGGCGTT 2213 ACGCCCTTCACTGCACCAG CTGGTGCAGTGAAGGGCGT 2214 CGCCCTTCACTGCACCAGA TCTGGTGCAGTGAAGGGCG 2215 GCCCTTCACTGCACCAGAG CTCTGGTGCAGTGAAGGGC 2216 CCCTTCACTGCACCAGAGG CCTCTGGTGCAGTGAAGGG 2217 CCTTCACTGCACCAGAGGG CCCTCTGGTGCAGTGAAGG 2218 CTTCACTGCACCAGAGGGA TCCCTCTGGTGCAGTGAAG 2219 TTCACTGCACCAGAGGGAT ATCCCTCTGGTGCAGTGAA 2220 TCACTGCACCAGAGGGATG CATCCCTCTGGTGCAGTGA 2221 CACTGCACCAGAGGGATGG CCATCCCTCTGGTGCAGTG 2222 ACTGCACCAGAGGGATGGA TCCATCCCTCTGGTGCAGT 2223 CTGCACCAGAGGGATGGAG CTCCATCCCTCTGGTGCAG 2224 TGCACCAGAGGGATGGAGA TCTCCATCCCTCTGGTGCA 2225 GCACCAGAGGGATGGAGAG CTCTCCATCCCTCTGGTGC 2226 CACCAGAGGGATGGAGAGA TCTCTCCATCCCTCTGGTG 2227 ACCAGAGGGATGGAGAGAT ATCTCTCCATCCCTCTGGT 2228 CCAGAGGGATGGAGAGATG CATCTCTCCATCCCTCTGG 2229 CAGAGGGATGGAGAGATGG CCATCTCTCCATCCCTCTG 2230 AGAGGGATGGAGAGATGGG CCCATCTCTCCATCCCTCT 2231 GAGGGATGGAGAGATGGGA TCCCATCTCTCCATCCCTC 2232 AGGGATGGAGAGATGGGAG CTCCCATCTCTCCATCCCT 2233 GGGATGGAGAGATGGGAGC GCTCCCATCTCTCCATCCC 2234 GGATGGAGAGATGGGAGCT AGCTCCCATCTCTCCATCC 2235 GATGGAGAGATGGGAGCTG CAGCTCCCATCTCTCCATC 2236 ATGGAGAGATGGGAGCTGG CCAGCTCCCATCTCTCCAT 2237 TGGAGAGATGGGAGCTGGC GCCAGCTCCCATCTCTCCA 2238 GGAGAGATGGGAGCTGGCC GGCCAGCTCCCATCTCTCC 2239 GAGAGATGGGAGCTGGCCG CGGCCAGCTCCCATCTCTC 2240 AGAGATGGGAGCTGGCCGG CCGGCCAGCTCCCATCTCT 2241 GAGATGGGAGCTGGCCGGC GCCGGCCAGCTCCCATCTC 2242 AGATGGGAGCTGGCCGGCA TGCCGGCCAGCTCCCATCT 2243 GATGGGAGCTGGCCGGCAG CTGCCGGCCAGCTCCCATC 2244 ATGGGAGCTGGCCGGCAGC GCTGCCGGCCAGCTCCCAT 2245 TGGGAGCTGGCCGGCAGCA TGCTGCCGGCCAGCTCCCA 2246 GGGAGCTGGCCGGCAGCAG CTGCTGCCGGCCAGCTCCC 2247 GGAGCTGGCCGGCAGCAGA TCTGCTGCCGGCCAGCTCC 2248 GAGCTGGCCGGCAGCAGAA TTCTGCTGCCGGCCAGCTC 2249 AGCTGGCCGGCAGCAGAAT ATTCTGCTGCCGGCCAGCT 2250 GCTGGCCGGCAGCAGAATC GATTCTGCTGCCGGCCAGC 2251 CTGGCCGGCAGCAGAATCC GGATTCTGCTGCCGGCCAG 2252 TGGCCGGCAGCAGAATCCT AGGATTCTGCTGCCGGCCA 2253 GGCCGGCAGCAGAATCCTT AAGGATTCTGCTGCCGGCC 2254 GCCGGCAGCAGAATCCTTG CAAGGATTCTGCTGCCGGC 2255 CCGGCAGCAGAATCCTTGC GCAAGGATTCTGCTGCCGG 2256 CGGCAGCAGAATCCTTGCC GGCAAGGATTCTGCTGCCG 2257 GGCAGCAGAATCCTTGCCC GGGCAAGGATTCTGCTGCC 2258 GCAGCAGAATCCTTGCCCG CGGGCAAGGATTCTGCTGC 2259 CAGCAGAATCCTTGCCCGC GCGGGCAAGGATTCTGCTG 2260 AGCAGAATCCTTGCCCGCT AGCGGGCAAGGATTCTGCT 2261 GCAGAATCCTTGCCCGCTC GAGCGGGCAAGGATTCTGC 2262 CAGAATCCTTGCCCGCTCT AGAGCGGGCAAGGATTCTG 2263 AGAATCCTTGCCCGCTCTT AAGAGCGGGCAAGGATTCT 2264 GAATCCTTGCCCGCTCTTC GAAGAGCGGGCAAGGATTC 2265 AATCCTTGCCCGCTCTTCC GGAAGAGCGGGCAAGGATT 2266 ATCCTTGCCCGCTCTTCCT AGGAAGAGCGGGCAAGGAT 2267 TCCTTGCCCGCTCTTCCTG CAGGAAGAGCGGGCAAGGA 2268 CCTTGCCCGCTCTTCCTGG CCAGGAAGAGCGGGCAAGG 2269 CTTGCCCGCTCTTCCTGGG CCCAGGAAGAGCGGGCAAG 2270 TTGCCCGCTCTTCCTGGGG CCCCAGGAAGAGCGGGCAA 2271 TGCCCGCTCTTCCTGGGGC GCCCCAGGAAGAGCGGGCA 2272 GCCCGCTCTTCCTGGGGCA TGCCCCAGGAAGAGCGGGC 2273 CCCGCTCTTCCTGGGGCAG CTGCCCCAGGAAGAGCGGG 2274 CCGCTCTTCCTGGGGCAGC GCTGCCCCAGGAAGAGCGG 2275 CGCTCTTCCTGGGGCAGCC GGCTGCCCCAGGAAGAGCG 2276 GCTCTTCCTGGGGCAGCCA TGGCTGCCCCAGGAAGAGC 2277 CTCTTCCTGGGGCAGCCAG CTGGCTGCCCCAGGAAGAG 2278 TCTTCCTGGGGCAGCCAGA TCTGGCTGCCCCAGGAAGA 2279 CTTCCTGGGGCAGCCAGAC GTCTGGCTGCCCCAGGAAG 2280 TTCCTGGGGCAGCCAGACA TGTCTGGCTGCCCCAGGAA 2281 TCCTGGGGCAGCCAGACAC GTGTCTGGCTGCCCCAGGA 2282 CCTGGGGCAGCCAGACACT AGTGTCTGGCTGCCCCAGG 2283 CTGGGGCAGCCAGACACTG CAGTGTCTGGCTGCCCCAG 2284 TGGGGCAGCCAGACACTGT ACAGTGTCTGGCTGCCCCA 2285 GGGGCAGCCAGACACTGTG CACAGTGTCTGGCTGCCCC 2286 GGGCAGCCAGACACTGTGC GCACAGTGTCTGGCTGCCC 2287 GGCAGCCAGACACTGTGCC GGCACAGTGTCTGGCTGCC 2288 GCAGCCAGACACTGTGCCC GGGCACAGTGTCTGGCTGC 2289 CAGCCAGACACTGTGCCCT AGGGCACAGTGTCTGGCTG 2290 AGCCAGACACTGTGCCCTG CAGGGCACAGTGTCTGGCT 2291 GCCAGACACTGTGCCCTGG CCAGGGCACAGTGTCTGGC 2292 CCAGACACTGTGCCCTGGA TCCAGGGCACAGTGTCTGG 2293 CAGACACTGTGCCCTGGAC GTCCAGGGCACAGTGTCTG 2294 AGACACTGTGCCCTGGACC GGTCCAGGGCACAGTGTCT 2295 GACACTGTGCCCTGGACCT AGGTCCAGGGCACAGTGTC 2296 ACACTGTGCCCTGGACCTC GAGGTCCAGGGCACAGTGT 2297 CACTGTGCCCTGGACCTCC GGAGGTCCAGGGCACAGTG 2298 ACTGTGCCCTGGACCTCCT AGGAGGTCCAGGGCACAGT 2299 CTGTGCCCTGGACCTCCTG CAGGAGGTCCAGGGCACAG 2300 TGTGCCCTGGACCTCCTGG CCAGGAGGTCCAGGGCACA 2301 GTGCCCTGGACCTCCTGGC GCCAGGAGGTCCAGGGCAC 2302 TGCCCTGGACCTCCTGGCC GGCCAGGAGGTCCAGGGCA 2303 GCCCTGGACCTCCTGGCCC GGGCCAGGAGGTCCAGGGC 2304 CCCTGGACCTCCTGGCCCG CGGGCCAGGAGGTCCAGGG 2305 CCTGGACCTCCTGGCCCGC GCGGGCCAGGAGGTCCAGG 2306 CTGGACCTCCTGGCCCGCT AGCGGGCCAGGAGGTCCAG 2307 TGGACCTCCTGGCCCGCTT AAGCGGGCCAGGAGGTCCA 2308 GGACCTCCTGGCCCGCTTG CAAGCGGGCCAGGAGGTCC 2309 GACCTCCTGGCCCGCTTGT ACAAGCGGGCCAGGAGGTC 2310 ACCTCCTGGCCCGCTTGTC GACAAGCGGGCCAGGAGGT 2311 CCTCCTGGCCCGCTTGTCC GGACAAGCGGGCCAGGAGG 2312 CTCCTGGCCCGCTTGTCCC GGGACAAGCGGGCCAGGAG 2313 TCCTGGCCCGCTTGTCCCC GGGGACAAGCGGGCCAGGA 2314 CCTGGCCCGCTTGTCCCCC GGGGGACAAGCGGGCCAGG 2315 CTGGCCCGCTTGTCCCCCA TGGGGGACAAGCGGGCCAG 2316 TGGCCCGCTTGTCCCCCAG CTGGGGGACAAGCGGGCCA 2317 GGCCCGCTTGTCCCCCAGG CCTGGGGGACAAGCGGGCC 2318 GCCCGCTTGTCCCCCAGGC GCCTGGGGGACAAGCGGGC 2319 CCCGCTTGTCCCCCAGGCC GGCCTGGGGGACAAGCGGG 2320 CCGCTTGTCCCCCAGGCCT AGGCCTGGGGGACAAGCGG 2321 CGCTTGTCCCCCAGGCCTT AAGGCCTGGGGGACAAGCG 2322 GCTTGTCCCCCAGGCCTTG CAAGGCCTGGGGGACAAGC 2323 CTTGTCCCCCAGGCCTTGT ACAAGGCCTGGGGGACAAG 2324 TTGTCCCCCAGGCCTTGTT AACAAGGCCTGGGGGACAA 2325 TGTCCCCCAGGCCTTGTTC GAACAAGGCCTGGGGGACA 2326 GTCCCCCAGGCCTTGTTCA TGAACAAGGCCTGGGGGAC 2327 TCCCCCAGGCCTTGTTCAT ATGAACAAGGCCTGGGGGA 2328 CCCCCAGGCCTTGTTCATA TATGAACAAGGCCTGGGGG 2329 CCCCAGGCCTTGTTCATAC GTATGAACAAGGCCTGGGG 2330 CCCAGGCCTTGTTCATACT AGTATGAACAAGGCCTGGG 2331 CCAGGCCTTGTTCATACTC GAGTATGAACAAGGCCTGG 2332 CAGGCCTTGTTCATACTCT AGAGTATGAACAAGGCCTG 2333 AGGCCTTGTTCATACTCTT AAGAGTATGAACAAGGCCT 2334 GGCCTTGTTCATACTCTTG CAAGAGTATGAACAAGGCC 2335 GCCTTGTTCATACTCTTGG CCAAGAGTATGAACAAGGC 2336 CCTTGTTCATACTCTTGGC GCCAAGAGTATGAACAAGG 2337 CTTGTTCATACTCTTGGCA TGCCAAGAGTATGAACAAG 2338 TTGTTCATACTCTTGGCAA TTGCCAAGAGTATGAACAA 2339 TGTTCATACTCTTGGCAAC GTTGCCAAGAGTATGAACA 2340 GTTCATACTCTTGGCAACG CGTTGCCAAGAGTATGAAC 2341 TTCATACTCTTGGCAACGT ACGTTGCCAAGAGTATGAA 2342 TCATACTCTTGGCAACGTC GACGTTGCCAAGAGTATGA 2343 CATACTCTTGGCAACGTCT AGACGTTGCCAAGAGTATG 2344 ATACTCTTGGCAACGTCTG CAGACGTTGCCAAGAGTAT 2345 TACTCTTGGCAACGTCTGG CCAGACGTTGCCAAGAGTA 2346 ACTCTTGGCAACGTCTGGG CCCAGACGTTGCCAAGAGT 2347 CTCTTGGCAACGTCTGGGC GCCCAGACGTTGCCAAGAG 2348 TCTTGGCAACGTCTGGGCT AGCCCAGACGTTGCCAAGA 2349 CTTGGCAACGTCTGGGCTG CAGCCCAGACGTTGCCAAG 2350 TTGGCAACGTCTGGGCTGG CCAGCCCAGACGTTGCCAA 2351 TGGCAACGTCTGGGCTGGG CCCAGCCCAGACGTTGCCA 2352 GGCAACGTCTGGGCTGGGC GCCCAGCCCAGACGTTGCC 2353 GCAACGTCTGGGCTGGGCC GGCCCAGCCCAGACGTTGC 2354 CAACGTCTGGGCTGGGCCA TGGCCCAGCCCAGACGTTG 2355 AACGTCTGGGCTGGGCCAG CTGGCCCAGCCCAGACGTT 2356 ACGTCTGGGCTGGGCCAGG CCTGGCCCAGCCCAGACGT 2357 CGTCTGGGCTGGGCCAGGC GCCTGGCCCAGCCCAGACG 2358 GTCTGGGCTGGGCCAGGCG CGCCTGGCCCAGCCCAGAC 2359 TCTGGGCTGGGCCAGGCGA TCGCCTGGCCCAGCCCAGA 2360 CTGGGCTGGGCCAGGCGAT ATCGCCTGGCCCAGCCCAG 2361 TGGGCTGGGCCAGGCGATG CATCGCCTGGCCCAGCCCA 2362 GGGCTGGGCCAGGCGATGG CCATCGCCTGGCCCAGCCC 2363 GGCTGGGCCAGGCGATGGG CCCATCGCCTGGCCCAGCC 2364 GCTGGGCCAGGCGATGGGA TCCCATCGCCTGGCCCAGC 2365 CTGGGCCAGGCGATGGGAA TTCCCATCGCCTGGCCCAG 2366 TGGGCCAGGCGATGGGAAC GTTCCCATCGCCTGGCCCA 2367 GGGCCAGGCGATGGGAACC GGTTCCCATCGCCTGGCCC 2368 GGCCAGGCGATGGGAACCT AGGTTCCCATCGCCTGGCC 2369 GCCAGGCGATGGGAACCTT AAGGTTCCCATCGCCTGGC 2370 CCAGGCGATGGGAACCTTG CAAGGTTCCCATCGCCTGG 2371 CAGGCGATGGGAACCTTGG CCAAGGTTCCCATCGCCTG 2372 AGGCGATGGGAACCTTGGG CCCAAGGTTCCCATCGCCT 2373 GGCGATGGGAACCTTGGGT ACCCAAGGTTCCCATCGCC 2374 GCGATGGGAACCTTGGGTA TACCCAAGGTTCCCATCGC 2375 CGATGGGAACCTTGGGTAC GTACCCAAGGTTCCCATCG 2376 GATGGGAACCTTGGGTACC GGTACCCAAGGTTCCCATC 2377 ATGGGAACCTTGGGTACCA TGGTACCCAAGGTTCCCAT 2378 TGGGAACCTTGGGTACCAG CTGGTACCCAAGGTTCCCA 2379 GGGAACCTTGGGTACCAGC GCTGGTACCCAAGGTTCCC 2380 GGAACCTTGGGTACCAGCT AGCTGGTACCCAAGGTTCC 2381 GAACCTTGGGTACCAGCTG CAGCTGGTACCCAAGGTTC 2382 AACCTTGGGTACCAGCTGG CCAGCTGGTACCCAAGGTT 2383 ACCTTGGGTACCAGCTGGG CCCAGCTGGTACCCAAGGT 2384 CCTTGGGTACCAGCTGGGG CCCCAGCTGGTACCCAAGG 2385 CTTGGGTACCAGCTGGGGC GCCCCAGCTGGTACCCAAG 2386 TTGGGTACCAGCTGGGGCC GGCCCCAGCTGGTACCCAA 2387 TGGGTACCAGCTGGGGCCA TGGCCCCAGCTGGTACCCA 2388 GGGTACCAGCTGGGGCCAC GTGGCCCCAGCTGGTACCC 2389 GGTACCAGCTGGGGCCACC GGTGGCCCCAGCTGGTACC 2390 GTACCAGCTGGGGCCACCA TGGTGGCCCCAGCTGGTAC 2391 TACCAGCTGGGGCCACCAG CTGGTGGCCCCAGCTGGTA 2392 ACCAGCTGGGGCCACCAGC GCTGGTGGCCCCAGCTGGT 2393 CCAGCTGGGGCCACCAGCA TGCTGGTGGCCCCAGCTGG 2394 CAGCTGGGGCCACCAGCAA TTGCTGGTGGCCCCAGCTG 2395 AGCTGGGGCCACCAGCAAC GTTGCTGGTGGCCCCAGCT 2396 GCTGGGGCCACCAGCAACA TGTTGCTGGTGGCCCCAGC 2397 CTGGGGCCACCAGCAACAC GTGTTGCTGGTGGCCCCAG 2398 TGGGGCCACCAGCAACACC GGTGTTGCTGGTGGCCCCA 2399 GGGGCCACCAGCAACACCA TGGTGTTGCTGGTGGCCCC 2400 GGGCCACCAGCAACACCAA TTGGTGTTGCTGGTGGCCC 2401 GGCCACCAGCAACACCAAG CTTGGTGTTGCTGGTGGCC 2402 GCCACCAGCAACACCAAGG CCTTGGTGTTGCTGGTGGC 2403 CCACCAGCAACACCAAGGT ACCTTGGTGTTGCTGGTGG 2404 CACCAGCAACACCAAGGTG CACCTTGGTGTTGCTGGTG 2405 ACCAGCAACACCAAGGTGC GCACCTTGGTGTTGCTGGT 2406 CCAGCAACACCAAGGTGCC GGCACCTTGGTGTTGCTGG 2407 CAGCAACACCAAGGTGCCC GGGCACCTTGGTGTTGCTG 2408 AGCAACACCAAGGTGCCCC GGGGCACCTTGGTGTTGCT 2409 GCAACACCAAGGTGCCCCT AGGGGCACCTTGGTGTTGC 2410 CAACACCAAGGTGCCCCTC GAGGGGCACCTTGGTGTTG 2411 AACACCAAGGTGCCCCTCT AGAGGGGCACCTTGGTGTT 2412 ACACCAAGGTGCCCCTCTC GAGAGGGGCACCTTGGTGT 2413 CACCAAGGTGCCCCTCTCC GGAGAGGGGCACCTTGGTG 2414 ACCAAGGTGCCCCTCTCCT AGGAGAGGGGCACCTTGGT 2415 CCAAGGTGCCCCTCTCCTG CAGGAGAGGGGCACCTTGG 2416 CAAGGTGCCCCTCTCCTGA TCAGGAGAGGGGCACCTTG 2417 AAGGTGCCCCTCTCCTGAG CTCAGGAGAGGGGCACCTT 2418 AGGTGCCCCTCTCCTGAGC GCTCAGGAGAGGGGCACCT 2419 GGTGCCCCTCTCCTGAGCC GGCTCAGGAGAGGGGCACC 2420 GTGCCCCTCTCCTGAGCCG CGGCTCAGGAGAGGGGCAC 2421 TGCCCCTCTCCTGAGCCGC GCGGCTCAGGAGAGGGGCA 2422 GCCCCTCTCCTGAGCCGCC GGCGGCTCAGGAGAGGGGC 2423 CCCCTCTCCTGAGCCGCCT AGGCGGCTCAGGAGAGGGG 2424 CCCTCTCCTGAGCCGCCTG CAGGCGGCTCAGGAGAGGG 2425 CCTCTCCTGAGCCGCCTGT ACAGGCGGCTCAGGAGAGG 2426 CTCTCCTGAGCCGCCTGTC GACAGGCGGCTCAGGAGAG 2427 TCTCCTGAGCCGCCTGTCA TGACAGGCGGCTCAGGAGA 2428 CTCCTGAGCCGCCTGTCAC GTGACAGGCGGCTCAGGAG 2429 TCCTGAGCCGCCTGTCACC GGTGACAGGCGGCTCAGGA 2430 CCTGAGCCGCCTGTCACCC GGGTGACAGGCGGCTCAGG 2431 CTGAGCCGCCTGTCACCCA TGGGTGACAGGCGGCTCAG 2432 TGAGCCGCCTGTCACCCAG CTGGGTGACAGGCGGCTCA 2433 GAGCCGCCTGTCACCCAGC GCTGGGTGACAGGCGGCTC 2434 AGCCGCCTGTCACCCAGCG CGCTGGGTGACAGGCGGCT 2435 GCCGCCTGTCACCCAGCGG CCGCTGGGTGACAGGCGGC 2436 CCGCCTGTCACCCAGCGGG CCCGCTGGGTGACAGGCGG 2437 CGCCTGTCACCCAGCGGGG CCCCGCTGGGTGACAGGCG 2438 GCCTGTCACCCAGCGGGGC GCCCCGCTGGGTGACAGGC 2439 CCTGTCACCCAGCGGGGCT AGCCCCGCTGGGTGACAGG 2440 CTGTCACCCAGCGGGGCTG CAGCCCCGCTGGGTGACAG 2441 TGTCACCCAGCGGGGCTGC GCAGCCCCGCTGGGTGACA 2442 GTCACCCAGCGGGGCTGCT AGCAGCCCCGCTGGGTGAC 2443 TCACCCAGCGGGGCTGCTG CAGCAGCCCCGCTGGGTGA 2444 CACCCAGCGGGGCTGCTGT ACAGCAGCCCCGCTGGGTG 2445 ACCCAGCGGGGCTGCTGTT AACAGCAGCCCCGCTGGGT 2446 CCCAGCGGGGCTGCTGTTC GAACAGCAGCCCCGCTGGG 2447 CCAGCGGGGCTGCTGTTCA TGAACAGCAGCCCCGCTGG 2448 CAGCGGGGCTGCTGTTCAT ATGAACAGCAGCCCCGCTG 2449 AGCGGGGCTGCTGTTCATC GATGAACAGCAGCCCCGCT 2450 GCGGGGCTGCTGTTCATCC GGATGAACAGCAGCCCCGC 2451 CGGGGCTGCTGTTCATCCT AGGATGAACAGCAGCCCCG 2452 GGGGCTGCTGTTCATCCTA TAGGATGAACAGCAGCCCC 2453 GGGCTGCTGTTCATCCTAC GTAGGATGAACAGCAGCCC 2454 GGCTGCTGTTCATCCTACC GGTAGGATGAACAGCAGCC 2455 GCTGCTGTTCATCCTACCC GGGTAGGATGAACAGCAGC 2456 CTGCTGTTCATCCTACCCA TGGGTAGGATGAACAGCAG 2457 TGCTGTTCATCCTACCCAC GTGGGTAGGATGAACAGCA 2458 GCTGTTCATCCTACCCACC GGTGGGTAGGATGAACAGC 2459 CTGTTCATCCTACCCACCC GGGTCGGTAGGATGAACAG 2460 TGTTCATCCTACCCACCCA TGGGTGGGTAGGATGAACA 2461 GTTCATCCTACCCACCCAC GTGGGTGGGTAGGATGAAC 2462 TTCATCCTACCCACCCACT AGTGGGTGGGTAGGATGAA 2463 TCATCCTACCCACCCACTA TAGTGGGTGGGTAGGATGA 2464 CATCCTACCCACCCACTAA TTAGTGGGTGGGTAGGATG 2465 ATCCTACCCACCCACTAAA TTTAGTGGGTGGGTAGGAT 2466 TCCTACCCACCCACTAAAG CTTTAGTGGGTGGGTAGGA 2467 CCTACCCACCCACTAAAGG CCTTTAGTGGGTGGGTAGG 2468 CTACCCACCCACTAAAGGT ACCTTTAGTGGGTGGGTAG 2469 TACCCACCCACTAAAGGTG CACCTTTAGTGGGTGGGTA 2470 ACCCACCCACTAAAGGTGG CCACCTTTAGTGGGTGGGT 2471 CCCACCCACTAAAGGTGGG CCCACCTTTAGTGGGTGGG 2472 CCACCCACTAAAGGTGGGG CCCCACCTTTAGTGGGTGG 2473 CACCCACTAAAGGTGGGGG CCCCCACCTTTAGTGGGTG 2474 ACCCACTAAAGGTGGGGGT ACCCCCACCTTTAGTGGGT 2475 CCCACTAAAGGTGGGGGTC GACCCCCACCTTTAGTGGG 2476 CCACTAAAGGTGGGGGTCT AGACCCCCACCTTTAGTGG 2477 CACTAAAGGTGGGGGTCTT AAGACCCCCACCTTTAGTG 2478 ACTAAAGGTGGGGGTCTTG CAAGACCCCCACCTTTAGT 2479 CTAAAGGTGGGGGTCTTGG CCAAGACCCCCACCTTTAG 2480 TAAAGGTGGGGGTCTTGGC GCCAAGACCCCCACCTTTA 2481 AAAGGTGGGGGTCTTGGCC GGCCAAGACCCCCACCTTT 2482 AAGGTGGGGGTCTTGGCCC GGGCCAAGACCCCCACCTT 2483 AGGTGGGGGTCTTGGCCCT AGGGCCAAGACCCCCACCT 2484 GGTGGGGGTCTTGGCCCTT AAGGGCCAAGACCCCCACC 2485 GTGGGGGTCTTGGCCCTTG CAAGGGCCAAGACCCCCAC 2486 TGGGGGTCTTGGCCCTTGT ACAAGGGCCAAGACCCCCA 2487 GGGGGTCTTGGCCCTTGTG CACAAGGGCCAAGACCCCC 2488 GGGGTCTTGGCCCTTGTGG CCACAAGGGCCAAGACCCC 2489 GGGTCTTGGCCCTTGTGGG CCCACAAGGGCCAAGACCC 2490 GGTCTTGGCCCTTGTGGGA TCCCACAAGGGCCAAGACC 2491 GTCTTGGCCCTTGTGGGAA TTCCCACAAGGGCCAAGAC 2492 TCTTGGCCCTTGTGGGAAG CTTCCCACAAGGGCCAAGA 2493 CTTGGCCCTTGTGGGAAGT ACTTCCCACAAGGGCCAAG 2494 TTGGCCCTTGTGGGAAGTG CACTTCCCACAAGGGCCAA 2495 TGGCCCTTGTGGGAAGTGC GCACTTCCCACAAGGGCCA 2496 GGCCCTTGTGGGAAGTGCC GGCACTTCCCACAAGGGCC 2497 GCCCTTGTGGGAAGTGCCA TGGCACTTCCCACAAGGGC 2498 CCCTTGTGGGAAGTGCCAG CTGGCACTTCCCACAAGGG 2499 CCTTGTGGGAAGTGCCAGG CCTGGCACTTCCCACAAGG 2500 CTTGTGGGAAGTGCCAGGA TCCTGGCACTTCCCACAAG 2501 TTGTGGGAAGTGCCAGGAG CTCCTGGCACTTCCCACAA 2502 TGTGGGAAGTGCCAGGAGG CCTCCTGGCACTTCCCACA 2503 GTGGGAAGTGCCAGGAGGG CCCTCCTGGCACTTCCCAC 2504 TGGGAAGTGCCAGGAGGGC GCCCTCCTGGCACTTCCCA 2505 GGGAAGTGCCAGGAGGGCC GGCCCTCCTGGCACTTCCC 2506 GGAAGTGCCAGGAGGGCCT AGGCCCTCCTGGCACTTCC 2507 GAAGTGCCAGGAGGGCCTG CAGGCCCTCCTGGCACTTC 2508 AAGTGCCAGGAGGGCCTGG CCAGGCCCTCCTGGCACTT 2509 AGTGCCAGGAGGGCCTGGA TCCAGGCCCTCCTGGCACT 2510 GTGCCAGGAGGGCCTGGAG CTCCAGGCCCTCCTGGCAC 2511 TGCCAGGAGGGCCTGGAGG CCTCCAGGCCCTCCTGGCA 2512 GCCAGGAGGGCCTGGAGGG CCCTCCAGGCCCTCCTGGC 2513 CCAGGAGGGCCTGGAGGGG CCCCTCCAGGCCCTCCTGG 2514 CAGGAGGGCCTGGAGGGGG CCCCCTCCAGGCCCTCCTG 2515 AGGAGGGCCTGGAGGGGGG CCCCCCTCCAGGCCCTCCT 2516 GGAGGGCCTGGAGGGGGGT ACCCCCCTCCAGGCCCTCC 2517 GAGGGCCTGGAGGGGGGTG CACCCCCCTCCAGGCCCTC 2518 AGGGCCTGGAGGGGGGTGC GCACCCCCCTCCAGGCCCT 2519 GGGCCTGGAGGGGGGTGCC GGCACCCCCCTCCAGGCCC 2520 GGCCTGGAGGGGGGTGCCA TGGCACCCCCCTCCAGGCC 2521 GCCTGGAGGGGGGTGCCAG CTGGCACCCCCCTCCAGGC 2522 CCTGGAGGGGGGTGCCAGT ACTGGCACCCCCCTCCAGG 2523 CTGGAGGGGGGTGCCAGTG CACTGGCACCCCCCTCCAG 2524 TGGAGGGGGGTGCCAGTGG CCACTGGCACCCCCCTCCA 2525 GGAGGGGGGTGCCAGTGGA TCCACTGGCACCCCCCTCC 2526 GAGGGGGGTGCCAGTGGAG CTCCACTGGCACCCCCCTC 2527 AGGGGGGTGCCAGTGGAGC GCTCCACTGGCACCCCCCT 2528 GGGGGGTGCCAGTGGAGCC GGCTCCACTGGCACCCCCC 2529 GGGGGTGCCAGTGGAGCCA TGGCTCCACTGGCACCCCC 2530 GGGGTGCCAGTGGAGCCAG CTGGCTCCACTGGCACCCC 2531 GGGTGCCAGTGGAGCCAGC GCTGGCTCCACTGGCACCC 2532 GGTGCCAGTGGAGCCAGCG CGCTGGCTCCACTGGCACC 2533 GTGCCAGTGGAGCCAGCGA TCGCTGGCTCCACTGGCAC 2534 TGCCAGTGGAGCCAGCGAA TTCGCTGGCTCCACTGGCA 2535 GCCAGTGGAGCCAGCGAAC GTTCGCTGGCTCCACTGGC 2536 CCAGTGGAGCCAGCGAACC GGTTCGCTGGCTCCACTGG 2537 CAGTGGAGCCAGCGAACCC GGGTTCGCTGGCTCCACTG 2538 AGTGGAGCCAGCGAACCCA TGGGTTCGCTGGCTCCACT 2539 GTGGAGCCAGCGAACCCAG CTGGGTTCGCTGGCTCCAC 2540 TGGAGCCAGCGAACCCAGC GCTGGGTTCGCTGGCTCCA 2541 GGAGCCAGCGAACCCAGCG CGCTGGGTTCGCTGGCTCC 2542 GAGCCAGCGAACCCAGCGA TCGCTGGGTTCGCTGGCTC 2543 AGCCAGCGAACCCAGCGAG CTCGCTGGGTTCGCTGGCT 2544 GCCAGCGAACCCAGCGAGG CCTCGCTGGGTTCGCTGGC 2545 CCAGCGAACCCAGCGAGGA TCCTCGCTGGGTTCGCTGG 2546 CAGCGAACCCAGCGAGGAA TTCCTCGCTGGGTTCGCTG 2547 AGCGAACCCAGCGAGGAAG CTTCCTCGCTGGGTTCGCT 2548 GCGAACCCAGCGAGGAAGT ACTTCCTCGCTGGGTTCGC 2549 CGAACCCAGCGAGGAAGTG CACTTCCTCGCTGGGTTCG 2550 GAACCCAGCGAGGAAGTGA TCACTTCCTCGCTGGGTTC 2551 AACCCAGCGAGGAAGTGAA TTCACTTCCTCGCTGGGTT 2552 ACCCAGCGAGGAAGTGAAC GTTCACTTCCTCGCTGGGT 2553 CCCAGCGAGGAAGTGAACA TGTTCACTTCCTCGCTGGG 2554 CCAGCGAGGAAGTGAACAA TTGTTCACTTCCTCGCTGG 2555 CAGCGAGGAAGTGAACAAG CTTGTTCACTTCCTCGCTG 2556 AGCGAGGAAGTGAACAAGG CCTTGTTCACTTCCTCGCT 2557 GCGAGGAAGTGAACAAGGC GCCTTGTTCACTTCCTCGC 2558 CGAGGAAGTGAACAAGGCC GGCCTTGTTCACTTCCTCG 2559 GAGGAAGTGAACAAGGCCT AGGCCTTGTTCACTTCCTC 2560 AGGAAGTGAACAAGGCCTC GAGGCCTTGTTCACTTCCT 2561 GGAAGTGAACAAGGCCTCT AGAGGCCTTGTTCACTTCC 2562 GAAGTGAACAAGGCCTCTG CAGAGGCCTTGTTCACTTC 2563 AAGTGAACAAGGCCTCTGG CCAGAGGCCTTGTTCACTT 2564 AGTGAACAAGGCCTCTGGC GCCAGAGGCCTTGTTCACT 2565 GTGAACAAGGCCTCTGGCC GGCCAGAGGCCTTGTTCAC 2566 TGAACAAGGCCTCTGGCCC GGGCCAGAGGCCTTGTTCA 2567 GAACAAGGCCTCTGGCCCC GGGGCCAGAGGCCTTGTTC 2568 AACAAGGCCTCTGGCCCCA TGGGGCCAGAGGCCTTGTT 2569 ACAAGGCCTCTGGCCCCAG CTGGGGCCAGAGGCCTTGT 2570 CAAGGCCTCTGGCCCCAGG CCTGGGGCCAGAGGCCTTG 2571 AAGGCCTCTGGCCCCAGGG CCCTGGGGCCAGAGGCCTT 2572 AGGCCTCTGGCCCCAGGGC GCCCTGGGGCCAGAGGCCT 2573 GGCCTCTGGCCCCAGGGCC GGCCCTGGGGCCAGAGGCC 2574 GCCTCTGGCCCCAGGGCCT AGGCCCTGGGGCCAGAGGC 2575 CCTCTGGCCCCAGGGCCTG CAGGCCCTGGGGCCAGAGG 2576 CTCTGGCCCCAGGGCCTGT ACAGGCCCTGGGGCCAGAG 2577 TCTGGCCCCAGGGCCTGTC GACAGGCCCTGGGGCCAGA 2578 CTGGCCCCAGGGCCTGTCC GGACAGGCCCTGGGGCCAG 2579 TGGCCCCAGGGCCTGTCCC GGGACAGGCCCTGGGGCCA 2580 GGCCCCAGGGCCTGTCCCC GGGGACAGGCCCTGGGGCC 2581 GCCCCAGGGCCTGTCCCCC GGGGGACAGGCCCTGGGGC 2582 CCCCAGGGCCTGTCCCCCC GGGGGGACAGGCCCTGGGG 2583 CCCAGGGCCTGTCCCCCCA TGGGGGGACAGGCCCTGGG 2584 CCAGGGCCTGTCCCCCCAG CTGGGGGGACAGGCCCTGG 2585 CAGGGCCTGTCCCCCCAGC GCTGGGGGGACAGGCCCTG 2586 AGGGCCTGTCGCCCCAGCC GGCTGGGGGGACAGGCCCT 2587 GGGCCTGTCCGCCCAGCCA TGGCTGGGGGGACAGGCCC 2588 GGCCTGTCCCCCCAGCCAC GTGGCTGGGGGGACAGGCC 2589 GCCTGTCCCCCCAGCCACC GGTGGCTGGGGGGACAGGC 2590 CCTGTCCCCCCAGCCACCA TGGTGGCTGGGGGGACAGG 2591 CTGTCCCCCCAGCGACCAC GTGGTGGCTGGGGGGACAG 2592 TGTCCCCCCAGCCACCACA TGTGGTGGCTGGGGGGACA 2593 GTCCCCCCAGCCACCACAC GTGTGGTGGCTGGGGGGAC 2594 TCCCCCCAGCCACCACACC GGTGTGGTGGCTGGGGGGA 2595 CCCCCCAGCCACCACACCA TGGTGTGGTGGCTGGGGGG 2596 CCCCCAGCCACCACACCAA TTGGTGTGGTGGCTGGGGG 2597 CCCCAGCCACCACACCAAG CTTGGTGTGGTGGCTGGGG 2598 CCCAGCCACCACACCAAGC GCTTGGTGTGGTGGCTGGG 2599 CCAGCCACCACACCAAGCT AGCTTGGTGTGGTGGCTGG 2600 CAGCCACCACACCAAGCTG CAGCTTGGTGTGGTGGCTG 2601 AGCCACCACACCAAGCTGA TCAGCTTGGTGTGGTGGCT 2602 GCCACCACACCAAGCTGAA TTCAGCTTGGTGTGGTGGC 2603 CCACCACACCAAGCTGAAG CTTCAGCTTGGTGTGGTGG 2604 CACCACACCAAGCTGAAGA TCTTCAGCTTGGTGTGGTG 2605 ACCACACCAAGCTGAAGAA TTCTTCAGCTTGGTGTGGT 2606 CCACACCAAGCTGAAGAAG CTTCTTCAGCTTGGTGTGG 2607 CACACCAAGCTGAAGAAGA TCTTCTTCAGCTTGGTGTG 2608 ACACCAAGCTGAAGAAGAC GTCTTCTTCAGCTTGGTGT 2609 CACCAAGCTGAAGAAGACA TGTCTTCTTCAGCTTGGTG 2610 ACCAAGCTGAAGAAGACAT ATGTCTTCTTCAGCTTGGT 2611 CCAAGCTGAAGAAGACATG CATGTCTTCTTCAGCTTGG 2612 CAAGCTGAAGAAGACATGG CCATGTCTTCTTCAGCTTG 2613 AAGCTGAAGAAGACATGGC GCCATGTCTTCTTCAGCTT 2614 AGCTGAAGAAGACATGGCT AGCCATGTCTTCTTCAGCT 2615 GCTGAAGAAGACATGGCTC GAGCCATGTCTTCTTCAGC 2616 CTGAAGAAGACATGGCTCA TGAGCCATGTCTTCTTCAG 2617 TGAAGAAGACATGGCTCAC GTGAGCCATGTCTTCTTCA 2618 GAAGAAGACATGGCTCACA TGTGAGCCATGTCTTCTTC 2619 AAGAAGACATGGCTCACAC GTGTGAGCCATGTCTTCTT 2620 AGAAGACATGGCTCACACG CGTGTGAGCCATGTCTTCT 2621 GAAGACATGGCTCACACGG CCGTGTGAGCCATGTCTTC 2622 AAGACATGGCTCACACGGC GCCGTGTGAGCCATGTCTT 2623 AGACATGGCTCACACGGCA TGCCGTGTGAGCCATGTCT 2624 GACATGGCTCACACGGCAC GTGCCGTGTGAGCCATGTC 2625 ACATGGCTCACACGGCACT AGTGCCGTGTGAGCCATGT 2626 CATGGCTCACACGGCACTC GAGTGCCGTGTGAGCCATG 2627 ATGGCTCACACGGCACTCG CGAGTGCCGTGTGAGCCAT 2628 TGGCTCACACGGCACTCGG CCGAGTGCCGTGTGAGCCA 2629 GGCTCACACGGCACTCGGA TCCGAGTGCCGTGTGAGCC 2630 GCTCACACGGCACTCGGAG CTCCGAGTGCCGTGTGAGC 2631 CTCACACGGCACTCGGAGC GCTCCGAGTGCCGTGTGAG 2632 TCACACGGCACTCGGAGCA TGCTCCGAGTGCCGTGTGA 2633 CACACGGCACTCGGAGCAG CTGCTCCGAGTGCCGTGTG 2634 ACACGGCACTCGGAGCAGT ACTGCTCCGAGTGCCGTGT 2635 CACGGCACTCGGAGCAGTT AACTGCTCCGAGTGCCGTG 2636 ACGGCACTCGGAGCAGTTT AAACTGCTCCGAGTGCCGT 2637 CGGCACTCGGAGCAGTTTG CAAACTGCTCCGAGTGCCG 2638 GGCACTCGGAGCAGTTTGA TCAAACTGCTCCGAGTGCC 2639 GCACTCGGAGCAGTTTGAA TTCAAACTGCTCCGAGTGC 2640 CACTCGGAGCAGTTTGAAT ATTCAAACTGCTCCGAGTG 2641 ACTCGGAGCAGTTTGAATG CATTCAAACTGCTCCGAGT 2642 CTCGGAGCAGTTTGAATGT ACATTCAAACTGCTCCGAG 2643 TCGGAGCAGTTTGAATGTC GACATTCAAACTGCTCCGA 2644 CGGAGCAGTTTGAATGTCC GGACATTCAAACTGCTCCG 2645 GGAGCAGTTTGAATGTCCA TGGACATTCAAACTGCTCC 2646 GAGCAGTTTGAATGTCCAC GTGGACATTCAAACTGCTC 2647 AGCAGTTTGAATGTCCACG CGTGGACATTCAAACTGCT 2648 GCAGTTTGAATGTCCACGC GCGTGGACATTCAAACTGC 2649 CAGTTTGAATGTCCACGCG CGCGTGGACATTCAAACTG 2650 AGTTTGAATGTCCACGCGG CCGCGTGGACATTCAAACT 2651 GTTTGAATGTCCACGCGGC GCCGCGTGGACATTCAAAC 2652 TTTGAATGTCCACGCGGCT AGCCGCGTGGACATTCAAA 2653 TTGAATGTCCACGCGGCTG CAGCCGCGTGGACATTCAA 2654 TGAATGTCCACGCGGCTGC GCAGCCGCGTGGACATTCA 2655 GAATGTCCACGCGGCTGCC GGCAGCCGCGTGGACATTC 2656 AATGTCCACGCGGCTGCCC GGGCAGCCGCGTGGACATT 2657 ATGTCCACGCGGCTGCCCT AGGGCAGCCGCGTGGACAT 2658 TGTCCACGCGGCTGCCCTG CAGGGCAGCCGCGTGGACA 2659 GTCCACGCGGCTGCCCTGA TCAGGGCAGCCGCGTGGAC 2660 TCCACGCGGCTGCCCTGAG CTCAGGGCAGCCGCGTGGA 2661 CCACGCGGCTGCCCTGAGG CCTCAGGGCAGCCGCGTGG 2662 CACGCGGCTGCCCTGAGGT ACCTCAGGGCAGCCGCGTG 2663 ACGCGGCTGCCCTGAGGTC GACCTCAGGGCAGCCGCGT 2664 CGCGGCTGCCCTGAGGTCG CGACCTCAGGGCAGCCGCG 2665 GCGGCTGCCCTGAGGTCGA TCGACCTCAGGGCAGCCGC 2666 CGGCTGCCCTGAGGTCGAG CTCGACCTCAGGGCAGCCG 2667 GGCTGCCCTGAGGTCGAGG CCTCGACCTCAGGGCAGCC 2668 GCTGCCCTGAGGTCGAGGA TCCTCGACCTCAGGGCAGC 2669 CTGCCCTGAGGTCGAGGAG CTCCTCGACCTCAGGGCAG 2670 TGCCCTGAGGTCGAGGAGA TCTCCTCGACCTCAGGGCA 2671 GCCCTGAGGTCGAGGAGAG CTCTCCTCGACCTCAGGGC 2672 CCCTGAGGTCGAGGAGAGG CCTCTCCTCGACCTCAGGG 2673 CCTGAGGTCGAGGAGAGGC GCCTCTCCTCGACCTCAGG 2674 CTGAGGTCGAGGAGAGGCC GGCCTCTCCTCGACCTCAG 2675 TGAGGTCGAGGAGAGGCCG CGGCCTCTCCTCGACCTCA 2676 GAGGTCGAGGAGAGGCCGG CCGGCCTCTCCTCGACCTC 2677 AGGTCGAGGAGAGGCCGGT ACCGGCCTCTCCTCGACCT 2678 GGTCGAGGAGAGGCCGGTT AACCGGCCTCTCCTCGACC 2679 GTCGAGGAGAGGCCGGTTG CAACCGGCCTCTCCTCGAC 2680 TCGAGGAGAGGCCGGTTGC GCAACCGGCCTCTCCTCGA 2681 CGAGGAGAGGCCGGTTGCT AGCAACCGGCCTCTCCTCG 2682 GAGGAGAGGCCGGTTGCTC GAGCAACCGGCCTCTCCTC 2683 AGGAGAGGCCGGTTGCTCG CGAGCAACCGGCCTCTCCT 2684 GGAGAGGCCGGTTGCTCGG CCGAGCAACCGGCCTCTCC 2685 GAGAGGCCGGTTGCTCGGC GCCGAGCAACCGGCCTCTC 2686 AGAGGCCGGTTGCTCGGCT AGCCGAGCAACCGGCCTCT 2687 GAGGCCGGTTGCTCGGCTC GAGCCGAGCAACCGGCCTC 2688 AGGCCGGTTGCTCGGCTCC GGAGCCGAGCAACCGGCCT 2689 GGCCGGTTGCTCGGCTCCG CGGAGCCGAGCAACCGGCC 2690 GCCGGTTGCTCGGCTCCGG CCGGAGCCGAGCAACCGGC 2691 CCGGTTGCTCGGCTCCGGG CCCGGAGCCGAGCAACCGG 2692 CGGTTGCTCGGCTCCGGGC GCCCGGAGCCGAGCAACCG 2693 GGTTGCTCGGCTCCGGGCC GGCCCGGAGCCGAGCAACC 2694 GTTGCTCGGCTCCGGGCCC GGGCCCGGAGCCGAGCAAC 2695 TTGCTCGGCTCCGGGCCCT AGGGCCCGGAGCCGAGCAA 2696 TGCTCGGCTCCGGGCCCTC GAGGGCCCGGAGCCGAGCA 2697 GCTCGGCTCCGGGCCCTCA TGAGGGCCCGGAGCCGAGC 2698 CTCGGCTCCGGGCCCTCAA TTGAGGGCCCGGAGCCGAG 2699 TCGGCTCCGGGCCCTCAAA TTTGAGGGCCCGGAGCCGA 2700 CGGCTCCGGGCCCTCAAAA TTTTGAGGGCCCGGAGCCG 2701 GGCTCCGGGCCCTCAAAAG CTTTTGAGGGCCCGGAGCC 2702 GCTCCGGGCCCTCAAAAGG CCTTTTGAGGGCCCGGAGC 2703 CTCCGGGCCCTCAAAAGGG CCCTTTTGAGGGCCCGGAG 2704 TCCGGGCCCTCAAAAGGGC GCCCTTTTGAGGGCCCGGA 2705 CCGGGCCCTCAAAAGGGCA TGCCCTTTTGAGGGCCCGG 2706 CGGGCCCTCAAAAGGGCAG CTGCCCTTTTGAGGGCCCG 2707 GGGCCCTCAAAAGGGCAGG CCTGCCCTTTTGAGGGCCC 2708 GGCCCTCAAAAGGGCAGGC GCCTGCCCTTTTGAGGGCC 2709 GCCCTCAAAAGGGCAGGCA TGCCTGCCCTTTTGAGGGC 2710 CCCTCAAAAGGGCAGGCAG CTGCCTGCCCTTTTGAGGG 2711 CCTCAAAAGGGCAGGCAGC GCTGCCTGCCCTTTTGAGG 2712 CTCAAAAGGGCAGGCAGCC GGCTGCCTGCCCTTTTGAG 2713 TCAAAAGGGCAGGCAGCCC GGGCTGCCTGCCCTTTTGA 2714 CAAAAGGGCAGGCAGCCCC GGGGCTGCCTGCCCTTTTG 2715 AAAAGGGCAGGCAGCCCCG CGGGGCTGCCTGCCCTTTT 2716 AAAGGGCAGGCAGCCCCGA TCGGGGCTGCCTGCCCTTT 2717 AAGGGCAGGCAGCCCCGAG CTCGGGGCTGCCTGCCCTT 2718 AGGGCAGGCAGCCCCGAGG CCTCGGGGCTGCCTGCCCT 2719 GGGCAGGCAGCCCCGAGGT ACCTCGGGGCTGCCTGCCC 2720 GGCAGGCAGCCCCGAGGTC GACCTCGGGGCTGCCTGCC 2721 GCAGGCAGCCCCGAGGTCC GGACCTCGGGGCTGCCTGC 2722 CAGGCAGCCCCGAGGTCCA TGGACCTCGGGGCTGCCTG 2723 AGGCAGCCCCGAGGTCCAG CTGGACCTCGGGGCTGCCT 2724 GGCAGCCCCGAGGTCCAGG CCTGGACCTCGGGGCTGCC 2725 GCAGCCCCGAGGTCCAGGG CCCTGGACCTCGGGGCTGC 2726 CAGCCCCGAGGTCCAGGGA TCCCTGGACCTCGGGGCTG 2727 AGCCCCGAGGTCCAGGGAG CTCCCTGGACCTCGGGGCT 2728 GCCCCGAGGTCCAGGGAGC GCTCCCTGGACCTCGGGGC 2729 CCCCGAGGTCCAGGGAGCA TGCTCCCTGGACCTCGGGG 2730 CCCGAGGTCCAGGGAGCAA TTGCTCCCTGGACCTCGGG 2731 CCGAGGTCCAGGGAGCAAT ATTGCTCCCTGGACCTCGG 2732 CGAGGTCCAGGGAGCAATG CATTGCTCCCTGGACCTCG 2733 GAGGTCCAGGGAGCAATGG CCATTGCTCCCTGGACCTC 2734 AGGTCCAGGGAGCAATGGG CCCATTGCTCCCTGGACCT 2735 GGTCCAGGGAGCAATGGGC GCCCATTGCTCCCTGGACC 2736 GTCCAGGGAGCAATGGGCA TGCCCATTGCTCCCTGGAC 2737 TCCAGGGAGCAATGGGCAG CTGCCCATTGCTCCCTGGA 2738 CCAGGGAGCAATGGGCAGT ACTGCCCATTGCTCCCTGG 2739 CAGGGAGCAATGGGCAGTC GACTGCCCATTGCTCCCTG 2740 AGGGAGCAATGGGCAGTCC GGACTGCCCATTGCTCCCT 2741 GGGAGCAATGGGCAGTCCA TGGACTGCCCATTGCTCCC 2742 GGAGCAATGGGCAGTCCAG CTGGACTGCCCATTGCTCC 2743 GAGCAATGGGCAGTCCAGC GCTGGACTGCCCATTGCTC 2744 AGCAATGGGCAGTCCAGCC GGCTGGACTGCCCATTGCT 2745 GCAATGGGCAGTCCAGCCC GGGCTGGACTGCCCATTGC 2746 CAATGGGCAGTCCAGCCCC GGGGCTGGACTGCCCATTG 2747 AATGGGCAGTCCAGCCCCC GGGGGCTGGACTGCCCATT 2748 ATGGGCAGTCCAGCCCCCA TGGGGGCTGGACTGCCCAT 2749 TGGGCAGTCCAGCCCCCAA TTGGGGGCTGGACTGCCCA 2750 GGGCAGTCCAGCCCCCAAG CTTGGGGGCTGGACTGCCC 2751 GGCAGTCCAGCCCCCAAGC GCTTGGGGGCTGGACTGCC 2752 GCAGTCCAGCCCCCAAGCG CGCTTGGGGGCTGGACTGC 2753 CAGTCCAGCCCCCAAGCGG CCGCTTGGGGGCTGGACTG 2754 AGTCCAGCCCCCAAGCGGC GCCGCTTGGGGGCTGGACT 2755 GTCCAGCCCCCAAGCGGCC GGCCGCTTGGGGGCTGGAC 2756 TCCAGCCCCCAAGCGGCCA TGGCCGCTTGGGGGCTGGA 2757 CCAGCCCCCAAGCGGCCAC GTGGCCGCTTGGGGGCTGG 2758 CAGCCCCCAAGCGGCCACC GGTGGCCGCTTGGGGGCTG 2759 AGCCCCCAAGCGGCCACCG CGGTGGCCGCTTGGGGGCT 2760 GCCCCCAAGCGGCCACCGG CCGGTGGCCGCTTGGGGGC 2761 CCCCCAAGCGGCCACCGGA TCCGGTGGCCGCTTGGGGG 2762 CCCCAAGCGGCCACCGGAC GTCCGGTGGCCGCTTGGGG 2763 CCCAAGCGGCCACCGGACC GGTCCGGTGGCCGCTTGGG 2764 CCAAGCGGCCACCGGACCC GGGTCCGGTGGCCGCTTGG 2765 CAAGCGGCCACCGGACCCT AGGGTCCGGTGGCCGCTTG 2766 AAGCGGCCACCGGACCCTT AAGGGTCCGGTGGCCGCTT 2767 AGCGGCCACCGGACCCTTT AAAGGGTCCGGTGGCCGCT 2768 GCGGCCACCGGACCCTTTT AAAAGGGTCCGGTGGCCGC 2769 CGGCCACCGGACCCTTTTC GAAAAGGGTCCGGTGGCCG 2770 GGCCACCGGACCCTTTTCC GGAAAAGGGTCCGGTGGCC 2771 GCCACCGGACCCTTTTCCA TGGAAAAGGGTCCGGTGGC 2772 CCACCGGACCCTTTTCCAG CTGGAAAAGGGTCCGGTGG 2773 CACCGGACCCTTTTCCAGG CCTGGAAAAGGGTCCGGTG 2774 ACCGGACCCTTTTCCAGGC GCCTGGAAAAGGGTCCGGT 2775 CCGGACCCTTTTCCAGGCA TGCCTGGAAAAGGGTCCGG 2776 CGGACCCTTTTCCAGGCAC GTGCCTGGAAAAGGGTCCG 2777 GGACCCTTTTCCAGGCACT AGTGCCTGGAAAAGGGTCC 2778 GACCCTTTTCCAGGCACTG CAGTGCCTGGAAAAGGGTC 2779 ACCCTTTTCCAGGCACTGC GCAGTGCCTGGAAAAGGGT 2780 CCCTTTTCCAGGCACTGCA TGCAGTGCCTGGAAAAGGG 2781 CCTTTTCCAGGCACTGCAG CTGCAGTGCCTGGAAAAGG 2782 CTTTTCCAGGCACTGCAGA TCTGCAGTGCCTGGAAAAG 2783 TTTTCCAGGCACTGCAGAA TTCTGCAGTGCCTGGAAAA 2784 TTTCCAGGCACTGCAGAAC GTTCTGCAGTGCCTGGAAA 2785 TTCCAGGCACTGCAGAACA TGTTCTGCAGTGCCTGGAA 2786 TCCAGGCACTGCAGAACAG CTGTTCTGCAGTGCCTGGA 2787 CCAGGCACTGCAGAACAGG CCTGTTCTGCAGTGCCTGG 2788 CAGGCACTGCAGAACAGGG CCCTGTTCTGCAGTGCCTG 2789 AGGCACTGCAGAACAGGGG CCCCTGTTCTGCAGTGCCT 2790 GGCACTGCAGAACAGGGGG CCCCCTGTTCTGCAGTGCC 2791 GCACTGCAGAACAGGGGGC GCCCCCTGTTCTGCAGTGC 2792 CACTGCAGAACAGGGGGCT AGCCCCCTGTTCTGCAGTG 2793 ACTGCAGAACAGGGGGCTG CAGCCCCCTGTTCTGCAGT 2794 CTGCAGAACAGGGGGCTGG CCAGCCCCCTGTTCTGCAG 2795 TGCAGAACAGGGGGCTGGG CCCAGCCCCCTGTTCTGCA 2796 GCAGAACAGGGGGCTGGGG CCCCAGCCCCCTGTTCTGC 2797 CAGAACAGGGGGCTGGGGG CCCCCAGCCCCCTGTTCTG 2798 AGAACAGGGGGCTGGGGGT ACCCCCAGCCCCCTGTTCT 2799 GAACAGGGGGCTGGGGGTT AACCCCCAGCCCCCTGTTC 2800 AACAGGGGGCTGGGGGTTG CAACCCCCAGCCCCCTGTT 2801 ACAGGGGGCTGGGGGTTGG CCAACCCCCAGCCCCCTGT 2802 CAGGGGGCTGGGGGTTGGC GCCAACCCCCAGCCCCCTG 2803 AGGGGGCTGGGGGTTGGCA TGCCAACCCCCAGCCCCCT 2804 GGGGGCTGGGGGTTGGCAG CTGCCAACCCCCAGCCCCC 2805 GGGGCTGGGGGTTGGCAGG CCTGCCAACCCCCAGCCCC 2806 GGGCTGGGGGTTGGCAGGA TCCTGCCAACCCCCAGCCC 2807 GGCTGGGGGTTGGCAGGAG CTCCTGCCAACCCCCAGCC 2808 GCTGGGGGTTGGCAGGAGG CCTCCTGCCAACCCCCAGC 2809 CTGGGGGTTGGCAGGAGGT ACCTCCTGCCAACCCCCAG 2810 TGGGGGTTGGCAGGAGGTG CACCTCCTGCCAACCCCCA 2811 GGGGGTTGGCAGGAGGTGC GCACCTCCTGCCAACCCCC 2812 GGGGTTGGCAGGAGGTGCG CGCACCTCCTGCCAACCCC 2813 GGGTTGGCAGGAGGTGCGG CCGCACCTCCTGCCAACCC 2814 GGTTGGCAGGAGGTGCGGG CCCGCACCTCCTGCCAACC 2815 GTTGGCAGGAGGTGCGGGA TCCCGCACCTCCTGCCAAC 2816 TTGGCAGGAGGTGCGGGAC GTCCCGCACCTCCTGCCAA 2817 TGGCAGGAGGTGCGGGACA TGTCCCGCACCTCCTGCCA 2818 GGCAGGAGGTGCGGGACAC GTGTCCCGCACCTCCTGCC 2819 GCAGGAGGTGCGGGACACA TGTGTCCCGCACCTCCTGC 2820 CAGGAGGTGCGGGACACAT ATGTGTCCCGCACCTCCTG 2821 AGGAGGTGCGGGACACATC GATGTGTCCCGCACCTCCT 2822 GGAGGTGCGGGACACATCG CGATGTGTCCCGCACCTCC 2823 GAGGTGCGGGACACATCGA TCGATGTGTCCCGCACCTC 2824 AGGTGCGGGACACATCGAT ATCGATGTGTCCCGCACCT 2825 GGTGCGGGACACATCGATA TATCGATGTGTCCCGCACC 2826 GTGCGGGACACATCGATAG CTATCGATGTGTCCCGCAC 2827 TGCGGGACACATCGATAGG CCTATCGATGTGTCCCGCA 2828 GCGGGACACATCGATAGGG CCCTATCGATGTGTCCCGC 2829 CGGGACACATCGATAGGGA TCCCTATCGATGTGTCCCG 2830 GGGACACATCGATAGGGAA TTCCCTATCGATGTGTCCC 2831 GGACACATCGATAGGGAAC GTTCCCTATCGATGTGTCC 2832 GACACATCGATAGGGAACA TGTTCCCTATCGATGTGTC 2833 ACACATCGATAGGGAACAA TTGTTCCCTATCGATGTGT 2834 CACATCGATAGGGAACAAG CTTGTTCCCTATCGATGTG 2835 ACATCGATAGGGAACAAGG CCTTGTTCCCTATCGATGT 2836 CATCGATAGGGAACAAGGA TCCTTGTTCCCTATCGATG 2837 ATCGATAGGGAACAAGGAT ATCCTTGTTCCCTATCGAT 2838 TCGATAGGGAACAAGGATG CATCCTTGTTCCCTATCGA 2839 CGATAGGGAACAAGGATGT ACATCCTTGTTCCCTATCG 2840 GATAGGGAACAAGGATGTG CACATCCTTGTTCCCTATC 2841 ATAGGGAACAAGGATGTGG CCACATCCTTGTTCCCTAT 2842 TAGGGAACAAGGATGTGGA TCCACATCCTTGTTCCCTA 2843 AGGGAACAAGGATGTGGAC GTCCACATCCTTGTTCCCT 2844 GGGAACAAGGATGTGGACT AGTCCACATCCTTGTTCCC 2845 GGAACAAGGATGTGGACTC GAGTCCACATCCTTGTTCC 2846 GAACAAGGATGTGGACTCG CGAGTCCACATCCTTGTTC 2847 AACAAGGATGTGGACTCGG CCGAGTCCACATCCTTGTT 2848 ACAAGGATGTGGACTCGGG CCCGAGTCCACATCCTTGT 2849 CAAGGATGTGGACTCGGGA TCCCGAGTCCACATCCTTG 2850 AAGGATGTGGACTCGGGAC GTCCCGAGTCCACATCCTT 2851 AGGATGTGGACTCGGGACA TGTCCCGAGTCCACATCCT 2852 GGATGTGGACTCGGGACAG CTGTCCCGAGTCCACATCC 2853 GATGTGGACTCGGGACAGC GCTGTCCCGAGTCCACATC 2854 ATGTGGACTCGGGACAGCA TGCTGTCCCGAGTCCACAT 2855 TGTGGACTCGGGACAGCAT ATGCTGTCCCGAGTCCACA 2856 GTGGACTCGGGACAGCATG CATGCTGTCCCGAGTCCAC 2857 TGGACTCGGGACAGCATGA TCATGCTGTCCCGAGTCCA 2858 GGACTCGGGACAGCATGAT ATCATGCTGTCCCGAGTCC 2859 GACTCGGGACAGCATGATG CATCATGCTGTCCCGAGTC 2860 ACTCGGGACAGCATGATGA TCATCATGCTGTCCCGAGT 2861 CTCGGGACAGCATGATGAG CTCATCATGCTGTCCCGAG 2862 TCGGGACAGCATGATGAGC GCTCATCATGCTGTCCCGA 2863 CGGGACAGCATGATGAGCA TGCTCATCATGCTGTCCCG 2864 GGGACAGCATGATGAGCAG CTGCTCATCATGCTGTCCC 2865 GGACAGCATGATGAGCAGA TCTGCTCATCATGCTGTCC 2866 GACAGCATGATGAGCAGAA TTCTGCTCATCATGCTGTC 2867 ACAGCATGATGAGCAGAAA TTTCTGCTCATCATGCTGT 2868 CAGCATGATGAGCAGAAAG CTTTCTGCTCATCATGCTG 2869 AGCATGATGAGCAGAAAGG CCTTTCTGCTCATCATGCT 2870 GCATGATGAGCAGAAAGGA TCCTTTCTGCTCATCATGC 2871 CATGATGAGCAGAAAGGAC GTCCTTTCTGCTCATCATG 2872 ATGATGAGCAGAAAGGACC GGTCCTTTCTGCTCATCAT 2873 TGATGAGCAGAAAGGACCC GGGTCCTTTCTGCTCATCA 2874 GATGAGCAGAAAGGACCCC GGGGTCCTTTCTGCTCATC 2875 ATGAGCAGAAAGGACCCCA TGGGGTCCTTTCTGCTCAT 2876 TGAGCAGAAAGGACCCCAA TTGGGGTCCTTTCTGCTCA 2877 GAGCAGAAAGGACCCCAAG CTTGGGGTCCTTTCTGCTC 2878 AGCAGAAAGGACCCCAAGA TCTTGGGGTCCTTTCTGCT 2879 GCAGAAAGGACCCCAAGAT ATCTTGGGGTCCTTTCTGC 2880 CAGAAAGGACCCCAAGATG CATCTTGGGGTCCTTTCTG 2881 AGAAAGGACCCCAAGATGG CCATCTTGGGGTCCTTTCT 2882 GAAAGGACCCCAAGATGGC GCCATCTTGGGGTCCTTTC 2883 AAAGGACCCCAAGATGGCC GGCCATCTTGGGGTCCTTT 2884 AAGGACCCCAAGATGGCCA TGGCCATCTTGGGGTCCTT 2885 AGGACCCCAAGATGGCCAG CTGGCCATCTTGGGGTCCT 2886 GGACCCCAAGATGGCCAGG CCTGGCCATCTTGGGGTCC 2887 GACCCCAAGATGGCCAGGC GCCTGGCCATCTTGGGGTC 2888 ACCCCAAGATGGCCAGGCC GGCCTGGCCATCTTGGGGT 2889 CCCCAAGATGGCCAGGCCA TGGCCTGGCCATCTTGGGG 2890 CCCAAGATGGCCAGGCCAG CTGGCCTGGCCATCTTGGG 2891 CCAAGATGGCCAGGCCAGT ACTGGCCTGGCCATCTTGG 2892 CAAGATGGCCAGGCCAGTC GACTGGCCTGGCCATCTTG 2893 AAGATGGCCAGGCCAGTCT AGACTGGCCTGGCCATCTT 2894 AGATGGCCAGGCCAGTCTC GAGACTGGCCTGGCCATCT 2895 GATGGCCAGGCCAGTCTCC GGAGACTGGCCTGGCCATC 2896 ATGGCCAGGCCAGTCTCCA TGGAGACTGGCCTGGCCAT 2897 TGGCCAGGCCAGTCTCCAG CTGGAGACTGGCCTGGCCA 2898 GGCCAGGCCAGTCTCCAGG CCTGGAGACTGGCCTGGCC 2899 GCCAGGCCAGTCTCCAGGA TCCTGGAGACTGGCCTGGC 2900 CCAGGCCAGTCTCCAGGAC GTCCTGGAGACTGGCCTGG 2901 CAGGCCAGTCTCCAGGACC GGTCCTGGAGACTGGCCTG 2902 AGGCCAGTCTCCAGGACCC GGGTCCTGGAGACTGGCCT 2903 GGCCAGTCTCCAGGACCCG CGGGTCCTGGAGACTGGCC 2904 GCCAGTCTCCAGGACCCGG CCGGGTCCTGGAGACTGGC 2905 CCAGTCTCCAGGACCCGGG CCCGGGTCCTGGAGACTGG 2906 CAGTCTCCAGGACCCGGGA TCCCGGGTCCTGGAGACTG 2907 AGTCTCCAGGACCCGGGAC GTCCCGGGTCCTGGAGACT 2908 GTCTCCAGGACCCGGGACT AGTCCCGGGTCCTGGAGAC 2909 TCTCCAGGACCCGGGACTT AAGTCCCGGGTCCTGGAGA 2910 CTCCAGGACCCGGGACTTC GAAGTCCCGGGTCCTGGAG 2911 TCCAGGACCCGGGACTTCA TGAAGTCCCGGGTCCTGGA 2912 CCAGGACCCGGGACTTCAG CTGAAGTCCCGGGTCCTGG 2913 CAGGACCCGGGACTTCAGG CCTGAAGTCCCGGGTCCTG 2914 AGGACCCGGGACTTCAGGA TCCTGAAGTCCCGGGTCCT 2915 GGACCCGGGACTTCAGGAC GTCCTGAAGTCCCGGGTCC 2916 GACCCGGGACTTCAGGACA TGTCCTGAAGTCCCGGGTC 2917 ACCCGGGACTTCAGGACAT ATGTCCTGAAGTCCCGGGT 2918 CCCGGGACTTCAGGACATA TATGTCCTGAAGTCCCGGG 2919 CCGGGACTTCAGGACATAC GTATGTCCTGAAGTCCCGG 2920 CGGGACTTCAGGACATACC GGTATGTCCTGAAGTCCCG 2921 GGGACTTCAGGACATACCA TGGTATGTCCTGAAGTCCC 2922 GGACTTCAGGACATACCAT ATGGTATGTCCTGAAGTCC 2923 GACTTCAGGACATACCATG CATGGTATGTCCTGAAGTC 2924 ACTTCAGGACATACCATGC GCATGGTATGTCCTGAAGT 2925 CTTCAGGACATACCATGCC GGCATGGTATGTCCTGAAG 2926 TTCAGGACATACCATGCCT AGGCATGGTATGTCCTGAA 2927 TCAGGACATACCATGCCTG CAGGCATGGTATGTCCTGA 2928 CAGGACATACCATGCCTGG CCAGGCATGGTATGTCCTG 2929 AGGACATACCATGCCTGGC GCCAGGCATGGTATGTCCT 2930 GGACATACCATGCCTGGCT AGCCAGGCATGGTATGTCC 2931 GACATACCATGCCTGGCTC GAGCCAGGCATGGTATGTC 2932 ACATACCATGCCTGGCTCT AGAGCCAGGCATGGTATGT 2933 CATACCATGCCTGGCTCTC GAGAGCCAGGCATGGTATG 2934 ATACCATGCCTGGCTCTCC GGAGAGCCAGGCATGGTAT 2935 TACCATGCCTGGCTCTCCC GGGAGAGCCAGGCATGGTA 2936 ACCATGCCTGGCTCTCCCT AGGGAGAGCCAGGCATGGT 2937 CCATGCCTGGCTCTCCCTG CAGGGAGAGCCAGGCATGG 2938 CATGCCTGGCTCTCCCTGC GCAGGGAGAGCCAGGCATG 2939 ATGCCTGGCTCTCCCTGCA TGCAGGGAGAGCCAGGCAT 2940 TGCCTGGCTCTCCCTGCAA TTGCAGGGAGAGCCAGGCA 2941 GCCTGGCTCTCCCTGCAAA TTTGCAGGGAGAGCCAGGC 2942 CCTGGCTCTCCCTGCAAAA TTTTGCAGGGAGAGCCAGG 2943 CTGGCTCTCCCTGCAAAAC GTTTTGCAGGGAGAGCCAG 2944 TGGCTCTCCCTGCAAAACT AGTTTTGCAGGGAGAGCCA 2945 GGCTCTCCCTGCAAAACTG CAGTTTTGCAGGGAGAGCC 2946 GCTCTCCCTGCAAAACTGG CCAGTTTTGCAGGGAGAGC 2947 CTCTCCCTGCAAAACTGGC GCCAGTTTTGCAGGGAGAG 2948 TCTCCCTGCAAAACTGGCT AGCCAGTTTTGCAGGGAGA 2949 CTCCCTGCAAAACTGGCTC GAGCCAGTTTTGCAGGGAG 2950 TCCCTGCAAAACTGGCTCA TGAGCCAGTTTTGCAGGGA 2951 CCCTGCAAAACTGGCTCAA TTGAGCCAGTTTTGCAGGG 2952 CCTGCAAAACTGGCTCAAT ATTGAGCCAGTTTTGCAGG 2953 CTGCAAAACTGGCTCAATG CATTGAGCCAGTTTTGCAG 2954 TGCAAAACTGGCTCAATGC GCATTGAGCCAGTTTTGCA 2955 GCAAAACTGGCTCAATGCC GGCATTGAGCCAGTTTTGC 2956 CAAAACTGGCTCAATGCCA TGGCATTGAGCCAGTTTTG 2957 AAAACTGGCTCAATGCCAA TTGGCATTGAGCCAGTTTT 2958 AAACTGGCTCAATGCCAAA TTTGGCATTGAGCCAGTTT 2959 AACTGGCTCAATGCCAAAG CTTTGGCATTGAGCCAGTT 2960 ACTGGCTCAATGCCAAAGT ACTTTGGCATTGAGCCAGT 2961 CTGGCTCAATGCCAAAGTT AACTTTGGCATTGAGCCAG 2962 TGGCTCAATGCCAAAGTTG CAACTTTGGCATTGAGCCA 2963 GGCTCAATGCCAAAGTTGT ACAACTTTGGCATTGAGCC 2964 GCTCAATGCCAAAGTTGTG CACAACTTTGGCATTGAGC 2965 CTCAATGCCAAAGTTGTGC GCACAACTTTGGCATTGAG 2966 TCAATGCCAAAGTTGTGCC GGCACAACTTTGGCATTGA 2967 CAATGCCAAAGTTGTGCCC GGGCACAACTTTGGCATTG 2968 AATGCCAAAGTTGTGCCCA TGGGCACAACTTTGGCATT 2969 ATGCCAAAGTTGTGCCCAG CTGGGCACAACTTTGGCAT 2970 TGCCAAAGTTGTGCCCAGG CCTGGGCACAACTTTGGCA 2971 GCCAAAGTTGTGCCCAGGC GCCTGGGCACAACTTTGGC 2972 CCAAAGTTGTGCCCAGGCA TGCCTGGGCACAACTTTGG 2973 CAAAGTTGTGCCCAGGCAG CTGCCTGGGCACAACTTTG 2974 AAAGTTGTGCCCAGGCAGC GCTGCCTGGGCACAACTTT 2975 AAGTTGTGCCCAGGCAGCT AGCTGCCTGGGCACAACTT 2976 AGTTGTGCCCAGGCAGCTG CAGCTGCCTGGGCACAACT 2977 GTTGTGCCCAGGCAGCTGG CCAGCTGCCTGGGCACAAC 2978 TTGTGCCCAGGCAGCTGGA TCCAGCTGCCTGGGCACAA 2979 TGTGCCCAGGCAGCTGGAG CTCCAGCTGCCTGGGCACA 2980 GTGCCCAGGCAGCTGGAGA TCTCCAGCTGCCTGGGCAC 2981 TGCCCAGGCAGCTGGAGAG CTCTCCAGCTGCCTGGGCA 2982 GCCCAGGCAGCTGGAGAGG CCTCTCCAGCTGCCTGGGC 2983 CCCAGGCAGCTGGAGAGGG CCCTCTCCAGCTGCCTGGG 2984 CCAGGCAGCTGGAGAGGGA TCCCTCTCCAGCTGCCTGG 2985 CAGGCAGCTGGAGAGGGAG CTCCCTCTCCAGCTGCCTG 2986 AGGCAGCTGGAGAGGGAGG CCTCCCTCTCCAGCTGCCT 2987 GGCAGCTGGAGAGGGAGGA TCCTCCCTCTCCAGCTGCC 2988 GCAGCTGGAGAGGGAGGAG CTCCTCCCTCTCCAGCTGC 2989 CAGCTGGAGAGGGAGGAGG CCTCCTCCCTCTCCAGCTG 2990 AGCTGGAGAGGGAGGAGGG CCCTCCTCCCTCTCCAGCT 2991 GCTGGAGAGGGAGGAGGGC GCCCTCCTCCCTCTCCAGC 2992 CTGGAGAGGGAGGAGGGCA TGCCCTCCTCCCTCTCCAG 2993 TGGAGAGGGAGGAGGGCAC GTGCCCTCCTCCCTCTCCA 2994 GGAGAGGGAGGAGGGCACG CGTGCCCTCCTCCCTCTCC 2995 GAGAGGGAGGAGGGCACGC GCGTGCCCTCCTCCCTCTC 2996 AGAGGGAGGAGGGCACGCC GGCGTGCCCTCCTCCCTCT 2997 GAGGGAGGAGGGCACGCCT AGGCGTGCCCTCCTCCCTC 2998 AGGGAGGAGGGCACGCCTG CAGGCGTGCCCTCCTCCCT 2999 GGGAGGAGGGCACGCCTGC GCAGGCGTGCCCTCCTCCC 3000 GGAGGAGGGCACGCCTGCC GGCAGGCGTGCCCTCCTCC 3001 GAGGAGGGCACGCCTGCCA TGGCAGGCGTGCCCTCCTC 3002 AGGAGGGCACGCCTGCCAC GTGGCAGGCGTGCCCTCCT 3003 GGAGGGCACGCCTGCCACT AGTGGCAGGCGTGCCCTCC 3004 GAGGGCACGCCTGCCACTC GAGTGGCAGGCGTGCCCTC 3005 AGGGCACGCCTGCCACTCT AGAGTGGCAGGCGTGCCCT 3006 GGGCACGCCTGCCACTCTC GAGAGTGGCAGGCGTGCCC 3007 GGCACGCCTGCCACTCTCA TGAGAGTGGCAGGCGTGCC 3008 GCACGCCTGCCACTCTCAG CTGAGAGTGGCAGGCGTGC 3009 CACGCCTGCCACTCTCAGC GCTGAGAGTGGCAGGCGTG 3010 ACGCCTGCCACTCTCAGCA TGCTGAGAGTGGCAGGCGT 3011 CGCCTGCCACTCTCAGCAA TTGCTGAGAGTGGCAGGCG 3012 GCCTGCCACTCTCAGCAAG CTTGCTGAGAGTGGCAGGC 3013 CCTGCCACTCTCAGCAAGT ACTTGCTGAGAGTGGCAGG 3014 CTGCCACTCTCAGCAAGTG CACTTGCTGAGAGTGGCAG 3015 TGCCACTCTCAGCAAGTGC GCACTTGCTGAGAGTGGCA 3016 GCCACTCTCAGCAAGTGCG CGCACTTGCTGAGAGTGGC 3017 CCACTCTCAGCAAGTGCGG CCGCACTTGCTGAGAGTGG 3018 CACTCTCAGCAAGTGCGGA TCCGCACTTGCTGAGAGTG 3019 ACTCTCAGCAAGTGCGGAG CTCCGCACTTGCTGAGAGT 3020 CTCTCAGCAAGTGCGGAGA TCTCCGCACTTGCTGAGAG 3021 TCTCAGCAAGTGCGGAGAT ATCTCCGCACTTGCTGAGA 3022 CTCAGCAAGTGCGGAGATC GATCTCCGCACTTGCTGAG 3023 TCAGCAAGTGCGGAGATCG CGATCTCCGCACTTGCTGA 3024 CAGCAAGTGCGGAGATCGC GCGATCTCCGCACTTGCTG 3025 AGCAAGTGCGGAGATCGCC GGCGATCTCCGCACTTGCT 3026 GCAAGTGCGGAGATCGCCT AGGCGATCTCCGCACTTGC 3027 CAAGTGCGGAGATCGCCTC GAGGCGATCTCCGCACTTG 3028 AAGTGCGGAGATCGCCTCT AGAGGCGATCTCCGCACTT 3029 AGTGCGGAGATCGCCTCTG CAGAGGCGATCTCCGCACT 3030 GTGCGGAGATCGCCTCTGG CCAGAGGCGATCTCCGCAC 3031 TGCGGAGATCGCCTCTGGG CCCAGAGGCGATCTCCGCA 3032 GCGGAGATCGCCTCTGGGA TCCCAGAGGCGATCTCCGC 3033 CGGAGATCGCCTCTGGGAG CTCCCAGAGGCGATCTCCG 3034 GGAGATCGCCTCTGGGAGG CCTCCCAGAGGCGATCTCC 3035 GAGATCGCCTCTGGGAGGG CCCTCCCAGAGGCGATCTC 3036 AGATCGCCTCTGGGAGGGG CCCCTCCCAGAGGCGATCT 3037 GATCGCCTCTGGGAGGGGA TCCCCTCCCAGAGGCGATC 3038 ATCGCCTCTGGGAGGGGAG CTCCCCTCCCAGAGGCGAT 3039 TCGCCTCTGGGAGGGGAGC GCTCCCCTCCCAGAGGCGA 3040 CGCCTCTGGGAGGGGAGCT AGCTCCCCTCCCAGAGGCG 3041 GCCTCTGGGAGGGGAGCTG CAGCTCCCCTCCCAGAGGC 3042 CCTCTGGGAGGGGAGCTGC GCAGCTCCCCTCCCAGAGG 3043 CTCTGGGAGGGGAGCTGCA TGCAGCTCCCCTCCCAGAG 3044 TCTGGGAGGGGAGCTGCAG CTGCAGCTCCCCTCCCAGA 3045 CTGGGAGGGGAGCTGCAGC GCTGCAGCTCCCCTCCCAG 3046 TGGGAGGGGAGCTGCAGCA TGCTGCAGCTCCCCTCCCA 3047 GGGAGGGGAGCTGCAGCAG CTGCTGCAGCTCCCCTCCC 3048 GGAGGGGAGCTGCAGCAGG CCTGCTGCAGCTCCCCTCC 3049 GAGGGGAGCTGCAGCAGGA TCCTGCTGCAGCTCCCCTC 3050 AGGGGAGCTGCAGCAGGAG CTCCTGCTGCAGCTCCCCT 3051 GGGGAGCTGCAGCAGGAGG CCTCCTGCTGCAGCTCCCC 3052 GGGAGCTGCAGCAGGAGGA TCCTCCTGCTGCAGCTCCC 3053 GGAGCTGCAGCAGGAGGAA TTCCTCCTGCTGCAGCTCC 3054 GAGCTGCAGCAGGAGGAAG CTTCCTCCTGCTGCAGCTC 3055 AGCTGCAGCAGGAGGAAGA TCTTCCTCCTGCTGCAGCT 3056 GCTGCAGCAGGAGGAAGAC GTCTTCCTCCTGCTGCAGC 3057 CTGCAGCAGGAGGAAGACA TGTCTTCCTCCTGCTGCAG 3058 TGCAGCAGGAGGAAGACAC GTGTCTTCCTCCTGCTGCA 3059 GCAGCAGGAGGAAGACACA TGTGTCTTCCTCCTGCTGC 3060 CAGCAGGAGGAAGACACAG CTGTGTCTTCCTCCTGCTG 3061 AGCAGGAGGAAGACACAGC GCTGTGTCTTCCTCCTGCT 3062 GCAGGAGGAAGACACAGCC GGCTGTGTCTTCCTCCTGC 3063 CAGGAGGAAGACACAGCCA TGGCTGTGTCTTCCTCCTG 3064 AGGAGGAAGACACAGCCAC GTGGCTGTGTCTTCCTCCT 3065 GGAGGAAGACACAGCCACC GGTGGCTGTGTCTTCCTCC 3066 GAGGAAGAGACAGCCACCA TGGTGGCTGTGTCTTCCTC 3067 AGGAAGACACAGCCACCAA TTGGTGGCTGTGTCTTCCT 3068 GGAAGACACAGCCACCAAC GTTGGTGGCTGTGTCTTCC 3069 GAAGACACAGCCACCAACT AGTTGGTGGCTGTGTCTTC 3070 AAGACACAGCCACCAACTC GAGTTGGTGGCTGTGTCTT 3071 AGACACAGCCACCAACTCC GGAGTTGGTGGCTGTGTCT 3072 GACACAGCCACCAACTCCA TGGAGTTGGTGGCTGTGTC 3073 ACACAGCCACCAACTCCAG CTGGAGTTGGTGGCTGTGT 3074 CACAGCCACCAACTCCAGC GCTGGAGTTGGTGGCTGTG 3075 ACAGCCACCAACTCCAGCT AGCTGGAGTTGGTGGCTGT 3076 CAGCCACCAACTCCAGCTC GAGCTGGAGTTGGTGGCTG 3077 AGCCACCAACTCCAGCTCT AGAGCTGGAGTTGGTGGCT 3078 GCCACCAACTCCAGCTCTG CAGAGCTGGAGTTGGTGGC 3079 CCACCAACTCCAGCTCTGA TCAGAGCTGGAGTTGGTGG 3080 CACCAACTCCAGCTCTGAG CTCAGAGCTGGAGTTGGTG 3081 ACCAACTCCAGCTCTGAGG CCTCAGAGCTGGAGTTGGT 3082 CCAACTCCAGCTCTGAGGA TCCTCAGAGCTGGAGTTGG 3083 CAACTCCAGCTCTGAGGAA TTCCTCAGAGCTGGAGTTG 3084 AACTCCAGCTCTGAGGAAG CTTCCTCAGAGCTGGAGTT 3085 ACTCCAGCTCTGAGGAAGG CCTTCCTCAGAGCTGGAGT 3086 CTCCAGCTCTGAGGAAGGC GCCTTCCTCAGAGCTGGAG 3087 TCCAGCTCTGAGGAAGGCC GGCCTTCCTCAGAGCTGGA 3088 CCAGCTCTGAGGAAGGCCC GGGCCTTCCTCAGAGCTGG 3089 CAGCTCTGAGGAAGGCCCA TGGGCCTTCCTCAGAGCTG 3090 AGCTCTGAGGAAGGCCCAG CTGGGCCTTCCTCAGAGCT 3091 GCTCTGAGGAAGGCCCAGG CCTGGGCCTTCCTCAGAGC 3092 CTCTGAGGAAGGCCCAGGG CCCTGGGCCTTCCTCAGAG 3093 TCTGAGGAAGGCCCAGGGT ACCCTGGGCCTTCCTCAGA 3094 CTGAGGAAGGCCCAGGGTC GACCCTGGGCCTTCCTCAG 3095 TGAGGAAGGCCCAGGGTCC GGACCCTGGGCCTTCCTCA 3096 GAGGAAGGCCCAGGGTCCG CCGACCCTGGGCCTTCCTC 3097 AGGAAGGCCCAGGGTCCGG CCGGACCCTGGGCCTTCCT 3098 GGAAGGCCCAGGGTCCGGC GCCGGACCCTGGGCCTTCC 3099 GAAGGCCCAGGGTCCGGCC GGCCGGACCCTGGGCCTTC 3100 AAGGCCCAGGGTCCGGCCC GGGCCGGACCCTGGGCCTT 3101 AGGCCCAGGGTCCGGCCCT AGGGCCGGACCCTGGGCCT 3102 GGCCCAGGGTCCGGCCCTG CAGGGCCGGACCCTGGGCC 3103 GCCCAGGGTCCGGCCCTGA TCAGGGCCGGACCCTGGGC 3104 CCCAGGGTCCGGCCCTGAC GTCAGGGCCGGACCCTGGG 3105 CCAGGGTCCGGCCCTGACA TGTCAGGGCCGGACCCTGG 3106 CAGGGTCCGGCCCTGACAG CTGTCAGGGCCGGACCCTG 3107 AGGGTCCGGCCCTGACAGC GCTGTCAGGGCCGGACCCT 3108 GGGTCCGGCCCTGACAGCG GGCTGTCAGGGCCGGACCC 3109 GGTCCGGCCCTGACAGCCG CGGCTGTCAGGGCCGGACC 3110 GTCCGGCCCTGACAGCCGG CCGGCTGTCAGGGCCGGAC 3111 TCCGGCCCTGACAGCCGGC GCCGGCTGTCAGGGCCGGA 3112 CCGGCCCTGACAGCCGGCT AGCCGGCTGTCAGGGCCGG 3113 CGGCCCTGACAGCCGGCTC GAGCCGGCTGTCAGGGCCG 3114 GGCCCTGACAGCCGGCTCA TGAGCCGGCTGTCAGGGCC 3115 GCCCTGACAGCCGGCTCAG CTGAGCCGGCTGTCAGGGC 3116 CCCTGACAGCCGGCTCAGC GCTGAGCCGGCTGTCAGGG 3117 CCTGACAGCCGGCTCAGCA TGCTGAGCCGGCTGTCAGG 3118 CTGACAGCCGGCTCAGCAC GTGCTGAGCCGGCTGTCAG 3119 TGACAGCCGGCTCAGCACA TGTGCTGAGCCGGCTGTCA 3120 GACAGCCGGCTCAGCACAG CTGTGCTGAGCCGGCTGTC 3121 ACAGCCGGCTCAGCACAGG CCTGTGCTGAGCCGGCTGT 3122 CAGCCGGCTCAGCACAGGC GCCTGTGCTGAGCCGGCTG 3123 AGCCGGCTCAGCACAGGCC GGCCTGTGCTGAGCCGGCT 3124 GCCGGCTCAGCACAGGCCT AGGCCTGTGCTGAGCCGGC 3125 CCGGCTCAGCACAGGCCTC GAGGCCTGTGCTGAGCCGG 3126 CGGCTCAGCACAGGCCTCG CGAGGCCTGTGCTGAGCCG 3127 GGCTCAGCACAGGCCTCGC GCGAGGCCTGTGCTGAGCC 3128 GCTCAGCACAGGCCTCGCC GGCGAGGCCTGTGCTGAGC 3129 CTCAGCACAGGCCTCGCCA TGGCGAGGCCTGTGCTGAG 3130 TCAGCACAGGCCTCGCCAA TTGGCGAGGCCTGTGCTGA 3131 CAGCACAGGCCTCGCCAAG CTTGGCGAGGCCTGTGCTG 3132 AGCACAGGCCTCGCCAAGC GCTTGGCGAGGCCTGTGCT 3133 GCACAGGCCTCGCCAAGCA TGCTTGGCGAGGCCTGTGC 3134 CACAGGCCTCGCCAAGCAC GTGCTTGGCGAGGCCTGTG 3135 ACAGGCCTCGCCAAGCACC GGTGCTTGGCGAGGCCTGT 3136 CAGGCCTCGCCAAGCACCT AGGTGCTTGGCGAGGCCTG 3137 AGGCCTCGCCAAGCACCTG CAGGTGCTTGGCGAGGCCT 3138 GGCCTCGCCAAGCACCTGC GCAGGTGCTTGGCGAGGCC 3139 GCCTCGCCAAGCACCTGCT AGCAGGTGCTTGGCGAGGC 3140 CCTCGCCAAGCACCTGCTC GAGCAGGTGCTTGGCGAGG 3141 CTCGCCAAGCACCTGCTCA TGAGCAGGTGCTTGGCGAG 3142 TCGCCAAGCACCTGCTCAG CTGAGCAGGTGCTTGGCGA 3143 CGCCAAGCACCTGCTCAGT ACTGAGCAGGTGCTTGGCG 3144 GCCAAGCACCTGCTCAGTG CACTGAGCAGGTGCTTGGC 3145 CCAAGCACCTGCTCAGTGG CCACTGAGCAGGTGCTTGG 3146 CAAGCACCTGCTCAGTGGT ACCACTGAGCAGGTGCTTG 3147 AAGCACCTGCTCAGTGGTT AACCACTGAGCAGGTCCTT 3148 AGCACCTGCTCAGTGGTTT AAACCACTGAGCAGGTGCT 3149 GCACCTGCTCAGTGGTTTG CAAACCACTGAGCAGGTGC 3150 CACCTGCTCAGTGGTTTGG CCAAACCACTGAGCAGGTG 3151 ACCTGCTCAGTGGTTTGGG CCCAAACCACTGAGCAGGT 3152 CCTGCTCAGTGGTTTGGGG CCCCAAACCACTGAGCAGG 3153 CTGCTCAGTGGTTTGGGGG CCCCCAAACCACTGAGCAG 3154 TGCTCAGTGGTTTGGGGGA TCCCCCAAACCACTGAGCA 3155 GCTCAGTGGTTTGGGGGAC GTCCCCCAAACCACTGAGC 3156 CTCAGTGGTTTGGGGGACC GGTCCCCCAAACCACTGAG 3157 TCAGTGGTTTGGGGGACCG CGGTCCCCCAAACCACTGA 3158 CAGTGGTTTGGGGGACCGA TCGGTCCCCCAAACCACTG 3159 AGTGGTTTGGGGGACCGAC GTCGGTCCCCCAAACCACT 3160 GTGGTTTGGGGGACCGACT AGTCGGTCCCCCAAACCAC 3161 TGGTTTGGGGGACCGACTG CAGTCGGTCCCCCAAACCA 3162 GGTTTGGGGGACCGACTGT ACAGTCGGTCCCCCAAACC 3163 GTTTGGGGGACCGACTGTG CACAGTCGGTCCCCCAAAC 3164 TTTGGGGGACCGACTGTGC GCACAGTCGGTCCCCCAAA 3165 TTGGGGGACCGACTGTGCC GGCACAGTCGGTCCCCCAA 3166 TGGGGGACCGACTGTGCCG CGGCACAGTCGGTCCCCCA 3167 GGGGGACCGACTGTGCCGC GCGGCACAGTCGGTCCCCC 3168 GGGGACCGACTGTGCCGCC GGCGGCACAGTCGGTCCCC 3169 GGGACCGACTGTGCCGCCT AGGCGGCACAGTCGGTCCC 3170 GGACCGACTGTGCCGCCTG CAGGCGGCACAGTCGGTCC 3171 GACCGACTGTGCCGCCTGC GCAGGCGGCACAGTCGGTC 3172 ACCGACTGTGCCGCCTGCT AGCAGGCGGCACAGTCGGT 3173 CCGACTGTGCCGCCTGCTG CAGCAGGCGGCACAGTCGG 3174 CGACTGTGCCGCCTGCTGC GCAGCAGGCGGCACAGTCG 3175 GACTGTGCCGCCTGCTGCG CGCAGCAGGCGGCACAGTC 3176 ACTGTGCCGCCTGCTGCGG CCGCAGCAGGCGGCACAGT 3177 CTGTGCCGCCTGCTGCGGA TCCGCAGCAGGCGGCACAG 3178 TGTGCCGCCTGCTGCGGAG CTCCGCAGCAGGCGGCACA 3179 GTGCCGCCTGCTGCGGAGG CCTCCGCAGCAGGCGGCAC 3180 TGCCGCCTGCTGCGGAGGG CCCTCCGCAGCAGGCGGCA 3181 GCCGCCTGCTGCGGAGGGA TCCCTCCGCAGCAGGCGGC 3182 CCGCCTGCTGCGGAGGGAG CTCCCTCCGCAGCAGGCGG 3183 CGCCTGCTGCGGAGGGAGC GCTCCCTCCGCAGCAGGCG 3184 GCCTGCTGCGGAGGGAGCG CGCTCCCTCCGCAGCAGGC 3185 CCTGCTGCGGAGGGAGCGG CCGCTCCCTCCGCAGCAGG 3186 CTGCTGCGGAGGGAGCGGG CCCGCTCCGTCCGCAGCAG 3187 TGCTGCGGAGGGAGCGGGA TCCCGCTCCCTCCGCAGCA 3188 GCTGCGGAGGGAGCGGGAG CTCCCGCTCCCTCCGCAGC 3189 CTGCGGAGGGAGCGGGAGG CCTCCCGCTCCCTCCGCAG 3190 TGCGGAGGGAGCGGGAGGC GCCTCCCGCTCCCTCCGCA 3191 GCGGAGGGAGCGGGAGGCC GGCCTCCCGCTCCCTCCGC 3192 CGGAGGGAGCGGGAGGCCC GGGCCTCCCGCTCCCTCCG 3193 GGAGGGAGCGGGAGGCCCT AGGGCCTCCCGCTCCCTCC 3194 GAGGGAGCGGGAGGCCCTG CAGGGCCTCCCGCTCCCTC 3195 AGGGAGCGGGAGGCCCTGG CCAGGGCCTCCCGCTCCCT 3196 GGGAGCGGGAGGCCCTGGC GCCAGGGCCTCCCGCTCCC 3197 GGAGCGGGAGGCCCTGGCT AGCCAGGGCCTCCCGCTCC 3198 GAGCGGGAGGCCCTGGCTT AAGCCAGGGCCTCCCGCTC 3199 AGCGGGAGGCCCTGGCTTG CAAGCCAGGGCCTCCCGCT 3200 GCGGGAGGCCCTGGCTTGG CCAAGCCAGGGCCTCCCGC 3201 CGGGAGGCCCTGGCTTGGG CCCAAGCCAGGGCCTCCCG 3202 GGGAGGCCCTGGCTTGGGC GCCCAAGCCAGGGCCTCCC 3203 GGAGGCCCTGGCTTGGGCC GGCCCAAGCCAGGGCCTCC 3204 GAGGCCCTGGCTTGGGCCC GGGCCCAAGCCAGGGCCTC 3205 AGGCCCTGGCTTGGGCCCA TGGGCCCAAGCCAGGGCCT 3206 GGCCCTGGCTTGGGCCCAG CTGGGCCCAAGCCAGGGCC 3207 GCCCTGGCTTGGGCCCAGC GCTGGGCCCAAGCCAGGGC 3208 CCCTGGCTTGGGCCCAGCG CGCTGGGCCCAAGCCAGGG 3209 CCTGGCTTGGGCCCAGCGG CCGCTGGGCCCAAGCCAGG 3210 CTGGCTTGGGCCCAGCGGG CCCGCTGGGCCCAAGCCAG 3211 TGGCTTGGGCCCAGCGGGA TCCCGCTGGGCCCAAGCCA 3212 GGCTTGGGCCCAGCGGGAA TTCCCGCTGGGCCCAAGCC 3213 GCTTGGGCCCAGCGGGAAG CTTCCCGCTGGGCCCAAGC 3214 CTTGGGCCCAGCGGGAAGG CCTTCCCGCTGGGCCCAAG 3215 TTGGGCCCAGCGGGAAGGC GCCTTCCCGCTGGGCCCAA 3216 TGGGCCCAGCGGGAAGGCC GGCCTTCCCGCTGGGCCCA 3217 GGGCCCAGCGGGAAGGCCA TGGCCTTCCCGCTGGGCCC 3218 GGCCCAGCGGGAAGGCCAA TTGGCCTTCCCGCTGGGCC 3219 GCCCAGCGGGAAGGCCAAG CTTGGCCTTCCCGCTGGGC 3220 CCCAGCGGGAAGGCCAAGG CCTTGGCCTTCCCGCTGGG 3221 CCAGCGGGAAGGCCAAGGG CCCTTGGCCTTCCCGCTGG 3222 CAGCGGGAAGGCCAAGGGC GCCCTTGGCCTTCCCGCTG 3223 AGCGGGAAGGCCAAGGGCC GGCCCTTGGCCTTCCCGCT 3224 GCGGGAAGGCCAAGGGCCA TGGCCCTTGGCCTTCCCGC 3225 CGGGAAGGCCAAGGGCCAG CTGGCCCTTGGCCTTCCCG 3226 GGGAAGGCCAAGGGCCAGC GCTGGCCCTTGGCCTTCCC 3227 GGAAGGCCAAGGGCCAGCC GGCTGGCCCTTGGCCTTCC 3228 GAAGGCCAAGGGCCAGCCG CGGCTGGCCCTTGGCCTTC 3229 AAGGCCAAGGGCCAGCCGT ACGGCTGGCCCTTGGCCTT 3230 AGGCCAAGGGCCAGCCGTG CACGGCTGGCCCTTGGCCT 3231 GGCCAAGGGCCAGCCGTGA TCACGGCTGGCCCTTGGCC 3232 GCCAAGGGCCAGCCGTGAC GTCACGGCTGGCCCTTGGC 3233 CCAAGGGCCAGCCGTGACA TGTCACGGCTGGCCCTTGG 3234 CAAGGGCCAGCCGTGACAG CTGTCACGGCTGGCCCTTG 3235 AAGGGCCAGCCGTGACAGA TCTGTCACGGCTGGCCCTT 3236 AGGGCCAGCCGTGACAGAG CTCTGTCACGGCTGGCCCT 3237 GGGCCAGCCGTGACAGAGG CCTCTGTCACGGCTGGCCC 3238 GGCCAGCCGTGACAGAGGA TCCTCTGTCACGGCTGGCC 3239 GCCAGCCGTGACAGAGGAC GTCCTCTGTCACGGCTGGC 3240 CCAGCCGTGACAGAGGACA TGTCCTCTGTCACGGCTGG 3241 CAGCCGTGACAGAGGACAG CTGTCCTCTGTCACGGCTG 3242 AGCCGTGACAGAGGACAGC GCTGTCCTCTGTCACGGCT 3243 GCCGTGACAGAGGACAGCC GGCTGTCCTCTGTCACGGC 3244 CCGTGACACAGGACAGCCC GGGCTGTCCTCTGTCACGG 3245 CGTGACAGAGGACAGCCCA TGGGCTGTCCTCTGTCACG 3246 GTGACAGAGGACAGCCCAG CTGGGCTGTCCTCTGTCAC 3247 TGACAGAGGACAGCCCAGG CCTGGGCTGTCCTCTGTCA 3248 GACAGAGGACAGCCCAGGC GCCTGGGCTGTCCTCTGTC 3249 ACAGAGGACAGCCCAGGCA TGCCTGGGCTGTCCTCTGT 3250 CAGAGGACAGCCCAGGCAT ATGCCTGGGCTGTCCTCTG 3251 AGAGGACAGCCCAGGCATT AATGCCTGGGCTGTCCTCT 3252 GAGGACAGCCCAGGCATTC GAATGCCTGGGCTGTCCTC 3253 AGGACAGCCCAGGCATTCC GGAATGCCTGGGCTGTCCT 3254 GGACAGCCCAGGCATTCCA TGGAATGCCTGGGCTGTCC 3255 GACAGCCCAGGCATTCCAC GTGGAATGCCTGGGCTGTC 3256 ACAGCCCAGGCATTCCACG CGTGGAATGCCTGGGCTGT 3257 CAGCCCAGGCATTCCACGC GCGTGGAATGCCTGGGCTG 3258 AGCCCAGGCATTCCACGCT AGCGTGGAATGCCTGGGCT 3259 GCCCAGGCATTCCACGCTG CAGCGTGGAATGCCTGGGC 3260 CCCAGGCATTCCACGCTGC GCAGCGTGGAATGCCTGGG 3261 CCAGGCATTCCACGCTGCT AGCAGCGTGGAATGCCTGG 3262 CAGGCATTCCACGCTGCTG CAGCAGCGTGGAATGCCTG 3263 AGGCATTCCACGCTGCTGC GCAGCAGCGTGGAATGCCT 3264 GGCATTCCACGCTGCTGCA TGCAGCAGCGTGGAATGCC 3265 GCATTCCACGCTGCTGCAG CTGCAGCAGCGTGGAATGC 3266 CATTCCACGCTGCTGCAGC GCTGCAGCAGCGTGGAATG 3267 ATTCCACGCTGCTGCAGCC GGCTGCAGCAGCGTGGAAT 3268 TTCCACGCTGCTGCAGCCG CGGCTGCAGCAGCGTGGAA 3269 TCCACGCTGCTGCAGCCGT ACGGCTGCAGCAGCGTGGA 3270 CCACGCTGCTGCAGCCGTT AACGGCTGCAGCAGCGTGG 3271 CACGCTGCTGCAGCCGTTG CAACGGCTGCAGCAGCGTG 3272 ACGCTGCTGCAGCCGTTGC GCAACGGCTGCAGCAGCGT 3273 CGCTGCTGCAGCCGTTGCC GGCAACGGCTGCAGCAGCG 3274 GCTGCTGCAGCCGTTGCCA TGGCAACGGCTGCAGCAGC 3275 CTGCTGCAGCCGTTGCCAC GTGGCAACGGCTGCAGCAG 3276 TGCTGCAGCCGTTGCCACC GGTGGCAACGGCTGCAGCA 3277 GCTGCAGCCGTTGCCACCA TGGTGGCAACGGCTGCAGC 3278 CTGCAGCCGTTGCCACCAT ATGGTGGCAACGGCTGCAG 3279 TGCAGCCGTTGCCACCATG CATGGTGGCAACGGCTGCA 3280 GCAGCCGTTGCCACCATGG CCATGGTGGCAACGGCTGC 3281 CAGCCGTTGCCACCATGGA TCCATGGTGGCAACGGCTG 3282 AGCCGTTGCCACCATGGAC GTCCATGGTGGCAACGGCT 3283 GCCGTTGCCACCATGGACT AGTCCATGGTGGCAAGGGC 3284 CCGTTGCCACCATGGACTC GAGTCCATGGTGGCAACGG 3285 CGTTGCCACCATGGACTCT AGAGTCCATGGTGGCAACG 3286 GTTGCCACCATGGACTCTT AAGAGTCCATGGTGGCAAC 3287 TTGCCACCATGGACTCTTC GAAGAGTCCATGGTGGCAA 3288 TGCCACCATGGACTCTTCA TGAAGAGTCCATGGTGGCA 3289 GCCACCATGGACTCTTCAA TTGAAGAGTCCATGGTGGC 3290 CCACCATGGACTCTTCAAC GTTGAAGAGTCCATGGTGG 3291 CACCATGGACTCTTCAACA TGTTGAAGAGTCCATGGTG 3292 ACCATGGACTCTTCAACAC GTGTTGAAGAGTCCATGGT 3293 CCATGGACTCTTCAACACC GGTGTTGAAGAGTCCATGG 3294 CATGGACTCTTCAACACCC GGGTGTTGAAGAGTCCATG 3295 ATGGACTCTTCAACACCCA TGGGTGTTGAAGAGTCCAT 3296 TGGACTCTTCAACACCCAC GTGGGTGTTGAAGAGTCCA 3297 GGACTCTTCAACACCCACT AGTGGGTGTTGAAGAGTCC 3298 GACTCTTCAACACCCACTG CAGTGGGTGTTGAAGAGTC 3299 ACTCTTCAACACCCACTGG CCAGTGGGTGTTGAAGAGT 3300 CTCTTCAACACCCACTGGC GCCAGTGGGTGTTGAAGAG 3301 TCTTCAACACCCACTGGCG CGCCAGTGGGTGTTGAAGA 3302 CTTCAACACCCACTGGCGA TCGCCAGTGGGTGTTGAAG 3303 TTCAACACCCACTGGCGAT ATCGCCAGTGGGTGTTGAA 3304 TCAACACCCACTGGCGATG CATCGCCAGTGGGTGTTGA 3305 CAACACCCACTGGCGATGT ACATCGCCAGTGGGTGTTG 3306 AACACCCACTGGCGATGTC GACATCGCCAGTGGGTGTT 3307 ACACCCACTGGCGATGTCC GGACATCGCCAGTGGGTGT 3308 CACCCACTGGCGATGTCCC GGGACATCGCCAGTGGGTG 3309 ACCCACTGGCGATGTCCCC GGGGACATCGCCAGTGGGT 3310 CCCACTGGCGATGTCCCCG CGGGGACATCGCCAGTGGG 3311 CCACTGGCGATGTCCCCGC GCGGGGACATCGCCAGTGG 3312 CACTGGCGATGTCCCCGCT AGCGGGGACATCGCCAGTG 3313 ACTGGCGATGTCCCCGCTG CAGCGGGGACATCGCCAGT 3314 CTGGCGATGTCCCCGCTGC GCAGCGGGGACATCGCCAG 3315 TGGCGATGTCCCCGCTGCA TGCAGCGGGGACATCGCCA 3316 GGCGATGTCCCCGCTGCAG CTGCAGCGGGGACATCGCC 3317 GCGATGTCCCCGCTGCAGC GCTGCAGCGGGGACATCGC 3318 CGATGTCCCCGCTGCAGCC GGCTGCAGCGGGGACATCG 3319 GATGTCCCCGCTGCAGCCA TGGCTGCAGCGGGGACATC 3320 ATGTCCCCGCTGCAGCCAC GTGGCTGCAGCGGGGACAT 3321 TGTCCCCGCTGCAGCCACC GGTGGCTGCAGCGGGGACA 3322 GTCCCCGCTGCAGCCACCG CGGTGGCTGCAGCGGGGAC 3323 TCCCCGCTGCAGCCACCGG CCGGTGGCTGCAGCGGGGA 3324 CCCCGCTGCAGCCACCGGC GCCGGTGGCTGCAGCGGGG 3325 CCCGCTGCAGCCACCGGCT AGCCGGTGGCTGCAGCGGG 3326 CCGCTGCAGCCACCGGCTG CAGCCGGTGGCTGCAGCGG 3327 CGCTGCAGCCACCGGCTGT ACAGCCGGTGGCTGCAGCG 3328 GCTGCAGCCACCGGCTGTG CACAGCCGGTGGCTGCAGC 3329 CTGCAGCCACCGGCTGTGT ACACAGCCGGTGGCTGCAG 3330 TGCAGCCACCGGCTGTGTG CACACAGCCGGTGGCTGCA 3331 GCAGCCACCGGCTGTGTGT ACACACAGCCGGTGGCTGC 3332 CAGCCACCGGCTGTGTGTG CACACACAGCCGGTGGCTG 3333 AGCCACCGGCTGTGTGTGG CCACACACAGCCGGTGGCT 3334 GCCACCGGCTGTGTGTGGC GCCACACACAGCCGGTGGC 3335 CCACCGGCTGTGTGTGGCC GGCCACACACAGCCGGTGG 3336 CACCGGCTGTGTGTGGCCT AGGCCACACACAGCCGGTG 3337 ACCGGCTGTGTGTGGCCTG CAGGCCACACACAGCCGGT 3338 CCGGCTGTGTGTGGCCTGT ACAGGCCACACACAGCCGG 3339 CGGCTGTGTGTGGCCTGTG CACAGGCCACACACAGCCG 3340 GGCTGTGTGTGGCCTGTGG CCACAGGCCACACACAGCC 3341 GCTGTGTGTGGCCTGTGGT ACCACAGGCCACACACAGC 3342 CTGTGTGTGGCCTGTGGTC GACCACAGGCCACACACAG 3343 TGTGTGTGGCCTGTGGTCG CGACCACAGGCCACACACA 3344 GTGTGTGGCCTGTGGTCGT ACGACCACAGGCCACACAC 3345 TGTGTGGCCTGTGGTCGTG CACGACCACAGGCCACACA 3346 GTGTGGCCTGTGGTCGTGT ACACGACCACAGGCCACAC 3347 TGTGGCCTGTGGTCGTGTG CACACGACCACAGGCCACA 3348 GTGGCCTGTGGTCGTGTGG CCACACGACCACAGGCCAC 3349 TGGCCTGTGGTCGTGTGGC GCCACACGACCACAGGCCA 3350 GGCCTGTGGTCGTGTGGCA TGCCACACGACCACAGGCC 3351 GCCTGTGGTCGTGTGGCAG CTGCCACACGACCACAGGC 3352 CCTGTGGTCGTGTGGCAGG CCTGCCACACGACCACAGG 3353 CTGTGGTCGTGTGGCAGGC GCCTGCCACACGACCACAG 3354 TGTGGTCGTGTGGCAGGCA TGCCTGCCACACGACCACA 3355 GTGGTCGTGTGGCAGGCAC GTGCCTGCCACACGACCAC 3356 TGGTCGTGTGGCAGGCACT AGTGCCTGCCACACGACCA 3357 GGTCGTGTGGCAGGCACTG CAGTGCCTGCCACACGACC 3358 GTCGTGTGGCAGGCACTGG CCAGTGCCTGCCACACGAC 3359 TCGTGTGGCAGGCACTGGG CCCAGTGCCTGCCACACGA 3360 CGTGTGGCAGGCACTGGGC GCCCAGTGCCTGCCACACG 3361 GTGTGGCAGGCACTGGGCG CGCCCAGTGCCTGCCACAC 3362 TGTGGCAGGCACTGGGCGG CCGCCCAGTGCCTGCCACA 3363 GTGGCAGGCACTGGGCGGG CCCGCCCAGTGCCTGCCAC 3364 TGGCAGGCACTGGGCGGGC GCCCGCCCAGTGCCTGCCA 3365 GGCAGGCACTGGGCGGGCC GGCCCGCCCAGTGCCTGCC 3366 GCAGGCACTGGGCGGGCCA TGGCCCGCCCAGTGCCTGC 3367 CAGGCACTGGGCGGGCCAG CTGGCCCGCCCAGTGCCTG 3368 AGGCACTGGGCGGGCCAGG CCTGGCCCGCCCAGTGCCT 3369 GGCACTGGGCGGGCCAGGG CCCTGGCCCGCCCAGTGCC 3370 GCACTGGGCGGGCCAGGGA TCCCTGGCCCGCCCAGTGC 3371 CACTGGGCGGGCCAGGGAG CTCCCTGGCCCGCCCAGTG 3372 ACTGGGCGGGCCAGGGAGA TCTCCCTGGCCCGCCCAGT 3373 CTGGGCGGGCCAGGGAGAA TTCTCCCTGGCCCGCCCAG 3374 TGGGCGGGCCAGGGAGAAA TTTCTCCCTGGCCCGCCCA 3375 GGGCGGGCCAGGGAGAAAG CTTTCTCCCTGGCCCGCCC 3376 GGCGGGCCAGGGAGAAAGC GCTTTCTCCCTGGCCCGCC 3377 GCGGGCCAGGGAGAAAGCA TGCTTTCTCCCTGGCCCGC 3378 CGGGCCAGGGAGAAAGCAG CTGCTTTCTCCCTGGCCCG 3379 GGGCCAGGGAGAAAGCAGG CCTGCTTTCTCCCTGGCCC 3380 GGCCAGGGAGAAAGCAGGC GCCTGCTTTCTCCCTGGCC 3381 GCCAGGGAGAAAGCAGGCT AGCCTGCTTTCTCCCTGGC 3382 CCAGGGAGAAAGCAGGCTT AAGCCTGCTTTCTCCCTGG 3383 CAGGGAGAAAGCAGGCTTT AAAGCCTGCTTTCTCCCTG 3384 AGGGAGAAAGCAGGCTTTC GAAAGCCTGCTTTCTCCCT 3385 GGGAGAAAGCAGGCTTTCA TGAAAGCCTGCTTTCTCCC 3386 GGAGAAAGCAGGCTTTCAG CTGAAAGCCTGCTTTCTCC 3387 GAGAAAGCAGGCTTTCAGG CCTGAAAGCCTGCTTTCTC 3388 AGAAAGCAGGCTTTCAGGA TCCTGAAAGCCTGCTTTCT 3389 GAAAGCAGGCTTTCAGGAG CTCCTGAAAGCCTGCTTTC 3390 AAAGCAGGCTTTCAGGAGC GCTCCTGAAAGCCTGCTTT 3391 AAGCAGGCTTTCAGGAGCA TGCTCCTGAAAGCCTGCTT 3392 AGCAGGCTTTCAGGAGCAG CTGCTCCTGAAAGCCTGCT 3393 GCAGGCTTTCAGGAGCAGT ACTGCTCCTGAAAGCCTGC 3394 CAGGCTTTCAGGAGCAGTC GACTGCTCCTGAAAGCCTG 3395 AGGCTTTCAGGAGCAGTCC GGACTGCTCCTGAAAGCCT 3396 GGCTTTCAGGAGCAGTCCG CGGACTGCTCCTGAAAGCC 3397 GCTTTCAGGAGCAGTCCGC GCGGACTGCTCCTGAAAGC 3398 CTTTCAGGAGCAGTCCGCG CGCGGACTGCTCCTGAAAG 3399 TTTCAGGAGCAGTCCGCGG CCGCGGACTGCTCCTGAAA 3400 TTCAGGAGCAGTCCGCGGA TCCGCGGACTGCTCCTGAA 3401 TCAGGAGCAGTCCGCGGAG CTCCGCGGACTGCTCCTGA 3402 CAGGAGCAGTCCGCGGAGG CCTCCGCGGACTGCTCCTG 3403 AGGAGCAGTCCGCGGAGGA TCCTCCGCGGACTGCTCCT 3404 GGAGCAGTCCGCGGAGGAG CTCCTCCGCGGACTGCTCC 3405 GAGCAGTCCGCGGAGGAGT ACTCCTCCGCGGACTGCTC 3406 AGCAGTCCGCGGAGGAGTG CACTCCTCCGCGGACTGCT 3407 GCAGTCCGCGGAGGAGTGC GCACTCCTCCGCGGACTGC 3408 CAGTCCGCGGAGGAGTGCA TGCACTCCTCCGCGGACTG 3409 AGTCCGCGGAGGAGTGCAC GTGCACTCCTCCGCGGACT 3410 GTCCGCGGAGGAGTGCACG CGTGCACTCCTCCGCGGAC 3411 TCCGCGGAGGAGTGCACGC GCGTGCACTCCTCCGCGGA 3412 CCGCGGAGGAGTGCACGCA TGCGTGCACTCCTCCGCGG 3413 CGCGGAGGAGTGCACGCAG CTGCGTGCACTCCTCCGCG 3414 GCGGAGGAGTGCACGCAGG CCTGCGTGCACTCCTCCGC 3415 CGGAGGAGTGCACGCAGGA TCCTGCGTGCACTCCTCCG 3416 GGAGGAGTGCACGCAGGAG CTCCTGCGTGCACTCCTCC 3417 GAGGAGTGCACGCAGGAGG CCTCCTGCGTGCACTCCTC 3418 AGGAGTGCACGCAGGAGGC GCCTCCTGCGTGCACTCCT 3419 GGAGTGCACGCAGGAGGCC GGCCTCCTGCGTGCACTCC 3420 GAGTGCACGCAGGAGGCCG CGGCCTCCTGCGTGCACTC 3421 AGTGCACGCAGGAGGCCGG CCGGCCTCCTGCGTGCACT 3422 GTGCACGCAGGAGGCCGGG CCCGGCCTCCTGCGTGCAC 3423 TGCACGCAGGAGGCCGGGC GCCCGGCCTCCTGCGTGCA 3424 GCACGCAGGAGGCCGGGCA TGCCCGGCCTCCTGCGTGC 3425 CACGCAGGAGGCCGGGCAC GTGCCCGGCCTCCTGCGTG 3426 ACGCAGGAGGCCGGGCACG CGTGCCCGGCCTCCTGCGT 3427 CGCAGGAGGCCGGGCACGC GCGTGCCCGGCCTCCTGCG 3428 GCAGGAGGCCGGGCACGCT AGCGTGCCCGGCCTCCTGC 3429 CAGGAGGCCGGGCACGCTG CAGCGTGCCCGGCCTCCTG 3430 AGGAGGCCGGGCACGCTGC GCAGCGTGCCCGGCCTCCT 3431 GGAGGCCGGGCACGCTGCC GGCAGCGTGCCCGGCCTCC 3432 GAGGCCGGGCACGCTGCCT AGGCAGCGTGCCCGGCCTC 3433 AGGCCGGGCACGCTGCCTG CAGGCAGCGTGCCCGGCCT 3434 GGCCGGGCACGCTGCCTGT ACAGGCAGCGTGCCCGGCC 3435 GCCGGGCACGCTGCCTGTT AACAGGCAGCGTGCCCGGC 3436 CCGGGCACGCTGCCTGTTC GAACAGGCAGCGTGCCCGG 3437 CGGGCACGCTGCCTGTTCC GGAACAGGCAGCGTGCCCG 3438 GGGCACGCTGCCTGTTCCC GGGAACAGGCAGCGTGCCC 3439 GGCACGCTGCCTGTTCCCT AGGGAACAGGCAGCGTGCC 3440 GCACGCTGCCTGTTCCCTG CAGGGAACAGGCAGCGTGC 3441 CACGCTGCCTGTTCCCTGA TCAGGGAACAGGCAGCGTG 3442 ACGCTGCCTGTTCCCTGAT ATCAGGGAACAGGCAGCGT 3443 CGCTGCCTGTTCCCTGATG CATCAGGGAACAGGCAGCG 3444 GCTGCCTGTTCCCTGATGC GCATCAGGGAACAGGCAGC 3445 CTGCCTGTTCCCTGATGCT AGCATCAGGGAACAGGCAG 3446 TGCCTGTTCCCTGATGCTG CAGCATCAGGGAACAGGCA 3447 GCCTGTTCCCTGATGCTGA TCAGCATCAGGGAACAGGC 3448 CCTGTTCCCTGATGCTGAC GTCAGCATCAGGGAACAGG 3449 CTGTTCCCTGATGCTGACC GGTCAGCATCAGGGAACAG 3450 TGTTCCCTGATGCTGACCC GGGTCAGCATCAGGGAACA 3451 GTTCCCTGATGCTGACCCA TGGGTCAGCATCAGGGAAC 3452 TTCCCTGATGCTGACCCAG CTGGGTCAGCATCAGGGAA 3453 TCCCTGATGCTGACCCAGT ACTGGGTCAGCATCAGGGA 3454 CCCTGATGCTGACCCAGTT AACTGGGTCAGCATCAGGG 3455 CCTGATGCTGACCCAGTTT AAACTGGGTCAGCATCAGG 3456 CTGATGCTGACCCAGTTTG CAAACTGGGTCAGCATCAG 3457 TGATGCTGACCCAGTTTGT ACAAACTGGGTCAGCATCA 3458 GATGCTGACCCAGTTTGTC GACAAACTGGGTCAGCATC 3459 ATGCTGACCCAGTTTGTCT AGACAAACTGGGTCAGCAT 3460 TGCTGACCCAGTTTGTCTC GAGACAAACTGGGTCAGCA 3461 GCTGACCCAGTTTGTCTCC GGAGACAAACTGGGTCAGC 3462 CTGACCCAGTTTGTCTCCA TGGAGACAAACTGGGTCAG 3463 TGACCCAGTTTGTCTCCAG CTGGAGACAAACTGGGTCA 3464 GACCCAGTTTGTCTCCAGC GCTGGAGACAAACTGGGTC 3465 ACCCAGTTTGTCTCCAGCC GGCTGGAGACAAACTGGGT 3466 CCCAGTTTGTCTCCAGCCA TGGCTGGAGACAAACTGGG 3467 CCAGTTTGTCTCCAGCCAG CTGGCTGGAGACAAACTGG 3468 CAGTTTGTCTCCAGCCAGG CCTGGCTGGAGACAAACTG 3469 AGTTTGTCTCCAGCCAGGC GCCTGGCTGGAGACAAACT 3470 GTTTGTCTCCAGCCAGGCT AGCCTGGCTGGAGACAAAC 3471 TTTGTCTCCAGCCAGGCTT AAGCCTGGCTGGAGACAAA 3472 TTGTCTCCAGCCAGGCTTT AAAGCCTGGCTGGAGACAA 3473 TGTCTCCAGCCAGGCTTTG CAAAGCCTGGCTGGAGACA 3474 GTCTCCAGCCAGGCTTTGG CCAAAGCCTGGCTGGAGAC 3475 TCTCCAGCCAGGCTTTGGC GCCAAAGCCTGGCTGGAGA 3476 CTCCAGCCAGGCTTTGGCA TGCCAAAGCCTGGCTGGAG 3477 TCCAGCCAGGCTTTGGCAG CTGCCAAAGCCTGGCTGGA 3478 CCAGCCAGGCTTTGGCAGA TCTGCCAAAGCCTGGCTGG 3479 CAGCCAGGCTTTGGCAGAG CTCTGCCAAAGCCTGGCTG 3480 AGCCAGGCTTTGGCAGAGC GCTCTGCCAAAGCCTGGCT 3481 GCCAGGCTTTGGCAGAGCT AGCTCTGCCAAAGCCTGGC 3482 CCAGGCTTTGGCAGAGCTG CAGCTCTGCCAAAGCCTGG 3483 CAGGCTTTGGCAGAGCTGA TCAGCTCTGCCAAAGCCTG 3484 AGGCTTTGGCAGAGCTGAG CTCAGCTCTGCCAAAGCCT 3485 GGCTTTGGCAGAGCTGAGC GCTCAGCTCTGCCAAAGCC 3486 GCTTTGGCAGAGCTGAGCA TGCTCAGCTCTGCCAAAGC 3487 CTTTGGCAGAGCTGAGCAC GTGCTCAGCTCTGCCAAAG 3488 TTTGGCAGAGCTGAGCACT AGTGCTCAGCTCTGCCAAA 3489 TTGGCAGAGCTGAGCACTG CAGTGCTCAGCTCTGCCAA 3490 TGGCAGAGCTGAGCACTGC GCAGTGCTCAGCTCTGCCA 3491 GGCAGAGCTGAGCACTGCA TGCAGTGCTCAGCTCTGCC 3492 GCAGAGCTGAGCACTGCAA TTGCAGTGCTCAGCTCTGC 3493 CAGAGCTGAGCACTGCAAT ATTGCAGTGCTCAGCTCTG 3494 AGAGCTGAGCACTGCAATG CATTGCAGTGCTCAGCTCT 3495 GAGCTGAGCACTGCAATGC GCATTGCAGTGCTCAGCTC 3496 AGCTGAGCACTGCAATGCA TGCATTGCAGTGCTCAGCT 3497 GCTGAGCACTGCAATGCAC GTGCATTGCAGTGCTCAGC 3498 CTGAGCACTGCAATGCACC GGTGCATTGCAGTGCTCAG 3499 TGAGCACTGCAATGCACCA TGGTGCATTGCAGTGCTCA 3500 GAGCACTGCAATGCACCAG CTGGTGCATTGCAGTGCTC 3501 AGCACTGCAATGCACCAGG CCTGGTGCATTGCAGTGCT 3502 GCACTGCAATGCACCAGGT ACCTGGTGCATTGCAGTGC 3503 CACTGCAATGCACCAGGTC GACCTGGTGCATTGCAGTG 3504 ACTGCAATGCACCAGGTCT AGACCTGGTGCATTGCAGT 3505 CTGCAATGCACCAGGTCTG CAGACCTGGTGCATTGCAG 3506 TGCAATGCACCAGGTCTGG CCAGACCTGGTGCATTGCA 3507 GCAATGCACCAGGTCTGGG CCCAGACCTGGTGCATTGC 3508 CAATGCACCAGGTCTGGGT ACCCAGACCTGGTGCATTG 3509 AATGCACCAGGTCTGGGTC GACCCAGACCTGGTGCATT 3510 ATGCACCAGGTCTGGGTCA TGACCCAGACCTGGTGCAT 3511 TGCACCAGGTCTGGGTCAA TTGACCCAGACCTGGTGCA 3512 GCACCAGGTCTGGGTCAAG CTTGACCCAGACCTGGTGC 3513 CACCAGGTCTGGGTCAAGT ACTTGACCCAGACCTGGTG 3514 ACCAGGTCTGGGTCAAGTT AACTTGACCCAGACCTGGT 3515 CCAGGTCTGGGTCAAGTTT AAACTTGACCCAGACCTGG 3516 CAGGTCTGGGTCAAGTTTG CAAACTTGACCCAGACCTG 3517 AGGTCTGGGTCAAGTTTGA TCAAACTTGACCCAGACCT 3518 GGTCTGGGTCAAGTTTGAT ATCAAACTTGACCCAGACC 3519 GTCTGGGTCAAGTTTGATA TATCAAACTTGACCCAGAC 3520 TCTGGGTCAAGTTTGATAT ATATCAAACTTGACCCAGA 3521 CTGGGTCAAGTTTGATATC GATATCAAACTTGACCCAG 3522 TGGGTCAAGTTTGATATCC GGATATCAAACTTGACCCA 3523 GGGTCAAGTTTGATATCCG CGGATATCAAACTTGACCC 3524 GGTCAAGTTTGATATCCGG CCGGATATCAAACTTGACC 3525 GTCAAGTTTGATATCCGGG CCCGGATATCAAACTTGAC 3526 TCAAGTTTGATATCCGGGG CCCCGGATATCAAACTTGA 3527 CAAGTTTGATATCCGGGGG CCCCCGGATATCAAACTTG 3528 AAGTTTGATATCCGGGGGC GCCCCCGGATATCAAACTT 3529 AGTTTGATATCCGGGGGCA TGCCCCCGGATATCAAACT 3530 GTTTGATATCCGGGGGCAC GTGCCCCCGGATATCAAAC 3531 TTTGATATCCGGGGGCACT AGTGCCCCCGGATATCAAA 3532 TTGATATCCGGGGGCACTG CAGTGCCCCCGGATATCAA 3533 TGATATCCGGGGGCACTGC GCAGTGCCCCCGGATATCA 3534 GATATCCGGGGGCACTGCC GGCAGTGCCCCCGGATATC 3535 ATATCCGGGGGCACTGCCC GGGCAGTGCCCCCGGATAT 3536 TATCCGGGGGCACTGCCCC GGGGCAGTGCCCCCGGATA 3537 ATCCGGGGGCACTGCCCCT AGGGGCAGTGCCCCCGGAT 3538 TCCGGGGGCACTGCCCCTG CAGGGGCAGTGCCCCCGGA 3539 CCGGGGGCACTGCCCCTGC GCAGGGGCAGTGCCCCCGG 3540 CGGGGGCACTGCCCCTGCC GGCAGGGGCAGTGCCCCCG 3541 GGGGGCACTGCCCCTGCCA TGGCAGGGGCAGTGCCCCC 3542 GGGGCACTGCCCCTGCCAA TTGGCAGGGGCAGTGCCCC 3543 GGGCACTGCCCCTGCCAAG CTTGGCAGGGGCAGTGCCC 3544 GGCACTGCCCCTGCCAAGC GCTTGGCAGGGGCAGTGCC 3545 GCACTGCCCCTGCCAAGCT AGCTTGGCAGGGGCAGTGC 3546 CACTGCCCCTGCCAAGCTG CAGCTTGGCAGGGGCAGTG 3547 ACTGCCCCTGCCAAGCTGA TCAGCTTGGCAGGGGCAGT 3548 CTGCCCCTGCCAAGCTGAT ATCAGCTTGGCAGGGGCAG 3549 TGCCCCTGCCAAGCTGATG CATCAGCTTGGCAGGGGCA 3550 GCCCCTGCCAAGCTGATGC GCATCAGCTTGGCAGGGGC 3551 CCCCTGCCAAGCTGATGCC GGCATCAGCTTGGCAGGGG 3552 CCCTGCCAAGCTGATGCCC GGGCATCAGCTTGGCAGGG 3553 CCTGCCAAGCTGATGCCCG CGGGCATCAGCTTGGCAGG 3554 CTGCCAAGCTGATGCCCGG CCGGGCATCAGCTTGGCAG 3555 TGCCAAGCTGATGCCCGGG CCCGGGCATCAGCTTGGCA 3556 GCCAAGCTGATGCCCGGGT ACCCGGGCATCAGCTTGGC 3557 CCAAGCTGATGCCCGGGTA TACCCGGGCATCAGCTTGG 3558 CAAGCTGATGCCCGGGTAT ATACCCGGGCATCAGCTTG 3559 AAGCTGATGCCCGGGTATG CATACCCGGGCATCAGCTT 3560 AGCTGATGCCCGGGTATGG CCATACCCGGGCATCAGCT 3561 GCTGATGCCCGGGTATGGG CCCATACCCGGGCATCAGC 3562 CTGATGCCCGGGTATGGGC GCCCATACCCGGGCATCAG 3563 TGATGCCCGGGTATGGGCC GGCCCATACCCGGGCATCA 3564 GATGCCCGGGTATGGGCCC GGGCCCATACCCGGGCATC 3565 ATGCCCGGGTATGGGCCCC GGGGCCCATACCCGGGCAT 3566 TGCCCGGGTATGGGCCCCC GGGGGCCCATACCCGGGCA 3567 GCCCGGGTATGGGCCCCCG CGGGGGCCCATACCCGGGC 3568 CCCGGGTATGGGCCCCCGG CCGGGGGCCCATACCCGGG 3569 CCGGGTATGGGCCCCCGGG CCCGGGGGCCCATACCCGG 3570 CGGGTATGGGCCCCCGGGG CCCCGGGGGCCCATACCCG 3571 GGGTATGGGCCCCCGGGGA TCCCCGGGGGCCCATACCC 3572 GGTATGGGCCCCCGGGGAT ATCCCCGGGGGCCCATACC 3573 GTATGGGCCCCCGGGGATG CATCCCCGGGGGCCCATAC 3574 TATGGGCCCCCGGGGATGC GCATCCCCGGGGGCCCATA 3575 ATGGGCCCCCGGGGATGCA TGCATCCCCGGGGGCCCAT 3576 TGGGCCCCCGGGGATGCAG CTGCATCCCCGGGGGCCCA 3577 GGGCCCCCGGGGATGCAGG CCTGCATCCCCGGGGGCCC 3578 GGCCCCCGGGGATGCAGGC GCCTGCATCCCCGGGGGCC 3579 GCCCCCGGGGATGCAGGCC GGCCTGCATCCCCGGGGGC 3580 CCCCCGGGGATGCAGGCCA TGGCCTGCATCCCCGGGGG 3581 CCCCGGGGATGCAGGCCAG CTGGCCTGCATCCCCGGGG 3582 CCCGGGGATGCAGGCCAGC GCTGGCCTGCATCCCCGGG 3583 CCGGGGATGCAGGCCAGCA TGCTGGCCTGCATCCCCGG 3584 CGGGGATGCAGGCCAGCAG CTGCTGGCCTGCATCCCCG 3585 GGGGATGCAGGCCAGCAGA TCTGCTGGCCTGCATCCCC 3586 GGGATGCAGGCCAGCAGAA TTCTGCTGGCCTGCATCCC 3587 GGATGCAGGCCAGCAGAAG CTTCTGCTGGCCTGCATCC 3588 GATGCAGGCCAGCAGAAGG CCTTCTGCTGGCCTGCATC 3589 ATGCAGGCCAGCAGAAGGA TCCTTCTGCTGGCCTGCAT 3590 TGCAGGCCAGCAGAAGGAA TTCCTTCTGCTGGCCTGCA 3591 GCAGGCCAGCAGAAGGAAT ATTCCTTCTGCTGGCCTGC 3592 CAGGCCAGCAGAAGGAATC GATTCCTTCTGCTGGCCTG 3593 AGGCCAGCAGAAGGAATCA TGATTCCTTCTGCTGGCCT 3594 GGCCAGCAGAAGGAATCAA TTGATTCCTTCTGCTGGCC 3595 GCCAGCAGAAGGAATCAAC GTTGATTCCTTCTGCTGGC 3596 CCAGCAGAAGGAATCAACA TGTTGATTCCTTCTGCTGG 3597 CAGCAGAAGGAATCAACAC GTGTTGATTCCTTCTGCTG 3598 AGCAGAAGGAATCAACACA TGTGTTGATTCCTTCTGCT 3599 GCAGAAGGAATCAACACAG CTGTGTTGATTCCTTCTGC 3600 CAGAAGGAATCAACACAGA TCTGTGTTGATTCCTTCTG 3601 AGAAGGAATCAACACAGAA TTCTGTGTTGATTCCTTCT 3602 GAAGGAATCAACACAGAAA TTTCTGTGTTGATTCCTTC 3603 AAGGAATCAACACAGAAAA TTTTCTGTGTTGATTCCTT 3604 AGGAATCAACACAGAAAAC GTTTTCTGTGTTGATTCCT 3605 GGAATCAACACAGAAAACG CGTTTTCTGTGTTGATTCC 3606 GAATCAACACAGAAAACGC GCGTTTTCTGTGTTGATTC 3607 AATCAACACAGAAAACGCC GGCGTTTTCTGTGTTGATT 3608 ATCAACACAGAAAACGCCC GGGCGTTTTCTGTGTTGAT 3609 TCAACACAGAAAACGCCCC GGGGCGTTTTCTGTGTTGA 3610 CAACACAGAAAACGCCCCC GGGGGCGTTTTCTGTGTTG 3611 AACACAGAAAACGCCCCCA TGGGGGCGTTTTCTGTGTT 3612 ACACAGAAAACGCCCCCAA TTGGGGGCGTTTTCTGTGT 3613 CACAGAAAACGCCCCCAAC GTTGGGGGCGTTTTCTGTG 3614 ACAGAAAACGCCCCCAACT AGTTGGGGGCGTTTTCTGT 3615 CAGAAAACGCCCCCAACTC GAGTTGGGGGCGTTTTCTG 3616 AGAAAACGCCCCCAACTCC GGAGTTGGGGGCGTTTTCT 3617 GAAAACGCCCCCAACTCCA TGGAGTTGGGGGCGTTTTC 3618 AAAACGCCCCCAACTCCAC GTGGAGTTGGGGGCGTTTT 3619 AAACGCCCCCAACTCCACA TGTGGAGTTGGGGGCGTTT 3620 AACGCCCCCAACTCCACAA TTGTGGAGTTGGGGGCGTT 3621 ACGCCCCCAACTCCACAAC GTTGTGGAGTTGGGGGCGT 3622 CGCCCCCAACTCCACAACC GGTTGTGGAGTTGGGGGCG 3623 GCCCCCAACTCCACAACCT AGGTTGTGGAGTTGGGGGC 3624 CCCCCAACTCCACAACCTT AAGGTTGTGGAGTTGGGGG 3625 CCCCAACTCCACAACCTTC GAAGGTTGTGGAGTTGGGG 3626 CCCAACTCCACAACCTTCC GGAAGGTTGTGGAGTTGGG 3627 CCAACTCCACAACCTTCCT AGGAAGGTTGTGGAGTTGG 3628 CAACTCCACAACCTTCCTG CAGGAAGGTTGTGGAGTTG 3629 AACTCCACAACCTTCCTGC GCAGGAAGGTTGTGGAGTT 3630 ACTCCACAACCTTCCTGCA TGCAGGAAGGTTGTGGAGT 3631 CTCCACAACCTTCCTGCAA TTGCAGGAAGGTTGTGGAG 3632 TCCACAACCTTCCTGCAAT ATTGCAGGAAGGTTGTGGA 3633 CCACAACCTTCCTGCAATG CATTGCAGGAAGGTTGTGG 3634 CACAACCTTCCTGCAATGG CCATTGCAGGAAGGTTGTG 3635 ACAACCTTCCTGCAATGGC GCCATTGCAGGAAGGTTGT 3636 CAACCTTCCTGCAATGGCG CGCCATTGCAGGAAGGTTG 3637 AACCTTCCTGCAATGGCGA TCGCCATTGCAGGAAGGTT 3638 ACCTTCCTGCAATGGCGAC GTCGCCATTGCAGGAAGGT 3639 CCTTCCTGCAATGGCGACA TGTCGCCATTGCAGGAAGG 3640 CTTCCTGCAATGGCGACAC GTGTCGCCATTGCAGGAAG 3641 TTCCTGCAATGGCGACACC GGTGTCGCCATTGCAGGAA 3642 TCCTGCAATGGCGACACCC GGGTGTCGCCATTGCAGGA 3643 CCTGCAATGGCGACACCCA TGGGTGTCGCCATTGCAGG 3644 CTGCAATGGCGACACCCAC GTGGGTGTCGCCATTGCAG 3645 TGCAATGGCGACACCCACA TGTGGGTGTCGCCATTGCA 3646 GCAATGGCGACACCCACAG CTGTGGGTGTCGCCATTGC 3647 CAATGGCGACACCCACAGG CCTGTGGGTGTCGCCATTG 3648 AATGGCGACACCCACAGGA TCCTGTGGGTGTCGCCATT 3649 ATGGCGACACCCACAGGAC GTCCTGTGGGTGTCGCCAT 3650 TGGCGACACCCACAGGACC GGTCCTGTGGGTGTCGCCA 3651 GGCGACACCCACAGGACCA TGGTCCTGTGGGTGTCGCC 3652 GCGACACCCACAGGACCAA TTGGTCCTGTGGGTGTCGC 3653 CGACACCCACAGGACCAAG CTTGGTCCTGTGGGTGTCG 3654 GACACCCACAGGACCAAGA TCTTGGTCCTGTGGGTGTC 3655 ACACCCACAGGACCAAGAG CTCTTGGTCCTGTGGGTGT 3656 CACCCACAGGACCAAGAGC GCTCTTGGTCCTGTGGGTG 3657 ACCCACAGGACCAAGAGCA TGCTCTTGGTCCTGTGGGT 3658 CCCACAGGACCAAGAGCAT ATGCTCTTGGTCCTGTGGG 3659 CCACAGGACCAAGAGCATC GATGCTCTTGGTCCTGTGG 3660 CACAGGACCAAGAGCATCA TGATGCTCTTGGTCCTGTG 3661 ACAGGACCAAGAGCATCAA TTGATGCTCTTGGTCCTGT 3662 CAGGACCAAGAGCATCAAA TTTGATGCTCTTGGTCCTG 3663 AGGACCAAGAGCATCAAAG CTTTGATGCTCTTGGTCCT 3664 GGACCAAGAGCATCAAAGA TCTTTGATGCTCTTGGTCC 3665 GACCAAGAGCATCAAAGAG CTCTTTGATGCTCTTGGTC 3666 ACCAAGAGCATCAAAGAGG CCTCTTTGATGCTCTTGGT 3667 CCAAGAGCATCAAAGAGGA TCCTCTTTGATGCTCTTGG 3668 CAAGAGCATCAAAGAGGAG CTCCTCTTTGATGCTCTTG 3669 AAGAGCATCAAAGAGGAGA TCTCCTCTTTGATGCTCTT 3670 AGAGCATCAAAGAGGAGAC GTCTCCTCTTTGATGCTCT 3671 GAGCATCAAAGAGGAGACC GGTCTCCTCTTTGATGCTC 3672 AGCATCAAAGAGGAGACCC GGGTCTCCTCTTTGATGCT 3673 GCATCAAAGAGGAGACCCC GGGGTCTCCTCTTTGATGC 3674 CATCAAAGAGGAGACCCCC GGGGGTCTCCTCTTTGATG 3675 ATCAAAGAGGAGACCCCCG CGGGGGTCTCCTCTTTGAT 3676 TCAAAGAGGAGACCCCCGA TCGGGGGTCTCCTCTTTGA 3677 CAAAGAGGAGACCCCCGAT ATCGGGGGTCTCCTCTTTG 3678 AAAGAGGAGACCCCCGATT AATCGGGGGTCTCCTCTTT 3679 AAGAGGAGACCCCCGATTC GAATCGGGGGTCTCCTCTT 3680 AGAGGAGACCCCCGATTCC GGAATCGGGGGTCTCCTCT 3681 GAGGAGACCCCCGATTCCG CGGAATCGGGGGTCTCCTC 3682 AGGAGACCCCCGATTCCGC GCGGAATCGGGGGTCTCCT 3683 GGAGACCCCCGATTCCGCT AGCGGAATCGGGGGTCTCC 3684 GAGACCCCCGATTCCGCTG CAGCGGAATCGGGGGTCTC 3685 AGACCCCCGATTCCGCTGA TCAGCGGAATCGGGGGTCT 3686 GACCCCCGATTCCGCTGAG CTCAGCGGAATCGGGGGTC 3687 ACCCCCGATTCCGCTGAGA TCTCAGCGGAATCGGGGGT 3688 CCCCCGATTCCGCTGAGAC GTCTCAGCGGAATCGGGGG 3689 CCCCGATTCCGCTGAGACC GGTCTCAGCGGAATCGGGG 3690 CCCGATTCCGCTGAGACCC GGGTCTCAGCGGAATCGGG 3691 CCGATTCCGCTGAGACCCC GGGGTCTCAGCGGAATCGG 3692 CGATTCCGCTGAGACCCCA TGGGGTCTCAGCGGAATCG 3693 GATTCCGCTGAGACCCCAG CTGGGGTCTCAGCGGAATC 3694 ATTCCGCTGAGACCCCAGC GCTGGGGTCTCAGCGGAAT 3695 TTCCGCTGAGACCCCAGCA TGCTGGGGTCTCAGCGGAA 3696 TCCGCTGAGACCCCAGCAG CTGCTGGGGTCTCAGCGGA 3697 CCGCTGAGACCCCAGCAGA TCTGCTGGGGTCTCAGCGG 3698 CGCTGAGACCCCAGCAGAG CTCTGCTGGGGTCTCAGCG 3699 GCTGAGACCCCAGCAGAGG CCTCTGCTGGGGTCTCAGC 3700 CTGAGACCCCAGCAGAGGA TCCTCTGCTGGGGTCTCAG 3701 TGAGACCCCAGCAGAGGAC GTCCTCTGCTGGGGTCTCA 3702 GAGACCCCAGCAGAGGACC GGTCCTCTGCTGGGGTCTC 3703 AGACCCCAGCAGAGGACCG CGGTCCTCTGCTGGGGTCT 3704 GACCCCAGCAGAGGACCGT ACGGTCCTCTGCTGGGGTC 3705 ACCCCAGCAGAGGACCGTG CACGGTCCTCTGCTGGGGT 3706 CCCCAGCAGAGGACCGTGC GCACGGTCCTCTGCTGGGG 3707 CCCAGCAGAGGACCGTGCT AGCACGGTCCTCTGCTGGG 3708 CCAGCAGAGGACCGTGCTG CAGCACGGTCCTCTGCTGG 3709 CAGCAGAGGACCGTGCTGG CCAGCACGGTCCTCTGCTG 3710 AGCAGAGGACCGTGCTGGC GCCAGCACGGTCCTCTGCT 3711 GCAGAGGACCGTGCTGGCC GGCCAGCACGGTCCTCTGC 3712 CAGAGGACCGTGCTGGCCG CGGCCAGCACGGTCCTCTG 3713 AGAGGACCGTGCTGGCCGA TCGGCCAGCACGGTCCTCT 3714 GAGGACCGTGCTGGCCGAG CTCGGCCAGCACGGTCCTC 3715 AGGACCGTGCTGGCCGAGG CCTCGGCCAGCACGGTCCT 3716 GGACCGTGCTGGCCGAGGG CCCTCGGCCAGCACGGTCC 3717 GACCGTGCTGGCCGAGGGC GCCCTCGGCCAGCACGGTC 3718 ACCGTGCTGGCCGAGGGCC GGCCCTCGGCCAGCACGGT 3719 CCGTGCTGGCCGAGGGCCC GGGCCCTCGGCCAGCACGG 3720 CGTGCTGGCCGAGGGCCCC GGGGCCCTCGGCCAGCACG 3721 GTGCTGGCCGAGGGCCCCT AGGGGCCCTCGGCCAGCAC 3722 TGCTGGCCGAGGGCCCCTG CAGGGGCCCTCGGCCAGCA 3723 GCTGGCCGAGGGCCCCTGC GCAGGGGCCCTCGGCCAGC 3724 CTGGCCGAGGGCCCCTGCC GGCAGGGGCCCTCGGCCAG 3725 TGGCCGAGGGCCCCTGCCT AGGCAGGGGCCCTCGGCCA 3726 GGCCGAGGGCCCCTGCCTT AAGGCAGGGGCCCTCGGCC 3727 GCCGAGGGCCCCTGCCTTG CAAGGCAGGGGCCCTCGGC 3728 CCGAGGGCCCCTGCCTTGT ACAAGGCAGGGGCCCTCGG 3729 CGAGGGCCCCTGCCTTGTC GACAAGGCAGGGGCCCTCG 3730 GAGGGCCCCTGCCTTGTCC GGACAAGGCAGGGGCCCTC 3731 AGGGCCCCTGCCTTGTCCT AGGACAAGGCAGGGGCCCT 3732 GGGCCCCTGCCTTGTCCTT AAGGACAAGGCAGGGGCCC 3733 GGCCCCTGCCTTGTCCTTC GAAGGACAAGGCAGGGGCC 3734 GCCCCTGCCTTGTCCTTCT AGAAGGACAAGGCAGGGGC 3735 CCCCTGCCTTGTCCTTCTC GAGAAGGACAAGGCAGGGG 3736 CCCTGCCTTGTCCTTCTCT AGAGAAGGACAAGGCAGGG 3737 CCTGCCTTGTCCTTCTCTC GAGAGAAGGACAAGGCAGG 3738 CTGCCTTGTCCTTCTCTCT AGAGAGAAGGACAAGGCAG 3739 TGCCTTGTCCTTCTCTCTG CAGAGAGAAGGACAAGGCA 3740 GCCTTGTCCTTCTCTCTGC GCAGAGAGAAGGACAAGGC 3741 CCTTGTCCTTCTCTCTGCG CGCAGAGAGAAGGACAAGG 3742 CTTGTCCTTCTCTCTGCGA TCGCAGAGAGAAGGACAAG 3743 TTGTCCTTCTCTCTGCGAA TTCGCAGAGAGAAGGACAA 3744 TGTCCTTCTCTCTGCGAAC GTTCGCAGAGAGAAGGACA 3745 GTCCTTCTCTCTGCGAACT AGTTCGCAGAGAGAAGGAC 3746 TCCTTCTCTCTGCGAACTG CAGTTCGCAGAGAGAAGGA 3747 CCTTCTCTCTGCGAACTGC GCAGTTCGCAGAGAGAAGG 3748 CTTCTCTCTGCGAACTGCT AGCAGTTCGCAGAGAGAAG 3749 TTCTCTCTGCGAACTGCTG CAGCAGTTCGCAGAGAGAA 3750 TCTCTCTGCGAACTGCTGG CCAGCAGTTCGCAGAGAGA 3751 CTCTCTGCGAACTGCTGGC GCCAGCAGTTCGCAGAGAG 3752 TCTCTGCGAACTGCTGGCT AGCCAGCAGTTCGCAGAGA 3753 CTCTGCGAACTGCTGGCTT AAGCCAGCAGTTCGCAGAG 3754 TCTGCGAACTGCTGGCTTC GAAGCCAGCAGTTCGCAGA 3755 CTGCGAACTGCTGGCTTCT AGAAGCCAGCAGTTCGCAG 3756 TGCGAACTGCTGGCTTCTA TAGAAGCCAGCAGTTCGCA 3757 GCGAACTGCTGGCTTCTAC GTAGAAGCCAGCAGTTCGC 3758 CGAACTGCTGGCTTCTACC GGTAGAAGCCAGCAGTTCG 3759 GAACTGCTGGCTTCTACCG CGGTAGAAGCCAGCAGTTC 3760 AACTGCTGGCTTCTACCGC GCGGTAGAAGCCAGCAGTT 3761 ACTGCTGGCTTCTACCGCG CGCGGTAGAAGCCAGCAGT 3762 CTGCTGGCTTCTACCGCGG CCGCGGTAGAAGCCAGCAG 3763 TGCTGGCTTCTACCGCGGT ACCGCGGTAGAAGCCAGCA 3764 GCTGGCTTCTACCGCGGTC GACCGCGGTAGAAGCCAGC 3765 CTGGCTTCTACCGCGGTCA TGACCGCGGTAGAAGCCAG 3766 TGGCTTCTACCGCGGTCAA TTGACCGCGGTAGAAGCCA 3767 GGCTTCTACCGCGGTCAAA TTTGACCGCGGTAGAAGCC 3768 GCTTCTACCGCGGTCAAAC GTTTGACCGCGGTAGAAGC 3769 CTTCTACCGCGGTCAAACT AGTTTGACCGCGGTAGAAG 3770 TTCTACCGCGGTCAAACTC GAGTTTGACCGCGGTAGAA 3771 TCTACCGCGGTCAAACTCT AGAGTTTGACCGCGGTAGA 3772 CTACCGCGGTCAAACTCTG CAGAGTTTGACCGCGGTAG 3773 TACCGCGGTCAAACTCTGC GCAGAGTTTGACCGCGGTA 3774 ACCGCGGTCAAACTCTGCT AGCAGAGTTTGACCGCGGT 3775 CCGCGGTCAAACTCTGCTT AAGCAGAGTTTGACCGCGG 3776 CGCGGTCAAACTCTGCTTG CAAGCAGAGTTTGACCGCG 3777 GCGGTCAAACTCTGCTTGG CCAAGCAGAGTTTGACCGC 3778 CGGTCAAACTCTGCTTGGG CCCAAGCAGAGTTTGACCG 3779 GGTCAAACTCTGCTTGGGC GCCCAAGCAGAGTTTGACC 3780 GTCAAACTCTGCTTGGGCC GGCCCAAGCAGAGTTTGAC 3781 TCAAACTCTGCTTGGGCCA TGGCCCAAGCAGAGTTTGA 3782 CAAACTCTGCTTGGGCCAT ATGGCCCAAGCAGAGTTTG 3783 AAACTCTGCTTGGGCCATG CATGGCCCAAGCAGAGTTT 3784 AACTCTGCTTGGGCCATGA TCATGGCCCAAGCAGAGTT 3785 ACTCTGCTTGGGCCATGAG CTCATGGCCCAAGCAGAGT 3786 CTCTGCTTGGGCCATGAGC GCTCATGGCCCAAGCAGAG 3787 TCTGCTTGGGCCATGAGCG CGCTCATGGCCCAAGCAGA 3788 CTGCTTGGGCCATGAGCGA TCGCTCATGGCCCAAGCAG 3789 TGCTTGGGCCATGAGCGAA TTCGCTCATGGCCCAAGCA 3790 GCTTGGGCCATGAGCGAAT ATTCGCTCATGGCCCAAGC 3791 CTTGGGCCATGAGCGAATA TATTCGCTCATGGCCCAAG 3792 TTGGGCCATGAGCGAATAC GTATTCGCTCATGGCCCAA 3793 TGGGCCATGAGCGAATACA TGTATTCGCTCATGGCCCA 3794 GGGCCATGAGCGAATACAC GTGTATTCGCTCATGGCCC 3795 GGCCATGAGCGAATACACA TGTGTATTCGCTCATGGCC 3796 GCCATGAGCGAATACACAT ATGTGTATTCGCTCATGGC 3797 CCATGAGCGAATACACATG CATGTGTATTCGCTCATGG 3798 CATGAGCGAATACACATGG CCATGTGTATTCGCTCATG 3799 ATGAGCGAATACACATGGC GCCATGTGTATTCGCTCAT 3800 TGAGCGAATACACATGGCC GGCCATGTGTATTCGCTCA 3801 GAGCGAATACACATGGCCT AGGCCATGTGTATTCGCTC 3802 AGCGAATACACATGGCCTT AAGGCCATGTGTATTCGCT 3803 GCGAATACACATGGCCTTC GAAGGCCATGTGTATTCGC 3804 CGAATACACATGGCCTTCG CGAAGGCCATGTGTATTCG 3805 GAATACACATGGCCTTCGC GCGAAGGCCATGTGTATTC 3806 AATACACATGGCCTTCGCC GGCGAAGGCCATGTGTATT 3807 ATACACATGGCCTTCGCCC GGGCGAAGGCCATGTGTAT 3808 TACACATGGCCTTCGCCCC GGGGCGAAGGCCATGTGTA 3809 ACACATGGCCTTCGCCCCC GGGGGCGAAGGCCATGTGT 3810 CACATGGCCTTCGCCCCCG CGGGGGCGAAGGCCATGTG 3811 ACATGGCCTTCGCCCCCGT ACGGGGGCGAAGGCCATGT 3812 CATGGCCTTCGCCCCCGTC GACGGGGGCGAAGGCCATG 3813 ATGGCCTTCGCCCCCGTCA TGACGGGGGCGAAGGCCAT 3814 TGGCCTTCGCCCCCGTCAC GTGACGGGGGCGAAGGCCA 3815 GGCCTTCGCCCCCGTCACT AGTGACGGGGGCGAAGGCC 3816 GCCTTCGCCCCCGTCACTC GAGTGACGGGGGCGAAGGC 3817 CCTTCGCCCCCGTCACTCC GGAGTGACGGGGGCGAAGG 3818 CTTCGCCCCCGTCACTCCG CGGAGTGACGGGGGCGAAG 3819 TTCGCCCCCGTCACTCCGG CCGGAGTGACGGGGGCGAA 3820 TCGCCCCCGTCACTCCGGC GCCGGAGTGACGGGGGCGA 3821 CGCCCCCGTCACTCCGGCC GGCCGGAGTGACGGGGGCG 3822 GCCCCCGTCACTCCGGCCC GGGCCGGAGTGACGGGGGC 3823 CCCCCGTCACTCCGGCCCT AGGGCCGGAGTGACGGGGG 3824 CCCCGTCACTCCGGCCCTG CAGGGCCGGAGTGACGGGG 3825 CCCGTCACTCCGGCCCTGC GCAGGGCCGGAGTGACGGG 3826 CCGTCACTCCGGCCCTGCC GGCAGGGCCGGAGTGACGG 3827 CGTCACTCCGGCCCTGCCC GGGCAGGGCCGGAGTGACG 3828 GTCACTCCGGCCCTGCCCA TGGGCAGGGCCGGAGTGAC 3829 TCACTCCGGCCCTGCCCAG CTGGGCAGGGCCGGAGTGA 3830 CACTCCGGCCCTGCCCAGT ACTGGGCAGGGCCGGAGTG 3831 ACTCCGGCCCTGCCCAGTG CACTGGGCAGGGCCGGAGT 3832 CTCCGGCCCTGCCCAGTGA TCACTGGGCAGGGCCGGAG 3833 TCCGGCCCTGCCCAGTGAT ATCACTGGGCAGGGCCGGA 3834 CCGGCCCTGCCCAGTGATG CATCACTGGGCAGGGCCGG 3835 CGGCCCTGCCCAGTGATGA TCATCACTGGGCAGGGCCG 3836 GGCCCTGCCCAGTGATGAC GTCATCACTGGGCAGGGCC 3837 GCCCTGCCCAGTGATGACC GGTCATCACTGGGCAGGGC 3838 CCCTGCCCAGTGATGACCG CGGTCATCACTGGGCAGGG 3839 CCTGCCCAGTGATGACCGC GCGGTCATCACTGGGCAGG 3840 CTGCCCAGTGATGACCGCA TGCGGTCATCACTGGGCAG 3841 TGCCCAGTGATGACCGCAT ATGCGGTCATCACTGGGCA 3842 GCCCAGTGATGACCGCATC GATGCGGTCATCACTGGGC 3843 CCCAGTGATGACCGCATCA TGATGCGGTCATCACTGGG 3844 CCAGTGATGACCGCATCAC GTGATGCGGTCATCACTGG 3845 CAGTGATGACCGCATCACC GGTGATGCGGTCATCACTG 3846 AGTGATGACCGCATCACCA TGGTGATGCGGTCATCACT 3847 GTGATGACCGCATCACCAA TTGGTGATGCGGTCATCAC 3848 TGATGACCGCATCACCAAC GTTGGTGATGCGGTCATCA 3849 GATGACCGCATCACCAACA TGTTGGTGATGCGGTCATC 3850 ATGACCGCATCACCAACAT ATGTTGGTGATGCGGTCAT 3851 TGACCGCATCACCAACATC GATGTTGGTGATGCGGTCA 3852 GACCGCATCACCAACATCC GGATGTTGGTGATGCGGTC 3853 ACCGCATCACCAACATCCT AGGATGTTGGTGATGCGGT 3854 CCGCATCACCAACATCCTG CAGGATGTTGGTGATGCGG 3855 CGCATCACCAACATCCTGG CCAGGATGTTGGTGATGCG 3856 GCATCACCAACATCCTGGA TCCAGGATGTTGGTGATGC 3857 CATCACCAACATCCTGGAC GTCCAGGATGTTGGTGATG 3858 ATCACCAACATCCTGGACA TGTCCAGGATGTTGGTGAT 3859 TCACCAACATCCTGGACAG CTGTCCAGGATGTTGGTGA 3860 CACCAACATCCTGGACAGC GCTGTCCAGGATGTTGGTG 3861 ACCAACATCCTGGACAGCA TGCTGTCCAGGATGTTGGT 3862 CCAACATCCTGGACAGCAT ATGCTGTCCAGGATGTTGG 3863 CAACATCCTGGACAGCATT AATGCTGTCCAGGATGTTG 3864 AACATCCTGGACAGCATTA TAATGCTGTCCAGGATGTT 3865 ACATCCTGGACAGCATTAT ATAATGCTGTCCAGGATGT 3866 CATCCTGGACAGCATTATC GATAATGCTGTCCAGGATG 3867 ATCCTGGACAGCATTATCG CGATAATGCTGTCCAGGAT 3868 TCCTGGACAGCATTATCGC GCGATAATGCTGTCCAGGA 3869 CCTGGACAGCATTATCGCA TGCGATAATGCTGTCCAGG 3870 CTGGACAGCATTATCGCAC GTGCGATAATGCTGTCCAG 3871 TGGACAGCATTATCGCACA TGTGCGATAATGCTGTCCA 3872 GGACAGCATTATCGCACAG CTGTGCGATAATGCTGTCC 3873 GACAGCATTATCGCACAGG CCTGTGCGATAATGCTGTC 3874 ACAGCATTATCGCACAGGT ACCTGTGCGATAATGCTGT 3875 CAGCATTATCGCACAGGTG CACCTGTGCGATAATGCTG 3876 AGCATTATCGCACAGGTGG CCACCTGTGCGATAATGCT 3877 GCATTATCGCACAGGTGGT ACCACCTGTGCGATAATGC 3878 CATTATCGCACAGGTGGTG CACCACCTGTGCGATAATG 3879 ATTATCGCACAGGTGGTGG CCACCACCTGTGCGATAAT 3880 TTATCGCACAGGTGGTGGA TCCACCACCTGTGCGATAA 3881 TATCGCACAGGTGGTGGAA TTCCACCACCTGTGCGATA 3882 ATCGCACAGGTGGTGGAAC GTTCCACCACCTGTGCGAT 3883 TCGCACAGGTGGTGGAACG CGTTCCACCACCTGTGCGA 3884 CGCACAGGTGGTGGAACGG CCGTTCCACCACCTGTGCG 3885 GCACAGGTGGTGGAACGGA TCCGTTCCACCACCTGTGC 3886 CACAGGTGGTGGAACGGAA TTCCGTTCCACCACCTGTG 3887 ACAGGTGGTGGAACGGAAG CTTCCGTTCCACCACCTGT 3888 CAGGTGGTGGAACGGAAGA TCTTCCGTTCCACCACCTG 3889 AGGTGGTGGAACGGAAGAT ATCTTCCGTTCCACCACCT 3890 GGTGGTGGAACGGAAGATC GATCTTCCGTTCCACCACC 3891 GTGGTGGAACGGAAGATCC GGATCTTCCGTTCCACCAC 3892 TGGTGGAACGGAAGATCCA TGGATCTTCCGTTCCACCA 3893 GGTGGAACGGAAGATCCAG CTGGATCTTCCGTTCCACC 3894 GTGGAACGGAAGATCCAGG CCTGGATCTTCCGTTCCAC 3895 TGGAACGGAAGATCCAGGA TCCTGGATCTTCCGTTCCA 3896 GGAACGGAAGATCCAGGAG CTCCTGGATCTTCCGTTCC 3897 GAACGGAAGATCCAGGAGA TCTCCTGGATCTTCCGTTC 3898 AACGGAAGATCCAGGAGAA TTCTCCTGGATCTTCCGTT 3899 ACGGAAGATCCAGGAGAAA TTTCTCCTGGATCTTCCGT 3900 CGGAAGATCCAGGAGAAAG CTTTCTCCTGGATCTTCCG 3901 GGAAGATCCAGGAGAAAGC GCTTTCTCCTGGATCTTCC 3902 GAAGATCCAGGAGAAAGCC GGCTTTCTCCTGGATCTTC 3903 AAGATCCAGGAGAAAGCCC GGGCTTTCTCCTGGATCTT 3904 AGATCCAGGAGAAAGCCCT AGGGCTTTCTCCTGGATCT 3905 GATCCAGGAGAAAGCCCTG CAGGGCTTTCTCCTGGATC 3906 ATCCAGGAGAAAGCCCTGG CCAGGGCTTTCTCCTGGAT 3907 TCCAGGAGAAAGCCCTGGG CCCAGGGCTTTCTCCTGGA 3908 CCAGGAGAAAGCCCTGGGG CCCCAGGGCTTTCTCCTGG 3909 CAGGAGAAAGCCCTGGGGC GCCCCAGGGCTTTCTCCTG 3910 AGGAGAAAGCCCTGGGGCC GGCCCCAGGGCTTTCTCCT 3911 GGAGAAAGCCCTGGGGCCG CGGCCCCAGGGCTTTCTCC 3912 GAGAAAGCCCTGGGGCCGG CCGGCCCCAGGGCTTTCTC 3913 AGAAAGCCCTGGGGCCGGG CCCGGCCCCAGGGCTTTCT 3914 GAAAGCCCTGGGGCCGGGG CCCCGGCCCCAGGGCTTTC 3915 AAAGCCCTGGGGCCGGGGC GCCCCGGCCCCAGGGCTTT 3916 AAGCCCTGGGGCCGGGGCT AGCCCCGGCCCCAGGGCTT 3917 AGCCCTGGGGCCGGGGCTT AAGCCCCGGCCCCAGGGCT 3918 GCCCTGGGGCCGGGGCTTC GAAGCCCCGGCCCCAGGGC 3919 CCCTGGGGCCGGGGCTTCG CGAAGCCCCGGCCCCAGGG 3920 CCTGGGGCCGGGGCTTCGA TCGAAGCCCCGGCCCCAGG 3921 CTGGGGCCGGGGCTTCGAG CTCGAAGCCCCGGCCCCAG 3922 TGGGGCCGGGGCTTCGAGC GCTCGAAGCCCCGGCCCCA 3923 GGGGCCGGGGCTTCGAGCT AGCTCGAAGCCCCGGCCCC 3924 GGGCCGGGGCTTCGAGCTG CAGCTCGAAGCCCCGGCCC 3925 GGCCGGGGCTTCGAGCTGG CCAGCTCGAAGCCCCGGCC 3926 GCCGGGGCTTCGAGCTGGC GCCAGCTCGAAGCCCCGGC 3927 CCGGGGCTTCGAGCTGGCC GGCCAGCTCGAAGCCCCGG 3928 CGGGGCTTCGAGCTGGCCC GGGCCAGCTCGAAGCCCCG 3929 GGGGCTTCGAGCTGGCCCG CGGGCCAGCTCGAAGCCCC 3930 GGGCTTCGAGCTGGCCCGG CCGGGCCAGCTCGAAGCCC 3931 GGCTTCGAGCTGGCCCGGG CCCGGGCCAGCTCGAAGCC 3932 GCTTCGAGCTGGCCCGGGT ACCCGGGCCAGCTCGAAGC 3933 CTTCGAGCTGGCCCGGGTC GACCCGGGCCAGCTCGAAG 3934 TTCGAGCTGGCCCGGGTCT AGACCCGGGCCAGCTCGAA 3935 TCGAGCTGGCCCGGGTCTG CAGACCCGGGCCAGCTCGA 3936 CGAGCTGGCCCGGGTCTGC GCAGACCCGGGCCAGCTCG 3937 GAGCTGGCCCGGGTCTGCG CGCAGACCCGGGCCAGCTC 3938 AGCTGGCCCGGGTCTGCGC GCGCAGACCCGGGCCAGCT 3939 GCTGGCCCGGGTCTGCGCA TGCGCAGACCCGGGCCAGC 3940 CTGGCCCGGGTCTGCGCAA TTGCGCAGACCCGGGCCAG 3941 TGGCCCGGGTCTGCGCAAG CTTGCGCAGACCCGGGCCA 3942 GGCCCGGGTCTGCGCAAGG CCTTGCGCAGACCCGGGCC 3943 GCCCGGGTCTGCGCAAGGG CCCTTGCGCAGACCCGGGC 3944 CCCGGGTCTGCGCAAGGGC GCCCTTGCGCAGACCCGGG 3945 CCGGGTCTGCGCAAGGGCC GGCCCTTGCGCAGACCCGG 3946 CGGGTCTGCGCAAGGGCCT AGGCCCTTGCGCAGACCCG 3947 GGGTCTGCGCAAGGGCCTG CAGGCCCTTGCGCAGACCC 3948 GGTCTGCGCAAGGGCCTGG CCAGGCCCTTGCGCAGACC 3949 GTCTGCGCAAGGGCCTGGG CCCAGGCCCTTGCGCAGAC 3950 TCTGCGCAAGGGCCTGGGC GCCCAGGCCCTTGCGCAGA 3951 CTGCGCAAGGGCCTGGGCC GGCCCAGGCCCTTGCGCAG 3952 TGCGCAAGGGCCTGGGCCT AGGCCCAGGCCCTTGCGCA 3953 GCGCAAGGGCCTGGGCCTG CAGGCCCAGGCCCTTGCGC 3954 CGCAAGGGCCTGGGCCTGC GCAGGCCCAGGCCCTTGCG 3955 GCAAGGGCCTGGGCCTGCC GGCAGGCCCAGGCCCTTGC 3956 CAAGGGCCTGGGCCTGCCC GGGCAGGCCCAGGCCCTTG 3957 AAGGGCCTGGGCCTGCCCC GGGGCAGGCCCAGGCCCTT 3958 AGGGCCTGGGCCTGCCCCT AGGGGCAGGCCCAGGCCCT 3959 GGGCCTGGGCCTGCCCCTC GAGGGGCAGGCCCAGGCCC 3960 GGCCTGGGCCTGCCCCTCT AGAGGGGCAGGCCCAGGCC 3961 GCCTGGGCCTGCCCCTCTC GAGAGGGGCAGGCCCAGGC 3962 CCTGGGCCTGCCCCTCTCT AGAGAGGGGCAGGCCCAGG 3963 CTGGGCCTGCCCCTCTCTC GAGAGAGGGGCAGGCCCAG 3964 TGGGCCTGCCCCTCTCTCC GGAGAGAGGGGCAGGCCCA 3965 GGGCCTGCCCCTCTCTCCA TGGAGAGAGGGGCAGGCCC 3966 GGCCTGCCCCTCTCTCCAG CTGGAGAGAGGGGCAGGCC 3967 GCCTGCCCCTCTCTCCAGT ACTGGAGAGAGGGGCAGGC 3968 CCTGCCCCTCTCTCCAGTG CACTGGAGAGAGGGGCAGG 3969 CTGCCCCTCTCTCCAGTGC GCACTGGAGAGAGGGGCAG 3970 TGCCCCTCTCTCCAGTGCG CGCACTGGAGAGAGGGGCA 3971 GCCCCTCTCTCCAGTGCGG CCGCACTGGAGAGAGGGGC 3972 CCCCTCTCTCCAGTGCGGC GCCGCACTGGAGAGAGGGG 3973 CCCTCTCTCCAGTGCGGCC GGCCGCACTGGAGAGAGGG 3974 CCTCTCTCCAGTGCGGCCC GGGCCGCACTGGAGAGAGG 3975 CTCTCTCCAGTGCGGCCCC GGGGCCGCACTGGAGAGAG 3976 TCTCTCCAGTGCGGCCCCG CGGGGCCGCACTGGAGAGA 3977 CTCTCCAGTGCGGCCCCGG CCGGGGCCGCACTGGAGAG 3978 TCTCCAGTGCGGCCCCGGC GCCGGGGCCGCACTGGAGA 3979 CTCCAGTGCGGCCCCGGCT AGCCGGGGCCGCACTGGAG 3980 TCCAGTGCGGCCCCGGCTG CAGCCGGGGCCGCACTGGA 3981 CCAGTGCGGCCCCGGCTGC GCAGCCGGGGCCGCACTGG 3982 CAGTGCGGCCCCGGCTGCC GGCAGCCGGGGCCGCACTG 3983 AGTGCGGCCCCGGCTGCCT AGGCAGCCGGGGCCGCACT 3984 GTGCGGCCCCGGCTGCCTC GAGGCAGCCGGGGCCGCAC 3985 TGCGGCCCCGGCTGCCTCC GGAGGCAGCCGGGGCCGCA 3986 GCGGCCCCGGCTGCCTCCC GGGAGGCAGCCGGGGCCGC 3987 CGGCCCCGGCTGCCTCCCC GGGGAGGCAGCCGGGGCCG 3988 GGCCCCGGCTGCCTCCCCC GGGGGAGGCAGCCGGGGCC 3989 GCCCCGGCTGCCTCCCCCA TGGGGGAGGCAGCCGGGGC 3990 CCCCGGCTGCCTCCCCCAG CTGGGGGAGGCAGCCGGGG 3991 CCCGGCTGCCTCCCCCAGG CCTGGGGGAGGCAGCCGGG 3992 CCGGCTGCCTCCCCCAGGG CCCTGGGGGAGGCAGCCGG 3993 CGGCTGCCTCCCCCAGGGG CCCCTGGGGGAGGCAGCCG 3994 GGCTGCCTCCCCCAGGGGC GCCCCTGGGGGAGGCAGCC 3995 GCTGCCTCCCCCAGGGGCT AGCCCCTGGGGGAGGCAGC 3996 CTGCCTCCCCCAGGGGCTT AAGCCCCTGGGGGAGGCAG 3997 TGCCTCCCCCAGGGGCTTT AAAGCCCCTGGGGGAGGCA 3998 GCCTCCCCCAGGGGCTTTG CAAAGCCCCTGGGGGAGGC 3999 CCTCCCCCAGGGGCTTTGC GCAAAGCCCCTGGGGGAGG 4000 CTCCCCCAGGGGCTTTGCT AGCAAAGCCCCTGGGGGAG 4001 TCCCCCAGGGGCTTTGCTG CAGCAAAGCCCCTGGGGGA 4002 CCCCCAGGGGCTTTGCTGT ACAGCAAAGCCCCTGGGGG 4003 CCCCAGGGGCTTTGCTGTG CACAGCAAAGCCCCTGGGG 4004 CCCAGGGGCTTTGCTGTGG CCACAGCAAAGCCCCTGGG 4005 CCAGGGGCTTTGCTGTGGC GCCACAGCAAAGCCCCTGG 4006 CAGGGGCTTTGCTGTGGCT AGCCACAGCAAAGCCCCTG 4007 AGGGGCTTTGCTGTGGCTG CAGCCACAGCAAAGCCCCT 4008 GGGGCTTTGCTGTGGCTGC GCAGCCACAGCAAAGCCCC 4009 GGGCTTTGCTGTGGCTGCA TGCAGCCACAGCAAAGCCC 4010 GGCTTTGCTGTGGCTGCAG CTGCAGCCACAGCAAAGCC 4011 GCTTTGCTGTGGCTGCAGG CCTGCAGCCACAGCAAAGC 4012 CTTTGCTGTGGCTGCAGGA TCCTGCAGCCACAGCAAAG 4013 TTTGCTGTGGCTGCAGGAG CTCCTGCAGCCACAGCAAA 4014 TTGCTGTGGCTGCAGGAGC GCTCCTGCAGCCACAGCAA 4015 TGCTGTGGCTGCAGGAGCC GGCTCCTGCAGCCACAGCA 4016 GCTGTGGCTGCAGGAGCCC GGGCTCCTGCAGCCACAGC 4017 CTGTGGCTGCAGGAGCCCC GGGGCTCCTGCAGCCACAG 4018 TGTGGCTGCAGGAGCCCCA TGGGGCTCCTGCAGCCACA 4019 GTGGCTGCAGGAGCCCCAG CTGGGGCTCCTGCAGCCAC 4020 TGGCTGCAGGAGCCCCAGC GCTGGGGCTCCTGCAGCCA 4021 GGCTGCAGGAGCCCCAGCC GGCTGGGGCTCCTGCAGCC 4022 GCTGCAGGAGCCCCAGCCT AGGCTGGGGCTCCTGCAGC 4023 CTGCAGGAGCCCCAGCCTT AAGGCTGGGGCTCCTGCAG 4024 TGCAGGAGCCCCAGCCTTG CAAGGCTGGGGCTCCTGCA 4025 GCAGGAGCCCCAGCCTTGC GCAAGGCTGGGGCTCCTGC 4026 CAGGAGCCCCAGCCTTGCC GGCAAGGCTGGGGCTCCTG 4027 AGGAGCCCCAGCCTTGCCC GGGCAAGGCTGGGGCTCCT 4028 GGAGCCCCAGCCTTGCCCT AGGGCAAGGCTGGGGCTCC 4029 GAGCCCCAGCCTTGCCCTC GAGGGCAAGGCTGGGGCTC 4030 AGCCCCAGCCTTGCCCTCG CGAGGGCAAGGCTGGGGCT 4031 GCCCCAGCCTTGCCCTCGG CCGAGGGCAAGGCTGGGGC 4032 CCCCAGCCTTGCCCTCGGC GCCGAGGGCAAGGCTGGGG 4033 CCCAGCCTTGCCCTCGGCG CGCCGAGGGCAAGGCTGGG 4034 CCAGCCTTGCCCTCGGCGT ACGCCGAGGGCAAGGCTGG 4035 CAGCCTTGCCCTCGGCGTG CACGCCGAGGGCAAGGCTG 4036 AGCCTTGCCCTCGGCGTGG CCACGCCGAGGGCAAGGCT 4037 GCCTTGCCCTCGGCGTGGC GCCACGCCGAGGGCAAGGC 4038 CCTTGCCCTCGGCGTGGCT AGCCACGCCGAGGGCAAGG 4039 CTTGCCCTCGGCGTGGCTT AAGCCACGCCGAGGGCAAG 4040 TTGCCCTCGGCGTGGCTTC GAAGCCACGCCGAGGGCAA 4041 TGCCCTCGGCGTGGCTTCC GGAAGCCACGCCGAGGGCA 4042 GCCCTCGGCGTGGCTTCCA TGGAAGCCACGCCGAGGGC 4043 CCCTCGGCGTGGCTTCCAC GTGGAAGCCACGCCGAGGG 4044 CCTCGGCGTGGCTTCCACC GGTGGAAGCCACGCCGAGG 4045 CTCGGCGTGGCTTCCACCT AGGTGGAAGCCACGCCGAG 4046 TCGGCGTGGCTTCCACCTC GAGGTGGAAGCCACGCCGA 4047 CGGCGTGGCTTCCACCTCT AGAGGTGGAAGCCACGCCG 4048 GGCGTGGCTTCCACCTCTT AAGAGGTGGAAGCCACGCC 4049 GCGTGGCTTCCACCTCTTC GAAGAGGTGGAAGCCACGC 4050 CGTGGCTTCCACCTCTTCC GGAAGAGGTGGAAGCCACG 4051 GTGGCTTCCACCTCTTCCA TGGAAGAGGTGGAAGCCAC 4052 TGGCTTCCACCTCTTCCAG CTGGAAGAGGTGGAAGCCA 4053 GGCTTCCACCTCTTCCAGG CCTGGAAGAGGTGGAAGCC 4054 GCTTCCACCTCTTCCAGGA TCCTGGAAGAGGTGGAAGC 4055 CTTCCACCTCTTCCAGGAG CTCCTGGAAGAGGTGGAAG 4056 TTCCACCTCTTCCAGGAGC GCTCCTGGAAGAGGTGGAA 4057 TCCACCTCTTCCAGGAGCA TGCTCCTGGAAGAGGTGGA 4058 CCACCTCTTCCAGGAGCAC GTGCTCCTGGAAGAGGTGG 4059 CACCTCTTCCAGGAGCACT AGTGCTCCTGGAAGAGGTG 4060 ACCTCTTCCAGGAGCACTG CAGTGCTCCTGGAAGAGGT 4061 CCTCTTCCAGGAGCACTGG CCAGTGCTCCTGGAAGAGG 4062 CTCTTCCAGGAGCACTGGA TCCAGTGCTCCTGGAAGAG 4063 TCTTCCAGGAGCACTGGAG CTCCAGTGCTCCTGGAAGA 4064 CTTCCAGGAGCACTGGAGG CCTCCAGTGCTCCTGGAAG 4065 TTCCAGGAGCACTGGAGGC GCCTCCAGTGCTCCTGGAA 4066 TCCAGGAGCACTGGAGGCA TGCCTCCAGTGCTCCTGGA 4067 CCAGGAGCACTGGAGGCAG CTGCCTCCAGTGCTCCTGG 4068 CAGGAGCACTGGAGGCAGG CCTGCCTCCAGTGCTCCTG 4069 AGGAGCACTGGAGGCAGGG CCCTGCCTCCAGTGCTCCT 4070 GGAGCACTGGAGGCAGGGC GCCCTGCCTCCAGTGCTCC 4071 GAGCACTGGAGGCAGGGCC GGCCCTGCCTCCAGTGCTC 4072 AGCACTGGAGGCAGGGCCA TGGCCCTGCCTCCAGTGCT 4073 GCACTGGAGGCAGGGCCAG CTGGCCCTGCCTCCAGTGC 4074 CACTGGAGGCAGGGCCAGC GCTGGCCCTGCCTCCAGTG 4075 ACTGGAGGCAGGGCCAGCC GGCTGGCCCTGCCTCCAGT 4076 CTGGAGGCAGGGCCAGCCT AGGCTGGCCCTGCCTCCAG 4077 TGGAGGCAGGGCCAGCCTG CAGGCTGGCCCTGCCTCCA 4078 GGAGGCAGGGCCAGCCTGT ACAGGCTGGCCCTGCCTCC 4079 GAGGCAGGGCCAGCCTGTG CACAGGCTGGCCCTGCCTC 4080 AGGCAGGGCCAGCCTGTGT ACACAGGCTGGCCCTGCCT 4081 GGCAGGGCCAGCCTGTGTT AACACAGGCTGGCCCTGCC 4082 GCAGGGCCAGCCTGTGTTG CAACACAGGCTGGCCCTGC 4083 CAGGGCCAGCCTGTGTTGG CCAACACAGGCTGGCCCTG 4084 AGGGCCAGCCTGTGTTGGT ACCAACACAGGCTGGCCCT 4085 GGGCCAGCCTGTGTTGGTG CACCAACACAGGCTGGCCC 4086 GGCCAGCCTGTGTTGGTGT ACACCAACACAGGCTGGCC 4087 GCCAGCCTGTGTTGGTGTC GACACCAACACAGGCTGGC 4088 CCAGCCTGTGTTGGTGTCA TGACACCAACACAGGCTGG 4089 CAGCCTGTGTTGGTGTCAG CTGACACCAACACAGGCTG 4090 AGCCTGTGTTGGTGTCAGG CCTGACACCAACACAGGCT 4091 GCCTGTGTTGGTGTCAGGG CCCTGACACCAACACAGGC 4092 CCTGTGTTGGTGTCAGGGA TCCCTGACACCAACACAGG 4093 CTGTGTTGGTGTCAGGGAT ATCCCTGACACCAACACAG 4094 TGTGTTGGTGTCAGGGATC GATCCCTGACACCAACACA 4095 GTGTTGGTGTCAGGGATCC GGATCCCTGACACCAACAC 4096 TGTTGGTGTCAGGGATCCA TGGATCCCTGACACCAACA 4097 GTTGGTGTCAGGGATCCAA TTGGATCCCTGACACCAAC 4098 TTGGTGTCAGGGATCCAAA TTTGGATCCCTGACACCAA 4099 TGGTGTCAGGGATCCAAAG CTTTGGATCCCTGACACCA 4100 GGTGTCAGGGATCCAAAGG CCTTTGGATCCCTGACACC 4101 GTGTCAGGGATCCAAAGGA TCCTTTGGATCCCTGACAC 4102 TGTCAGGGATCCAAAGGAC GTCCTTTGGATCCCTGACA 4103 GTCAGGGATCCAAAGGACA TGTCCTTTGGATCCCTGAC 4104 TCAGGGATCCAAAGGACAT ATGTCCTTTGGATCCCTGA 4105 CAGGGATCCAAAGGACATT AATGTCCTTTGGATCCCTG 4106 AGGGATCCAAAGGACATTG CAATGTCCTTTGGATCCCT 4107 GGGATCCAAAGGACATTGC GCAATGTCCTTTGGATCCC 4108 GGATCCAAAGGACATTGCA TGCAATGTCCTTTGGATCC 4109 GATCCAAAGGACATTGCAG CTGCAATGTCCTTTGGATC 4110 ATCCAAAGGACATTGCAGG CCTGCAATGTCCTTTGGAT 4111 TCCAAAGGACATTGCAGGG CCCTGCAATGTCCTTTGGA 4112 CCAAAGGACATTGCAGGGC GCCCTGCAATGTCCTTTGG 4113 CAAAGGACATTGCAGGGCA TGCCCTGCAATGTCCTTTG 4114 AAAGGACATTGCAGGGCAA TTGCCCTGCAATGTCCTTT 4115 AAGGACATTGCAGGGCAAC GTTGCCCTGCAATGTCCTT 4116 AGGACATTGCAGGGCAACC GGTTGCCCTGCAATGTCCT 4117 GGACATTGCAGGGCAACCT AGGTTGCCCTGCAATGTCC 4118 GACATTGCAGGGCAACCTG CAGGTTGCCCTGCAATGTC 4119 ACATTGCAGGGCAACCTGT ACAGGTTGCCCTGCAATGT 4120 CATTGCAGGGCAACCTGTG CACAGGTTGCCCTGCAATG 4121 ATTGCAGGGCAACCTGTGG CCACAGGTTGCCCTGCAAT 4122 TTGCAGGGCAACCTGTGGG CCCACAGGTTGCCCTGCAA 4123 TGCAGGGCAACCTGTGGGG CCCCACAGGTTGCCCTGCA 4124 GCAGGGCAACCTGTGGGGG CCCCCACAGGTTGCCCTGC 4125 CAGGGCAACCTGTGGGGGA TCCCCCACAGGTTGCCCTG 4126 AGGGCAACCTGTGGGGGAC GTCCCCCACAGGTTGCCCT 4127 GGGCAACCTGTGGGGGACA TGTCCCCCACAGGTTGCCC 4128 GGCAACCTGTGGGGGACAG CTGTCCCCCACAGGTTGCC 4129 GCAACCTGTGGGGGACAGA TCTGTCCCCCACAGGTTGC 4130 CAACCTGTGGGGGACAGAA TTCTGTCCCCCACAGGTTG 4131 AACCTGTGGGGGACAGAAG CTTCTGTCCCCCACAGGTT 4132 ACCTGTGGGGGACAGAAGC GCTTCTGTCCCCCACAGGT 4133 CCTGTGGGGGACAGAAGCT AGCTTCTGTCCCCCACAGG 4134 CTGTGGGGGACAGAAGCTC GAGCTTCTGTCCCCCACAG 4135 TGTGGGGGACAGAAGCTCT AGAGCTTCTGTCCCCCACA 4136 GTGGGGGACAGAAGCTCTT AAGAGCTTCTGTCCCCCAC 4137 TGGGGGACAGAAGCTCTTG CAAGAGCTTCTGTCCCCCA 4138 GGGGGACAGAAGCTCTTGG CCAAGAGCTTCTGTCCCCC 4139 GGGGACAGAAGCTCTTGGG CCCAAGAGCTTCTGTCCCC 4140 GGGACAGAAGCTCTTGGGG CCCCAAGAGCTTCTGTCCC 4141 GGACAGAAGCTCTTGGGGC GCCCCAAGAGCTTCTGTCC 4142 GACAGAAGCTCTTGGGGCA TGCCCCAAGAGCTTCTGTC 4143 ACAGAAGCTCTTGGGGCAC GTGCCCCAAGAGCTTCTGT 4144 CAGAAGCTCTTGGGGCACT AGTGCCCCAAGAGCTTCTG 4145 AGAAGCTGTTGGGGCACTT AAGTGCCCCAAGAGCTTCT 4146 GAAGCTCTTGGGGCACTTG CAAGTGCCCCAAGAGCTTC 4147 AAGCTCTTGGGGCACTTGG CCAAGTGCCCCAAGAGCTT 4148 AGCTCTTGGGGCACTTGGA TCCAAGTGCCCCAAGAGCT 4149 GCTCTTGGGGCACTTGGAG CTCCAAGTGCCCCAAGAGC 4150 CTCTTGGGGCACTTGGAGG CCTCCAAGTGCCCCAAGAG 4151 TCTTGGGGCACTTGGAGGC GCCTCCAAGTGCCCCAAGA 4152 CTTGGGGCACTTGGAGGCC GGCCTCCAAGTGCCCCAAG 4153 TTGGGGCACTTGGAGGCCA TGGCCTCCAAGTGCCCCAA 4154 TGGGGCACTTGGAGGCCAG CTGGCCTCCAAGTGCCCCA 4155 GGGGCACTTGGAGGCCAGG CCTGGCCTCCAAGTGCCCC 4156 GGGCACTTGGAGGCCAGGT ACCTGGCCTCCAAGTGCCC 4157 GGCACTTGGAGGCCAGGTG CACCTGGCCTCCAAGTGCC 4158 GCACTTGGAGGCCAGGTGC GCACCTGGCCTCCAAGTGC 4159 CACTTGGAGGCCAGGTGCA TGCACCTGGCCTCCAAGTG 4160 ACTTGGAGGCCAGGTGCAG CTGCACCTGGCCTCCAAGT 4161 CTTGGAGGCCAGGTGCAGG CCTGCACCTGGCCTCCAAG 4162 TTGGAGGCCAGGTGCAGGC GCCTGCACCTGGCCTCCAA 4163 TGGAGGCCAGGTGCAGGCG CGCCTGCACCTGGCCTCCA 4164 GGAGGCCAGGTGCAGGCGC GCGCCTGCACCTGGCCTCC 4165 GAGGCCAGGTGCAGGCGCT AGCGCCTGCACCTGGCCTC 4166 AGGCCAGGTGCAGGCGCTG CAGCGCCTGCACCTGGCCT 4167 GGCCAGGTGCAGGCGCTGA TCAGCGCCTGCACCTGGCC 4168 GCCAGGTGCAGGCGCTGAG CTCAGCGCCTGCACCTGGC 4169 CCAGGTGCAGGCGCTGAGC GCTCAGCGCCTGCACCTGG 4170 CAGGTGCAGGCGCTGAGCC GGCTCAGCGCCTGCACCTG 4171 AGGTGCAGGCGCTGAGCCC GGGCTCAGCGCCTGCACCT 4172 GGTGCAGGCGCTGAGCCCC GGGGCTCAGCGCCTGCACC 4173 GTGCAGGCGCTGAGCCCCC GGGGGCTCAGCGCCTGCAC 4174 TGCAGGCGCTGAGCCCCCT AGGGGGCTCAGCGCCTGCA 4175 GCAGGCGCTGAGCCCCCTC GAGGGGGCTCAGCGCCTGC 4176 CAGGCGCTGAGCCCCCTCG CGAGGGGGCTCAGCGCCTG 4177 AGGCGCTGAGCCCCCTCGG CCGAGGGGGCTCAGCGCCT 4178 GGCGCTGAGCCCCCTCGGA TCCGAGGGGGCTCAGCGCC 4179 GCGCTGAGCCCCCTCGGAC GTCCGAGGGGGCTCAGCGC 4180 CGCTGAGCCCCCTCGGACC GGTCCGAGGGGGCTCAGCG 4181 GCTGAGCCCCCTCGGACCT AGGTCCGAGGGGGCTCAGC 4182 CTGAGCCCCCTCGGACCTC GAGGTCCGAGGGGGCTCAG 4183 TGAGCCCCCTCGGACCTCC GGAGGTCCGAGGGGGCTCA 4184 GAGCCCCCTCGGACCTCCC GGGAGGTCCGAGGGGGCTC 4185 AGCCCCCTCGGACCTCCCC GGGGAGGTCCGAGGGGGCT 4186 GCCCCCTCGGACCTCCCCA TGGGGAGGTCCGAGGGGGC 4187 CCCCCTCGGACCTCCCCAG CTGGGGAGGTCCGAGGGGG 4188 CCCCTCGGACCTCCCCAGC GCTGGGGAGGTCCGAGGGG 4189 CCCTCGGACCTCCCCAGCC GGCTGGGGAGGTCCGAGGG 4190 CCTCGGACCTCCCCAGCCC GGGCTGGGGAGGTCCGAGG 4191 CTCGGACCTCCCCAGCCCA TGGGCTGGGGAGGTCCGAG 4192 TCGGACCTCCCCAGCCCAG CTGGGCTGGGGAGGTCCGA 4193 CGGACCTCCCCAGCCCAGC GCTGGGCTGGGGAGGTCCG 4194 GGACCTCCCCAGCCCAGCA TGCTGGGCTGGGGAGGTCC 4195 GACCTCCCCAGCCCAGCAG CTGCTGGGCTGGGGAGGTC 4196 ACCTCCCCAGCCCAGCAGC GCTGCTGGGCTGGGGAGGT 4197 CCTCCCCAGCCCAGCAGCC GGCTGCTGGGCTGGGGAGG 4198 CTCCCCAGCCCAGCAGCCT AGGCTGCTGGGCTGGGGAG 4199 TCCCCAGCCCAGCAGCCTG CAGGCTGCTGGGCTGGGGA 4200 CCCCAGCCCAGCAGCCTGG CCAGGCTGCTGGGCTGGGG 4201 CCCAGCCCAGCAGCCTGGG CCCAGGCTGCTGGGCTGGG 4202 CCAGCCCAGCAGCCTGGGC GCCCAGGCTGCTGGGCTGG 4203 CAGCCCAGCAGCCTGGGCA TGCCCAGGCTGCTGGGCTG 4204 AGCCCAGCAGCCTGGGCAG CTGCCCAGGCTGCTGGGCT 4205 GCCCAGCAGCCTGGGCAGC GCTGCCCAGGCTGCTGGGC 4206 CCCAGCAGCCTGGGCAGCA TGCTGCCCAGGCTGCTGGG 4207 CCAGCAGCCTGGGCAGCAC GTGCTGCCCAGGCTGCTGG 4208 CAGCAGCCTGGGCAGCACA TGTGCTGCCCAGGCTGCTG 4209 AGCAGCCTGGGCAGCACAA TTGTGCTGCCCAGGCTGCT 4210 GCAGCCTGGGCAGCACAAC GTTGTGCTGCCCAGGCTGC 4211 CAGCCTGGGCAGCACAACA TGTTGTGCTGCCCAGGCTG 4212 AGCCTGGGCAGCACAACAT ATGTTGTGCTGCCCAGGCT 4213 GCCTGGGCAGCACAACATT AATGTTGTGCTGCCCAGGC 4214 CCTGGGCAGCACAACATTC GAATGTTGTGCTGCCCAGG 4215 CTGGGCAGCACAACATTCT AGAATGTTGTGCTGCCCAG 4216 TGGGCAGCACAACATTCTG CAGAATGTTGTGCTGCCCA 4217 GGGCAGCACAACATTCTGG CCAGAATGTTGTGCTGCCC 4218 GGCAGCACAACATTCTGGG CCCAGAATGTTGTGCTGCC 4219 GCAGCACAACATTCTGGGA TCCCAGAATGTTGTGCTGC 4220 CAGCACAACATTCTGGGAG CTCCCAGAATGTTGTGCTG 4221 AGCACAACATTCTGGGAGG CCTCCCAGAATGTTGTGCT 4222 GCACAACATTCTGGGAGGG CCCTCCCAGAATGTTGTGC 4223 CACAACATTCTGGGAGGGC GCCCTCCCAGAATGTTGTG 4224 ACAACATTCTGGGAGGGCT AGCCCTCCCAGAATGTTGT 4225 CAACATTCTGGGAGGGCTT AAGCCCTCCCAGAATGTTG 4226 AACATTCTGGGAGGGCTTC GAAGCCCTCCCAGAATGTT 4227 ACATTCTGGGAGGGCTTCT AGAAGCCCTCCCAGAATGT 4228 CATTCTGGGAGGGCTTCTC GAGAAGCCCTCCCAGAATG 4229 ATTCTGGGAGGGCTTCTCC GGAGAAGCCCTCCCAGAAT 4230 TTCTGGGAGGGCTTCTCCT AGGAGAAGCCCTCCCAGAA 4231 TCTGGGAGGGCTTCTCCTG CAGGAGAAGCCCTCCCAGA 4232 CTGGGAGGGCTTCTCCTGG CCAGGAGAAGCCCTCCCAG 4233 TGGGAGGGCTTCTCCTGGC GCCAGGAGAAGCCCTCCCA 4234 GGGAGGGCTTCTCCTGGCC GGCCAGGAGAAGCCCTCCC 4235 GGAGGGCTTCTCCTGGCCT AGGCCAGGAGAAGCCCTCC 4236 GAGGGCTTCTCCTGGCCTG CAGGCCAGGAGAAGCCCTC 4237 AGGGCTTCTCCTGGCCTGA TCAGGCCAGGAGAAGCCCT 4238 GGGCTTCTCCTGGCCTGAG CTCAGGCCAGGAGAAGCCC 4239 GGCTTCTCCTGGCCTGAGC GCTCAGGCCAGGAGAAGCC 4240 GCTTCTCCTGGCCTGAGCT AGCTCAGGCCAGGAGAAGC 4241 CTTCTCCTGGCCTGAGCTT AAGCTCAGGCCAGGAGAAG 4242 TTCTCCTGGCCTGAGCTTC GAAGCTCAGGCCAGGAGAA 4243 TCTCCTGGCCTGAGCTTCG CGAAGCTCAGGCCAGGAGA 4244 CTCCTGGCCTGAGCTTCGC GCGAAGCTCAGGCCAGGAG 4245 TCCTGGCCTGAGCTTCGCC GGCGAAGCTCAGGCCAGGA 4246 CCTGGCCTGAGCTTCGCCC GGGCGAAGCTCAGGCCAGG 4247 CTGGCCTGAGCTTCGCCCA TGGGCGAAGCTCAGGCCAG 4248 TGGCCTGAGCTTCGCCCAA TTGGGCGAAGCTCAGGCCA 4249 GGCCTGAGCTTCGCCCAAA TTTGGGCGAAGCTCAGGCC 4250 GCCTGAGCTTCGCCCAAAG CTTTGGGCGAAGCTCAGGC 4251 CCTGAGCTTCGCCCAAAGT ACTTTGGGCGAAGCTCAGG 4252 CTGAGCTTCGCCCAAAGTC GACTTTGGGCGAAGCTCAG 4253 TGAGCTTCGCCCAAAGTCA TGACTTTGGGCGAAGCTCA 4254 GAGCTTCGCCCAAAGTCAG CTGACTTTGGGCGAAGCTC 4255 AGCTTCGCCCAAAGTCAGA TCTGACTTTGGGCGAAGCT 4256 GCTTCGCCCAAAGTCAGAC GTCTGACTTTGGGCGAAGC 4257 CTTCGCCCAAAGTCAGACG CGTCTGACTTTGGGCGAAG 4258 TTCGCCCAAAGTCAGACGA TCGTCTGACTTTGGGCGAA 4259 TCGCCCAAAGTCAGACGAG CTCGTCTGACTTTGGGCGA 4260 CGCCCAAAGTCAGACGAGG CCTCGTCTGACTTTGGGCG 4261 GCCCAAAGTCAGACGAGGG CCCTCGTCTGACTTTGGGC 4262 CCCAAAGTCAGACGAGGGC GCCCTCGTCTGACTTTGGG 4263 CCAAAGTCAGACGAGGGCT AGCCCTCGTCTGACTTTGG 4264 CAAAGTCAGACGAGGGCTC GAGCCCTCGTCTGACTTTG 4265 AAAGTCAGACGAGGGCTCT AGAGCCCTCGTCTGACTTT 4266 AAGTCAGACGAGGGCTCTG CAGAGCCCTCGTCTGACTT 4267 AGTCAGACGAGGGCTCTGT ACAGAGCCCTCGTCTGACT 4268 GTCAGACGAGGGCTCTGTC GACAGAGCCCTCGTCTGAC 4269 TCAGACGAGGGCTCTGTCC GGACAGAGCCCTCGTCTGA 4270 CAGACGAGGGCTCTGTCCT AGGACAGAGCCCTCGTCTG 4271 AGACGAGGGCTCTGTCCTC GAGGACAGAGCCCTCGTCT 4272 GACGAGGGCTCTGTCCTCC GGAGGACAGAGCCCTCGTC 4273 ACGAGGGCTCTGTCCTCCT AGGAGGACAGAGCCCTCGT 4274 CGAGGGCTCTGTCCTCCTG CAGGAGGACAGAGCCCTCG 4275 GAGGGCTCTGTCCTCCTGC GCAGGAGGACAGAGCCCTC 4276 AGGGCTCTGTCCTCCTGCT AGCAGGAGGACAGAGCCCT 4277 GGGCTCTGTCCTCCTGCTG CAGCAGGAGGACAGAGCCC 4278 GGCTCTGTCCTCCTGCTGC GCAGCAGGAGGACAGAGCC 4279 GCTCTGTCCTCCTGCTGCA TGCAGCAGGAGGACAGAGC 4280 CTCTGTCCTCCTGCTGCAC GTGCAGCAGGAGGACAGAG 4281 TCTGTCCTCCTGCTGCACC GGTGCAGCAGGAGGACAGA 4282 CTGTCCTCCTGCTGCACCG CGGTGCAGCAGGAGGACAG 4283 TGTCCTCCTGCTGCACCGA TCGGTGCAGCAGGAGGACA 4284 GTCCTCCTGCTGCACCGAG CTCGGTGCAGCAGGAGGAC 4285 TCCTCCTGCTGCACCGAGC GCTCGGTGCAGCAGGAGGA 4286 CCTCCTGCTGCACCGAGCT AGCTCGGTGCAGCAGGAGG 4287 CTCCTGCTGCACCGAGCTT AAGCTCGGTGCAGCAGGAG 4288 TCCTGCTGCACCGAGCTTT AAAGCTCGGTGCAGCAGGA 4289 CCTGCTGCACCGAGCTTTG CAAAGCTCGGTGCAGCAGG 4290 CTGCTGCACCGAGCTTTGG CCAAAGCTCGGTGCAGCAG 4291 TGCTGCACCGAGCTTTGGG CCCAAAGCTCGGTGCAGCA 4292 GCTGCACCGAGCTTTGGGG CCCCAAAGCTCGGTGCAGC 4293 CTGCACCGAGCTTTGGGGG CCCCCAAAGCTCGGTGCAG 4294 TGCACCGAGCTTTGGGGGA TCCCCCAAAGCTCGGTGCA 4295 GCACCGAGCTTTGGGGGAT ATCCCCCAAAGCTCGGTGC 4296 CACCGAGCTTTGGGGGATG CATCCCCCAAAGCTCGGTG 4297 ACCGAGCTTTGGGGGATGA TCATCCCCCAAAGCTCGGT 4298 CCGAGCTTTGGGGGATGAG CTCATCCCCCAAAGCTCGG 4299 CGAGCTTTGGGGGATGAGG CCTCATCCCCCAAAGCTCG 4300 GAGCTTTGGGGGATGAGGA TCCTCATCCCCCAAAGCTC 4301 AGCTTTGGGGGATGAGGAC GTCCTCATCCCCCAAAGCT 4302 GCTTTGGGGGATGAGGACA TGTCCTCATCCCCCAAAGC 4303 CTTTGGGGGATGAGGACAC GTGTCCTCATCCCCCAAAG 4304 TTTGGGGGATGAGGACACC GGTGTCCTCATCCCCCAAA 4305 TTGGGGGATGAGGACACCA TGGTGTCCTCATCCCCCAA 4306 TGGGGGATGAGGACACCAG CTGGTGTCCTCATCCCCCA 4307 GGGGGATGAGGACACCAGC GCTGGTGTCCTCATCCCCC 4308 GGGGATGAGGACACCAGCA TGCTGGTGTCCTCATCCCC 4309 GGGATGAGGACACCAGCAG CTGCTGGTGTCCTCATCCC 4310 GGATGAGGACACCAGCAGG CCTGCTGGTGTCCTCATCC 4311 GATGAGGACACCAGCAGGG CCCTGCTGGTGTCCTCATC 4312 ATGAGGACACCAGCAGGGT ACCCTGCTGGTGTCCTCAT 4313 TGAGGACACCAGCAGGGTG CACCCTGCTGGTGTCCTCA 4314 GAGGACACCAGCAGGGTGG CCACCCTGCTGGTGTCCTC 4315 AGGACACCAGCAGGGTGGA TCCACCCTGCTGGTGTCCT 4316 GGACACCAGCAGGGTGGAG CTCCACCCTGCTGGTGTCC 4317 GACACCAGCAGGGTGGAGA TCTCCACCCTGCTGGTGTC 4318 ACACCAGCAGGGTGGAGAA TTCTCCACCCTGCTGGTGT 4319 CACCAGCAGGGTGGAGAAC GTTCTCCACCCTGCTGGTG 4320 ACCAGCAGGGTGGAGAACC GGTTCTCCACCCTGCTGGT 4321 CCAGCAGGGTGGAGAACCT AGGTTCTCCACCCTGCTGG 4322 CAGCAGGGTGGAGAACCTA TAGGTTCTCCACCCTGCTG 4323 AGCAGGGTGGAGAACCTAG CTAGGTTCTCCACCCTGCT 4324 GCAGGGTGGAGAACCTAGC GCTAGGTTCTCCACCCTGC 4325 CAGGGTGGAGAACCTAGCT AGCTAGGTTCTCCACCCTG 4326 AGGGTGGAGAACCTAGCTG CAGCTAGGTTCTCCACCCT 4327 GGGTGGAGAACCTAGCTGC GCAGCTAGGTTCTCCACCC 4328 GGTGGAGAACCTAGCTGCC GGCAGCTAGGTTCTCCACC 4329 GTGGAGAACCTAGCTGCCA TGGCAGCTAGGTTCTCCAC 4330 TGGAGAACCTAGCTGCCAG CTGGCAGCTAGGTTCTCCA 4331 GGAGAACCTAGCTGCCAGT ACTGGCAGCTAGGTTCTCC 4332 GAGAACCTAGCTGCCAGTC GACTGGCAGCTAGGTTCTC 4333 AGAACCTAGCTGCCAGTCT AGACTGGCAGCTAGGTTCT 4334 GAACCTAGCTGCCAGTCTG CAGACTGGCAGCTAGGTTC 4335 AACCTAGCTGCCAGTCTGC GCAGACTGGCAGCTAGGTT 4336 ACCTAGCTGCCAGTCTGCC GGCAGACTGGCAGCTAGGT 4337 CCTAGCTGCCAGTCTGCCA TGGCAGACTGGCAGCTAGG 4338 CTAGCTGCCAGTCTGCCAC GTGGCAGACTGGCAGCTAG 4339 TAGCTGCCAGTCTGCCACT AGTGGCAGACTGGCAGCTA 4340 AGCTGCCAGTCTGCCACTT AAGTGGCAGACTGGCAGCT 4341 GCTGCCAGTCTGCCACTTC GAAGTGGCAGACTGGCAGC 4342 CTGCCAGTCTGCCACTTCC GGAAGTGGCAGACTGGCAG 4343 TGCCAGTCTGCCACTTCCG CGGAAGTGGCAGACTGGCA 4344 GCCAGTCTGCCACTTCCGG CCGGAAGTGGCAGACTGGC 4345 CCAGTCTGCCACTTCCGGA TCCGGAAGTGGCAGACTGG 4346 CAGTCTGCCACTTCCGGAG CTCCGGAAGTGGCAGACTG 4347 AGTCTGCCACTTCCGGAGT ACTCCGGAAGTGGCAGACT 4348 GTCTGCCACTTCCGGAGTA TACTCCGGAAGTGGCAGAC 4349 TCTGCCACTTCCGGAGTAC GTACTCCGGAAGTGGCAGA 4350 CTGCCACTTCCGGAGTACT AGTACTCCGGAAGTGGCAG 4351 TGCCACTTCCGGAGTACTG CAGTACTCCGGAAGTGGCA 4352 GCCACTTCCGGAGTACTGC GCAGTACTCCGGAAGTGGC 4353 CCACTTCCGGAGTACTGCG CGCAGTACTCCGGAAGTGG 4354 CACTTCCGGAGTACTGCGC GCGCAGTACTCCGGAAGTG 4355 ACTTCCGGAGTACTGCGCC GGCGCAGTACTCCGGAAGT 4356 CTTCCGGAGTACTGCGCCC GGGCGCAGTACTCCGGAAG 4357 TTCCGGAGTACTGCGCCCT AGGGCGCAGTACTCCGGAA 4358 TCCGGAGTACTGCGCCCTC GAGGGCGCAGTACTCCGGA 4359 CCGGAGTACTGCGCCCTCC GGAGGGCGCAGTACTCCGG 4360 CGGAGTACTGCGCCCTCCA TGGAGGGCGCAGTACTCCG 4361 GGAGTACTGCGCCCTCCAT ATGGAGGGCGCAGTACTCC 4362 GAGTACTGCGCCCTCCATG CATGGAGGGCGCAGTACTC 4363 AGTACTGCGCCCTCCATGG CCATGGAGGGCGCAGTACT 4364 GTACTGCGCCCTCCATGGA TCCATGGAGGGCGCAGTAC 4365 TACTGCGCCCTCCATGGAA TTCCATGGAGGGCGCAGTA 4366 ACTGCGCCCTCCATGGAAA TTTCCATGGAGGGCGCAGT 4367 CTGCGCCCTCCATGGAAAA TTTTCCATGGAGGGCGCAG 4368 TGCGCCCTCCATGGAAAAC GTTTTCCATGGAGGGCGCA 4369 GCGCCCTCCATGGAAAACT AGTTTTCCATGGAGGGCGC 4370 CGCCCTCCATGGAAAACTC GAGTTTTCCATGGAGGGCG 4371 GCCCTCCATGGAAAACTCA TGAGTTTTCCATGGAGGGC 4372 CCCTCCATGGAAAACTCAA TTGAGTTTTCCATGGAGGG 4373 CCTCCATGGAAAACTCAAC GTTGAGTTTTCCATGGAGG 4374 CTCCATGGAAAACTCAACC GGTTGAGTTTTCCATGGAG 4375 TCCATGGAAAACTCAACCT AGGTTGAGTTTTCCATGGA 4376 CCATGGAAAACTCAACCTG CAGGTTGAGTTTTCCATGG 4377 CATGGAAAACTCAACCTGG CCAGGTTGAGTTTTCCATG 4378 ATGGAAAACTCAACCTGGC GCCAGGTTGAGTTTTCCAT 4379 TGGAAAACTCAACCTGGCT AGCCAGGTTGAGTTTTCCA 4380 GGAAAACTCAACCTGGCTT AAGCCAGGTTGAGTTTTCC 4381 GAAAACTCAACCTGGCTTC GAAGCCAGGTTGAGTTTTC 4382 AAAACTCAACCTGGCTTCC GGAAGCCAGGTTGAGTTTT 4383 AAACTCAACCTGGCTTCCT AGGAAGCCAGGTTGAGTTT 4384 AACTCAACCTGGCTTCCTA TAGGAAGCCAGGTTGAGTT 4385 ACTCAACCTGGCTTCCTAC GTAGGAAGCCAGGTTGAGT 4386 CTCAACCTGGCTTCCTACC GGTAGGAAGCCAGGTTGAG 4387 TCAACCTGGCTTCCTACCT AGGTAGGAAGCCAGGTTGA 4388 CAACCTGGCTTCCTACCTC GAGGTAGGAAGCCAGGTTG 4389 AACCTGGCTTCCTACCTCC GGAGGTAGGAAGCCAGGTT 4390 ACCTGGCTTCCTACCTCCC GGGAGGTAGGAAGCCAGGT 4391 CCTGGCTTCCTACCTCCCA TGGGAGGTAGGAAGCCAGG 4392 CTGGCTTCCTACCTCCCAC GTGGGAGGTAGGAAGCCAG 4393 TGGCTTCCTACCTCCCACC GGTGGGAGGTAGGAAGCCA 4394 GGCTTCCTACCTCCCACCG CGGTGGGAGGTAGGAAGCC 4395 GCTTCCTACCTCCCACCGG CCGGTGGGAGGTAGGAAGC 4396 CTTCCTACCTCCCACCGGG CCCGGTGGGAGGTAGGAAG 4397 TTCCTACCTCCCACCGGGC GCCCGGTGGGAGGTAGGAA 4398 TCCTACCTCCCACCGGGCC GGCCCGGTGGGAGGTAGGA 4399 CCTACCTCCCACCGGGCCT AGGCCCGGTGGGAGGTAGG 4400 CTACCTCCCACCGGGCCTT AAGGCCCGGTGGGAGGTAG 4401 TACCTCCCACCGGGCCTTG CAAGGCCCGGTGGGAGGTA 4402 ACCTCCCACCGGGCCTTGC GCAAGGCCCGGTGGGAGGT 4403 CCTCCCACCGGGCCTTGCC GGCAAGGCCCGGTGGGAGG 4404 CTCCCACCGGGCCTTGCCC GGGCAAGGCCCGGTGGGAG 4405 TCCCACCGGGCCTTGCCCT AGGGCAAGGCCCGGTGGGA 4406 CCCACCGGGCCTTGCCCTG CAGGGCAAGGCCCGGTGGG 4407 CCACCGGGCCTTGCCCTGC GCAGGGCAAGGCCCGGTGG 4408 CACCGGGCCTTGCCCTGCG CGCAGGGCAAGGCCCGGTG 4409 ACCGGGCCTTGCCCTGCGT ACGCAGGGCAAGGCCCGGT 4410 CCGGGCCTTGCCCTGCGTC GACGCAGGGCAAGGCCCGG 4411 CGGGCCTTGCCCTGCGTCC GGACGCAGGGCAAGGCCCG 4412 GGGCCTTGCCCTGCGTCCA TGGACGCAGGGCAAGGCCC 4413 GGCCTTGCCCTGCGTCCAC GTGGACGCAGGGCAAGGCC 4414 GCCTTGCCCTGCGTCCACT AGTGGACGCAGGGCAAGGC 4415 CCTTGCCCTGCGTCCACTG CAGTGGACGCAGGGCAAGG 4416 CTTGCCCTGCGTCCACTGG CCAGTGGACGCAGGGCAAG 4417 TTGCCCTGCGTCCACTGGA TCCAGTGGACGCAGGGCAA 4418 TGCCCTGCGTCCACTGGAG CTCCAGTGGACGCAGGGCA 4419 GCCCTGCGTCCACTGGAGC GCTCCAGTGGACGCAGGGC 4420 CCCTGCGTCCACTGGAGCC GGCTCCAGTGGACGCAGGG 4421 CCTGCGTCCACTGGAGCCC GGGCTCCAGTGGACGCAGG 4422 CTGCGTCCACTGGAGCCCC GGGGCTCCAGTGGACGCAG 4423 TGCGTCCACTGGAGCCCCA TGGGGCTCCAGTGGACGCA 4424 GCGTCCACTGGAGCCCCAG CTGGGGCTCCAGTGGACGC 4425 CGTCCACTGGAGCCCCAGC GCTGGGGCTCCAGTGGACG 4426 GTCCACTGGAGCCCCAGCT AGCTGGGGCTCCAGTGGAC 4427 TCCACTGGAGCCCCAGCTC GAGCTGGGGCTCCAGTGGA 4428 CCACTGGAGCCCCAGCTCT AGAGCTGGGGCTCCAGTGG 4429 CACTGGAGCCCCAGCTCTG CAGAGCTGGGGCTCCAGTG 4430 ACTGGAGCCCCAGCTCTGG CCAGAGCTGGGGCTCCAGT 4431 CTGGAGCCCCAGCTCTGGG CCCAGAGCTGGGGCTCCAG 4432 TGGAGCCCCAGCTCTGGGC GCCCAGAGCTGGGGCTCCA 4433 GGAGCCCCAGCTCTGGGCA TGCCCAGAGCTGGGGCTCC 4434 GAGCCCCAGCTCTGGGCAG CTGCCCAGAGCTGGGGCTC 4435 AGCCCCAGCTCTGGGCAGC GCTGCCCAGAGCTGGGGCT 4436 GCCCCAGCTCTGGGCAGCC GGCTGCCCAGAGCTGGGGC 4437 CCCCAGCTCTGGGCAGCCT AGGCTGCCCAGAGCTGGGG 4438 CCCAGCTCTGGGCAGCCTA TAGGCTGCCCAGAGCTGGG 4439 CCAGCTCTGGGCAGCCTAT ATAGGCTGCCCAGAGCTGG 4440 CAGCTCTGGGCAGCCTATG CATAGGCTGCCCAGAGCTG 4441 AGCTCTGGGCAGCCTATGG CCATAGGCTGCCCAGAGCT 4442 GCTCTGGGCAGCCTATGGT ACCATAGGCTGCCCAGAGC 4443 CTCTGGGCAGCCTATGGTG CACCATAGGCTGCCCAGAG 4444 TCTGGGCAGCCTATGGTGT ACACCATAGGCTGCCCAGA 4445 CTGGGCAGCCTATGGTGTG CACACCATAGGCTGCCCAG 4446 TGGGCAGCCTATGGTGTGA TCACACCATAGGCTGCCCA 4447 GGGCAGCCTATGGTGTGAG CTCACACCATAGGCTGCCC 4448 GGCAGCCTATGGTGTGAGC GCTCACACCATAGGCTGCC 4449 GCAGCCTATGGTGTGAGCC GGCTCACACCATAGGCTGC 4450 CAGCCTATGGTGTGAGCCC GGGCTCACACCATAGGCTG 4451 AGCCTATGGTGTGAGCCCG CGGGCTCACACCATAGGCT 4452 GCCTATGGTGTGAGCCCGC GCGGGCTCACACCATAGGC 4453 CCTATGGTGTGAGCCCGCA TGCGGGCTCACACCATAGG 4454 CTATGGTGTGAGCCCGCAC GTGCGGGCTCACACCATAG 4455 TATGGTGTGAGCCCGCACC GGTGCGGGCTCACACCATA 4456 ATGGTGTGAGCCCGCACCG CGGTGCGGGCTCACACCAT 4457 TGGTGTGAGCCCGCACCGG CCGGTGCGGGCTCACACCA 4458 GGTGTGAGCCCGCACCGGG CCCGGTGCGGGCTCACACC 4459 GTGTGAGCCCGCACCGGGG CCCCGGTGCGGGCTCACAC 4460 TGTGAGCCCGCACCGGGGA TCCCCGGTGCGGGCTCACA 4461 GTGAGCCCGCACCGGGGAC GTCCCCGGTGCGGGCTCAC 4462 TGAGCCCGCACCGGGGACA TGTCCCCGGTGCGGGCTCA 4463 GAGCCCGCACCGGGGACAC GTGTCCCCGGTGCGGGCTC 4464 AGCCCGCACCGGGGACACC GGTGTCCCCGGTGCGGGCT 4465 GCCCGCACCGGGGACACCT AGGTGTCCCCGGTGCGGGC 4466 CCCGCACCGGGGACACCTG CAGGTGTCCCCGGTGCGGG 4467 CCGCACCGGGGACACCTGG CCAGGTGTCCCCGGTGCGG 4468 CGCACCGGGGACACCTGGG CCCAGGTGTCCCCGGTGCG 4469 GCACCGGGGACACCTGGGG CCCCAGGTGTCCCCGGTGC 4470 CACCGGGGACACCTGGGGA TCCCCAGGTGTCCCCGGTG 4471 ACCGGGGACACCTGGGGAC GTCCCCAGGTGTCCCCGGT 4472 CCGGGGACACCTGGGGACC GGTCCCCAGGTGTCCCCGG 4473 CGGGGACACCTGGGGACCA TGGTCCCCAGGTGTCCCCG 4474 GGGGACACCTGGGGACCAA TTGGTCCCCAGGTGTCCCC 4475 GGGACACCTGGGGACCAAG CTTGGTCCCCAGGTGTCCC 4476 GGACACCTGGGGACCAAGA TCTTGGTCCCCAGGTGTCC 4477 GACACCTGGGGACCAAGAA TTCTTGGTCCCCAGGTGTC 4478 ACACCTGGGGACCAAGAAC GTTCTTGGTCCCCAGGTGT 4479 CACCTGGGGACCAAGAACC GGTTCTTGGTCCCCAGGTG 4480 ACCTGGGGACCAAGAACCT AGGTTCTTGGTCCCCAGGT 4481 CCTGGGGACCAAGAACCTC GAGGTTCTTGGTCCCCAGG 4482 CTGGGGACCAAGAACCTCT AGAGGTTCTTGGTCCCCAG 4483 TGGGGACCAAGAACCTCTG CAGAGGTTCTTGGTCCCCA 4484 GGGGACCAAGAACCTCTGT ACAGAGGTTCTTGGTCCCC 4485 GGGACCAAGAACCTCTGTG CACAGAGGTTCTTGGTCCC 4486 GGACCAAGAACCTCTGTGT ACACAGAGGTTCTTGGTCC 4487 GACCAAGAACCTCTGTGTG CACACAGAGGTTCTTGGTC 4488 ACCAAGAACCTCTGTGTGG CCACACAGAGGTTCTTGGT 4489 CCAAGAACCTCTGTGTGGA TCCACACAGAGGTTCTTGG 4490 CAAGAACCTCTGTGTGGAG CTCCACACAGAGGTTCTTG 4491 AAGAACCTCTGTGTGGAGG CCTCCACACAGAGGTTCTT 4492 AGAACCTCTGTGTGGAGGT ACCTCCACACAGAGGTTCT 4493 GAACCTCTGTGTGGAGGTG CACCTCCACACAGAGGTTC 4494 AACCTCTGTGTGGAGGTGG CCACCTCCACACAGAGGTT 4495 ACCTCTGTGTGGAGGTGGC GCCACCTCCACACAGAGGT 4496 CCTCTGTGTGGAGGTGGCC GGCCACCTCCACACAGAGG 4497 CTCTGTGTGGAGGTGGCCG CGGCCACCTCCACACAGAG 4498 TCTGTGTGGAGGTGGCCGA TCGGCCACCTCCACACAGA 4499 CTGTGTGGAGGTGGCCGAC GTCGGCCACCTCCACACAG 4500 TGTGTGGAGGTGGCCGACC GGTCGGCCACCTCCACACA 4501 GTGTGGAGGTGGCCGACCT AGGTCGGCCACCTCCACAC 4502 TGTGGAGGTGGCCGACCTG CAGGTCGGCCACCTCCACA 4503 GTGGAGGTGGCCGACCTGG CCAGGTCGGCCACCTCCAC 4504 TGGAGGTGGCCGACCTGGT ACCAGGTCGGCCACCTCCA 4505 GGAGGTGGCCGACCTGGTC GACCAGGTCGGCCACCTCC 4506 GAGGTGGCCGACCTGGTCA TGACCAGGTCGGCCACCTC 4507 AGGTGGCCGACCTGGTCAG CTGACCAGGTCGGCCACCT 4508 GGTGGCCGACCTGGTCAGC GCTGACCAGGTCGGCCACC 4509 GTGGCCGACCTGGTCAGCA TGCTGACCAGGTCGGCCAC 4510 TGGCCGACCTGGTCAGCAT ATGCTGACCAGGTCGGCCA 4511 GGCCGACCTGGTCAGCATC GATGCTGACCAGGTCGGCC 4512 GCCGACCTGGTCAGCATCC GGATGCTGACCAGGTCGGC 4513 CCGACCTGGTCAGCATCCT AGGATGCTGACCAGGTCGG 4514 CGACCTGGTCAGCATCCTG CAGGATGCTGACCAGGTCG 4515 GACCTGGTCAGCATCCTGG CCAGGATGCTGACCAGGTC 4516 ACCTGGTCAGCATCCTGGT ACCAGGATGCTGACCAGGT 4517 CCTGGTCAGCATCCTGGTG CACCAGGATGCTGACCAGG 4518 CTGGTCAGCATCCTGGTGC GCACCAGGATGCTGACCAG 4519 TGGTCAGCATCCTGGTGCA TGCACCAGGATGCTGACCA 4520 GGTCAGCATCCTGGTGCAT ATGCACCAGGATGCTGACC 4521 GTCAGCATCCTGGTGCATG CATGCACCAGGATGCTGAC 4522 TCAGCATCCTGGTGCATGC GCATGCACCAGGATGCTGA 4523 CAGCATCCTGGTGCATGCC GGCATGCACCAGGATGCTG 4524 AGCATCCTGGTGCATGCCG CGGCATGCACCAGGATGCT 4525 GCATCCTGGTGCATGCCGA TCGGCATGCACCAGGATGC 4526 CATCCTGGTGCATGCCGAC GTCGGCATGCACCAGGATG 4527 ATCCTGGTGCATGCCGACA TGTCGGCATGCACCAGGAT 4528 TCCTGGTGCATGCCGACAC GTGTCGGCATGCACCAGGA 4529 CCTGGTGCATGCCGACACA TGTGTCGGCATGCACCAGG 4530 CTGGTGCATGCCGACACAC GTGTGTCGGCATGCACCAG 4531 TGGTGCATGCCGACACACC GGTGTGTCGGCATGCACCA 4532 GGTGCATGCCGACACACCA TGGTGTGTCGGCATGCACC 4533 GTGCATGCCGACACACCAC GTGGTGTGTCGGCATGCAC 4534 TGCATGCCGACACACCACT AGTGGTGTGTCGGCATGCA 4535 GCATGCCGACACACCACTG CAGTGGTGTGTCGGCATGC 4536 CATGCCGACACACCACTGC GCAGTGGTGTGTCGGCATG 4537 ATGCCGACACACCACTGCC GGCAGTGGTGTGTCGGCAT 4538 TGCCGACACACCACTGCCT AGGCAGTGGTGTGTCGGCA 4539 GCCGACACACCACTGCCTG CAGGCAGTGGTGTGTCGGC 4540 CCGACACACCACTGCCTGC GCAGGCAGTGGTGTGTCGG 4541 CGACACACCACTGCCTGCC GGCAGGCAGTGGTGTGTCG 4542 GACACACCACTGCCTGCCT AGGCAGGCAGTGGTGTGTC 4543 ACACACCACTGCCTGCCTG CAGGCAGGCAGTGGTGTGT 4544 CACACCACTGCCTGCCTGG CCAGGCAGGCAGTGGTGTG 4545 ACACCACTGCCTGCCTGGC GCCAGGCAGGCAGTGGTGT 4546 CACCACTGCCTGCCTGGCA TGCCAGGCAGGCAGTGGTG 4547 ACCACTGCCTGCCTGGCAC GTGCCAGGCAGGCAGTGGT 4548 CCACTGCCTGCCTGGCACC GGTGCCAGGCAGGCAGTGG 4549 CACTGCCTGCCTGGCACCG CGGTGCCAGGCAGGCAGTG 4550 ACTGCCTGCCTGGCACCGG CCGGTGCCAGGCAGGCAGT 4551 CTGCCTGCCTGGCACCGGG CCCGGTGCCAGGCAGGCAG 4552 TGCCTGCCTGGCACCGGGC GCCCGGTGCCAGGCAGGCA 4553 GCCTGCCTGGCACCGGGCA TGCCCGGTGCCAGGCAGGC 4554 CCTGCCTGGCACCGGGCAC GTGCCCGGTGCCAGGCAGG 4555 CTGCCTGGCACCGGGCACA TGTGCCCGGTGCCAGGCAG 4556 TGCCTGGCACCGGGCACAG CTGTGCCCGGTGCCAGGCA 4557 GCCTGGCACCGGGCACAGA TCTGTGCCCGGTGCCAGGC 4558 CCTGGCACCGGGCACAGAA TTCTGTGCCCGGTGCCAGG 4559 CTGGCACCGGGCACAGAAA TTTCTGTGCCCGGTGCCAG 4560 TGGCACCGGGCACAGAAAG CTTTCTGTGCCCGGTGCCA 4561 GGCACCGGGCACAGAAAGA TCTTTCTGTGCCCGGTGCC 4562 GCACCGGGCACAGAAAGAC GTCTTTCTGTGCCCGGTGC 4563 CACCGGGCACAGAAAGACT AGTCTTTCTGTGCCCGGTG 4564 ACCGGGCACAGAAAGACTT AAGTCTTTCTGTGCCCGGT 4565 CCGGGCACAGAAAGACTTC GAAGTCTTTCTGTGCCCGG 4566 CGGGCACAGAAAGACTTCC GGAAGTCTTTCTGTGCCCG 4567 GGGCACAGAAAGACTTCCT AGGAAGTCTTTCTGTGCCC 4568 GGCACAGAAAGACTTCCTT AAGGAAGTCTTTCTGTGCC 4569 GCACAGAAAGACTTCCTTT AAAGGAAGTCTTTCTGTGC 4570 CACAGAAAGACTTCCTTTC GAAAGGAAGTCTTTCTGTG 4571 ACAGAAAGACTTCCTTTCA TGAAAGGAAGTCTTTCTGT 4572 CAGAAAGACTTCCTTTCAG CTGAAAGGAAGTCTTTCTG 4573 AGAAAGACTTCCTTTCAGG CCTGAAAGGAAGTCTTTCT 4574 GAAAGACTTCCTTTCAGGC GCCTGAAAGGAAGTCTTTC 4575 AAAGACTTCCTTTCAGGCC GGCCTGAAAGGAAGTCTTT 4576 AAGACTTCCTTTCAGGCCT AGGCCTGAAAGGAAGTCTT 4577 AGACTTCCTTTCAGGCCTG CAGGCCTGAAAGGAAGTCT 4578 GACTTCCTTTCAGGCCTGG CCAGGCCTGAAAGGAAGTC 4579 ACTTCCTTTCAGGCCTGGA TCCAGGCCTGAAAGGAAGT 4580 CTTCCTTTCAGGCCTGGAC GTCCAGGCCTGAAAGGAAG 4581 TTCCTTTCAGGCCTGGACG CGTCCAGGCCTGAAAGGAA 4582 TCCTTTCAGGCCTGGACGG CCGTCCAGGCCTGAAAGGA 4583 CCTTTCAGGCCTGGACGGG CCCGTCCAGGCCTGAAAGG 4584 CTTTCAGGCCTGGACGGGG CCCCGTCCAGGCCTGAAAG 4585 TTTCAGGCCTGGACGGGGA TCCCCGTCCAGGCCTGAAA 4586 TTCAGGCCTGGACGGGGAG CTCCCCGTCCAGGCCTGAA 4587 TCAGGCCTGGACGGGGAGG CCTCCCCGTCCAGGCCTGA 4588 CAGGCCTGGACGGGGAGGG CCCTCCCCGTCCAGGCCTG 4589 AGGCCTGGACGGGGAGGGG CCCCTCCCCGTCCAGGCCT 4590 GGCCTGGACGGGGAGGGGC GCCCCTCCCCGTCCAGGCC 4591 GCCTGGACGGGGAGGGGCT AGCCCCTCCCCGTCCAGGC 4592 CCTGGACGGGGAGGGGCTC GAGCCCCTCCCCGTCCAGG 4593 CTGGACGGGGAGGGGCTCT AGAGCCCCTCCCCGTCCAG 4594 TGGACGGGGAGGGGCTCTG CAGAGCCCCTCCCCGTCCA 4595 GGACGGGGAGGGGCTCTGG CCAGAGCCCCTCCCCGTCC 4596 GACGGGGAGGGGCTCTGGT ACCAGAGCCCCTCCCCGTC 4597 ACGGGGAGGGGCTCTGGTC GACCAGAGCCCCTCCCCGT 4598 CGGGGAGGGGCTCTGGTCT AGACCAGAGCCCCTCCCCG 4599 GGGGAGGGGCTCTGGTCTC GAGACCAGAGCCCCTCCCC 4600 GGGAGGGGCTCTGGTCTCC GGAGACCAGAGCCCCTCCC 4601 GGAGGGGCTCTGGTCTCCG CGGAGACCAGAGCCCCTCC 4602 GAGGGGCTCTGGTCTCCGG CCGGAGACCAGAGCCCCTC 4603 AGGGGCTCTGGTCTCCGGG CCCGGAGACCAGAGCCCCT 4604 GGGGCTCTGGTCTCCGGGC GCCCGGAGACCAGAGCCCC 4605 GGGCTCTGGTCTCCGGGCA TGCCCGGAGACCAGAGCCC 4606 GGCTCTGGTCTCCGGGCAG CTGCCCGGAGACCAGAGCC 4607 GCTCTGGTCTCCGGGCAGC GCTGCCCGGAGACCAGAGC 4608 CTCTGGTCTCCGGGCAGCC GGCTGCCCGGAGACCAGAG 4609 TCTGGTCTCCGGGCAGCCA TGGCTGCCCGGAGACCAGA 4610 CTGGTCTCCGGGCAGCCAG CTGGCTGCCCGGAGACCAG 4611 TGGTCTCCGGGCAGCCAGG CCTGGCTGCCCGGAGACCA 4612 GGTCTCCGGGCAGCCAGGT ACCTGGCTGCCCGGAGACC 4613 GTCTCCGGGCAGCCAGGTC GACCTGGCTGCCCGGAGAC 4614 TCTCCGGGCAGCCAGGTCA TGACCTGGCTGCCCGGAGA 4615 CTCCGGGCAGCCAGGTCAG CTGACCTGGCTGCCCGGAG 4616 TCCGGGCAGCCAGGTCAGC GCTGACCTGGCTGCCCGGA 4617 CCGGGCAGCCAGGTCAGCA TGCTGACCTGGCTGCCCGG 4618 CGGGCAGCCAGGTCAGCAC GTGCTGACCTGGCTGCCCG 4619 GGGCAGCCAGGTCAGCACT AGTGCTGACCTGGCTGCCC 4620 GGCAGCCAGGTCAGCACTG CAGTGCTGACCTGGCTGCC 4621 GCAGCCAGGTCAGCACTGT ACAGTGCTGACCTGGCTGC 4622 CAGCCAGGTCAGCACTGTG CACAGTGCTGACCTGGCTG 4623 AGCCAGGTCAGCACTGTGT ACACAGTGCTGACCTGGCT 4624 GCCAGGTCAGCACTGTGTG CACACAGTGCTGACCTGGC 4625 CCAGGTCAGCACTGTGTGG CCACACAGTGCTGACCTGG 4626 CAGGTCAGCACTGTGTGGC GCCACACAGTGCTGACCTG 4627 AGGTCAGCACTGTGTGGCA TGCCACACAGTGCTGACCT 4628 GGTCAGCACTGTGTGGCAC GTGCCACACAGTGCTGACC 4629 GTCAGCACTGTGTGGCACG CGTGCCACACAGTGCTGAC 4630 TCAGCACTGTGTGGCACGT ACGTGCCACACAGTGCTGA 4631 CAGCACTGTGTGGCACGTG CACGTGCCACACAGTGCTG 4632 AGCACTGTGTGGCACGTGT ACACGTGCCACACAGTGCT 4633 GCACTGTGTGGCACGTGTT AACACGTGCCACACAGTGC 4634 CACTGTGTGGCACGTGTTC GAACACGTGCCACACAGTG 4635 ACTGTGTGGCACGTGTTCC GGAACACGTGCCACACAGT 4636 CTGTGTGGCACGTGTTCCG CGGAACACGTGCCACACAG 4637 TGTGTGGCACGTGTTCCGG CCGGAACACGTGCCACACA 4638 GTGTGGCACGTGTTCCGGG CCCGGAACACGTGCCACAC 4639 TGTGGCACGTGTTCCGGGC GCCCGGAACACGTGCCACA 4640 GTGGCACGTGTTCCGGGCA TGCCCGGAACACGTGCCAC 4641 TGGCACGTGTTCCGGGCAC GTGCCCGGAACACGTGCCA 4642 GGCACGTGTTCCGGGCACA TGTGCCCGGAACACGTGCC 4643 GCACGTGTTCCGGGCACAG CTGTGCCCGGAACACGTGC 4644 CACGTGTTCCGGGCACAGG CCTGTGCCCGGAACACGTG 4645 ACGTGTTCCGGGCACAGGA TCCTGTGCCCGGAACACGT 4646 CGTGTTCCGGGCACAGGAC GTCCTGTGCCCGGAACACG 4647 GTGTTCCGGGCACAGGACG CGTCCTGTGCCCGGAACAC 4648 TGTTCCGGGCACAGGACGC GCGTCCTGTGCCCGGAACA 4649 GTTCCGGGCACAGGACGCC GGCGTCCTGTGCCCGGAAC 4650 TTCCGGGCACAGGACGCCC GGGCGTCCTGTGCCCGGAA 4651 TCCGGGCACAGGACGCCCA TGGGCGTCCTGTGCCCGGA 4652 CCGGGCACAGGACGCCCAG CTGGGCGTCCTGTGCCCGG 4653 CGGGCACAGGACGCCCAGC GCTGGGCGTCCTGTGCCCG 4654 GGGCACAGGACGCCCAGCG CGCTGGGCGTCCTGTGCCC 4655 GGCACAGGACGCCCAGCGC GCGCTGGGCGTCCTGTGCC 4656 GCACAGGACGCCCAGCGCA TGCGCTGGGCGTCCTGTGC 4657 CACAGGACGCCCAGCGCAT ATGCGCTGGGCGTCCTGTG 4658 ACAGGACGCCCAGCGCATC GATGCGCTGGGCGTCCTGT 4659 CAGGACGCCCAGCGCATCC GGATGCGCTGGGCGTCCTG 4660 AGGACGCCCAGCGCATCCG CGGATGCGCTGGGCGTCCT 4661 GGACGCCCAGCGCATCCGC GCGGATGCGCTGGGCGTCC 4662 GACGCCCAGCGCATCCGCC GGCGGATGCGCTGGGCGTC 4663 ACGCCCAGCGCATCCGCCG CGGCGGATGCGCTGGGCGT 4664 CGCCCAGCGCATCCGCCGC GCGGCGGATGCGCTGGGCG 4665 GCCCAGCGCATCCGCCGCT AGCGGCGGATGCGCTGGGC 4666 CCCAGCGCATCCGCCGCTT AAGCGGCGGATGCGCTGGG 4667 CCAGCGCATCCGCCGCTTT AAAGCGGCGGATGCGCTGG 4668 CAGCGCATCCGCCGCTTTC GAAAGCGGCGGATGCGCTG 4669 AGCGCATCCGCCGCTTTCT AGAAAGCGGCGGATGCGCT 4670 GCGCATCCGCCGCTTTCTC GAGAAAGCGGCGGATGCGC 4671 CGCATCCGCCGCTTTCTCC GGAGAAAGCGGCGGATGCG 4672 GCATCCGCCGCTTTCTCCA TGGAGAAAGCGGCGGATGC 4673 CATCCGCCGCTTTCTCCAG CTGGAGAAAGCGGCGGATG 4674 ATCCGCCGCTTTCTCCAGA TCTGGAGAAAGCGGCGGAT 4675 TCCGCCGCTTTCTCCAGAT ATCTGGAGAAAGCGGCGGA 4676 CCGCCGCTTTCTCCAGATG CATCTGGAGAAAGCGGCGG 4677 CGCCGCTTTCTCCAGATGG CCATCTGGAGAAAGCGGCG 4678 GCCGCTTTCTCCAGATGGT ACCATCTGGAGAAAGCGGC 4679 CCGCTTTCTCCAGATGGTG CACCATCTGGAGAAAGCGG 4680 CGCTTTCTCCAGATGGTGT ACACCATCTGGAGAAAGCG 4681 GCTTTCTCCAGATGGTGTG CACACCATCTGGAGAAAGC 4682 CTTTCTCCAGATGGTGTGC GCACACCATCTGGAGAAAG 4683 TTTCTCCAGATGGTGTGCC GGCACACCATCTGGAGAAA 4684 TTCTCCAGATGGTGTGCCC GGGCACACCATCTGGAGAA 4685 TCTCCAGATGGTGTGCCCG CGGGCACACCATCTGGAGA 4686 CTCCAGATGGTGTGCCCGG CCGGGCACACCATCTGGAG 4687 TCCAGATGGTGTGCCCGGC GCCGGGCACACCATCTGGA 4688 CCAGATGGTGTGCCCGGCC GGCCGGGCACACCATCTGG 4689 CAGATGGTGTGCCCGGCCG CGGCCGGGCACACCATCTG 4690 AGATGGTGTGCCCGGCCGG CCGGCCGGGCACACCATCT 4691 GATGGTGTGCCCGGCCGGG CCCGGCCGGGCACACCATC 4692 ATGGTGTGCCCGGCCGGGG CCCCGGCCGGGCACACCAT 4693 TGGTGTGCCCGGCCGGGGC GCCCCGGCCGGGCACACCA 4694 GGTGTGCCCGGCCGGGGCA TGCCCCGGCCGGGCACACC 4695 GTGTGCCCGGCCGGGGCAG CTGCCCCGGCCGGGCACAC 4696 TGTGCCCGGCCGGGGCAGG CCTGCCCCGGCCGGGCACA 4697 GTGCCCGGCCGGGGCAGGC GCCTGCCCCGGCCGGGCAC 4698 TGCCCGGCCGGGGCAGGCG CGCCTGCCCCGGCCGGGCA 4699 GCCCGGCCGGGGCAGGCGC GCGCCTGCCCCGGCCGGGC 4700 CCCGGCCGGGGCAGGCGCC GGCGCCTGCCCCGGCCGGG 4701 CCGGCCGGGGCAGGCGCCC GGGCGCCTGCCCCGGCCGG 4702 CGGCCGGGGCAGGCGCCCT AGGGCGCCTGCCCCGGCCG 4703 GGCCGGGGCAGGCGCCCTG CAGGGCGCCTGCCCCGGCC 4704 GCCGGGGCAGGCGCCCTGG CCAGGGCGCCTGCCCCGGC 4705 CCGGGGCAGGCGCCCTGGA TCCAGGGCGCCTGCCCCGG 4706 CGGGGCAGGCGCCCTGGAG CTCCAGGGCGCCTGCCCCG 4707 GGGGCAGGCGCCCTGGAGC GCTCCAGGGCGCCTGCCCC 4708 GGGCAGGCGCCCTGGAGCC GGCTCCAGGGCGCCTGCCC 4709 GGCAGGCGCCCTGGAGCCT AGGCTCCAGGGCGCCTGCC 4710 GCAGGCGCCCTGGAGCCTG CAGGCTCCAGGGCGCCTGC 4711 CAGGCGCCCTGGAGCCTGG CCAGGCTCCAGGGCGCCTG 4712 AGGCGCCCTGGAGCCTGGC GCCAGGCTCCAGGGCGCCT 4713 GGCGCCCTGGAGCCTGGCG CGCCAGGCTCCAGGGCGCC 4714 GCGCCCTGGAGCCTGGCGC GCGCCAGGCTCCAGGGCGC 4715 CGCCCTGGAGCCTGGCGCC GGCGCCAGGCTCCAGGGCG 4716 GCCCTGGAGCCTGGCGCCC GGGCGCCAGGCTCCAGGGC 4717 CCCTGGAGCCTGGCGCCCC GGGGCGCCAGGCTCCAGGG 4718 CCTGGAGCCTGGCGCCCCA TGGGGCGCCAGGCTCCAGG 4719 CTGGAGCCTGGCGCCCCAG CTGGGGCGCCAGGCTCCAG 4720 TGGAGCCTGGCGCCCCAGG CCTGGGGCGCCAGGCTCCA 4721 GGAGCCTGGCGCCCCAGGC GCCTGGGGCGCCAGGCTCC 4722 GAGCCTGGCGCCCCAGGCA TGCCTGGGGCGCCAGGCTC 4723 AGCCTGGCGCCCCAGGCAG CTGCCTGGGGCGCCAGGCT 4724 GCCTGGCGCCCCAGGCAGC GCTGCCTGGGGCGCCAGGC 4725 CCTGGCGCCCCAGGCAGCT AGCTGCCTGGGGCGCCAGG 4726 CTGGCGCCCCAGGCAGCTG CAGCTGCCTGGGGCGCCAG 4727 TGGCGCCCCAGGCAGCTGC GCAGCTGCCTGGGGCGCCA 4728 GGCGCCCCAGGCAGCTGCT AGCAGCTGCCTGGGGCGCC 4729 GCGCCCCAGGCAGCTGCTA TAGCAGCTGCCTGGGGCGC 4730 CGCCCCAGGCAGCTGCTAC GTAGCAGCTGCCTGGGGCG 4731 GCCCCAGGCAGCTGCTACC GGTAGCAGCTGCCTGGGGC 4732 CCCCAGGCAGCTGCTACCT AGGTAGCAGCTGCCTGGGG 4733 CCCAGGCAGCTGCTACCTG CAGGTAGCAGCTGCCTGGG 4734 CCAGGCAGCTGCTACCTGG CCAGGTAGCAGCTGCCTGG 4735 CAGGCAGCTGCTACCTGGA TCCAGGTAGCAGCTGCCTG 4736 AGGCAGCTGCTACCTGGAT ATCCAGGTAGCAGCTGCCT 4737 GGCAGCTGCTACCTGGATG CATCCAGGTAGCAGCTGCC 4738 GCAGCTGCTACCTGGATGC GCATCCAGGTAGCAGCTGC 4739 CAGCTGCTACCTGGATGCA TGCATCCAGGTAGCAGCTG 4740 AGCTGCTACCTGGATGCAG CTGCATCCAGGTAGCAGCT 4741 GCTGCTACCTGGATGCAGG CCTGCATCCAGGTAGCAGC 4742 CTGCTACCTGGATGCAGGG CCCTGCATCCAGGTAGCAG 4743 TGCTACCTGGATGCAGGGC GCCCTGCATCCAGGTAGCA 4744 GCTACCTGGATGCAGGGCT AGCCCTGCATCCAGGTAGC 4745 CTACCTGGATGCAGGGCTG CAGCCCTGCATCCAGGTAG 4746 TACCTGGATGCAGGGCTGC GCAGCCCTGCATCCAGGTA 4747 ACCTGGATGCAGGGCTGCG CGCAGCCCTGCATCCAGGT 4748 CCTGGATGCAGGGCTGCGG CCGCAGCCCTGCATCCAGG 4749 CTGGATGCAGGGCTGCGGC GCCGCAGCCCTGCATCCAG 4750 TGGATGCAGGGCTGCGGCG CGCCGCAGCCCTGCATCCA 4751 GGATGCAGGGCTGCGGCGG CCGCCGCAGCCCTGCATCC 4752 GATGCAGGGCTGCGGCGGC GCCGCCGCAGCCCTGCATC 4753 ATGCAGGGCTGCGGCGGCG CGCCGCCGCAGCCCTGCAT 4754 TGCAGGGCTGCGGCGGCGC GCGCCGCCGCAGCCCTGCA 4755 GCAGGGCTGCGGCGGCGCC GGCGCCGCCGCAGCCCTGC 4756 CAGGGCTGCGGCGGCGCCT AGGCGCCGCCGCAGCCCTG 4757 AGGGCTGCGGCGGCGCCTG CAGGCGCCGCCGCAGCCCT 4758 GGGCTGCGGCGGCGCCTGC GCAGGCGCCGCCGCAGCCC 4759 GGCTGCGGCGGCGCCTGCG CGCAGGCGCCGCCGCAGCC 4760 GCTGCGGCGGCGCCTGCGG CCGCAGGCGCCGCCGCAGC 4761 CTGCGGCGGCGCCTGCGGG CCCGCAGGCGCCGCCGCAG 4762 TGCGGCGGCGCCTGCGGGA TCCCGCAGGCGCCGCCGCA 4763 GCGGCGGCGCCTGCGGGAG CTCCCGCAGGCGCCGCCGC 4764 CGGCGGCGCCTGCGGGAGG CCTCCCGCAGGCGCCGCCG 4765 GGCGGCGCCTGCGGGAGGA TCCTCCCGCAGGCGCCGCC 4766 GCGGCGCCTGCGGGAGGAG CTCCTCCCGCAGGCGCCGC 4767 CGGCGCCTGCGGGAGGAGT ACTCCTCCCGCAGGCGCCG 4768 GGCGCCTGCGGGAGGAGTG CACTCCTCCCGCAGGCGCC 4769 GCGCCTGCGGGAGGAGTGG CCACTCCTCCCGCAGGCGC 4770 CGCCTGCGGGAGGAGTGGG CCCACTCCTCCCGCAGGCG 4771 GCCTGCGGGAGGAGTGGGG CCCCACTCCTCCCGCAGGC 4772 CCTGCGGGAGGAGTGGGGC GCCCCACTCCTCCCGCAGG 4773 CTGCGGGAGGAGTGGGGCG CGCCCCACTCCTCCCGCAG 4774 TGCGGGAGGAGTGGGGCGT ACGCCCCACTCCTCCCGCA 4775 GCGGGAGGAGTGGGGCGTG CACGCCCCACTCCTCCCGC 4776 CGGGAGGAGTGGGGCGTGA TCACGCCCCACTCCTCCCG 4777 GGGAGGAGTGGGGCGTGAG CTCACGCCCCACTCCTCCC 4778 GGAGGAGTGGGGCGTGAGC GCTCACGCCCCACTCCTCC 4779 GAGGAGTGGGGCGTGAGCT AGCTCACGCCCCACTCCTC 4780 AGGAGTGGGGCGTGAGCTG CAGCTCACGCCCCACTCCT 4781 GGAGTGGGGCGTGAGCTGC GCAGCTCACGCCCCACTCC 4782 GAGTGGGGCGTGAGCTGCT AGCAGCTCACGCCCCACTC 4783 AGTGGGGCGTGAGCTGCTG CAGCAGCTCACGCCCCACT 4784 GTGGGGCGTGAGCTGCTGG CCAGCAGCTCACGCCCCAC 4785 TGGGGCGTGAGCTGCTGGA TCCAGCAGCTCACGCCCCA 4786 GGGGCGTGAGCTGCTGGAC GTCCAGCAGCTCACGCCCC 4787 GGGCGTGAGCTGCTGGACC GGTCCAGCAGCTCACGCCC 4788 GGCGTGAGCTGCTGGACCC GGGTCCAGCAGCTCACGCC 4789 GCGTGAGCTGCTGGACCCT AGGGTCCAGCAGCTCACGC 4790 CGTGAGCTGCTGGACCCTG CAGGGTCCAGCAGCTCACG 4791 GTGAGCTGCTGGACCCTGC GCAGGGTCCAGCAGCTCAC 4792 TGAGCTGCTGGACCCTGCT AGCAGGGTCCAGCAGCTCA 4793 GAGCTGCTGGACCCTGCTC GAGCAGGGTCCAGCAGCTC 4794 AGCTGCTGGACCCTGCTCC GGAGCAGGGTCCAGCAGCT 4795 GCTGCTGGACCCTGCTCCA TGGAGCAGGGTCCAGCAGC 4796 CTGCTGGACCCTGCTCCAG CTGGAGCAGGGTCCAGCAG 4797 TGCTGGACCCTGCTCCAGG CCTGGAGCAGGGTCCAGCA 4798 GCTGGACCCTGCTCCAGGC GCCTGGAGCAGGGTCCAGC 4799 CTGGACCCTGCTCCAGGCC GGCCTGGAGCAGGGTCCAG 4800 TGGACCCTGCTCCAGGCCC GGGCCTGGAGCAGGGTCCA 4801 GGACCCTGCTCCAGGCCCC GGGGCCTGGAGCAGGGTCC 4802 GACCCTGCTCCAGGCCCCC GGGGGCCTGGAGCAGGGTC 4803 ACCCTGCTCCAGGCCCCCG CGGGGGCCTGGAGCAGGGT 4804 CCCTGCTCCAGGCCCCCGG CCGGGGGCCTGGAGCAGGG 4805 CCTGCTCCAGGCCCCCGGA TCCGGGGGCCTGGAGCAGG 4806 CTGCTCCAGGCCCCCGGAG CTCCGGGGGCCTGGAGCAG 4807 TGCTCCAGGCCCCCGGAGA TCTCCGGGGGCCTGGAGCA 4808 GCTCCAGGCCCCCGGAGAG CTCTCCGGGGGCCTGGAGC 4809 CTCCAGGCCCCCGGAGAGG CCTCTCCGGGGGCCTGGAG 4810 TCCAGGCCCCCGGAGAGGC GCCTCTCCGGGGGCCTGGA 4811 CCAGGCCCCCGGAGAGGCC GGCCTCTCCGGGGGCCTGG 4812 CAGGCCCCCGGAGAGGCCG CGGCCTCTCCGGGGGCCTG 4813 AGGCCCCCGGAGAGGCCGT ACGGCCTCTCCGGGGGCCT 4814 GGCCCCCGGAGAGGCCGTG CACGGCCTCTCCGGGGGCC 4815 GCCCCCGGAGAGGCCGTGC GCACGGCCTCTCCGGGGGC 4816 CCCCCGGAGAGGCCGTGCT AGCACGGCCTCTCCGGGGG 4817 CCCCGGAGAGGCCGTGCTG CAGCACGGCCTCTCCGGGG 4818 CCCGGAGAGGCCGTGCTGG CCAGCACGGCCTCTCCGGG 4819 CCGGAGAGGCCGTGCTGGT ACCAGCACGGCCTCTCCGG 4820 CGGAGAGGCCGTGCTGGTG CACCAGCACGGCCTCTCCG 4821 GGAGAGGCCGTGCTGGTGC GCACCAGCACGGCCTCTCC 4822 GAGAGGCCGTGCTGGTGCC GGCACCAGCACGGCCTCTC 4823 AGAGGCCGTGCTGGTGCCT AGGCACCAGCACGGCCTCT 4824 GAGGCCGTGCTGGTGCCTG CAGGCACCAGCACGGCCTC 4825 AGGCCGTGCTGGTGCCTGC GCAGGCACCAGCACGGCCT 4826 GGCCGTGCTGGTGCCTGCA TGCAGGCACCAGCACGGCC 4827 GCCGTGCTGGTGCCTGCAG CTGCAGGCACCAGCACGGC 4828 CCGTGCTGGTGCCTGCAGG CCTGCAGGCACCAGCACGG 4829 CGTGCTGGTGCCTGCAGGG CCCTGCAGGCACCAGCACG 4830 GTGCTGGTGCCTGCAGGGG CCCCTGCAGGCACCAGCAC 4831 TGCTGGTGCCTGCAGGGGC GCCCCTGCAGGCACCAGCA 4832 GCTGGTGCCTGCAGGGGCT AGCCCCTGCAGGCACCAGC 4833 CTGGTGCCTGCAGGGGCTC GAGCCCCTGCAGGCACCAG 4834 TGGTGCCTGCAGGGGCTCC GGAGCCCCTGCAGGCACCA 4835 GGTGCCTGCAGGGGCTCCC GGGAGCCCCTGCAGGCACC 4836 GTGCCTGCAGGGGCTCCCC GGGGAGCCCCTGCAGGCAC 4837 TGCCTGCAGGGGCTCCCCA TGGGGAGCCCCTGCAGGCA 4838 GCCTGCAGGGGCTCCCCAC GTGGGGAGCCCCTGCAGGC 4839 CCTGCAGGGGCTCCCCACC GGTGGGGAGCCCCTGCAGG 4840 CTGCAGGGGCTCCCCACCA TGGTGGGGAGCCCCTGCAG 4841 TGCAGGGGCTCCCCACCAG CTGGTGGGGAGCCCCTGCA 4842 GCAGGGGCTCCCCACCAGG CCTGGTGGGGAGCCCCTGC 4843 CAGGGGCTCCCCACCAGGT ACCTGGTGGGGAGCCCCTG 4844 AGGGGCTCCCCACCAGGTG CACCTGGTGGGGAGCCCCT 4845 GGGGCTCCCCACCAGGTGC GCACCTGGTGGGGAGCCCC 4846 GGGCTCCCCACCAGGTGCA TGCACCTGGTGGGGAGCCC 4847 GGCTCCCCACCAGGTGCAG CTGCACCTGGTGGGGAGCC 4848 GCTCCCCACCAGGTGCAGG CCTGCACCTGGTGGGGAGC 4849 CTCCCCACCAGGTGCAGGG CCCTGCACCTGGTGGGGAG 4850 TCCCCACCAGGTGCAGGGC GCCCTGCACCTGGTGGGGA 4851 CCCCACCAGGTGCAGGGCC GGCCCTGCACCTGGTGGGG 4852 CCCACCAGGTGCAGGGCCT AGGCCCTGCACCTGGTGGG 4853 CCACCAGGTGCAGGGCCTG CAGGCCCTGCACCTGGTGG 4854 CACCAGGTGCAGGGCCTGG CCAGGCCCTGCACCTGGTG 4855 ACCAGGTGCAGGGCCTGGT ACCAGGCCCTGCACCTGGT 4856 CCAGGTGCAGGGCCTGGTG CACCAGGCCCTGCACCTGG 4857 CAGGTGCAGGGCCTGGTGA TCACCAGGCCCTGCACCTG 4858 AGGTGCAGGGCCTGGTGAG CTCACCAGGCCCTGCACCT 4859 GGTGCAGGGCCTGGTGAGC GCTCACCAGGCCCTGCACC 4860 GTGCAGGGCCTGGTGAGCA TGCTCACCAGGCCCTGCAC 4861 TGCAGGGCCTGGTGAGCAC GTGCTCACCAGGCCCTGCA 4862 GCAGGGCCTGGTGAGCACA TGTGCTCACCAGGCCCTGC 4863 CAGGGCCTGGTGAGCACAG CTGTGCTCACCAGGCCCTG 4864 AGGGCCTGGTGAGCACAGT ACTGTGCTCACCAGGCCCT 4865 GGGCCTGGTGAGCACAGTC GACTGTGCTCACCAGGCCC 4866 GGCCTGGTGAGCACAGTCA TGACTGTGCTCACCAGGCC 4867 GCCTGGTGAGCACAGTCAG CTGACTGTGCTCACCAGGC 4868 CCTGGTGAGCACAGTCAGC GCTGACTGTGCTCACCAGG 4869 CTGGTGAGCACAGTCAGCG CGCTGACTGTGCTCACCAG 4870 TGGTGAGCACAGTCAGCGT ACGCTGACTGTGCTCACCA 4871 GGTGAGCACAGTCAGCGTC GACGCTGACTGTGCTCACC 4872 GTGAGCACAGTCAGCGTCA TGACGCTGACTGTGCTCAC 4873 TGAGCACAGTCAGCGTCAC GTGACGCTGACTGTGCTCA 4874 GAGCACAGTCAGCGTCACT AGTGACGCTGACTGTGCTC 4875 AGCACAGTCAGCGTCACTC GAGTGACGCTGACTGTGCT 4876 GCACAGTCAGCGTCACTCA TGAGTGACGCTGACTGTGC 4877 CACAGTCAGCGTCACTCAG CTGAGTGACGCTGACTGTG 4878 ACAGTCAGCGTCACTCAGC GCTGAGTGACGCTGACTGT 4879 CAGTCAGCGTCACTCAGCA TGCTGAGTGACGCTGACTG 4880 AGTCAGCGTCACTCAGCAC GTGCTGAGTGACGCTGACT 4881 GTCAGCGTCACTCAGCACT AGTGCTGAGTGACGCTGAC 4882 TCAGCGTCACTCAGCACTT AAGTGCTGAGTGACGCTGA 4883 CAGCGTCACTCAGCACTTC GAAGTGCTGAGTGACGCTG 4884 AGCGTCACTCAGCACTTCC GGAAGTGCTGAGTGACGCT 4885 GCGTCACTCAGCACTTCCT AGGAAGTGCTGAGTGACGC 4886 CGTCACTCAGCACTTCCTC GAGGAAGTGCTGAGTGACG 4887 GTCACTCAGCACTTCCTCT AGAGGAAGTGCTGAGTGAC 4888 TCACTCAGCACTTCCTCTC GAGAGGAAGTGCTGAGTGA 4889 CACTCAGCACTTCCTCTCC GGAGAGGAAGTGCTGAGTG 4890 ACTCAGCACTTCCTCTCCC GGGAGAGGAAGTGCTGAGT 4891 CTCAGCACTTCCTCTCCCC GGGGAGAGGAAGTGCTGAG 4892 TCAGCACTTCCTCTCCCCT AGGGGAGAGGAAGTGCTGA 4893 CAGCACTTCCTCTCCCCTG CAGGGGAGAGGAAGTGCTG 4894 AGCACTTCCTCTCCCCTGA TCAGGGGAGAGGAAGTGCT 4895 GCACTTCCTCTCCCCTGAG CTCAGGGGAGAGGAAGTGC 4896 CACTTCCTCTCCCCTGAGA TCTCAGGGGAGAGGAAGTG 4897 ACTTCCTCTCCCCTGAGAC GTCTCAGGGGAGAGGAAGT 4898 CTTCCTCTCCCCTGAGACC GGTCTCAGGGGAGAGGAAG 4899 TTCCTCTCCCCTGAGACCT AGGTCTCAGGGGAGAGGAA 4900 TCCTCTCCCCTGAGACCTC GAGGTCTCAGGGGAGAGGA 4901 CCTCTCCCCTGAGACCTCT AGAGGTCTCAGGGGAGAGG 4902 CTCTCCCCTGAGACCTCTG CAGAGGTCTCAGGGGAGAG 4903 TCTCCCCTGAGACCTCTGC GCAGAGGTCTCAGGGGAGA 4904 CTCCCCTGAGACCTCTGCC GGCAGAGGTCTCAGGGGAG 4905 TCCCCTGAGACCTCTGCCC GGGCAGAGGTCTCAGGGGA 4906 CCCCTGAGACCTCTGCCCT AGGGCAGAGGTCTCAGGGG 4907 CCCTGAGACCTCTGCCCTC GAGGGCAGAGGTCTCAGGG 4908 CCTGAGACCTCTGCCCTCT AGAGGGCAGAGGTCTCAGG 4909 CTGAGACCTCTGCCCTCTC GAGAGGGCAGAGGTCTCAG 4910 TGAGACCTCTGCCCTCTCT AGAGAGGGCAGAGGTCTCA 4911 GAGACCTCTGCCCTCTCTG CAGAGAGGGCAGAGGTCTC 4912 AGACCTCTGCCCTCTCTGC GCAGAGAGGGCAGAGGTCT 4913 GACCTCTGCCCTCTCTGCT AGCAGAGAGGGCAGAGGTC 4914 ACCTCTGCCCTCTCTGCTC GAGCAGAGAGGGCAGAGGT 4915 CCTCTGCCCTCTCTGCTCA TGAGCAGAGAGGGCAGAGG 4916 CTCTGCCCTCTCTGCTCAG CTGAGCAGAGAGGGCAGAG 4917 TCTGCCCTCTCTGCTCAGC GCTGAGCAGAGAGGGCAGA 4918 CTGCCCTCTCTGCTCAGCT AGCTGAGCAGAGAGGGCAG 4919 TGCCCTCTCTGCTCAGCTC GAGCTGAGCAGAGAGGGCA 4920 GCCCTCTCTGCTCAGCTCT AGAGCTGAGCAGAGAGGGC 4921 CCCTCTCTGCTCAGCTCTG CAGAGCTGAGCAGAGAGGG 4922 CCTCTCTGCTCAGCTCTGC GCAGAGCTGAGCAGAGAGG 4923 CTCTCTGCTCAGCTCTGCC GGCAGAGCTGAGCAGAGAG 4924 TCTCTGCTCAGCTCTGCCA TGGCAGAGCTGAGCAGAGA 4925 CTCTGCTCAGCTCTGCCAC GTGGCAGAGCTGAGCAGAG 4926 TCTGCTCAGCTCTGCCACC GGTGGCAGAGCTGAGCAGA 4927 CTGCTCAGCTCTGCCACCA TGGTGGCAGAGCTGAGCAG 4928 TGCTCAGCTCTGCCACCAG CTGGTGGCAGAGCTGAGCA 4929 GCTCAGCTCTGCCACCAGG CCTGGTGGCAGAGCTGAGC 4930 CTCAGCTCTGCCACCAGGG CCCTGGTGGCAGAGCTGAG 4931 TCAGCTCTGCCACCAGGGA TCCCTGGTGGCAGAGCTGA 4932 CAGCTCTGCCACCAGGGAC GTCCCTGGTGGCAGAGCTG 4933 AGCTCTGCCACCAGGGACC GGTCCCTGGTGGCAGAGCT 4934 GCTCTGCCACCAGGGACCC GGGTCCCTGGTGGCAGAGC 4935 CTCTGCCACCAGGGACCCA TGGGTCCCTGGTGGCAGAG 4936 TCTGCCACCAGGGACCCAG CTGGGTCCCTGGTGGCAGA 4937 CTGCCACCAGGGACCCAGC GCTGGGTCCCTGGTGGCAG 4938 TGCCACCAGGGACCCAGCC GGCTGGGTCCCTGGTGGCA 4939 GCCACCAGGGACCCAGCCT AGGCTGGGTCCCTGGTGGC 4940 CCACCAGGGACCCAGCCTT AAGGCTGGGTCCCTGGTGG 4941 CACCAGGGACCCAGCCTTC GAAGGCTGGGTCCCTGGTG 4942 ACCAGGGACCCAGCCTTCC GGAAGGCTGGGTCCCTGGT 4943 CCAGGGACCCAGCCTTCCC GGGAAGGCTGGGTCCCTGG 4944 CAGGGACCCAGCCTTCCCC GGGGAAGGCTGGGTCCCTG 4945 AGGGACCCAGCCTTCCCCC GGGGGAAGGCTGGGTCCCT 4946 GGGACCCAGCCTTCCCCCT AGGGGGAAGGCTGGGTCCC 4947 GGACCCAGCCTTCCCCCTG CAGGGGGAAGGCTGGGTCC 4948 GACCCAGCCTTCCCCCTGA TCAGGGGGAAGGCTGGGTC 4949 ACCCAGCCTTCCCCCTGAC GTCAGGGGGAAGGCTGGGT 4950 CCCAGCCTTCCCCCTGACT AGTCAGGGGGAAGGCTGGG 4951 CCAGCCTTCCCCCTGACTG CAGTCAGGGGGAAGGCTGG 4952 CAGCCTTCCCCCTGACTGC GCAGTCAGGGGGAAGGCTG 4953 AGCCTTCCCCCTGACTGCC GGCAGTCAGGGGGAAGGCT 4954 GCCTTCCCCCTGACTGCCA TGGCAGTCAGGGGGAAGGC 4955 CCTTCCCCCTGACTGCCAC GTGGCAGTCAGGGGGAAGG 4956 CTTCCCCCTGACTGCCACC GGTGGCAGTCAGGGGGAAG 4957 TTCCCCCTGACTGCCACCT AGGTGGCAGTCAGGGGGAA 4958 TCCCCCTGACTGCCACCTG CAGGTGGCAGTCAGGGGGA 4959 CCCCCTGACTGCCACCTGC GCAGGTGGCAGTCAGGGGG 4960 CCCCTGACTGCCACCTGCT AGCAGGTGGCAGTCAGGGG 4961 CCCTGACTGCCACCTGCTT AAGCAGGTGGCAGTCAGGG 4962 CCTGACTGCCACCTGCTTT AAAGCAGGTGGCAGTCAGG 4963 CTGACTGCCACCTGCTTTA TAAAGCAGGTGGCAGTCAG 4964 TGACTGCCACCTGCTTTAT ATAAAGCAGGTGGCAGTCA 4965 GACTGCCACCTGCTTTATG CATAAAGCAGGTGGCAGTC 4966 ACTGCCACCTGCTTTATGC GCATAAAGCAGGTGGCAGT 4967 CTGCCACCTGCTTTATGCC GGCATAAAGCAGGTGGCAG 4968 TGCCACCTGCTTTATGCCC GGGCATAAAGCAGGTGGCA 4969 GCCACCTGCTTTATGCCCA TGGGCATAAAGCAGGTGGC 4970 CCACCTGCTTTATGCCCAG CTGGGCATAAAGCAGGTGG 4971 CACCTGCTTTATGCCCAGA TCTGGGCATAAAGCAGGTG 4972 ACCTGCTTTATGCCCAGAT ATCTGGGCATAAAGCAGGT 4973 CCTGCTTTATGCCCAGATG CATCTGGGCATAAAGCAGG 4974 CTGCTTTATGCCCAGATGG CCATCTGGGCATAAAGCAG 4975 TGCTTTATGCCCAGATGGA TCCATCTGGGCATAAAGCA 4976 GCTTTATGCCCAGATGGAC GTCCATCTGGGCATAAAGC 4977 CTTTATGCCCAGATGGACT AGTCCATCTGGGCATAAAG 4978 TTTATGCCCAGATGGACTG CAGTCCATCTGGGCATAAA 4979 TTATGCCCAGATGGACTGG CCAGTCCATCTGGGCATAA 4980 TATGCCCAGATGGACTGGG CCCAGTCCATCTGGGCATA 4981 ATGCCCAGATGGACTGGGC GCCCAGTCCATCTGGGCAT 4982 TGCCCAGATGGACTGGGCT AGCCCAGTCCATCTGGGCA 4983 GCCCAGATGGACTGGGCTG CAGCCCAGTCCATCTGGGC 4984 CCCAGATGGACTGGGCTGT ACAGCCCAGTCCATCTGGG 4985 CCAGATGGACTGGGCTGTG CACAGCCCAGTCCATCTGG 4986 CAGATGGACTGGGCTGTGT ACACAGCCCAGTCCATCTG 4987 AGATGGACTGGGCTGTGTT AACACAGCCCAGTCCATCT 4988 GATGGACTGGGCTGTGTTC GAACACAGCCCAGTCCATC 4989 ATGGACTGGGCTGTGTTCC GGAACACAGCCCAGTCCAT 4990 TGGACTGGGCTGTGTTCCA TGGAACACAGCCCAGTCCA 4991 GGACTGGGCTGTGTTCCAA TTGGAACACAGCCCAGTCC 4992 GACTGGGCTGTGTTCCAAG CTTGGAACACAGCCCAGTC 4993 ACTGGGCTGTGTTCCAAGC GCTTGGAACACAGCCCAGT 4994 CTGGGCTGTGTTCCAAGCA TGCTTGGAACACAGCCCAG 4995 TGGGCTGTGTTCCAAGCAG CTGCTTGGAACACAGCCCA 4996 GGGCTGTGTTCCAAGCAGT ACTGCTTGGAACACAGCCC 4997 GGCTGTGTTCCAAGCAGTG CACTGCTTGGAACACAGCC 4998 GCTGTGTTCCAAGCAGTGA TCACTGCTTGGAACACAGC 4999 CTGTGTTCCAAGCAGTGAA TTCACTGCTTGGAACACAG 5000 TGTGTTCCAAGCAGTGAAG CTTCACTGCTTGGAACACA 5001 GTGTTCCAAGCAGTGAAGG CCTTCACTGCTTGGAACAC 5002 TGTTCCAAGCAGTGAAGGT ACCTTCACTGCTTGGAACA 5003 GTTCCAAGCAGTGAAGGTG CACCTTCACTGCTTGGAAC 5004 TTCCAAGCAGTGAAGGTGG CCACCTTCACTGCTTGGAA 5005 TCCAAGCAGTGAAGGTGGC GCCACCTTCACTGCTTGGA 5006 CCAAGCAGTGAAGGTGGCC GGCCACCTTCACTGCTTGG 5007 CAAGCAGTGAAGGTGGCCG CGGCCACCTTCACTGCTTG 5008 AAGCAGTGAAGGTGGCCGT ACGGCCACCTTCACTGCTT 5009 AGCAGTGAAGGTGGCCGTG CACGGCCACCTTCACTGCT 5010 GCAGTGAAGGTGGCCGTGG CCACGGCCACCTTCACTGC 5011 CAGTGAAGGTGGCCGTGGG CCCACGGCCACCTTCACTG 5012 AGTGAAGGTGGCCGTGGGG CCCCACGGCCACCTTCACT 5013 GTGAAGGTGGCCGTGGGGA TCCCCACGGCCACCTTCAC 5014 TGAAGGTGGCCGTGGGGAC GTCCCCACGGCCACCTTCA 5015 GAAGGTGGCCGTGGGGACA TGTCCCCACGGCCACCTTC 5016 AAGGTGGCCGTGGGGACAT ATGTCCCCACGGCCACCTT 5017 AGGTGGCCGTGGGGACATT AATGTCCCCACGGCCACCT 5018 GGTGGCCGTGGGGACATTA TAATGTCCCCACGGCCACC 5019 GTGGCCGTGGGGACATTAC GTAATGTCCCCACGGCCAC 5020 TGGCCGTGGGGACATTACA TGTAATGTCCCCACGGCCA 5021 GGCCGTGGGGACATTACAG CTGTAATGTCCCCACGGCC 5022 GCCGTGGGGACATTACAGG CCTGTAATGTCCCCACGGC 5023 CCGTGGGGACATTACAGGA TCCTGTAATGTCCCCACGG 5024 CGTGGGGACATTACAGGAG CTCCTGTAATGTCCCCACG 5025 GTGGGGACATTACAGGAGG CCTCCTGTAATGTCCCCAC 5026 TGGGGACATTACAGGAGGC GCCTCCTGTAATGTCCCCA 5027 GGGGACATTACAGGAGGCC GGCCTCCTGTAATGTCCCC 5028 GGGACATTACAGGAGGCCA TGGCCTCCTGTAATGTCCC 5029 GGACATTACAGGAGGCCAA TTGGCCTCCTGTAATGTCC 5030 GACATTACAGGAGGCCAAA TTTGGCCTCCTGTAATGTC 5031 ACATTACAGGAGGCCAAAT ATTTGGCCTCCTGTAATGT 5032 CATTACAGGAGGCCAAATA TATTTGGCCTCCTGTAATG 5033 ATTACAGGAGGCCAAATAG CTATTTGGCCTCCTGTAAT 5034 TTACAGGAGGCCAAATAGA TCTATTTGGCCTCCTGTAA 5035 TACAGGAGGCCAAATAGAG CTCTATTTGGCCTCCTGTA 5036 ACAGGAGGCCAAATAGAGG CCTCTATTTGGCCTCCTGT 5037 CAGGAGGCCAAATAGAGGG CCCTCTATTTGGCCTCCTG 5038 AGGAGGCCAAATAGAGGGA TCCCTCTATTTGGCCTCCT 5039 GGAGGCCAAATAGAGGGAT ATCCCTCTATTTGGCCTCC 5040 GAGGCCAAATAGAGGGATG CATCCCTCTATTTGGCCTC 5041 AGGCCAAATAGAGGGATGC GCATCCCTCTATTTGGCCT 5042 GGCCAAATAGAGGGATGCT AGCATCCCTCTATTTGGCC 5043 GCCAAATAGAGGGATGCTA TAGCATCCCTCTATTTGGC 5044 CCAAATAGAGGGATGCTAG CTAGCATCCCTCTATTTGG 5045 CAAATAGAGGGATGCTAGG CCTAGCATCCCTCTATTTG 5046 AAATAGAGGGATGCTAGGT ACCTAGCATCCCTCTATTT 5047 AATAGAGGGATGCTAGGTG CACCTAGCATCCCTCTATT 5048 ATAGAGGGATGCTAGGTGT ACACCTAGCATCCCTCTAT 5049 TAGAGGGATGCTAGGTGTC GACACCTAGCATCCCTCTA 5050 AGAGGGATGCTAGGTGTCT AGACACCTAGCATCCCTCT 5051 GAGGGATGCTAGGTGTCTG CAGACACCTAGCATCCCTC 5052 AGGGATGCTAGGTGTCTGG CCAGACACCTAGCATCCCT 5053 GGGATGCTAGGTGTCTGGG CCCAGACACCTAGCATCCC 5054 GGATGCTAGGTGTCTGGGA TCCCAGACACCTAGCATCC 5055 GATGCTAGGTGTCTGGGAT ATCCCAGACACCTAGCATC 5056 ATGCTAGGTGTCTGGGATC GATCCCAGACACCTAGCAT 5057 TGCTAGGTGTCTGGGATCG CGATCCCAGACACCTAGCA 5058 GCTAGGTGTCTGGGATCGG CCGATCCCAGACACCTAGC 5059 CTAGGTGTCTGGGATCGGG CCCGATCCCAGACACCTAG 5060 TAGGTGTCTGGGATCGGGG CCCCGATCCCAGACACCTA 5061 AGGTGTCTGGGATCGGGGT ACCCCGATCCCAGACACCT 5062 GGTGTCTGGGATCGGGGTG CACCCCGATCCCAGACACC 5063 GTGTCTGGGATCGGGGTGG CCACCCCGATCCCAGACAC 5064 TGTCTGGGATCGGGGTGGG CCCACCCCGATCCCAGACA 5065 GTCTGGGATCGGGGTGGGG CCCCACCCCGATCCCAGAC 5066 TCTGGGATCGGGGTGGGGA TCCCCACCCCGATCCCAGA 5067 CTGGGATCGGGGTGGGGAC GTCCCCACCCCGATCCCAG 5068 TGGGATCGGGGTGGGGACA TGTCCCCACCCCGATCCCA 5069 GGGATCGGGGTGGGGACAG CTGTCCCCACCCCGATCCC 5070 GGATCGGGGTGGGGACAGG CCTGTCCCCACCCCGATCC 5071 GATCGGGGTGGGGACAGGT ACCTGTCCCCACCCCGATC 5072 ATCGGGGTGGGGACAGGTA TACCTGTCCCCACCCCGAT 5073 TCGGGGTGGGGACAGGTAG CTACCTGTCCCCACCCCGA 5074 CGGGGTGGGGACAGGTAGA TCTACCTGTCCCCACCCCG 5075 GGGGTGGGGACAGGTAGAC GTCTACCTGTCCCCACCCC 5076 GGGTGGGGACAGGTAGACC GGTCTACCTGTCCCCACCC 5077 GGTGGGGACAGGTAGACCA TGGTCTACCTGTCCCCACC 5078 GTGGGGACAGGTAGACCAG CTGGTCTACCTGTCCCCAC 5079 TGGGGACAGGTAGACCAGG CCTGGTCTACCTGTCCCCA 5080 GGGGACAGGTAGACCAGGT ACCTGGTCTACCTGTCCCC 5081 GGGACAGGTAGACCAGGTG CACCTGGTCTACCTGTCCC 5082 GGACAGGTAGACCAGGTGC GCACCTGGTCTACCTGTCC 5083 GACAGGTAGACCAGGTGCT AGCACCTGGTCTACCTGTC 5084 ACAGGTAGACCAGGTGCTC GAGCACCTGGTCTACCTGT 5085 CAGGTAGACCAGGTGCTCA TGAGCACCTGGTCTACCTG 5086 AGGTAGACCAGGTGCTCAG CTGAGCACCTGGTCTACCT 5087 GGTAGACCAGGTGCTCAGC GCTGAGCACCTGGTCTACC 5088 GTAGACCAGGTGCTCAGCC GGCTGAGCACCTGGTCTAC 5089 TAGACCAGGTGCTCAGCCC GGGCTGAGCACCTGGTCTA 5090 AGACCAGGTGCTCAGCCCA TGGGCTGAGCACCTGGTCT 5091 GACCAGGTGCTCAGCCCAG CTGGGCTGAGCACCTGGTC 5092 ACCAGGTGCTCAGCCCAGG CCTGGGCTGAGCACCTGGT 5093 CCAGGTGCTCAGCCCAGGC GCCTGGGCTGAGCACCTGG 5094 CAGGTGCTCAGCCCAGGCA TGCCTGGGCTGAGCACCTG 5095 AGGTGCTCAGCCCAGGCAC GTGCCTGGGCTGAGCACCT 5096 GGTGCTCAGCCCAGGCACA TGTGCCTGGGCTGAGCACC 5097 GTGCTCAGCCCAGGCACAA TTGTGCCTGGGCTGAGCAC 5098 TGCTCAGCCCAGGCACAAC GTTGTGCCTGGGCTGAGCA 5099 GCTCAGCCCAGGCACAACT AGTTGTGCCTGGGCTGAGC 5100 CTCAGCCCAGGCACAACTT AAGTTGTGCCTGGGCTGAG 5101 TCAGCCCAGGCACAACTTC GAAGTTGTGCCTGGGCTGA 5102 CAGCCCAGGCACAACTTCA TGAAGTTGTGCCTGGGCTG 5103 AGCCCAGGCACAACTTCAG CTGAAGTTGTGCCTGGGCT 5104 GCCCAGGCACAACTTCAGC GCTGAAGTTGTGCCTGGGC 5105 CCCAGGCACAACTTCAGCA TGCTGAAGTTGTGCCTGGG 5106 CCAGGCACAACTTCAGCAG CTGCTGAAGTTGTGCCTGG 5107 CAGGCACAACTTCAGCAGG CCTGCTGAAGTTGTGCCTG 5108 AGGCACAACTTCAGCAGGG CCCTGCTGAAGTTGTGCCT 5109 GGCACAACTTCAGCAGGGG CCCCTGCTGAAGTTGTGCC 5110 GCACAACTTCAGCAGGGGA TCCCCTGCTGAAGTTGTGC 5111 GACAACTTCAGCAGGGGAT ATCCCCTGCTGAAGTTGTG 5112 ACAACTTCAGCAGGGGATG CATCCCCTGCTGAAGTTGT 5113 CAACTTCAGCAGGGGATGG CCATCCCCTGCTGAAGTTG 5114 AACTTCAGCAGGGGATGGC GCCATCCCCTGCTGAAGTT 5115 ACTTCAGCAGGGGATGGCG CGCCATCCCCTGCTGAAGT 5116 CTTCAGCAGGGGATGGCGC GCGCCATCCCCTGCTGAAG 5117 TTCAGCAGGGGATGGCGCT AGCGCCATCCCCTGCTGAA 5118 TCAGCAGGGGATGGCGCTA TAGCGCCATCCCCTGCTGA 5119 CAGCAGGGGATGGCGCTAG CTAGCGCCATCCCCTGCTG 5120 AGCAGGGGATGGCGCTAGG CCTAGCGCCATCCCCTGCT 5121 GCAGGGGATGGCGCTAGGG CCCTAGCGCCATCCCCTGC 5122 CAGGGGATGGCGCTAGGGG CCCCTAGCGCCATCCCCTG 5123 AGGGGATGGCGCTAGGGGA TCCCCTAGCGCCATCCCCT 5124 GGGGATGGCGCTAGGGGAC GTCCCCTAGCGCCATCCCC 5125 GGGATGGCGCTAGGGGACT AGTCCCCTAGCGCCATCCC 5126 GGATGGCGCTAGGGGACTT AAGTCCCCTAGCGCCATCC 5127 GATGGCGCTAGGGGACTTG CAAGTCCCCTAGCGCCATC 5128 ATGGCGCTAGGGGACTTGG CCAAGTCCCCTAGCGCCAT 5129 TGGCGCTAGGGGACTTGGG CCCAAGTCCCCTAGCGCCA 5130 GGCGCTAGGGGACTTGGGG CCCCAAGTCCCCTAGCGCC 5131 GCGCTAGGGGACTTGGGGA TCCCCAAGTCCCCTAGCGC 5132 CGCTAGGGGACTTGGGGAT ATCCCCAAGTCCCCTAGCG 5133 GCTAGGGGACTTGGGGATT AATCCCCAAGTCCCCTAGC 5134 CTAGGGGACTTGGGGATTT AAATCCCCAAGTCCCCTAG 5135 TAGGGGACTTGGGGATTTC GAAATCCCCAAGTCCCCTA 5136 AGGGGACTTGGGGATTTCT AGAAATCCCCAAGTCCCCT 5137 GGGGACTTGGGGATTTCTG CAGAAATCCCCAAGTCCCC 5138 GGGACTTGGGGATTTCTGG CCAGAAATCCCCAAGTCCC 5139 GGACTTGGGGATTTCTGGT ACCAGAAATCCCCAAGTCC 5140 GACTTGGGGATTTCTGGTC GACCAGAAATCCCCAAGTC 5141 ACTTGGGGATTTCTGGTCA TGACCAGAAATCCCCAAGT 5142 CTTGGGGATTTCTGGTCAA TTGACCAGAAATCCCCAAG 5143 TTGGGGATTTCTGGTCAAC GTTGACCAGAAATCCCCAA 5144 TGGGGATTTCTGGTCAACC GGTTGACCAGAAATCCCCA 5145 GGGGATTTCTGGTCAACCC GGGTTGACCAGAAATCCCC 5146 GGGATTTCTGGTCAACCCC GGGGTTGACCAGAAATCCC 5147 GGATTTCTGGTCAACCCCA TGGGGTTGACCAGAAATCC 5148 GATTTCTGGTCAACCCCAC GTGGGGTTGACCAGAAATC 5149 ATTTCTGGTCAACCCCACA TGTGGGGTTGACCAGAAAT 5150 TTTCTGGTCAACCCCACAA TTGTGGGGTTGACCAGAAA 5151 TTCTGGTCAACCCCACAAG CTTGTGGGGTTGACCAGAA 5152 TCTGGTCAACCCCACAAGC GCTTGTGGGGTTGACCAGA 5153 CTGGTCAACCCCACAAGCA TGCTTGTGGGGTTGACCAG 5154 TGGTCAACCCCACAAGCAC GTGCTTGTGGGGTTGACCA 5155 GGTCAACCCCACAAGCACC GGTGCTTGTGGGGTTGACC 5156 GTCAACCCCACAAGCACCA TGGTGCTTGTGGGGTTGAC 5157 TCAACCCCACAAGCACCAC GTGGTGCTTGTGGGGTTGA 5158 CAACCCCACAAGCACCACT AGTGGTGCTTGTGGGGTTG 5159 AACCCCACAAGCACCACTC GAGTGGTGCTTGTGGGGTT 5160 ACCCCACAAGCACCACTCT AGAGTGGTGCTTGTGGGGT 5161 CCCCACAAGCACCACTCTG CAGAGTGGTGCTTGTGGGG 5162 CCCACAAGCACCACTCTGG CCAGAGTGGTGCTTGTGGG 5163 CCACAAGCACCACTCTGGG CCCAGAGTGGTGCTTGTGG 5164 CACAAGCACCACTCTGGGC GCCCAGAGTGGTGCTTGTG 5165 ACAAGCACCACTCTGGGCA TGCCCAGAGTGGTGCTTGT 5166 CAAGCACCACTCTGGGCAC GTGCCCAGAGTGGTGCTTG 5167 AAGCACCACTCTGGGCACA TGTGCCCAGAGTGGTGCTT 5168 AGCACCACTCTGGGCACAA TTGTGCCCAGAGTGGTGCT 5169 GCACCACTCTGGGCACAAG CTTGTGCCCAGAGTGGTGC 5170 CACCACTCTGGGCACAAGC GCTTGTGCCCAGAGTGGTG 5171 ACCACTCTGGGCACAAGCA TGCTTGTGCCCAGAGTGGT 5172 CCACTCTGGGCACAAGCAG CTGCTTGTGCCCAGAGTGG 5173 CACTCTGGGCACAAGCAGG CCTGCTTGTGCCCAGAGTG 5174 ACTCTGGGCACAAGCAGGG CCCTGCTTGTGCCCAGAGT 5175 CTCTGGGCACAAGCAGGGC GCCCTGCTTGTGCCCAGAG 5176 TCTGGGCACAAGCAGGGCA TGCCCTGCTTGTGCCCAGA 5177 CTGGGCACAAGCAGGGCAC GTGCCCTGCTTGTGCCCAG 5178 TGGGCACAAGCAGGGCACT AGTGCCCTGCTTGTGCCCA 5179 GGGCACAAGCAGGGCACTC GAGTGCCCTGCTTGTGCCC 5180 GGCACAAGCAGGGCACTCT AGAGTGCCCTGCTTGTGCC 5181 GCACAAGCAGGGCACTCTG CAGAGTGCCCTGCTTGTGC 5182 CACAAGCAGGGCACTCTGT ACAGAGTGCCCTGCTTGTG 5183 ACAAGCAGGGCACTCTGTT AACAGAGTGCCCTGCTTGT 5184 CAAGCAGGGCACTCTGTTC GAACAGAGTGCCCTGCTTG 5185 AAGCAGGGCACTCTGTTCC GGAACAGAGTGCCCTGCTT 5186 AGCAGGGCACTCTGTTCCC GGGAACAGAGTGCCCTGCT 5187 GCAGGGCACTCTGTTCCCC GGGGAACAGAGTGCCCTGC 5188 CAGGGCACTCTGTTCCCCT AGGGGAACAGAGTGCCCTG 5189 AGGGCACTCTGTTCCCCTC GAGGGGAACAGAGTGCCCT 5190 GGGCACTCTGTTCCCCTCC GGAGGGGAACAGAGTGCCC 5191 GGCACTCTGTTCCCCTCCC GGGAGGGGAACAGAGTGCC 5192 GCACTCTGTTCCCCTCCCC GGGGAGGGGAACAGAGTGC 5193 CACTCTGTTCCCCTCCCCC GGGGGAGGGGAACAGAGTG 5194 ACTCTGTTCCCCTCCCCCT AGGGGGAGGGGAACAGAGT 5195 CTCTGTTCCCCTCCCCCTT AAGGGGGAGGGGAACAGAG 5196 TCTGTTCCCCTCCCCCTTA TAAGGGGGAGGGGAACAGA 5197 CTGTTCCCCTCCCCCTTAA TTAAGGGGGAGGGGAACAG 5198 TGTTCCCCTCCCCCTTAAG CTTAAGGGGGAGGGGAACA 5199 GTTCCCCTCCCCCTTAAGC GCTTAAGGGGGAGGGGAAC 5200 TTCCCCTCCCCCTTAAGCC GGCTTAAGGGGGAGGGGAA 5201 TCCCCTCCCCCTTAAGCCA TGGCTTAAGGGGGAGGGGA 5202 CCCCTCCCCCTTAAGCCAA TTGGCTTAAGGGGGAGGGG 5203 CCCTCCCCCTTAAGCCAAC GTTGGCTTAAGGGGGAGGG 5204 CCTCCCCCTTAAGCCAACA TGTTGGCTTAAGGGGGAGG 5205 CTCCCCCTTAAGCCAACAA TTGTTGGCTTAAGGGGGAG 5206 TCCCCCTTAAGCCAACAAC GTTGTTGGCTTAAGGGGGA 5207 CCCCCTTAAGCCAACAACC GGTTGTTGGCTTAAGGGGG 5208 CCCCTTAAGCCAACAACCA TGGTTGTTGGCTTAAGGGG 5209 CCCTTAAGCCAACAACCAC GTGGTTGTTGGCTTAAGGG 5210 CCTTAAGCCAACAACCACA TGTGGTTGTTGGCTTAAGG 5211 CTTAAGCCAACAACCACAG CTGTGGTTGTTGGCTTAAG 5212 TTAAGCCAACAACCACAGT ACTGTGGTTGTTGGCTTAA 5213 TAAGCCAACAACCACAGTG CACTGTGGTTGTTGGCTTA 5214 AAGCCAACAACCACAGTGC GCACTGTGGTTGTTGGCTT 5215 AGCCAACAACCACAGTGCC GGCACTGTGGTTGTTGGCT 5216 GCCAACAACCACAGTGCCA TGGCACTGTGGTTGTTGGC 5217 CCAACAACCACAGTGCCAC GTGGCACTGTGGTTGTTGG 5218 CAACAACCACAGTGCCACC GGTGGCACTGTGGTTGTTG 5219 AACAACCACAGTGCCACCA TGGTGGCACTGTGGTTGTT 5220 ACAACCACAGTGCCACCAA TTGGTGGCACTGTGGTTGT 5221 CAACCACAGTGCCACCAAG CTTGGTGGCACTGTGGTTG 5222 AACCACAGTGCCACCAAGC GCTTGGTGGCACTGTGGTT 5223 ACCACAGTGCCACCAAGCT AGCTTGGTGGCACTGTGGT 5224 CCACAGTGCCACCAAGCTC GAGCTTGGTGGCACTGTGG 5225 CACAGTGCCACCAAGCTCA TGAGCTTGGTGGCACTGTG 5226 ACAGTGCCACCAAGCTCAC GTGAGCTTGGTGGCACTGT 5227 CAGTGCCACCAAGCTCACA TGTGAGCTTGGTGGCACTG 5228 AGTGCCACCAAGCTCACAC GTGTGAGCTTGGTGGCACT 5229 GTGCCACCAAGCTCACACC GGTGTGAGCTTGGTGGCAC 5230 TGCCACCAAGCTCACACCT AGGTGTGAGCTTGGTGGCA 5231 GCCACCAAGCTCACACCTG CAGGTGTGAGCTTGGTGGC 5232 CCACCAAGCTCACACCTGT ACAGGTGTGAGCTTGGTGG 5233 CACCAAGCTCACACCTGTC GACAGGTGTGAGCTTGGTG 5234 ACCAAGCTCACACCTGTCC GGACAGGTGTGAGCTTGGT 5235 CCAAGCTCACACCTGTCCT AGGACAGGTGTGAGCTTGG 5236 CAAGCTCACACCTGTCCTT AAGGACAGGTGTGAGCTTG 5237 AAGCTCACACCTGTCCTTC GAAGGACAGGTGTGAGCTT 5238 AGCTCACACCTGTCCTTCT AGAAGGACAGGTGTGAGCT 5239 GCTCACACCTGTCCTTCTC GAGAAGGACAGGTGTGAGC 5240 CTCACACCTGTCCTTCTCA TGAGAAGGACAGGTGTGAG 5241 TCACACCTGTCCTTCTCAG CTGAGAAGGACAGGTGTGA 5242 CACACCTGTCCTTCTCAGG CCTGAGAAGGACAGGTGTG 5243 ACACCTGTCCTTCTCAGGC GCCTGAGAAGGACAGGTGT 5244 CACCTGTCCTTCTCAGGCT AGCCTGAGAAGGACAGGTG 5245 ACCTGTCCTTCTCAGGCTG CAGCCTGAGAAGGACAGGT 5246 CCTGTCCTTCTCAGGCTGG CCAGCCTGAGAAGGACAGG 5247 CTGTCCTTCTCAGGCTGGC GCCAGCCTGAGAAGGACAG 5248 TGTCCTTCTCAGGCTGGCA TGCCAGCCTGAGAAGGACA 5249 GTCCTTCTCAGGCTGGCAT ATGCCAGCCTGAGAAGGAC 5250 TCCTTCTCAGGCTGGCATC GATGCCAGCCTGAGAAGGA 5251 CCTTCTCAGGCTGGCATCT AGATGCCAGCCTGAGAAGG 5252 CTTCTCAGGCTGGCATCTC GAGATGCCAGCCTGAGAAG 5253 TTCTCAGGCTGGCATCTCC GGAGATGCCAGCCTGAGAA 5254 TCTCAGGCTGGCATCTCCC GGGAGATGCCAGCCTGAGA 5255 CTCAGGCTGGCATCTCCCC GGGGAGATGCCAGCCTGAG 5256 TCAGGCTGGCATCTCCCCC GGGGGAGATGCCAGCCTGA 5257 CAGGCTGGCATCTCCCCCA TGGGGGAGATGCCAGCCTG 5258 AGGCTGGCATCTCCCCCAC GTGGGGGAGATGCCAGCCT 5259 GGCTGGCATCTCCCCCACC GGTGGGGGAGATGCCAGCC 5260 GCTGGCATCTCCCCCACCC GGGTGGGGGAGATGCCAGC 5261 CTGGCATCTCCCCCACCCT AGGGTGGGGGAGATGCCAG 5262 TGGCATCTCCCCCACCCTG CAGGGTGGGGGAGATGCCA 5263 GGCATCTCCCCCACCCTGT ACAGGGTGGGGGAGATGCC 5264 GCATCTCCCCCACCCTGTG CACAGGGTGGGGGAGATGC 5265 CATCTCCCCCACCCTGTGC GCACAGGGTGGGGGAGATG 5266 ATCTCCCCCACCCTGTGCC GGCACAGGGTGGGGGAGAT 5267 TCTCCCCCACCCTGTGCCC GGGCACAGGGTGGGGGAGA 5268 CTCCCCCACCCTGTGCCCC GGGGCACAGGGTGGGGGAG 5269 TCCCCCACCCTGTGCCCCT AGGGGCACAGGGTGGGGGA 5270 CCCCCACCCTGTGCCCCTT AAGGGGCACAGGGTGGGGG 5271 CCCCACCCTGTGCCCCTTT AAAGGGGCACAGGGTGGGG 5272 CCCACCCTGTGCCCCTTTT AAAAGGGGCACAGGGTGGG 5273 CCACCCTGTGCCCCTTTTC GAAAAGGGGCACAGGGTGG 5274 CACCCTGTGCCCCTTTTCA TGAAAAGGGGCACAGGGTG 5275 ACCCTGTGCCCCTTTTCAT ATGAAAAGGGGCACAGGGT 5276 CCCTGTGCCCCTTTTCATG CATGAAAAGGGGCACAGGG 5277 CCTGTGCCCCTTTTCATGG CCATGAAAAGGGGCACAGG 5278 CTGTGCCCCTTTTCATGGT ACCATGAAAAGGGGCACAG 5279 TGTGCCCCTTTTCATGGTA TACCATGAAAAGGGGCACA 5280 GTGCCCCTTTTCATGGTAC GTACCATGAAAAGGGGCAC 5281 TGCCCCTTTTCATGGTACC GGTACCATGAAAAGGGGCA 5282 GCCCCTTTTCATGGTACCA TGGTACCATGAAAAGGGGC 5283 CCCCTTTTCATGGTACCAG CTGGTACCATGAAAAGGGG 5284 CCCTTTTCATGGTACCAGG CCTGGTACCATGAAAAGGG 5285 CCTTTTCATGGTACCAGGC GCCTGGTACCATGAAAAGG 5286 CTTTTCATGGTACCAGGCC GGCCTGGTACCATGAAAAG 5287 TTTTCATGGTACCAGGCCC GGGCCTGGTACCATGAAAA 5288 TTTCATGGTACCAGGCCCG CGGGCCTGGTACCATGAAA 5289 TTCATGGTACCAGGCCCGC GCGGGCCTGGTACCATGAA 5290 TCATGGTACCAGGCCCGCA TGCGGGCCTGGTACCATGA 5291 CATGGTACCAGGCCCGCAC GTGCGGGCCTGGTACCATG 5292 ATGGTACCAGGCCCGCACT AGTGCGGGCCTGGTACCAT 5293 TGGTACCAGGCCCGCACTG CAGTGCGGGCCTGGTACCA 5294 GGTACCAGGCCCGCACTGG CCAGTGCGGGCCTGGTACC 5295 GTACCAGGCCCGCACTGGG CCCAGTGCGGGCCTGGTAC 5296 TACCAGGCCCGCACTGGGG CCCCAGTGCGGGCCTGGTA 5297 ACCAGGCCCGCACTGGGGG CCCCCAGTGCGGGCCTGGT 5298 CCAGGCCCGCACTGGGGGC GCCCCCAGTGCGGGCCTGG 5299 CAGGCCCGCACTGGGGGCA TGCCCCCAGTGCGGGCCTG 5300 AGGCCCGCACTGGGGGCAA TTGCCCCCAGTGCGGGCCT 5301 GGCCCGCACTGGGGGCAAT ATTGCCCCCAGTGCGGGCC 5302 GCCCGCACTGGGGGCAATT AATTGCCCCCAGTGCGGGC 5303 CCCGCACTGGGGGCAATTG CAATTGCCCCCAGTGCGGG 5304 CCGCACTGGGGGCAATTGA TCAATTGCCCCCAGTGCGG 5305 CGCACTGGGGGCAATTGAC GTCAATTGCCCCCAGTGCG 5306 GCACTGGGGGCAATTGACT AGTCAATTGCCCCCAGTGC 5307 CACTGGGGGCAATTGACTT AAGTCAATTGCCCCCAGTG 5308 ACTGGGGGCAATTGACTTC GAAGTCAATTGCCCCCAGT 5309 CTGGGGGCAATTGACTTCC GGAAGTCAATTGCCCCCAG 5310 TGGGGGCAATTGACTTCCT AGGAAGTCAATTGCCCCCA 5311 GGGGGCAATTGACTTCCTC GAGGAAGTCAATTGCCCCC 5312 GGGGCAATTGACTTCCTCC GGAGGAAGTCAATTGCCCC 5313 GGGCAATTGACTTCCTCCA TGGAGGAAGTCAATTGCCC 5314 GGCAATTGACTTCCTCCAA TTGGAGGAAGTCAATTGCC 5315 GCAATTGACTTCCTCCAAT ATTGGAGGAAGTCAATTGC 5316 CAATTGACTTCCTCCAATC GATTGGAGGAAGTCAATTG 5317 AATTGACTTCCTCCAATCC GGATTGGAGGAAGTCAATT 5318 ATTGACTTCCTCCAATCCC GGGATTGGAGGAAGTCAAT 5319 TTGACTTCCTCCAATCCCC GGGGATTGGAGGAAGTCAA 5320 TGACTTCCTCCAATCCCCA TGGGGATTGGAGGAAGTCA 5321 GACTTCCTCCAATCCCCAC GTGGGGATTGGAGGAAGTC 5322 ACTTCCTCCAATCCCCACT AGTGGGGATTGGAGGAAGT 5323 CTTCCTCCAATCCCCACTC GAGTGGGGATTGGAGGAAG 5324 TTCCTCCAATCCCCACTCC GGAGTGGGGATTGGAGGAA 5325 TCCTCCAATCCCCACTCCT AGGAGTGGGGATTGGAGGA 5326 CCTCCAATCCCCACTCCTC GAGGAGTGGGGATTGGAGG 5327 CTCCAATCCCCACTCCTCC GGAGGAGTGGGGATTGGAG 5328 TCCAATCCCCACTCCTCCG CGGAGGAGTGGGGATTGGA 5329 CCAATCCCCACTCCTCCGA TCGGAGGAGTGGGGATTGG 5330 CAATCCCCACTCCTCCGAG CTCGGAGGAGTGGGGATTG 5331 AATCCCCACTCCTCCGAGA TCTCGGAGGAGTGGGGATT 5332 ATCCCCACTCCTCCGAGAC GTCTCGGAGGAGTGGGGAT 5333 TCCCCACTCCTCCGAGACC GGTCTCGGAGGAGTGGGGA 5334 CCCCACTCCTCCGAGACCC GGGTCTCGGAGGAGTGGGG 5335 CCCACTCCTCCGAGACCCA TGGGTCTCGGAGGAGTGGG 5336 CCACTCCTCCGAGACCCAG CTGGGTCTCGGAGGAGTGG 5337 CACTCCTCCGAGACCCAGG CCTGGGTCTCGGAGGAGTG 5338 ACTCCTCCGAGACCCAGGA TCCTGGGTCTCGGAGGAGT 5339 CTCCTCCGAGACCCAGGAG CTCCTGGGTCTCGGAGGAG 5340 TCCTCCGAGACCCAGGAGA TCTCCTGGGTCTCGGAGGA 5341 CCTCCGAGACCCAGGAGAC GTCTCCTGGGTCTCGGAGG 5342 CTCCGAGACCCAGGAGACA TGTCTCCTGGGTCTCGGAG 5343 TCCGAGACCCAGGAGACAA TTGTCTCCTGGGTCTCGGA 5344 CCGAGACCCAGGAGACAAA TTTGTCTCCTGGGTCTCGG 5345 CGAGACCCAGGAGACAAAC GTTTGTCTCCTGGGTCTCG 5346 GAGACCCAGGAGACAAACA TGTTTGTCTCCTGGGTCTC 5347 AGACCCAGGAGACAAACAG CTGTTTGTCTCCTGGGTCT 5348 GACCCAGGAGACAAACAGC GCTGTTTGTCTCCTGGGTC 5349 ACCCAGGAGACAAACAGCC GGCTGTTTGTCTCCTGGGT 5350 CCCAGGAGACAAACAGCCC GGGCTGTTTGTCTCCTGGG 5351 CCAGGAGACAAACAGCCCT AGGGCTGTTTGTCTCCTGG 5352 CAGGAGACAAACAGCCCTT AAGGGCTGTTTGTCTCCTG 5353 AGGAGACAAACAGCCCTTC GAAGGGCTGTTTGTCTCCT 5354 GGAGACAAACAGCCCTTCC GGAAGGGCTGTTTGTCTCC 5355 GAGACAAACAGCCCTTCCT AGGAAGGGCTGTTTGTCTC 5356 AGACAAACAGCCCTTCCTT AAGGAAGGGCTGTTTGTCT 5357 GACAAACAGCCCTTCCTTG CAAGGAAGGGCTGTTTGTC 5358 ACAAACAGCCCTTCCTTGG CCAAGGAAGGGCTGTTTGT 5359 CAAACAGCCCTTCCTTGGG CCCAAGGAAGGGCTGTTTG 5360 AAACAGCCCTTCCTTGGGG CCCCAAGGAAGGGCTGTTT 5361 AACAGCCCTTCCTTGGGGA TCCCCAAGGAAGGGCTGTT 5362 ACAGCCCTTCCTTGGGGAA TTCCCCAAGGAAGGGCTGT 5363 CAGCCCTTCCTTGGGGAAA TTTCCCCAAGGAAGGGCTG 5364 AGCCCTTCCTTGGGGAAAC GTTTCCCCAAGGAAGGGCT 5365 GCCCTTCCTTGGGGAAACT AGTTTCCCCAAGGAAGGGC 5366 CCCTTCCTTGGGGAAACTT AAGTTTCCCCAAGGAAGGG 5367 CCTTCCTTGGGGAAACTTG CAAGTTTCCCCAAGGAAGG 5368 CTTCCTTGGGGAAACTTGG CCAAGTTTCCCCAAGGAAG 5369 TTCCTTGGGGAAACTTGGG CCCAAGTTTCCCCAAGGAA 5370 TCCTTGGGGAAACTTGGGA TCCCAAGTTTCCCCAAGGA 5371 CCTTGGGGAAACTTGGGAA TTCCCAAGTTTCCCCAAGG 5372 CTTGGGGAAACTTGGGAAT ATTCCCAAGTTTCCCCAAG 5373 TTGGGGAAACTTGGGAATC GATTCCCAAGTTTCCCCAA 5374 TGGGGAAACTTGGGAATCA TGATTCCCAAGTTTCCCCA 5375 GGGGAAACTTGGGAATCAT ATGATTCCCAAGTTTCCCC 5376 GGGAAACTTGGGAATCATT AATGATTCCCAAGTTTCCC 5377 GGAAACTTGGGAATCATTC GAATGATTCCCAAGTTTCC 5378 GAAACTTGGGAATCATTCT AGAATGATTCCCAAGTTTC 5379 AAACTTGGGAATCATTCTG CAGAATGATTCCCAAGTTT 5380 AACTTGGGAATCATTCTGG CCAGAATGATTCCCAAGTT 5381 ACTTGGGAATCATTCTGGC GCCAGAATGATTCCCAAGT 5382 CTTGGGAATCATTCTGGCT AGCCAGAATGATTCCCAAG 5383 TTGGGAATCATTCTGGCTT AAGCCAGAATGATTCCCAA 5384 TGGGAATCATTCTGGCTTA TAAGCCAGAATGATTCCCA 5385 GGGAATCATTCTGGCTTAA TTAAGCCAGAATGATTCCC 5386 GGAATCATTCTGGCTTAAA TTTAAGCCAGAATGATTCC 5387 GAATCATTCTGGCTTAAAC GTTTAAGCCAGAATGATTC 5388 AATCATTCTGGCTTAAACA TGTTTAAGCCAGAATGATT 5389 ATCATTCTGGCTTAAACAA TTGTTTAAGCCAGAATGAT 5390 TCATTCTGGCTTAAACAAC GTTGTTTAAGCCAGAATGA 5391 CATTCTGGCTTAAACAACA TGTTGTTTAAGCCAGAATG 5392 ATTCTGGCTTAAACAACAC GTGTTGTTTAAGCCAGAAT 5393 TTCTGGCTTAAACAACACC GGTGTTGTTTAAGCCAGAA 5394 TCTGGCTTAAACAACACCT AGGTGTTGTTTAAGCCAGA 5395 CTGGCTTAAACAACACCTC GAGGTGTTGTTTAAGCCAG 5396 TGGCTTAAACAACACCTCC GGAGGTGTTGTTTAAGCCA 5397 GGCTTAAACAACACCTCCT AGGAGGTGTTGTTTAAGCC 5398 GCTTAAACAACACCTCCTC GAGGAGGTGTTGTTTAAGC 5399 CTTAAACAACACCTCCTCC GGAGGAGGTGTTGTTTAAG 5400 TTAAACAACACCTCCTCCT AGGAGGAGGTGTTGTTTAA 5401 TAAACAACACCTCCTCCTG CAGGAGGAGGTGTTGTTTA 5402 AAACAACACCTCCTCCTGC GCAGGAGGAGGTGTTGTTT 5403 AACAACACCTCCTCCTGCT AGCAGGAGGAGGTGTTGTT 5404 ACAACACCTCCTCCTGCTG CAGCAGGAGGAGGTGTTGT 5405 CAACACCTCCTCCTGCTGC GCAGCAGGAGGAGGTGTTG 5406 AACACCTCCTCCTGCTGCT AGCAGCAGGAGGAGGTGTT 5407 ACACCTCCTCCTGCTGCTC GAGCAGCAGGAGGAGGTGT 5408 CACCTCCTCCTGCTGCTCA TGAGCAGCAGGAGGAGGTG 5409 ACCTCCTCCTGCTGCTCAC GTGAGCAGCAGGAGGAGGT 5410 CCTCCTCCTGCTGCTCACT AGTGAGCAGCAGGAGGAGG 5411 CTCCTCCTGCTGCTCACTC GAGTGAGCAGCAGGAGGAG 5412 TCCTCCTGCTGCTCACTCC GGAGTGAGCAGCAGGAGGA 5413 CCTCCTGCTGCTCACTCCC GGGAGTGAGCAGCAGGAGG 5414 CTCCTGCTGCTCACTCCCG CGGGAGTGAGCAGCAGGAG 5415 TCCTGCTGCTCACTCCCGC GCGGGAGTGAGCAGCAGGA 5416 CCTGCTGCTCACTCCCGCT AGCGGGAGTGAGCAGCAGG 5417 CTGCTGCTCACTCCCGCTG CAGCGGGAGTGAGCAGCAG 5418 TGCTGCTCACTCCCGCTGA TCAGCGGGAGTGAGCAGCA 5419 GCTGCTCACTCCCGCTGAG CTCAGCGGGAGTGAGCAGC 5420 CTGCTCACTCCCGCTGAGC GCTCAGCGGGAGTGAGCAG 5421 TGCTCACTCCCGCTGAGCC GGCTCAGCGGGAGTGAGCA 5422 GCTCACTCCCGCTGAGCCC GGGCTCAGCGGGAGTGAGC 5423 CTCACTCCCGCTGAGCCCA TGGGCTCAGCGGGAGTGAG 5424 TCACTCCCGCTGAGCCCAC GTGGGCTCAGCGGGAGTGA 5425 CACTCCCGCTGAGCCCACT AGTGGGCTCAGCGGGAGTG 5426 ACTCCCGCTGAGCCCACTC GAGTGGGCTCAGCGGGAGT 5427 CTCCCGCTGAGCCCACTCT AGAGTGGGCTCAGCGGGAG 5428 TCCCGCTGAGCCCACTCTA TAGAGTGGGCTCAGCGGGA 5429 CCCGCTGAGCCCACTCTAC GTAGAGTGGGCTCAGCGGG 5430 CCGCTGAGCCCACTCTACT AGTAGAGTGGGCTCAGCGG 5431 CGCTGAGCCCACTCTACTG CAGTAGAGTGGGCTCAGCG 5432 GCTGAGCCCACTCTACTGC GCAGTAGAGTGGGCTCAGC 5433 CTGAGCCCACTCTACTGCC GGCAGTAGAGTGGGCTCAG 5434 TGAGCCCACTCTACTGCCC GGGCAGTAGAGTGGGCTCA 5435 GAGCCCACTCTACTGCCCC GGGGCAGTAGAGTGGGCTC 5436 AGCCCACTCTACTGCCCCA TGGGGCAGTAGAGTGGGCT 5437 GCCCACTCTACTGCCCCAG CTGGGGCAGTAGAGTGGGC 5438 CCCACTCTACTGCCCCAGC GCTGGGGCAGTAGAGTGGG 5439 CCACTCTACTGCCCCAGCT AGCTGGGGCAGTAGAGTGG 5440 CACTCTACTGCCCCAGCTC GAGCTGGGGCAGTAGAGTG 5441 ACTCTACTGCCCCAGCTCC GGAGCTGGGGCAGTAGAGT 5442 CTCTACTGCCCCAGCTCCG CGGAGCTGGGGCAGTAGAG 5443 TCTACTGCCCCAGCTCCGT ACGGAGCTGGGGCAGTAGA 5444 CTACTGCCCCAGCTCCGTT AACGGAGCTGGGGCAGTAG 5445 TACTGCCCCAGCTCCGTTT AAACGGAGCTGGGGCAGTA 5446 ACTGCCCCAGCTCCGTTTC GAAACGGAGCTGGGGCAGT 5447 CTGCCCCAGCTCCGTTTCT AGAAACGGAGCTGGGGCAG 5448 TGCCCCAGCTCCGTTTCTA TAGAAACGGAGCTGGGGCA 5449 GCCCCAGCTCCGTTTCTAC GTAGAAACGGAGCTGGGGC 5450 CCCCAGCTCCGTTTCTACC GGTAGAAACGGAGCTGGGG 5451 CCCAGCTCCGTTTCTACCA TGGTAGAAACGGAGCTGGG 5452 CCAGCTCCGTTTCTACCAC GTGGTAGAAACGGAGCTGG 5453 CAGCTCCGTTTCTACCACC GGTGGTAGAAACGGAGCTG 5454 AGCTCCGTTTCTACCACCG CGGTGGTAGAAACGGAGCT 5455 GCTCCGTTTCTACCACCGC GCGGTGGTAGAAACGGAGC 5456 CTCCGTTTCTACCACCGCA TGCGGTGGTAGAAACGGAG 5457 TCCGTTTCTACCACCGCAT ATGCGGTGGTAGAAACGGA 5458 CCGTTTCTACCACCGCATC GATGCGGTGGTAGAAACGG 5459 CGTTTCTACCACCGCATCC GGATGCGGTGGTAGAAACG 5460 GTTTCTACCACCGCATCCT AGGATGCGGTGGTAGAAAC 5461 TTTCTACCACCGCATCCTC GAGGATGCGGTGGTAGAAA 5462 TTCTACCACCGCATCCTCA TGAGGATGCGGTGGTAGAA 5463 TCTACCACCGCATCCTCAC GTGAGGATGCGGTGGTAGA 5464 CTACCACCGCATCCTCACT AGTGAGGATGCGGTGGTAG 5465 TACCACCGCATCCTCACTG CAGTGAGGATGCGGTGGTA 5466 ACCACCGCATCCTCACTGG CCAGTGAGGATGCGGTGGT 5467 CCACCGCATCCTCACTGGG CCCAGTGAGGATGCGGTGG 5468 CACCGCATCCTCACTGGGC GCCCAGTGAGGATGCGGTG 5469 ACCGCATCCTCACTGGGCT AGCCCAGTGAGGATGCGGT 5470 CCGCATCCTCACTGGGCTC GAGCCCAGTGAGGATGCGG 5471 CGCATCCTCACTGGGCTCA TGAGCCCAGTGAGGATGCG 5472 GCATCCTCACTGGGCTCAC GTGAGCCCAGTGAGGATGC 5473 CATCCTCACTGGGCTCACT AGTGAGCCCAGTGAGGATG 5474 ATCCTCACTGGGCTCACTG CAGTGAGCCCAGTGAGGAT 5475 TCCTCACTGGGCTCACTGC GCAGTGAGCCCAGTGAGGA 5476 CCTCACTGGGCTCACTGCA TGCAGTGAGCCCAGTGAGG 5477 CTCACTGGGCTCACTGCAG CTGCAGTGAGCCCAGTGAG 5478 TCACTGGGCTCACTGCAGG CCTGCAGTGAGCCCAGTGA 5479 CACTGGGCTCACTGCAGGC GCCTGCAGTGAGCCCAGTG 5480 ACTGGGCTCACTGCAGGCA TGCCTGCAGTGAGCCCAGT 5481 CTGGGCTCACTGCAGGCAT ATGCCTGCAGTGAGCCCAG 5482 TGGGCTCACTGCAGGCATG CATGCCTGCAGTGAGCCCA 5483 GGGCTCACTGCAGGCATGC GCATGCCTGCAGTGAGCCC 5484 GGCTCACTGCAGGCATGCT AGCATGCCTGCAGTGAGCC 5485 GCTCACTGCAGGCATGCTG CAGCATGCCTGCAGTGAGC 5486 CTCACTGCAGGCATGCTGA TCAGCATGCCTGCAGTGAG 5487 TCACTGCAGGCATGCTGAA TTCAGCATGCCTGCAGTGA 5488 CACTGCAGGCATGCTGAAC GTTCAGCATGCCTGCAGTG 5489 ACTGCAGGCATGCTGAACA TGTTCAGCATGCCTGCAGT 5490 CTGCAGGCATGCTGAACAA TTGTTCAGCATGCCTGCAG 5491 TGCAGGCATGCTGAACAAG CTTGTTCAGCATGCCTGCA 5492 GCAGGCATGCTGAACAAGG CCTTGTTCAGCATGCCTGC 5493 CAGGCATGCTGAACAAGGG CCCTTGTTCAGCATGCCTG 5494 AGGCATGCTGAACAAGGGG CCCCTTGTTCAGCATGCCT 5495 GGCATGCTGAACAAGGGGC GCCCCTTGTTCAGCATGCC 5496 GCATGCTGAACAAGGGGCC GGCCCCTTGTTCAGCATGC 5497 CATGCTGAACAAGGGGCCT AGGCCCCTTGTTCAGCATG 5498 ATGCTGAACAAGGGGCCTC GAGGCCCCTTGTTCAGCAT 5499 TGCTGAACAAGGGGCCTCC GGAGGCCCCTTGTTCAGCA 5500 GCTGAACAAGGGGCCTCCA TGGAGGCCCCTTGTTCAGC 5501 CTGAACAAGGGGCCTCCAA TTGGAGGCCCCTTGTTCAG 5502 TGAACAAGGGGCCTCCAAC GTTGGAGGCCCCTTGTTCA 5503 GAACAAGGGGCCTCCAACC GGTTGGAGGCCCCTTGTTC 5504 AACAAGGGGCCTCCAACCT AGGTTGGAGGCCCCTTGTT 5505 ACAAGGGGCCTCCAACCTT AAGGTTGGAGGCCCCTTGT 5506 CAAGGGGCCTCCAACCTTC GAAGGTTGGAGGCCCCTTG 5507 AAGGGGCCTCCAACCTTCT AGAAGGTTGGAGGCCCCTT 5508 AGGGGCCTCCAACCTTCTG CAGAAGGTTGGAGGCCCCT 5509 GGGGCCTCCAACCTTCTGC GCAGAAGGTTGGAGGCCCC 5510 GGGCCTCCAACCTTCTGCC GGCAGAAGGTTGGAGGCCC 5511 GGCCTCCAACCTTCTGCCC GGGCAGAAGGTTGGAGGCC 5512 GCCTCCAACCTTCTGCCCT AGGGCAGAAGGTTGGAGGC 5513 CCTCCAACCTTCTGCCCTC GAGGGCAGAAGGTTGGAGG 5514 CTCCAACCTTCTGCCCTCC GGAGGGCAGAAGGTTGGAG 5515 TCCAACCTTCTGCCCTCCT AGGAGGGCAGAAGGTTGGA 5516 CCAACCTTCTGCCCTCCTG CAGGAGGGCAGAAGGTTGG 5517 CAACCTTCTGCCCTCCTGC GCAGGAGGGCAGAAGGTTG 5518 AACCTTCTGCCCTCCTGCC GGCAGGAGGGCAGAAGGTT 5519 ACCTTCTGCCCTCCTGCCA TGGCAGGAGGGCAGAAGGT 5520 CCTTCTGCCCTCCTGCCAA TTGGCAGGAGGGCAGAAGG 5521 CTTCTGCCCTCCTGCCAAA TTTGGCAGGAGGGCAGAAG 5522 TTCTGCCCTCCTGCCAAAA TTTTGGCAGGAGGGCAGAA 5523 TCTGCCCTCCTGCCAAAAG CTTTTGGCAGGAGGGCAGA 5524 CTGCCCTCCTGCCAAAAGA TCTTTTGGCAGGAGGGCAG 5525 TGCCCTCCTGCCAAAAGAT ATCTTTTGGCAGGAGGGCA 5526 GCCCTCCTGCCAAAAGATC GATCTTTTGGCAGGAGGGC 5527 CCCTCCTGCCAAAAGATCT AGATCTTTTGGCAGGAGGG 5528 CCTCCTGCCAAAAGATCTG CAGATCTTTTGGCAGGAGG 5529 CTCCTGCCAAAAGATCTGG CCAGATCTTTTGGCAGGAG 5530 TCCTGCCAAAAGATCTGGG CCCAGATCTTTTGGCAGGA 5531 CCTGCCAAAAGATCTGGGG CCCCAGATCTTTTGGCAGG 5532 CTGCCAAAAGATCTGGGGA TCCCCAGATCTTTTGGCAG 5533 TGCCAAAAGATCTGGGGAG CTCCCCAGATCTTTTGGCA 5534 GCCAAAAGATCTGGGGAGT ACTCCCCAGATCTTTTGGC 5535 CCAAAAGATCTGGGGAGTG CACTCCCCAGATCTTTTGG 5536 CAAAAGATCTGGGGAGTGT ACACTCCCCAGATCTTTTG 5537 AAAAGATCTGGGGAGTGTG CACACTCCCCAGATCTTTT 5538 AAAGATCTGGGGAGTGTGA TCACACTCCCCAGATCTTT 5539 AAGATCTGGGGAGTGTGAG CTCACACTCCCCAGATCTT 5540 AGATCTGGGGAGTGTGAGG CCTCACACTCCCCAGATCT 5541 GATCTGGGGAGTGTGAGGA TCCTCACACTCCCCAGATC 5542 ATCTGGGGAGTGTGAGGAG CTCCTCACACTCCCCAGAT 5543 TCTGGGGAGTGTGAGGAGA TCTCCTCACACTCCCCAGA 5544 CTGGGGAGTGTGAGGAGAG CTCTCCTCACACTCCCCAG 5545 TGGGGAGTGTGAGGAGAGG CCTCTCCTCACACTCCCCA 5546 GGGGAGTGTGAGGAGAGGG CCCTCTCCTCACACTCCCC 5547 GGGAGTGTGAGGAGAGGGT ACCCTCTCCTCACACTCCC 5548 GGAGTGTGAGGAGAGGGTG CACCCTCTCCTCACACTCC 5549 GAGTGTGAGGAGAGGGTGG CCACCCTCTCCTCACACTC 5550 AGTGTGAGGAGAGGGTGGC GCCACCCTCTCCTCACACT 5551 GTGTGAGGAGAGGGTGGCA TGCCACCCTCTCCTCACAC 5552 TGTGAGGAGAGGGTGGCAT ATGCCACCCTCTCCTCACA 5553 GTGAGGAGAGGGTGGCATC GATGCCACCCTCTCCTCAC 5554 TGAGGAGAGGGTGGCATCA TGATGCCACCCTCTCCTCA 5555 GAGGAGAGGGTGGCATCAG CTGATGCCACCCTCTCCTC 5556 AGGAGAGGGTGGCATCAGG CCTGATGCCACCCTCTCCT 5557 GGAGAGGGTGGCATCAGGA TCCTGATGCCACCCTCTCC 5558 GAGAGGGTGGCATCAGGAG CTCCTGATGCCACCCTCTC 5559 AGAGGGTGGCATCAGGAGC GCTCCTGATGCCACCCTCT 5560 GAGGGTGGCATCAGGAGCT AGCTCCTGATGCCACCCTC 5561 AGGGTGGCATCAGGAGCTG CAGCTCCTGATGCCACCCT 5562 GGGTGGCATCAGGAGCTGC GCAGCTCCTGATGCCACCC 5563 GGTGGCATCAGGAGCTGCT AGCAGCTCCTGATGCCACC 5564 GTGGCATCAGGAGCTGCTC GAGCAGCTCCTGATGCCAC 5565 TGGCATCAGGAGCTGCTCA TGAGCAGCTCCTGATGCCA 5566 GGCATCAGGAGCTGCTCAG CTGAGCAGCTCCTGATGCC 5567 GCATCAGGAGCTGCTCAGG CCTGAGCAGCTCCTGATGC 5568 CATCAGGAGCTGCTCAGGC GCCTGAGCAGCTCCTGATG 5569 ATCAGGAGCTGCTCAGGCT AGCCTGAGCAGCTCCTGAT 5570 TCAGGAGCTGCTCAGGCTT AAGCCTGAGCAGCTCCTGA 5571 CAGGAGCTGCTCAGGCTTG CAAGCCTGAGCAGCTCCTG 5572 AGGAGCTGCTCAGGCTTGG CCAAGCCTGAGCAGCTCCT 5573 GGAGCTGCTCAGGCTTGGC GCCAAGCCTGAGCAGCTCC 5574 GAGCTGCTCAGGCTTGGCG CGCCAAGCCTGAGCAGCTC 5575 AGCTGCTCAGGCTTGGCGG CCGCCAAGCCTGAGCAGCT 5576 GCTGCTCAGGCTTGGCGGA TCCGCCAAGCCTGAGCAGC 5577 CTGCTCAGGCTTGGCGGAG CTCCGCCAAGCCTGAGCAG 5578 TGCTCAGGCTTGGCGGAGG CCTCCGCCAAGCCTGAGCA 5579 GCTCAGGCTTGGCGGAGGG CCCTCCGCCAAGCCTGAGC 5580 CTCAGGCTTGGCGGAGGGA TCCCTCCGCCAAGCCTGAG 5581 TCAGGCTTGGCGGAGGGAG CTCCCTCCGCCAAGCCTGA 5582 CAGGCTTGGCGGAGGGAGC GCTCCCTCCGCCAAGCCTG 5583 AGGCTTGGCGGAGGGAGCG CGCTCCCTCCGCCAAGCCT 5584 GGCTTGGCGGAGGGAGCGG CCGCTCCCTCCGCCAAGCC 5585 GCTTGGCGGAGGGAGCGGC GCCGCTCCCTCCGCCAAGC 5586 CTTGGCGGAGGGAGCGGCA TGCCGCTCCCTCCGCCAAG 5587 TTGGCGGAGGGAGCGGCAT ATGCCGCTCCCTCCGCCAA 5588 TGGCGGAGGGAGCGGCATG CATGCCGCTCCCTCCGCCA 5589 GGCGGAGGGAGCGGCATGG CCATGCCGCTCCCTCCGCC 5590 GCGGAGGGAGCGGCATGGG CCCATGCCGCTCCCTCCGC 5591 CGGAGGGAGCGGCATGGGC GCCCATGCCGCTCCCTCCG 5592 GGAGGGAGCGGCATGGGCG CGCCCATGCCGCTCCCTCC 5593 GAGGGAGCGGCATGGGCGA TCGCCCATGCCGCTCCCTC 5594 AGGGAGCGGCATGGGCGAT ATCGCCCATGCCGCTCCCT 5595 GGGAGCGGCATGGGCGATG CATCGCCCATGCCGCTCCC 5596 GGAGCGGCATGGGCGATGT ACATCGCCCATGCCGCTCC 5597 GAGCGGCATGGGCGATGTC GACATCGCCCATGCCGCTC 5598 AGCGGCATGGGCGATGTCA TGACATCGCCCATGCCGCT 5599 GCGGCATGGGCGATGTCAC GTGACATCGCCCATGCCGC 5600 CGGCATGGGCGATGTCACT AGTGACATCGCCCATGCCG 5601 GGCATGGGCGATGTCACTC GAGTGACATCGCCCATGCC 5602 GCATGGGCGATGTCACTCA TGAGTGACATCGCCCATGC 5603 CATGGGCGATGTCACTCAG CTGAGTGACATCGCCCATG 5604 ATGGGCGATGTCACTCAGC GCTGAGTGACATCGCCCAT 5605 TGGGCGATGTCACTCAGCC GGCTGAGTGACATCGCCCA 5606 GGGCGATGTCACTCAGCCC GGGCTGAGTGACATCGCCC 5607 GGCGATGTCACTCAGCCCC GGGGCTGAGTGACATCGCC 5608 GCGATGTCACTCAGCCCCT AGGGGCTGAGTGACATCGC 5609 CGATGTCACTCAGCCCCTT AAGGGGCTGAGTGACATCG 5610 GATGTCACTCAGCCCCTTC GAAGGGGCTGAGTGACATC 5611 ATGTCACTCAGCCCCTTCC GGAAGGGGCTGAGTGACAT 5612 TGTCACTCAGCCCCTTCCC GGGAAGGGGCTGAGTGACA 5613 GTCACTCAGCCCCTTCCCG CGGGAAGGGGCTGAGTGAC 5614 TCACTCAGCCCCTTCCCGG CCGGGAAGGGGCTGAGTGA 5615 CACTCAGCCCCTTCCCGGT ACCGGGAAGGGGCTGAGTG 5616 ACTCAGCCCCTTCCCGGTC GACCGGGAAGGGGCTGAGT 5617 CTCAGCCCCTTCCCGGTCC GGACCGGGAAGGGGCTGAG 5618 TCAGCCCCTTCCCGGTCCG CGGACCGGGAAGGGGCTGA 5619 CAGCCCCTTCCCGGTCCGC GCGGACCGGGAAGGGGCTG 5620 AGCCCCTTCCCGGTCCGCC GGCGGACCGGGAAGGGGCT 5621 GCCCCTTCCCGGTCCGCCC GGGCGGACCGGGAAGGGGC 5622 CCCCTTCCCGGTCCGCCCG CGGGCGGACCGGGAAGGGG 5623 CCCTTCCCGGTCCGCCCGC GCGGGCGGACCGGGAAGGG 5624 CCTTCCCGGTCCGCCCGCT AGCGGGCGGACCGGGAAGG 5625 CTTCCCGGTCCGCCCGCTT AAGCGGGCGGACCGGGAAG 5626 TTCCCGGTCCGCCCGCTTC GAAGCGGGCGGACCGGGAA 5627 TCCCGGTCCGCCCGCTTCC GGAAGCGGGCGGACCGGGA 5628 CCCGGTCCGCCCGCTTCCC GGGAAGCGGGCGGACCGGG 5629 CCGGTCCGCCCGCTTCCCT AGGGAAGCGGGCGGACCGG 5630 CGGTCCGCCCGCTTCCCTC GAGGGAAGCGGGCGGACCG 5631 GGTCCGCCCGCTTCCCTCC GGAGGGAAGCGGGCGGACC 5632 GTCCGCCCGCTTCCCTCCT AGGAGGGAAGCGGGCGGAC 5633 TCCGCCCGCTTCCCTCCTT AAGGAGGGAAGCGGGCGGA 5634 CCGCCCGCTTCCCTCCTTC GAAGGAGGGAAGCGGGCGG 5635 CGCCCGCTTCCCTCCTTCA TGAAGGAGGGAAGCGGGCG 5636 GCCCGCTTCCCTCCTTCAT ATGAAGGAGGGAAGCGGGC 5637 CCCGCTTCCCTCCTTCATG CATGAAGGAGGGAAGCGGG 5638 CCGCTTCCCTCCTTCATGA TCATGAAGGAGGGAAGCGG 5639 CGCTTCCCTCCTTCATGAT ATCATGAAGGAGGGAAGCG 5640 GCTTCCCTCCTTCATGATT AATCATGAAGGAGGGAAGC 5641 CTTCCCTCCTTCATGATTT AAATCATGAAGGAGGGAAG 5642 TTCCCTCCTTCATGATTTC GAAATCATGAAGGAGGGAA 5643 TCCCTCCTTCATGATTTCC GGAAATCATGAAGGAGGGA 5644 CCCTCCTTCATGATTTCCA TGGAAATCATGAAGGAGGG 5645 CCTCCTTCATGATTTCCAT ATGGAAATCATGAAGGAGG 5646 CTCCTTCATGATTTCCATT AATGGAAATCATGAAGGAG 5647 TCCTTCATGATTTCCATTA TAATGGAAATCATGAAGGA 5648 CCTTCATGATTTCCATTAA TTAATGGAAATCATGAAGG 5649 CTTCATGATTTCCATTAAA TTTAATGGAAATCATGAAG 5650 TTCATGATTTCCATTAAAG CTTTAATGGAAATCATGAA 5651 TCATGATTTCCATTAAAGT ACTTTAATGGAAATCATGA 5652 CATGATTTCCATTAAAGTC GACTTTAATGGAAATCATG 5653 ATGATTTCCATTAAAGTCT AGACTTTAATGGAAATCAT 5654 TGATTTCCATTAAAGTCTG CAGACTTTAATGGAAATCA 5655 GATTTCCATTAAAGTCTGT ACAGACTTTAATGGAAATC 5656 ATTTCCATTAAAGTCTGTT AACAGACTTTAATGGAAAT 5657 TTTCCATTAAAGTCTGTTG CAACAGACTTTAATGGAAA 5658 TTCCATTAAAGTCTGTTGT ACAACAGACTTTAATGGAA 5659 TCCATTAAAGTCTGTTGTT AACAACAGACTTTAATGGA 5660 CCATTAAAGTCTGTTGTTT AAACAACAGACTTTAATGG 5661 CATTAAAGTCTGTTGTTTT AAAACAACAGACTTTAATG 5662 ATTAAAGTCTGTTGTTTTG CAAAACAACAGACTTTAAT 5663 TTAAAGTCTGTTGTTTTGT ACAAAACAACAGACTTTAA 5664 TAAAGTCTGTTGTTTTGTG CACAAAACAACAGACTTTA

TABLE 2 Human and Mouse Hairless Polymorphisms mRNA Accession Postion Gene (bp) number (nt) From/To Comments Human 5699 NM_005144 867 C/A Homo sapiens Hairless 1330 T/G hairless 1677 C/T homolog 1686 C/T (mouse) (HR), 2437 C/A transcript 2491 G/A variant 1, 2671 G/A mRNA 2672 C/T 2786 T/C 3058 T/C 3064 A/G 3208 C/T 3253 G/A 3340 G/A 3695 C/T 3812 A/T 3851 C/T 3854 C/T 4545 A/G 4715 C/G 4820 C/A Mouse 5599 NM_021877 402 A/G Mus musculus hairless 535 C/A hairless (hr), 1603 G/A mRNA 1681 A/G 1895 C/T 2251 G/A 2482 T/C 2569 T/C 2917 T/C 3232 C/T 3371 A/T 3610 C/A 4065 T/G

TABLE 3 Exemplary siRNA target sequences in mammalian hairless mRNAs (shown as cDNA sequences) Start Sequence Region Mouse (Mus musculus) hairless (hr), mRNA, NM_021877 2023 GCAGGAGACACCGGAGACAATCATA ORF (SEQ ID NO: 11373) 2495 GGACTCTTCAACACCCACTGGAGAT ORF (SEQ ID NO: 11374) 2713 CCAAGTCTGGGCCAAGTTTGACATT ORF (SEQ ID NO: 11375) 2831 CCACAACCTTCCTGCAATGGAGATT ORF (SEQ ID NO: 11376) 2844 GCAATGGAGATTCCAATCGGACCAA ORF (SEQ ID NO: 11377) 3042 CCAGTGATGACCGCATTACCAACAT ORF (SEQ ID NO: 11378) 3085 GCAGGTAGTAGAACGGAAGATCCAA ORF (SEQ ID NO: 11379) 3750 CCTGGTATCGAGCACAGAAAGATTT ORF (SEQ ID NO: 11380) 4068 GCACAATCAGTGTCACTCAGCACTT ORF (SEQ ID NO: 11381) Homo sapiens hairless homolog (mouse) (HR), transcript variant 1, mRNA, NM_005144 2151 GCGGAACCTGGGTTGTTTGGCTTAA ORF (SEQ ID NO: 11382) 2831 GGACACATCGATAGGGAACAAGGAT ORF (SEQ ID NO: 11383) 3626 CCCAACTCCACAACCTTCCTGCAAT ORF (SEQ ID NO: 11384) 3796 GCCATGAGCGAATACACATGGCCTT ORF (SEQ ID NO: 11385) 4092 CCTGTGTTGGTGTCAGGGATCCAAA ORF (SEQ ID NO: 11386) Rat (Rattus norvegicus) hairless (hr) mRNA, NM-024364 913 CCAAGATTCTAGAGCGAGCTCCCTT ORF (SEQ ID NO: 11387) 2045 GGATTCCTGTGCCACTTCTGAGGAA ORF (SEQ ID NO: 11388) 2601 CCACAACTTTCCTGCAATGGAGATT ORF (SEQ ID NO: 11389) 2614 GCAATGGAGATTCCAATCGGACCAA ORF (SEQ ID NO: 11390) 2729 GCTGCTAGCCTCTACAGCTGTCAAA ORF (SEQ ID NO: 11391) 2765 GCATGAGCGGATTCACATGGCCTTT ORF (SEQ ID NO: 11392) 2812 CCAGTGATGACCGCATTACCAACAT ORF (SEQ ID NO: 11393) 2855 GCAGGTAGTAGAACGGAAGATCCAA ORF (SEQ ID NO: 11394) 3520 CCTGGTACCGAGCACAGAAAGATTT ORF (SEQ ID NO: 11395) 3838 GCACAATCAGTGTCACTCAGCACTT ORF (SEQ ID NO: 11396) Monkey (Macaca mulatto) hairless mRNA, complete cds, AF_361864 1152 GCACTCGGAGCAGTTTGAATGTCCA ORF (SEQ ID NO: 11397) 1344 GGACACATCGATAGGGAACAAGGAG ORF (SEQ ID NO: 11398) 2025 GCACCAGGTCTGGGTCAAGTTTGAT ORF (SEQ ID NO: 11399) 2172 CCACAGGACCAAGAGCATCAAAGAG ORF (SEQ ID NO: 113400) 2605 CCTGTGTTGGTGTCAGGGATCCAAA ORF (SEQ ID NO: 11401) Pig (Sus scrofa) hairless mRNA, partical cds, AY279972 490 CAGATATGGGCAGCCTATGGTGTGA ORF (SEQ ID NO: 11402) 918 CCTGGTAAGCACAGTGAGCATCACT ORF (SEQ ID NO: 11403) 921 GGTAAGCACAGTGAGCATCACTCAG ORF (SEQ ID NO: 11404) 926 GCACAGTGAGCATCACTCAGCACTT ORF (SEQ ID NO: 11405) 927 CACAGTGAGCATCACTCAGCACTTC ORF (SEQ ID NO: 11406) Sheep (Ovis aries) hairless mRNA, partial cds, AY130969 366 GGATCCTGAGCATAATGGTGGCCAT ORF (SEQ ID NO: 11407) 1140 GCTTACTCGACACTCTGAGCAGTTT ORF (SEQ ID NO: 11408) 1798 GGACTGTTCAATACCCACTGGAGAT ORF (SEQ ID NO: 11409) 1967 CCCAGTTTGTCTCCAGTCAGCCTTT ORF (SEQ ID NO: 11410) 2016 CCAGGTCTGGGTCAAGTTTGACATT ORF (SEQ ID NO: 11411)

TABLE 4 Human hairless target/siRNA sequences human hairless NM_005144 Loop: 475-615 Loop: 651-752 Loop:  951-1137 Loop: 1968-2183 Loop: 2348-2568 Loop: 2769-2806 Loop: 3024-3365 Loop: 3069-3277 Loop: 4577-4698 Loop: 3605-3724 Loop: 4861-5079 Loop: 310-436 Loop: 1953-2248 Loop:  919-1265 Loop: 4286-4465 Loop: 2373-2555 Loop: 4853-5284 Loop: 1916-2288 Loop: 2739-2863 Loop: 4874-5043 Loop: 3047-3318 Loop:  959-1123 Loop: 4477-4534 Loop:  871-1302 Loop: 4325-4459 Loop: 4913-5029 Loop:  940-1166 Loop: 1946-2277 Loop: 4086-4199 Loop: 5093-5247

TABLE 5 Mouse hairless target/siRNA sequences mouse hairless NM_021877 Loop: 318-523 Loop: 2422-2459 Loop: 1870-1913 Loop: 5010-5089 Loop: 3614-3736 Loop: 20-23 Loop: 1048-1390 Loop: 1122-1304 Loop: 3434-3550 Loop: 3257-3337 Loop: 4272-4504 Loop: 3009-3024 Loop: 4879-4967 Loop: 668-845 Loop: 4050-4222 Loop: 1702-1800 Loop: 3364-3567 Loop: 1015-1029 Loop: 4730-4780 Loop: 1712-1792 Loop: 4540-4566 Loop: 4070-4135 Loop: 1220-1260 Loop: 3579-3701 Loop: 445-459 Loop: 3491-3516 Loop: 205-238 Loop: 1691-1926 Loop: 2320-2337 Loop: 896-951 Loop: 2212-2244 Loop: 5156-5179 Loop: 2850-3948 Loop: 1141-1201 Loop: 2588-2648 Loop: 403-518 Loop: 3370-3407 Loop: 412-510 Loop: 4517-4594 Loop: 659-871 Loop: 1087-1103 Loop: 1600-1624 Loop: 4389-4461 Loop: 3423-3561 Loop: 713-812 Loop: 176-302 Loop: 1073-1336 Loop: 675-837 Loop: 4395-4417 Loop: 1082-1316 Loop: 4152-4215 Loop: 2877-2944 

1. A method of removing hair from an area of a human, comprising: (A) first synchronizing hair growth cycles for hair follicles in said area, wherein said synchronization is accomplished by: (i) twice pulling the hair from said follicles; or (ii) administering a follicle growth inducer to said area; and (B) subsequently applying to said area a double stranded nucleic acid molecule comprising: (i) a sense sequence corresponding to 19-29 contiguous nucleotides of SEQ ID NO: 11412; and (ii) an antisense sequence complementary thereto, wherein said double stranded nucleic acid molecule inhibits expression of human hairless protein, whereby hair growth in said area is inhibited.
 2. The method of claim 1, wherein inhibition of hair growth in said area persists at least one month.
 3. The method of claim 1, wherein said double stranded nucleic acid comprises at least one 3′-overhang.
 4. The method of claim 3, wherein said 3′-overhang is a 2- or 3′-base overhang.
 5. The method of claim 3, wherein said 3′-overhang comprises at least one deoxynucleotide.
 6. The method of claim 1, wherein at least one strand of said double stranded nucleic acid comprises at least one nucleotide analog or internucleotidic linkage different from unmodified RNA.
 7. The method of claim 1, wherein said sense sequence comprises SEQ ID NO:11329.
 8. The method of claim 1, wherein said sense sequence and said antisense sequence each comprises 19 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 9. The method of claim 1, wherein said sense sequence and said antisense sequence each comprises 20 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 10. The method of claim 1, wherein said sense sequence and said antisense sequence each comprises 21 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 11. The method of claim 1, wherein said sense sequence and said antisense sequence each comprises 22 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 12. The method of claim 1, wherein said sense sequence and said antisense sequence each comprises 23 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 13. The method of claim 1, wherein said sense sequence and said antisense sequence each comprises 24 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 14. The method of claim 1, wherein said sense sequence and said antisense sequence each comprises 25 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 15. The method of claim 1, wherein said sense sequence and said antisense sequence each comprises 26 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 16. The method of claim 1, wherein said sense sequence and said antisense sequence each comprises 27 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 17. The method of claim 1, wherein said sense sequence and said antisense sequence each comprises 28 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 18. A method for removing hair from an area of a mammal, comprising: (A) synchronizing hair growth cycles for hair follicles in said area, wherein said synchronization is accomplished by: (i) twice pulling the hair from said follicles; or (ii) administering a follicle growth inducer to said area; and (B) subsequently applying to said area a double stranded nucleic acid molecule comprising: (i) a sense sequence corresponding to 19-29 contiguous nucleotides of SEQ ID NO: 11412 and (ii) an antisense sequence complementary thereto, wherein said double stranded nucleic acid molecule inhibits hairless mRNA translation.
 19. The method of claim 18, wherein said mammal is a human.
 20. The method of claim 18, wherein inhibition of hair growth in said area persists at least one month.
 21. The method of claim 18, wherein said double stranded nucleic acid comprises at least one 3′-overhang.
 22. The method of claim 21 wherein said 3′-overhang is a 2- or 3′-base overhang.
 23. The method of claim 22 wherein said 3′-overhang comprises at least one deoxynucleotide.
 24. The method of claim 18, wherein at least one strand of said double stranded nucleic acid comprises at least one nucleotide analog or internucleotidic linkage different from unmodified RNA.
 25. The method of claim 18, wherein said sense sequence comprises SEQ ID NO:11329.
 26. The method of claim 18, wherein said sense sequence and said antisense sequence each comprises 19 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 27. The method of claim 18, wherein said sense sequence and said antisense sequence each comprises 20 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 28. The method of claim 18, wherein said sense sequence and said antisense sequence each comprises 21 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 29. The method of claim 18, wherein said sense sequence and said antisense sequence each comprises 22 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 30. The method of claim 18, wherein said sense sequence and said antisense sequence each comprises 23 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 31. The method of claim 18, wherein said sense sequence and said antisense sequence each comprises 24 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 32. The method of claim 18, wherein said sense sequence and said antisense sequence each comprises 25 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 33. The method of claim 18, wherein said sense sequence and said antisense sequence each comprises 26 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 34. The method of claim 18, wherein said sense sequence and said antisense sequence each comprises 27 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 35. The method of claim 18, wherein said sense sequence and said antisense sequence each comprises 28 complementary nucleotides and 1 to 3 non-complementary 3′-nucleotides.
 36. A method of inhibiting expression of hairless protein in an area of a mammal, comprising: (A) first synchronizing hair growth cycles for hair follicles in said area, wherein said synchronization is accomplished by: (i) twice pulling the hair from said follicles; or (ii) administering a follicle growth inducer to said area; and (B) subsequently applying to said area a double stranded nucleic acid molecule comprising: (i) a sense sequence corresponding to 19-29 contiguous nucleotides of SEQ ID NO: 11412; and (ii) an antisense sequence complementary thereto.
 37. A method for treating a human desirous of losing hair in an area, comprising: (A) first synchronizing hair growth cycles for hair follicles in said area, wherein said synchronization is accomplished by: (i) twice pulling the hair from said follicles; or (ii) administering a follicle growth inducer to said area; and (B) subsequently applying to said area a double stranded nucleic acid molecule comprising: (i) a sense sequence corresponding to 19-29 contiguous nucleotides of SEQ ID NO: 11412; and (ii) an antisense sequence complementary thereto. 